# **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51)	International Patent Classification :
	C12N 15/12, C07K 14/47, C12N 15/11,
	C12Q 1/68, C07K 16/18, G01N 33/68,
	A61K 38/17

1 D 4 4 Cl - : C - 4: - 6

(11) International Publication Number:

WO 00/00610

A2 |

(43) International Publication Date:

6 January 2000 (06.01.00)

(21) International Application Number:

PCT/US99/14484

(22) International Filing Date:

25 June 1999 (25.06.99)

(30) Priority Data:

60/090,762	26 June 1998 (26.06.98)	US
60/094,983	31 July 1998 (31.07.98)	US
60/102,686	1 October 1998 (01.10.98)	US
60/112,129	11 December 1998 (11,12,98)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

(CII) to Lanner Expendition	1.0
US	60/090,762 (CIP)
Filed on	26 June 1998 (26.06.98)
US	60/094,983 (CIP)
Filed on	31 July 1998 (31.07.98)
US	60/102,686 (CIP)
Filed on	1 October 1998 (01.10.98)
US	60/112,129 (CIP)
Filed on	11 December 1998 (11.12.98)

(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and

(75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AKERBLOM, Ingrid, E. [US/US]; 1234 Johnson Street, Redwood City, CA 94061 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US).

(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published

Without international search report and to be republished upon receipt of that report.

#### (54) Title: HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS

## (57) Abstract

The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which indentify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.

arch.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Scnegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	<b>Greece</b>		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML,	Mali	TT	Trinidad and Tobago
ВЈ	Benîn	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

#### **HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS**

#### **TECHNICAL FIELD**

5

This invention relates to nucleic acid and amino acid sequences of human signal peptidecontaining proteins and to the use of these sequences in the diagnosis, treatment, and prevention of
cell proliferative disorders including cancer; inflammation; and cardiovascular, neurological,
reproductive, and developmental disorders.

#### **BACKGROUND OF THE INVENTION**

Protein transport is essential for cellular function. Transport of a protein may be 15 mediated by a signal peptide located at the amino terminus of the protein itself. The signal peptide is comprised of about ten to twenty hydrophobic amino acids which target the nascent protein from the ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory pathway or remain in any of the secretory organelles such as the ER. Golgi 20 apparatus, or lysosomes. Proteins that transit through the secretory pathway are either secreted into the extracellular space or retained in the plasma membrane. Secreted proteins are often synthesized as inactive precursors that are activated by post-translational processing events during transit through the secretory pathway. Such events include glycosylation, phosphorylation, proteolysis, and removal of the signal peptide by a signal 25 peptidase. Other events that may occur during protein transport include chaperonedependent unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptides are discussed below and include receptors, extracellular matrix molecules, cytokines, hormones, growth and differentiation factors, neuropeptides, vasomediators, 30 phosphokinases, phosphatases, phospholipases, phosphodiesterases, G and Ras-related proteins, ion channels, transporters/pumps, proteases, and transcription factors. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York, NY, pp. 557-560, 582-592.)

G-protein coupled receptors (GPCRs) comprise a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines such as dopamine, epinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin; for lipid mediators of inflammation such as prostaglandins, platelet activating factor, and leukotrienes; for peptide hormones such as calcitonin, C5a anaphylatoxin, follicle stimulating hormone, gonadotropin releasing hormone, neurokinin, oxytocin, and thrombin; and for sensory signal mediators such as retinal photopigments and olfactory stimulatory molecules. The structure of these highly conserved receptors consists of seven hydrophobic transmembrane regions, cysteine disulfide bridges between the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus. The N-terminus interacts with ligands, the disulfide bridges interact with agonists and antagonists, and the large third intracellular loop interacts with G proteins to activate second messengers such as cyclic AMP, phospholipase C, inositol triphosphate, or ion 15 channels. (Reviewed in Watson, S. and Arkinstall, S. (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego, CA, pp. 2-6; and Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego, CA, pp. 162-176.)

Other types of receptors include cell surface antigens identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based "shot gun" techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation" based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a "CD" number. Some of the genes encoding proteins identified by CD antigens have been isolated and characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A. N. et al. (1993) The

Leucocyte Antigen Facts Book, Academic Press, San Diego, CA, pp. 144-145; Noel, L. S. et al. (1998) J. Biol. Chem. 273:3878-3883.)

Tetraspanins are a superfamily of membrane proteins which facilitate the formation

and stability of cell-surface signaling complexes containing lineage-specific proteins, integrins, and other tetraspanins. They are involved in cell activation, proliferation (including cancer), differentiation, adhesion, and motility. These proteins cross the membrane four times, have conserved intracellular – and C-termini and an extracellular, non-conserved hydrophilic domain. Tetraspanins include, e.g., platelet and endothelial cell membrane proteins, leukocyte surface proteins, tissue specific and tumorous antigens, and the retinitis pigmentosa-associated gene peripherin. (Maecker, H.T. et al. (1997) FASEB J. 11:428-442.)

Matrix proteins (MPs) are transmembrane and extracellular proteins which

function in formation, growth, remodeling, and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases. In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in the immune response. MPs are frequently characterized by the presence of one or more domains which may include collagen-like domains, EGF-like domains, immunoglobulin-like domains, and fibronectin-like domains. In addition, some MPs are heavily glycosylated. MPs include extracellular proteins such as fibronectin, collagen, and galectin and cell adhesion receptors such as cell adhesion molecules (CAMs), cadherins, and integrins. (Reviewed in Ayad, S. et al. (1994) The

Extracellular Matrix Facts Book, Academic Press, San Diego, CA, pp. 2-16; Ruoslahti, E. (1997) Kidney Int. 51:1413-1417; Sjaastad, M.D. and Nelson, W.J. (1997) BioEssays 19:47-55.)

Lectins are proteins characterized by their ability to bind carbohydrates on cell membranes by means of discrete, modular carbohydrate recognition domains, CRDs.

25 (Kishore, U. et al. (1997) Matrix Biol. 15:583-592.) Certain cytokines and membrane-spanning proteins have CRDs which may enhance interactions with extracellular or intracellular ligands, with proteins in secretory pathways, or with molecules in signal transduction pathways. The lipocalin superfamily constitutes a phylogenetically conserved group of more than forty proteins that function by binding to and transporting a variety of physiologically important ligands. (Tanaka, T. et al. (1997) J. Biol. Chem. 272:15789-15795; and van't Hof, W. et al. (1997) J. Biol. Chem. 272:1837-1841.)

Selectins are a family of calcium ion-dependent lectins expressed on inflamed vascular

endothelium and the surface of some leukocytes. (Rossiter, H. et al. (1997) Mol. Med. Today 3:214-222.)

Protein kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Reversible protein phosphorylation is a key strategy for controlling protein functional activity in eukaryotic cells. The high energy phosphate which drives this activation is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals, cell cycle checkpoints, and environmental or nutritional stresses.

Protein kinases may be roughly divided into two groups; protein tyrosine kinases (PTKs) which phosphorylate tyrosine residues, and serine/threonine kinases (STKs) which phosphorylate serine or threonine residues. A few protein kinases have dual specificity. A majority of kinases contain a similar 250-300 amino acid catalytic domain. (Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book, Vol I, pp. 7-47, Academic Press,

San Diego, CA.)

Protein phosphatases remove phosphate groups from molecules previously modified by protein kinases thus participating in cell signaling, proliferation, differentiation, contacts, and oncogenesis. Protein phosphorylation is a key strategy used to control protein functional activity in eukaryotic cells. The high energy phosphate is 20 transferred from ATP to a protein by protein kinases and removed by protein phosphatases. There appear to be three, evolutionarily-distinct protein phosphatase gene families: protein phosphatases (PPs); protein tyrosine phosphatases (PTPs); and acid/alkaline phosphatases (APs). PPs dephosphorylate phosphoserine/threonine residues and are an important regulator of many cAMP mediated, hormone responses in cells.

SHE

25 PTPs reverse the effects of protein tyrosine kinases and therefore play a significant role in cell cycle and cell signaling processes. Although APs dephosphorylate substrates in vitro, their role in vivo is not well known. (Charbonneau, H. and Tonks, N.K. (1992) Annu. Rev. Cell Biol. 8:463-493.)

Cyclic nucleotides (cAMP and cGMP) function as intracellular second messengers to transduce a variety of extracellular signals, including hormones, light and neurotransmitters. Cyclic nucleotide phosphodiesterases (PDEs) degrade cyclic nucleotides to their corresponding monophosphates, thereby regulating the intracellular

concentrations of cyclic nucleotides and their effects on signal transduction. At least seven families of mammalian PDEs have been identified based on substrate specificity and affinity, sensitivity to cofactors and sensitivity to inhibitory drugs. (Beavo, J.A. (1995) Physiological Reviews 75: 725-748.)

5

15

Phospholipases (PLs) are enzymes that catalyze the removal of fatty acid residues from phosphoglycerides. PLs play an important role in transmembrane signal transduction and are named according to the specific ester bond in phosphoglycerides that is hydrolyzed, i.e., A<sub>1</sub>, A<sub>2</sub>, C or D. PLA<sub>2</sub> cleaves the ester bond at position 2 of the glycerol moiety of membrane phospholipids giving rise to arachidonic acid. Arachidonic acid is the common precursor to four major classes of eicosanoids, namely prostaglandins, prostacyclins, thromboxanes and leukotrienes. Eicosanoids are signaling molecules involved in the contraction of smooth muscle, platelet aggregation, and pain and inflammatory responses. (Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, Inc., New York, NY, pp. 85, 211, 239-240, 642-645.)

The nucleotide cyclases, i.e., adenylate and guanylate cyclase, catalyze the synthesis of the cyclic nucleotides, cAMP and cGMP, from ATP and GTP, respectively. They act in concert with phosphodiesterases, which degrade cAMP and cGMP, to regulate the cellular levels of these molecules and their functions. cAMP and cGMP function as intracellular second messengers to transduce a variety of extracellular signals, e.g., hormones, and light and neurotransmitters. (Stryer, L. (1988) <u>Biochemistry</u> W.H. Freeman and Co., New York, pp. 975-980, 1029-1035.)

Arch W

Cytokines are produced in response to cell perturbation. Some cytokines are produced as precursor forms, and some form multimers in order to become active. They are produced in groups and in patterns characteristic of the particular stimulus or disease, and the members of the group interact with one another and other molecules to produce an overall biological response. Interleukins, neurotrophins, growth factors, interferons, and chemokines are all families of cytokines which work in conjunction with cellular receptors to regulate cell proliferation and differentiation and to affect such activities as leukocyte migration and function, hematopoietic cell proliferation, temperature regulation, acute response to infections, tissue remodeling, apoptosis, and cell survival. Studies using antibodies or other drugs that modify the activity of a particular cytokine are used to elucidate the roles of individual cytokines in pathology and physiology.

Chemokines, in particular, are small chemoattractant cytokines involved in inflammation, leukocyte proliferation and migration, angiogenesis and angiostasis, regulation of hematopoiesis, HIV infectivity, and stimulation of cytokine secretion. Chemokines generally contain 70-100 amino acids and are subdivided into four subfamilies based on the presence of conserved cysteine-based motifs. (Callard, R. and Gearing, A. (1994) The Cytokine Facts Book. Academic Press, New York, NY, pp. 181-190, 210-213, 223-227.)

Growth and differentiation factors are secreted proteins which function in intercellular communication. Some factors require oligomerization or association with 10 MPs for activity. Complex interactions among these factors and their receptors trigger intracellular signal transduction pathways that stimulate or inhibit cell division, cell differentiation, cell signaling, and cell motility. Most growth and differentiation factors act on cells in their local environment (paracrine signaling). There are three broad classes of growth and differentiation factors. The first class includes the large polypeptide growth 15 factors such as epidermal growth factor, fibroblast growth factor, transforming growth factor, insulin-like growth factor, and platelet-derived growth factor. The second class includes the hematopoietic growth factors such as the colony stimulating factors (CSFs). Hematopoietic growth factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, 20 neutrophils, macrophages, and their stem cell precursors. The third class includes small peptide factors such as bombesin, vasopressin, oxytocin, endothelin, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin which function as hormones to regulate cellular functions other than proliferation.

Growth and differentiation factors play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of melanotic tumors.

During hematopoiesis, growth factor misregulation can result in anemias, leukemias, and lymphomas. Certain growth factors such as interferon are cytotoxic to tumor cells both in vivo and in vitro. Moreover, some growth factors and growth factor receptors are related both structurally and functionally to oncoproteins. In addition, growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes. (Reviewed in Pimentel, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor, MI, pp. 1-9.)

PCT/US99/14484 WO 00/00610

Proteolytic enzymes or proteases either activate or deactivate proteins by hydrolyzing peptide bonds. Proteases are found in the cytosol, in membrane-bound compartments, and in the extracellular space. The major families are the zinc, serine, cysteine, thiol, and carboxyl proteases.

5

Zinc proteases, e.g., carboxypeptidase A, have a zinc ion bound to the active site. These proteases recognize C-terminal residues that contain an aromatic or bulky aliphatic side chain, and hydrolyze the peptide bond adjacent to the C-terminal residues. Serine proteases have an active site serine residue and include digestive enzymes, e.g., trypsin and chymotrypsin, components of the complement and blood-clotting cascades, and 10 enzymes that control the degradation and turnover of extracellular matrix (ECM) molecules. Cysteine proteases (e.g. cathepsin) are produced by monocytes, macrophages and other immune cells, and are involved in diverse cellular processes ranging from the processing of precursor proteins to intracellular degradation. Overproduction of these enzymes can cause the tissue destruction associated with rheumatoid arthritis and asthma. 15 Thiol proteases, e.g., papain, contain an active site cysteine and are widely distributed within tissues. Carboxyl proteases, e.g., pepsin, are active only under acidic conditions (pH 2 to 3).

Guanosine triphosphate-binding proteins (G proteins) can be grouped into two major classes: heterotrimeric G proteins and small G proteins. Heterotrimeric G proteins interact with GPCRs that respond to hormones, growth factors, neuromodulators, or other signaling molecules. The interaction between GPCR and G protein allows the G protein to exchange GTP for guanosine diphosphate (GDP). This exchange activates the G protein, allowing it to dissociate from the receptor and interact with the its cognate second messenger-generating protein, e.g., adenylate cyclase, guanylate cyclase, phospholipase C, or ion channels. The hydrolysis of GTP to GDP by the G protein acts as an on-off switch, terminating the action of the G protein and preparing it to interact with another receptor molecule, thus beginning another round of signal transduction.

The small G proteins consist of single 21-30 kDa polypeptides. They can be classified into five subfamilies: Ras, Rho, Ran, Rab, and ADP-ribosylation factor. These proteins regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. In particular, the Ras proteins are essential in transducing signals from receptor tyrosine kinases to serine/threonine kinases which control cell growth and

differentiation. Mutant Ras proteins, which bind but can not hydrolyze GTP, are permanently activated and cause continuous cell proliferation or cancer. All five subfamilies share common structural features and four conserved motifs. Most of the membrane-bound G proteins require a carboxy terminal isoprenyl group (CAAX), added posttranslationally, for membrane association and biological activity. The G proteins also have a variable effector region, located between motifs I and II, which is characterized as the interaction site for guanine nucleotide exchange factors or GTPase-activating proteins.

Eukaryotic cells are bound by a membrane and subdivided into membrane-bound compartments. Membranes are impermeable to many ions and polar molecules, therefore transport of these molecules is mediated by ion channels, ion pumps, transport proteins, or pumps. Symporters and antiporters regulate cytosolic pH by transporting ions and small molecules, e.g., amino acids, glucose, and drugs, across membranes; symporters transport small molecules and ions in the same direction, and antiporters, in the opposite direction. Transporter superfamilies include facilitative transporters and active ATP binding cassette transporters involved in multiple-drug resistance and the targeting of antigenic peptides to MHC Class I molecules. These transporters bind to a specific ion or other molecule and undergo conformational changes in order to transfer the ion or molecule across a membrane. Transport can occur by a passive, concentration-dependent mechanism or can be linked to an energy source such as ATP hydrolysis or an ion gradient.

lon channels, ion pumps, and transport proteins mediate the transport of molecules across cellular membranes. Symporters and antiporters regulate cytosolic pH by transporting ions and small molecules such as amino acids, glucose, and drugs. Symporters transport small molecules and ions unidirectionally, and antiporters, bidirectionally. Transporter superfamilies include facilitative transporters and active ATP-binding cassette transporters which are involved in multiple-drug resistance and the targeting of antigenic peptides to MHC Class I molecules. These transporters bind to a specific ion or other molecule and undergo a conformational change in order to transfer the ion or molecule across the membrane. Transport can occur by a passive, concentration-dependent mechanism or can be linked to an energy source such as ATP hydrolysis. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York, NY, pp. 523-546.)

Ion channels are formed by transmembrane proteins which create a lined passageway across the membrane through which water and ions, such as Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>, and Cl<sup>-</sup>, enter and exit the cell. For example, chloride channels are involved in the regulation of the membrane electric potential as well as absorption and secretion of ions across the membrane. Chloride channels also regulate the internal pH of membrane-bound organelles.

Ion pumps are ATPases which actively maintain membrane gradients. Ion pumps are classified as P, V, or F according to their structure and function. All have one or more binding sites for ATP in their cytosolic domains. The P-class ion pumps include Ca<sup>2+</sup>

10 ATPase and Na<sup>+</sup>/K<sup>+</sup> ATPase and function in transporting H<sup>+</sup>, Na<sup>+</sup>, K<sup>+</sup>, and Ca<sup>2+</sup> ions. P-class pumps consist of two α and two β transmembrane subunits. The V- and F-class ion pumps have similar structures and but transport only H<sup>+</sup>. F class H<sup>+</sup> pumps mediate transport across the membranes of mitochondria and chloroplasts, while V-class H<sup>+</sup> pumps regulate acidity inside lysosomes, endosomes, and plant vacuoles.

A family of structurally related intrinsic membrane proteins known as facilitative glucose transporters catalyze the movement of glucose and other selected sugars across the plasma membrane. The proteins in this family contain a highly conserved, large transmembrane domain comprised of 12 α-helices, and several weakly conserved, cytoplasmic and exoplasmic domains (Pessin, J. E., and Bell, G.I. (1992) Annu. Rev. Physiol. 54:911-930).

15

Amino acid transport is mediated by Na<sup>+</sup> dependent amino acid transporters.

These transporters are involved in gastrointestinal and renal uptake of dietary and cellular amino acids and in neuronal reuptake of neurotransmitters. Transport of cationic amino acids is mediated by the system y+ family and the cationic amino acid transporter (CAT)

family. Members of the CAT family share a high degree of sequence homology, and each contains 12-14 putative transmembrane domains (Ito, K. and Groudine, M. (1997) J. Biol. Chem. 272:26780-26786).

Proton-coupled, 12 membrane-spanning domain transporters such as PEPT 1 and PEPT 2 are responsible for gastrointestinal absorption and for renal reabsorbtion of peptides using an electrochemical H<sup>+</sup> gradient as the driving force. A heterodimeric peptide transporter, consisting of TAP 1 and TAP 2, is associated with antigen processing. Peptide antigens are transported across the membrane of the endoplasmic reticulum so

PCT/US99/14484 WO 00/00610

they can be presented to the major histocompatibility complex class I molecules. Each TAP protein consists of multiple hydrophobic membrane spanning segments and a highly conserved ATP-binding cassette. (Boll, M. et al. (1996) Proc. Natl. Acad. Sci. 93:284-289.)

5

Hormones are secreted molecules that travel through the circulation and bind to specific receptors on the surface of, or within, target cells. Although they have diverse biochemical compositions and mechanisms of action, hormones can be grouped into two categories. One category consists of small lipophilic hormones that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a 10 complex that alters gene expression. Examples of these molecules include retinoic acid, thyroxine, and the cholesterol-derived steroid hormones such as progesterone, estrogen, testosterone, cortisol, and aldosterone. The second category consists of hydrophilic hormones that function by binding to cell surface receptors that transduce signals across the plasma membrane. Examples of such hormones include amino acid derivatives such as catecholamines and peptide hormones such as glucagon, insulin, gastrin, secretin, cholecystokinin, adrenocorticotropic hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, and vasopressin. (See, for example, Lodish et al. (1995) Molecular Cell Biology, Scientific American Books Inc., New York, NY, pp. 856-864.)

Neuropeptides and vasomediators (NP/VM) comprise a large family of 20 endogenous signaling molecules. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins, urotensin II and related peptides involved in smooth muscle stimulation, vasopressin, vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C. R. et al. 30 (1985) Endocrine Physiology, Oxford University Press, New York, NY, pp. 57-62.)

Regulatory molecules turn individual genes or groups of genes on and off in response to various inductive mechanisms of the cell or organism; act as transcription factors by determining

whether or not transcription is initiated, enhanced, or repressed; and splice transcripts as dictated in a particular cell or tissue. Although they interact with short stretches of DNA scattered throughout the entire genome, most gene expression is regulated near the site at which transcription starts or within the open reading frame of the gene being expressed. Many of the transcription factors incorporate one of a set of DNA-binding structural motifs, each of which contains either α helices or β sheets and binds to the major groove of DNA. (Pabo, C.O. and R.T. Sauer (1992) Ann. Rev. Biochem. 61:1053-95.) Other domains of transcription factors may form crucial contacts with the DNA. In addition, accessory proteins provide important interactions which may convert a particular protein complex to an activator or a repressor or may prevent binding. (Alberts, B. et al. (1994) Molecular Biology of the Cell, Garland Publishing Co, New York, NY pp. 401-474.)

The discovery of new human signal peptide-containing proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative disorders including cancer; inflammation; and cardiovascular, neurological, reproductive, and developmental disorders.

### SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, proteins with signal 20 peptides, referred to collectively as "HSPP" and individually as "HSPP-1", "HSPP-2", "HSPP-3", "HSPP-4", "HSPP-5", "HSPP-6", "HSPP-7", "HSPP-8", "HSPP-9", "HSPF-10", "HSPP-11", "HSPP-12", "HSPP-13", "HSPP-14", "HSPP-15", "HSPP-16", "HSPP-17", "HSPP-18", "HSPP-19", "HSPP-20", "HSPP-21", "HSPP-22", "HSPP-23", "HSPP-24", "HSPP-25", "HSPP-26", "HSPP-27", "HSPP-28", "HSPP-29", "HSPP-30", "HSPP-25 31", "HSPP-32", "HSPP-33", "HSPP-34", "HSPP-35", "HSPP-36", "HSPP-37", "HSPP-38", "HSPP-39", "HSPP-40", "HSPP-41", "HSPP-42", "HSPP-43", "HSPP-44", "HSPP-45", "HSPP-46", "HSPP-47", "HSPP-48", "HSPP-49", "HSPP-50", "HSPP-51", "HSPP-52", "HSPP-53", "HSPP-54", "HSPP-55", "HSPP-56", "HSPP-57", "HSPP-58", "HSPP-59", "HSPP-60", "HSPP-61", "HSPP-62", "HSPP-63", "HSPP-64", "HSPP-65", "HSPP-30 66", "HSPP-67", "HSPP-68", "HSPP-69", "HSPP-70", "HSPP-71", "HSPP-72", "HSPP-73", "HSPP-74", "HSPP-75", HSPP-76", "HSPP-77", "HSPP-78", "HSPP-79", "HSPP-80", "HSPP-81", "HSPP-82", "HSPP-83", "HSPP-84", "HSPP-85", "HSPP-86", "HSPP-87", "HSPP-88", "HSPP-89", "HSPP-90", "HSPP-91", "HSPP-92", "HSPP-93", "HSPP-94", "HSPP-95", "HSPP-96", "HSPP-97", "HSPP-98", "HSPP-99", "HSPP-100", "HSPP-

101", "HSPP-102", "HSPP-103", "HSPP-104", "HSPP-105", "HSPP-106", "HSPP-107", "HSPP-108", "HSPP-109", "HSPP-110", HSPP-111", "HSPP-112", "HSPP-113", "HSPP-114", "HSPP-115", "HSPP-116", "HSPP-117", "HSPP-118", "HSPP-119", "HSPP-120", "HSPP-121", "HSPP-122", "HSPP-123", "HSPP-124", "HSPP-125", "HSPP-126", 5 "HSPP-127", "HSPP-128", "HSPP-129", "HSPP-130", "HSPP-131", "HSPP-132", "HSPP-133", and "HSPP-134". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID 10 NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO: 28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, 15 SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID 20 NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ 25 ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID 30 NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID

NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134 (SEQ ID NO:1-134), and fragments thereof.

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-134, and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:115 134, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:135, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:180, SEQ ID NO:191, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:195

NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID 5 NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID 10 NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID 15 NO:266, SEQ ID NO:267, SEQ ID NO:268 (SEQ ID NO:135-268), and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:135-268, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:135-268, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention further provides an expression vector containing at least a fragment
of the polynucleotide encoding the polypeptide comprising an amino acid sequence
selected from the group consisting of SEQ ID NO:1-134, and fragments thereof. In
another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-134, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of HSPP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of HSPP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and fragments thereof.

25

30

10

## BRIEF DESCRIPTION OF THE TABLE

Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NO), clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding HSPP.

Table 2 shows features of each polypeptide sequence, including predicted signal peptide sequences, and methods and algorithms used for identification of HSPP.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis, diseases, disorders, or conditions associated with these tissues, and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which

Incyte cDNA clones encoding HSPP were isolated.

Table 5 shows the programs, their descriptions, references, and threshold parameters used to analyze HSPP.

Table 6 shows the regions of the full-length nucleotide sequences of HSPP to which cDNA fragments of Table 1 correspond.

10

## **DESCRIPTION OF THE INVENTION**

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

#### **DEFINITIONS**

"HSPP" refers to the amino acid sequences of substantially purified HSPP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to HSPP, increases or prolongs the duration of the effect of HSPP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of HSPP.

An "allelic variant" is an alternative form of the gene encoding HSPP. Allelic

variants may result from at least one mutation in the nucleic acid sequence and may result
in altered mRNAs or in polypeptides whose structure or function may or may not be
altered. Any given natural or recombinant gene may have none, one, or many allelic
forms. Common mutational changes which give rise to allelic variants are generally
ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these
types of changes may occur alone, or in combination with the others, one or more times in
a given sequence.

"Altered" nucleic acid sequences encoding HSPP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as HSPP or a polypeptide with at least one functional characteristic of HSPP.

Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HSPP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HSPP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HSPP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of HSPP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine,

isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of HSPP which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of HSPP. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

15

The term "antagonist" refers to a molecule which, when bound to HSPP, decreases the amount or the duration of the effect of the biological or immunological activity of HSPP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of HSPP.

The term "antibody" refers to intact molecules as well as to fragments thereof, such 20 as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind HSPP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete

with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence.

5 Antisense molecules may be produced by any method including synthesis or transcription.

Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic HSPP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

10

15

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding HSPP or fragments of HSPP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

PCT/US99/14484 WO 00/00610

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW Fragment Assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding HSPP, by northern analysis is indicative of the presence of nucleic acids encoding HSPP in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding HSPP.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

15

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is ane modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an 25 identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the 30 binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require

that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences 10 according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of 15 sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) Methods Enzymol. 183:626-645.) Identity between sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary

bases. A hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have 5 been fixed).

The words "insertion" or "addition" refer to changes in an amino acid or nucleotide ... sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, 10 immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" or "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

15

20

The term "modulate" refers to a change in the activity of HSPP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of HSPP.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers 25 to those nucleic acid sequences which, comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:135-268, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:135-268 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:135-268 from related polynucleotide sequences. A fragment of 30 SEQ ID NO:135-268 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:135-268 and the region of SEQ ID NO:135-268 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based

on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" or "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding HSPP, or fragments thereof, or HSPP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the

presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

15

30

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

20 "Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of HSPP polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g.,

replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to HSPP. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants.

10 A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state,

#### THE INVENTION

The invention is based on the discovery of new human signal peptide-containing proteins (HSPP), the polynucleotides encoding HSPP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative disorders including cancer; inflammation; and cardiovascular, neurological, reproductive, and developmental disorders.

Table 1 lists the Incyte Clones used to derive full length nucleotide sequences encoding HSPP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NO) of the amino acid and nucleic acid sequences, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each HSPP were identified, and column 4, the cDNA libraries from which these clones were isolated. Column 5

shows Incyte clones, their corresponding cDNA libraries, and shotgun sequences. The clones and shotgun sequences are part of the consensus nucleotide sequence of each HSPP and are useful as fragments in hybridization technologies.

Table 6 shows the regions of the full-length nucleotide sequences of HSPP to which cDNA fragments of Table 1 correspond. Column 1 lists nucleotide sequence identifiers and column 2 shows the clone ID of the Incyte clone in which nucleic acids encoding each HSPP were identified. Column 3 shows Incyte clones and shotgun sequences which are part of the consensus nucleotide sequence of each HSPP and are useful as fragments in hybridization technologies. Column 4 lists the starting nucleotide position and column 5 the ending nucleotide position of the region of the full-length HSPP to which the cDNA fragment corresponds.

The columns of Table 2 show various properties of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3, potential phosphorylation sites; column 4, 15 potential glycosylation sites; column 5, the amino acid residues comprising signature sequences and motifs; column 6, the identity of each protein; and column 7, analytical methods used to identify each HSPP as a signal peptide-containing protein. Note that in column 5, the first line of each cell lists the amino acid residues comprising predicted signal peptide sequences. Additional identifying motifs or signatures are also listed in column 5. Of particular note is the presence of a glycosyl hydrolase family 9 active site signature in SEQ ID NO:126, a ribosomal protein S18 signature in SEQ ID NO:127, an adrenodoxin family iron-sulfur binding region signature and a cytochrome c family hemebinding site signature in SEQ ID NO:132, and a urotensin II signature sequence in SEQ ID NO:96.

Using BLAST, SEQ ID NO:68 (HSPP-68) has been identified as a TWIK-related acid-sensitive K+ channel, and SEQ ID NO:92 (HSPP-92) has been identified as a tyrosine-specific protein phosphatases. The tyrosine-specific protein phosphatases signature in SEQ ID NO:92 (HSPP-92) from about V328 through about F340 (including the putative active site cysteine residue at C330) was identified using BLOCKS and 30 PRINTS. Also of note is the identification of SEQ ID NO:66 (HSPP-66) as a steroid binding protein using BLAST.

25

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding HSPP. The first column of Table 3 lists the nucleotide sequence identifiers. The second column lists tissue categories which express HSPP as a fraction of total tissue categories expressing HSPP. The third 5 column lists the diseases, disorders, or conditions associated with those tissues expressing HSPP. The fourth column lists the vectors used to subclone the cDNA library. Of particular note is the expression of SEQ ID NO:200, SEQ ID NO:203, and SEQ ID NO:225 in lung tissues; the expression of SEQ ID NO:212, SEQ ID NO:216, and SEQ ID NO:220 in reproductive tissues; the expression of SEQ ID NO:223 in cancerous tissues; the expression of SEQ ID NO:232 in gastrointestinal tissue, specifically the small intestine or colon (fifteen out of sixteen (93.8%) cDNA libraries); and the expression of SEO ID NO:224 in cancerous and proliferating tissues. Also of particular interest is the tissuespecific expression of SEQ ID NO:252 and SEQ ID NO:257. SEQ ID NO:252 is derived from OVARTUT01, an ovarian tumor cDNA library and is exclusively expressed in 15 reproductive tumor tissue. SEQ ID NO:257 is derived from THP1AZT01, a 5-aza-2'-deoxycytidine treated human promonocyte cDNA library and is exclusively expressed in hematopoietic tissue.

The following fragments of the nucleotide sequences encoding HSPP are useful in hybridization or amplification technologies to identify SEQ ID NO:135-268 and to distinguish between SEQ ID NO:135-268 and related polynucleotide sequences. The useful fragments are the fragment of SEQ ID NO:230 from about nucleotide 75 to about nucleotide 104; the fragment of SEQ ID NO:231 from about nucleotide 210 to about nucleotide 239; the fragment of SEQ ID NO:232 from about nucleotide 157 to about nucleotide 186; the fragment of SEQ ID NO:233 from about nucleotide 268 to about nucleotide 297; the fragment of SEQ ID NO:234 from about nucleotide 160 to about nucleotide 186; the fragment of SEQ ID NO:235 from about nucleotide 201 to about nucleotide 230; the fragment of SEQ ID NO:236 from about nucleotide 165 to about nucleotide 194; the fragment of SEQ ID NO:237 from about nucleotide 366 to about nucleotide 395; the fragment of SEQ ID NO:238 from about nucleotide 714 to about nucleotide 743; the fragment of SEQ ID NO:239 from about nucleotide 1731 to about nucleotide 1760; the fragment of SEQ ID NO:240 from about nucleotide 419 to about nucleotide 448; the fragment of SEQ ID NO:241 from about nucleotide 494 to about

nucleotide 523; the fragment of SEQ ID NO:242 from about nucleotide 100 to about nucleotide 129; the fragment of SEQ ID NO:243 from about nucleotide 104 to about nucleotide 133; the fragment of SEQ ID NO:244 from about nucleotide 136 to about nucleotide 165; the fragment of SEQ ID NO:245 from about nucleotide 140 to about nucleotide 169; the fragment of SEQ ID NO:246 from about nucleotide 125 to about nucleotide 154; the fragment of SEQ ID NO:247 from about nucleotide 687 to about nucleotide 758; the fragment of SEQ ID NO:248 from about nucleotide 327 to about nucleotide 398; the fragment of SEQ ID NO:249 from about nucleotide 741 to about nucleotide 785; the fragment of SEQ ID NO:250 from about nucleotide 184 to about nucleotide 255; the fragment of SEQ ID NO:251 from about nucleotide 165 to about nucleotide 242; the fragment of SEQ ID NO:252 from about nucleotide 271 to about nucleotide 342; the fragment of SEQ ID NO:253 from about nucleotide 1081 to about nucleotide 1152; the fragment of SEQ ID NO:254 from about nucleotide 781 to about nucleotide 852; the fragment of SEQ ID NO:255 from about nucleotide 620 to about nucleotide 691; the fragment of SEQ ID NO:256 from about nucleotide 872 to about nucleotide 916; the fragment of SEQ ID NO:257 from about nucleotide 242 to about nucleotide 313; the fragment of SEQ ID NO:258 from about nucleotide 595 to about nucleotide 648; the fragment of SEQ ID NO:259 from about nucleotide 163 to about nucleotide 216; the fragment of SEQ ID NO:260 from about nucleotide 244 to about nucleotide 315; the fragment of SEQ ID NO:261 from about nucleotide 75 to about nucleotide 128; the fragment of SEQ ID NO:262 from about nucleotide 650 to about nucleotide 703; the fragment of SEQ ID NO:263 from about nucleotide 143 to about nucleotide 214; the fragment of SEQ ID NO:264 from about nucleotide 434 to about nucleotide 487; the fragment of SEQ ID NO:265 from about nucleotide 218 to about 25 nucleotide 271; the fragment of SEQ ID NO:266 from about nucleotide 89 to about nucleotide 145; the fragment of SEQ ID NO:267 from about nucleotide 198 to about nucleotide 254; and the fragment of SEQ ID NO:268 from about nucleotide 10 to about nucleotide 54.

The invention also encompasses HSPP variants. A preferred HSPP variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the HSPP amino acid sequence, and which contains at least one functional or structural characteristic of HSPP.

The invention also encompasses polynucleotides which encode HSPP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:135-268, which encodes HSPP.

5

15

The invention also encompasses a variant of a polynucleotide sequence encoding HSPP. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding HSPP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:135-268 which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:135-268. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of HSPP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding HSPP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring HSPP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HSPP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HSPP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HSPP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HSPP and its derivatives without altering the encoded amino acid sequences include the

production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode
HSPP and HSPP derivatives, or fragments thereof, entirely by synthetic chemistry. After
production, the synthetic sequence may be inserted into any of the many available
expression vectors and cell systems using reagents well known in the art. Moreover,
synthetic chemistry may be used to introduce mutations into a sequence encoding HSPP or
any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable 10 of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:135-268 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably 15 less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily 20 include temperatures of at least about 30°C; more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as 25 needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200  $\mu$ g/ml ssDNA. Useful variations on these conditions will be

readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

15 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading 20 exemucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the Hamilton MICROLAB 2200 (Hamilton, Reno NV), Peltier Thermal Cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using either ABI 373 or 377 DNA 25 sequencing systems (Perkin-Elmer) or the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA). The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding HSPP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect

upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-306).

Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to

15 Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g.,

GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HSPP may be cloned in recombinant DNA molecules that direct expression of HSPP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express HSPP.

5

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HSPP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding HSPP may be synthesized, in whole or impart, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, HSPP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.)

Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of HSPP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g, Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid

analysis or by sequencing. (See, e.g., Creighton, T. (1984) <u>Proteins, Structures and Molecular Properties</u>, WH Freeman, New York NY.)

In order to express a biologically active HSPP, the nucleotide sequences encoding HSPP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding HSPP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HSPP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding HSPP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding 15 sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HSPP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding HSPP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral

expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected

depending upon the use intended for polynucleotide sequences encoding HSPP. For
example, routine cloning, subcloning, and propagation of polynucleotide sequences
encoding HSPP can be achieved using a multifunctional <u>E. coli</u> vector such as

PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies).

Ligation of sequences encoding HSPP into the vector's multiple cloning site disrupts the

lacZ gene, allowing a colorimetric screening procedure for identification of transformed
bacteria containing recombinant molecules. In addition, these vectors may be useful for <u>in</u>
vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and
creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.
Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of HSPP are

needed, e.g. for the production of antibodies, vectors which direct high level expression of
HSPP may be used. For example, vectors containing the strong, inducible T5 or T7
bacteriophage promoter may be used.

Yeast expression systems may be used for production of HSPP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast <u>Saccharomyces cerevisiae</u> or <u>Pichia pastoris</u>. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, <u>supra;</u> Grant et al. (1987) Methods Enzymol. 153:516-54; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

25

Plant systems may also be used for expression of HSPP. Transcription of sequences encoding HSPP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated

transfection. (See, e.g., <u>The McGraw Hill Yearbook of Science and Technology</u> (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HSPP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses HSPP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods

(liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of HSPP in cell lines is preferred. For example, sequences encoding HSPP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr*<sup>-</sup> cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to

the aminoglycosides, neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding HSPP is inserted within a marker gene sequence, transformed cells containing sequences encoding HSPP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HSPP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding HSPP and that express HSPP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of HSPP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HSPP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al.

(1990) <u>Serological Methods</u>, a <u>Laboratory Manual</u>, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) <u>Current Protocols in Immunology</u>, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) <u>Immunochemical Protocols</u>, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HSPP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HSPP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HSPP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HSPP may be designed to contain signal sequences which direct secretion of HSPP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK,

HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Manassas, VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HSPP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric HSPP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of HSPP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, cmyc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the HSPP encoding sequence and the heterologous protein sequence, so that 20 HSPP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled HSPP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably <sup>35</sup>S-methionine.

Fragments of HSPP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, <u>supra</u>, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide

Synthesizer (Perkin-Elmer). Various fragments of HSPP may be synthesized separately and then combined to produce the full length molecule.

## **THERAPEUTICS**

5 Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of HSPP and signal peptide sequences. In addition, chemical and structural similarity, in the context of sequences and motifs, exists between HSPP-66 and prostatic steriod-binding C3 precursor from rat (GI 206453); between HSPP-68 and TWIK-related acid-sensitive K+channel from human (GI 2465542); and between HSPP-92 10 and tyrosine specific protein phosphatases (PROSITE PDOC00323). In addition, the expression of HSPP is closely associated with proliferative, cancerous, inflamed, cardiovascular, nervous, reproductive. hematopoietic/immune, and developmental tissue. Therefore, HSPP appears to play a role in cell proliferative disorders including cancer; inflammation; and cardiovascular, 15 neurological, reproductive, and developmental disorders. In the treatment of cell proliferative disorders including cancer; inflammation; and cardiovascular, neurological, reproductive, and developmental disorders associated with increased HSPP expression or activity, it is desirable to decrease the expression or activity of HSPP. In the treatment of the above conditions associated with decreased HSPP expression or activity, it is desirable 20 to increase the expression or activity of HSPP.

Therefore, in one embodiment, HSPP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSPP. Examples of such disorders include, but are not limited to, cell proliferative disorders such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia,

30 gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus;

inflammatory disorders, such as acquired immunodeficiency syndrome (AIDS), Addison's

disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyenodocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; cardiovascular disorders including disorders of the blood vessels such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, and vascular tumors; disorders of the heart such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve 20 stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, and congenital heart disease; and disorders of the lungs such as congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse

\*\*\*

30 interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary

hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, and pleural tumors; neurological disorders such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, 20 anxiety; and schizophrenic disorders; akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; reproductive disorders such as disorders of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis; disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian 25 hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis; cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, carcinoma of the male breast, and gynecomastia; and developmental disorders, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis,

WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental

retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss.

In another embodiment, a vector capable of expressing HSPP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSPP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified HSPP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSPP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of HSPP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSPP including, but not limited to, those listed above.

15

In a further embodiment, an antagonist of HSPP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of HSPP. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds HSPP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HSPP.

In an additional embodiment, a vector expressing the complement of the

25 polynucleotide encoding HSPP may be administered to a subject to treat or prevent a
disorder associated with increased expression or activity of HSPP including, but not
limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act

synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of HSPP may be produced using methods which are generally known in the art. In particular, purified HSPP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HSPP. Antibodies to HSPP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with HSPP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium paryum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to HSPP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HSPP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to HSPP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42;

Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.)

Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HSPP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:10134-10137.)

Antibodies may also be produced by inducing <u>in vivo</u> production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for HSPP may also be generated. For example, such fragments include, but are not limited to, F(ab')2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the
desired specificity. Numerous protocols for competitive binding or immunoradiometric
assays using either polyclonal or monoclonal antibodies with established specificities are
well known in the art. Such immunoassays typically involve the measurement of complex
formation between HSPP and its specific antibody. A two-site, monoclonal-based
immunoassay utilizing monoclonal antibodies reactive to two non-interfering HSPP
epitopes is preferred, but a competitive binding assay may also be employed (Pound,
supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for HSPP. Affinity is expressed as an association constant, K<sub>a</sub>, which is defined as the molar concentration of HSPP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K<sub>a</sub> determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple HSPP epitopes, represents the average affinity, or avidity, of the antibodies for HSPP. The K<sub>a</sub> determined for a preparation of monoclonal antibodies, which are monospecific for a particular HSPP epitope, represents a true measure of affinity. Highaffinity antibody preparations with K<sub>a</sub> ranging from about 10° to 10<sup>12</sup> L/mole are preferred for use in immunoassays in which the HSPP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K<sub>a</sub> ranging from about 10<sup>6</sup> to 10<sup>7</sup> L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of HSPP, preferably in active form, from the antibody 15 (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of HSPP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding HSPP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding HSPP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HSPP. Thus, complementary molecules or fragments may be used to modulate HSPP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and

sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding HSPP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding HSPP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding HSPP can be turned off by transforming a cell or tissue with

expression vectors which express high levels of a polynucleotide, or fragment thereof,
encoding HSPP. Such constructs may be used to introduce untranslatable sense or
antisense sequences into a cell. Even in the absence of integration into the DNA, such
vectors may continue to transcribe RNA molecules until they are disabled by endogenous
nucleases. Transient expression may last for a month or more with a non-replicating
vector, and may last even longer if appropriate replication elements are part of the vector
system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding HSPP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by

endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HSPP.

Specific ribozyme cleavage sites within any potential RNA target are initially

identified by scanning the target molecule for ribozyme cleavage sites, including the
following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of
between 15 and 20 ribonucleotides, corresponding to the region of the target gene
containing the cleavage site, may be evaluated for secondary structural features which may
render the oligonucleotide inoperable. The suitability of candidate targets may also be
evaluated by testing accessibility to hybridization with complementary oligonucleotides
using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules.

These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HSPP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell

RNA molecules may be modified to increase intracellular stability and half-life.

Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and
equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or

by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HSPP, antibodies to HSPP, and mimetics, agonists, antagonists, or inhibitors of HSPP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

15

25

30

In addition to the active ingredients, these pharmaceutical compositions may 200 contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be

added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules

made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as
glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or
binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and,
optionally, stabilizers. In soft capsules, the active compounds may be dissolved or
suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with
or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HSPP, such labeling would include amount, frequency, and method of administration.

15

Pharmaceutical compositions suitable for use in the invention include compositions
wherein the active ingredients are contained in an effective amount to achieve the intended
purpose. The determination of an effective dose is well within the capability of those
skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HSPP or fragments thereof, antibodies of HSPP, and agonists, antagonists or inhibitors of HSPP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED<sub>50</sub> (the dose therapeutically



effective in 50% of the population) or LD<sub>50</sub> (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the LD<sub>50</sub>/ED<sub>50</sub> ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about  $0.1~\mu g$  to  $100,000~\mu g$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

### 25 DIAGNOSTICS

In another embodiment, antibodies which specifically bind HSPP may be used for the diagnosis of disorders characterized by expression of HSPP, or in assays to monitor patients being treated with HSPP or agonists, antagonists, or inhibitors of HSPP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for HSPP include methods which utilize the antibody and a label to detect HSPP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled

by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring HSPP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of HSPP expression. Normal or standard values for HSPP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HSPP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of HSPP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HSPP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HSPP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of HSPP, and to monitor regulation of HSPP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting

20 polynucleotide sequences, including genomic sequences, encoding HSPP or closely
related molecules may be used to identify nucleic acid sequences which encode HSPP.

The specificity of the probe, whether it is made from a highly specific region, e.g., the 5'
regulatory region, or from a less specific region, e.g., a conserved motif, and the
stringency of the hybridization or amplification (maximal, high, intermediate, or low), will

determine whether the probe identifies only naturally occurring sequences encoding
HSPP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the HSPP encoding sequences.

The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:135-268 or from genomic sequences including promoters, enhancers, and introns of the HSPP gene.

Means for producing specific hybridization probes for DNAs encoding HSPP include the cloning of polynucleotide sequences encoding HSPP or HSPP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as <sup>32</sup>P or <sup>35</sup>S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HSPP may be used for the diagnosis of disorders associated with expression of HSPP. Examples of such disorders include, but are not limited to, cell proliferative disorders such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; inflammatory disorders, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyenodocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with 25 lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic,

protozoal, and helminthic infections, and trauma; cardiovascular disorders including disorders of the blood vessels such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, and vascular tumors; disorders of the heart such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, and congenital heart disease; and disorders of the lungs such as congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, 15 emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary 20 hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, and pleural tumors; neurological disorders such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, 25 dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous 30 system disease; prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia, nutritional and metabolic diseases

of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal

hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis; inherited, metabolic, endocrine, and toxic myopathies; myasthenia gravis, periodic paralysis; mental disorders including mood, anxiety, and schizophrenic disorders; akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; reproductive disorders such as disorders of prolactin production; infertility, including tubal disease, ovulatory defects, and endometriosis; disruptions of the estrous cycle, disruptions of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometrial and ovarian tumors, uterine fibroids, autoimmune disorders, ectopic pregnancies, and teratogenesis: cancer of the breast, fibrocystic breast disease, and galactorrhea; disruptions of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, carcinoma of the male breast, and gynecomastia; and developmental disorders, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary 20 mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss. The polynucleotide sequences encoding HSPP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered HSPP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HSPP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding HSPP may be labeled by standard methods and added

30

to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding HSPP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with

expression of HSPP, a normal or standard profile for expression is established. This may
be accomplished by combining body fluids or cell extracts taken from normal subjects,
either animal or human, with a sequence, or a fragment thereof, encoding HSPP, under
conditions suitable for hybridization or amplification. Standard hybridization may be
quantified by comparing the values obtained from normal subjects with values from an
experiment in which a known amount of a substantially purified polynucleotide is used.
Standard values obtained in this manner may be compared with values obtained from
samples from patients who are symptomatic for a disorder. Deviation from standard
values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding HSPP may involve the use of PCR. These oligomers may be chemically

synthesized, generated enzymatically, or produced <u>in vitro</u>. Oligomers will preferably contain a fragment of a polynucleotide encoding HSPP, or a fragment of a polynucleotide complementary to the polynucleotide encoding HSPP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HSPP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of
the polynucleotide sequences described herein may be used as targets in a microarray. The
microarray can be used to monitor the expression level of large numbers of genes
simultaneously and to identify genetic variants, mutations, and polymorphisms. This
information may be used to determine gene function, to understand the genetic basis of a
disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding HSPP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries.

(See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding HSPP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, HSPP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between HSPP and the agent being tested may be measured.

25

30

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen,

et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with HSPP, or fragments thereof, and washed. Bound HSPP is then detected by methods well known in the art. Purified HSPP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HSPP specifically compete with a test compound for binding HSPP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HSPP.

In additional embodiments, the nucleotide sequences which encode HSPP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all applications, patents, and publications, mentioned above and below, in particular US Ser. No. 60/090,762, US Ser. No. 60/094,983, US Ser. No. 60/102,686, and US Ser. No. 60/112,129, are hereby expressly incorporated by reference.

#### **EXAMPLES**

## 25 I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4.

Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate 15 restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), pSPORT1 20 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5a, DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids were recovered from host cells by <u>in vivo</u> excision, using the UNIZAP vector system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a MAGIC or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the REAL Prep 96 plasmid kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

## III. Sequencing and Analysis

The cDNAs were prepared for sequencing using the ABI CATALYST 800

(Perkin-Elmer) or the HYDRA microdispenser (Robbins Scientific) or MICROLAB 2200

(Hamilton) systems in combination with the PTC-200 thermal cyclers (MJ Research). The cDNAs were sequenced using the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) and standard ABI protocols, base calling software, and kits. In one alternative, cDNAs were sequenced using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics). In another alternative, the cDNAs were amplified and sequenced using the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). In yet another alternative, cDNAs were sequenced using solutions and dyes from Amersham Pharmacia Biotech. Reading frames for the ESTs were determined using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA, extension, and shotgun sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the software programs, descriptions, references, and threshold parameters used. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides a brief description thereof, the third column presents the references which are incorporated by reference herein, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the probability the greater the homology). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based

on BLAST, dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation, using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probalistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Cur. Opin. Str. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:135-268. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

# IV. Northern Analysis

20,

30

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

% sequence identity x % maximum BLAST score

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding HSPP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

# V. Extension of HSPP Encoding Polynucleotides

Full length nucleic acid sequences of SEQ ID NOs:135-229 were produced by extension of the component fragments described in Table 1, column 5, using oligonucleotide primers based on these fragments. For each nucleic acid sequence, one primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO<sup>TM</sup> 4.06 (National Biosciences, Plymouth, MN), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (GIBCO BRL) were used to extend the sequence.

If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR<sup>TM</sup> kit (The Perkin-Elmer Corp., Norwalk, CT) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the PTC-200 thermal cycler (MJ Research, Inc., Watertown, MA), beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
10	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
	Step 7	Repeat steps 4 through 6 for an additional 15 cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
15	Step 10	68° C for 7:15 min
	Step 11	Repeat steps 8 through 10 for an additional 12 cycles
	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQUICK<sup>TM</sup> (QIAGEN Inc.), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13  $\mu$ l of ligation buffer,  $1\mu$ l T4-DNA ligase (15 units) and  $1\mu$ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent E. coli cells (in 40  $\mu$ l of appropriate media) were transformed with 3  $\mu$ l of ligation mixture and cultured in 80  $\mu$ l of SOC medium. (See, e.g., Sambrook, supra,

- Appendix A, p. 2.) After incubation for one hour at 37°C, the <u>E. coli</u> mixture was plated on Luria Bertani (LB) agar (See, e.g., Sambrook, <u>supra</u>, Appendix A, p. 1) containing carbenicillin (2x carb). The following day, several colonies were randomly picked from each plate and cultured in 150 μl of liquid LB/2x carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The
- following day, 5  $\mu$ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5  $\mu$ l from each sample was transferred into a PCR array.

For PCR amplification, 18  $\mu$ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

5	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2 through 4 for an additional 29 cycles
10	Step 6	72° C for 180 sec
	Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

The full length nucleic acid sequences of SEQ ID NO:230-268 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

25

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg<sup>2+</sup>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as



follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl pICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells: Transformed cells were selected on antibiotic containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:135-268 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

# 5 VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:135-268 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba1, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the blots to film for several hours, hybridization patterns are compared visually.

## 25 VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, <u>supra.</u>) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of

complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

## VIII. Complementary Polynucleotides

Sequences complementary to the HSPP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring HSPP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of HSPP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the HSPP-encoding transcript.

# 25 IX. Expression of HSPP

15

Expression and purification of HSPP is achieved using bacterial or virus-based expression systems. For expression of HSPP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria

express HSPP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG).

Expression of HSPP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding HSPP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, HSPP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from HSPP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification

20 Vising commercially available monoclonal and polyclonial anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified HSPP obtained by these methods can be used directly in the following activity assay.

25

30

# X. Demonstration of HSPP Activity HSPP-68

HSPP-68 activity is measured by determining the potassium current using voltage clamp analysis on single <u>Xenopus laevis</u> oocytes injected with HSPP-68 cRNA. HSPP-68 cRNA is synthesized <u>in vitro</u> from linearized HSPP-68 encoding plasmids using the T7

RNA polymerase and injected into oocytes.. Injected oocytes are used two to four days after injection. In a 0.3 ml perfusion chamber, a single oocyte is impaled with two standard microelectrodes (1-2.5 MΩ) filled with 3 M KCl. The oocyte is maintained under voltage clamp by using a Dagan TEV 200 amplifier, in buffer containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 5 mM HEPES, pH 7.4 with NaOH. Stimulation of the preparation, data acquisition, and analysis is performed using a computer. All experiments are performed at room temperature (21-22 °C). Following a depolarizing pulse, the characteristics of the resulting potassium current are measured via the recording electrode. The amount of potassium current that flows in response to a unit depolarization is proportional to the activity of HSPP-68 in the cell. (Duprat, F. et al. (1997) EMBO J. 16:5464-5471.)

#### HSPP-92

HSPP-92 protein phosphatase activity is measured by the hydrolysis of P-nitrophenyl phosphate (PNPP). HSPP-92 is incubated together with PNPP in HEPES buffer pH 7.5, in the presence of 0.1% b-mercaptoethanol at 37°C for 60 min. The reaction is stopped by the addition of 6 ml of 10 N NaOH and the increase in light absorbance at 410 nm resulting from the hydrolysis of PNPP is measured using a spectrophotometer. The increase in light absorbance is proportional to the activity of PP in the assay. (Diamond R.H. et al (1994) Mol Cell Biol 14:3752-62.)

Alternatively, HSPP, or biologically active fragments thereof, are labeled with <sup>133</sup>1

Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HSPP, washed, and any wells with labeled HSPP complex are assayed. Data obtained using different concentrations of HSPP are used to calculate values for the number, affinity, and association of HSPP with the candidate molecules.

Alternatively, an assay for HSPP activity measures the expression of HSPP on the cell surface. cDNA encoding HSPP is subcloned into an appropriate mammalian expression vector suitable for high levels of cDNA expression. The resulting construct is transfected into a nonhuman cell line such as NIH3T3. Cell surface proteins are labeled with biotin using methods known in the art. Immunoprecipitations are performed using HSPP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to

unlabeled immunoprecipitant is proportional to the amount of HSPP expressed on the cell surface.

Alternatively, an assay for HSPP activity measures the amount of HSPP in secretory, membrane-bound organelles. Transfected cells as described above are harvested and lysed. The lysate is fractionated using methods known to those of skill in the art, for example, sucrose gradient ultracentrifugation. Such methods allow the isolation of subcellular components such as the Golgi apparatus, ER, small membrane-bound vesicles, and other secretory organelles. Immunoprecipitations from fractionated and total cell lysates are performed using HSPP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The concentration of HSPP in secretory organelles relative to HSPP in total cell lysate is proportional to the amount of HSPP in transit through the secretory pathway.

#### XI. Functional Assays

HSPP function is assessed by expressing the sequences encoding HSPP at 15 physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, preferably 20 of critothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent 25 Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP, and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as 30 measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in

expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of HSPP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding HSPP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding HSPP and other genes of interest can be analyzed by northern analysis or microarray techniques.

#### 15 XII. Production of HSPP Specific Antibodies

HSPP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

20 Alternatively; the HSPP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A Peptide Synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, <a href="mailto:supra">supra</a>.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic,

blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG.

#### XIII. Purification of Naturally Occurring HSPP Using Specific Antibodies

Naturally occurring or recombinant HSPP is substantially purified by

5 immunoaffinity chromatography using antibodies specific for HSPP. An immunoaffinity column is constructed by covalently coupling anti-HSPP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HSPP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HSPP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HSPP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HSPP is collected.

#### 5 XIV. Identification of Molecules Which Interact with HSPP

10

HSPP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HSPP, washed, and any wells with labeled HSPP complex are assayed. Data 20 cohtained using different concentrations of HSPP are used to calculate values for the number, affinity, and association of HSPP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

#### **FABLE**

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library -	Fragments
-	135	443531	MPHGNOT03	443531H1 (MPHGNOT03), 1406807F6 (LATRTUT02), 443531T6 (MPHGNOT03), SBBA00451F1, SBBA00676F1
2	136	632860	NEUTGMTOI	632860H1 (NEUTGMT01), 784715R3 (PROSNOT05), 509590H1 (MPHGNOT03)
m	137	670010	CRBLNOTO	670010H1 (CRBLNOT01), 669971R1 (CRBLNOT01), 1553045F1 (BLADTUT04)
4	138	726498	SYNOOATO	726498H1 (SYNOOAT01), 726498R6 (SYNOOAT01), 866599R3 (BRAITUT03)
۶	139	795064	OVARNOT03	795064H1 (OVARNOT03), 4339458H1 (BRAUNOT02), 937605R3 (CERVNOT01), 2381151F6 (ISLTNOT01), 1466346F6 (PANCTUT02)
9	140	924925	BRAINOT04	924925H1 (BRAINOT04), 3268330H1 (BRAINOT20), 759120R3 (BRAITUT02)
7	141	962390	BRSTTUTO3	962390H1 (BRSTTUT03), 1907958F6 (CONNTUT01), 023569F1 (ADENINB01), 167282F1 (LIVRNOT01), 1309211F1 (COLNFET02), SAUA00696F1, SAUA02860F1
8	142	1259405	MENITUT03	1259405H1 (MENITUT03), 2472425H1 (THPINOT03), 774303R1 (COLNNOT05), 1520779F1 (BLADTUT04), 1693833F6 (COLNNOT23), 1831858T6.comp (THPIAZT01), 1527737T6.comp (UCMCL5T01)
6	143	1297384	BRSTNOT07	1297384HI (BRSTNOT07), 1269310F6 (BRAINOT09), 1457367FI (COLNFET02), 415587RI (BRSTNOT01), SANA02967FI
10	144	1299627	BRSTNOT07	1299627H1 (BRSTNOT07), 1359140F6 (LUNGNOT09), 1349224F1 (LATRTUT02), SBAA01431F1, SBAA02909F1, SBAA01156F1
=	145	1306026	PLACNOT02	1306026H1 (PLACNOT02), 1464088R6 (PANCNOT04), SBAA02496F1, SBAA04305F1
12	146	1316219	BLADTUT02	1316219H1 (BLADTUT02), 2458603F6 (ENDANOT01), 2504756T6 (CONUTUT01)
13	147	1329031	PANCNOT07	1329031H1 (PANCNOT07), 1329031T6 (PANCNOT07), 1329031F6 (PANCNOT07),

-75-

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
14	148	1483050	CORPNOT02	1483050H1 (CORPNOT02), 855049H1 (NGANNOT01), 077017F1 (SYNORAB01), 1483050F6 (CORPNOT02), 1480024T6 (CORPNOT02), 1483050T6 (CORPNOT02), 759486R1 (BRAITUT02)
15	671	1514160	PANCTUT01	1514160H1 (PANCTUT01), 1866765T7 (SKINBIT01), 782676R1 (MYOMNOT01), 008055X4 (HMC1NOT01), 008055X5 (HMC1NOT01), 1866765F6 (SKINBIT01), SAOA03127F1
91	051	1603403	FUNDNOTIS	1603403H1 (LUNGNOT15), 372910F1 (LUNGNOT02), 733299R7 (LUNGNOT03)
17	151	1652303	PROSTUT08	1652303HI (PROSTUT08), 1671806HI (BLADNOT05), 1341743TI (COLNTUT03), 3803812HI (BLADTUT03), 1878546F6 (LEUKNOT03), 1428640FI (SINTBST01), 2058609R6 (OVARNOT03), 1331621FI (PANCNOT07), 1306331TI (PLACNOT02)
18	152	1693358	COLNNOT23	1693358H1 (COLNNOT23), 2498265H1 (ADRETUT05), 1867125F6 (SKINBIT01), 1693358T6 (COLNNOT23), 2245848R6 (HIPONON02)
19	153	1707711	DUODNOT02	1707711H1 (DUODNOT02), 1484609T1 (CORPNOT02), 1707711F6 (DUODNOT02), 1267959F1 (BRAINOT09), 1484609F1 (CORPNOT02), SAJA00930F1, SAJA01300R1, SAJA00999R1
20	154	1738735	COLNNOT22	1738735H1 (COLNNOT22), SAJA00944R1, SAJA00137F1, SAJA03629F1
21	155	1749147	STOMTUT02	1749147H1 (STOMTUT02), 1749147F6 (STOMTUT02), 1749147T6 (STOMTUT02)
22	156	1817722	PROSNOT20	1817722H1 (PROSNOT20), 2011085H1 (TESTNOT03)
23	157	1831290	THPIAZT01	1831290H1 (THPIAZT01), 3473958H1 (LUNGNOT27), 1972268F6 (UCMCL5T01), 1301277F1 (BRSTNOT07), 1521574F1 (BLADTUT04), 1561690T6 (SPLNNOT04), 891461R1 (STOMTUT01)

<del>-</del>76-

#### TABLE 1 (cont.

	0.50	<u> </u>	<u> </u>	<del></del>	<del></del>		·	Ī	Ī	<del> </del>	T
Fragments	1831477H1 (THP1AZT01), 1582867H1 (DUODNOT01), 1336769T1 (COLNNOT13), 1933092H1 (COLNNOT16), 1519909F1 (BLADTUT04), 1220946H1 (NEUTGMT01), 809556T1 (LUNGNOT04), 1217559T1 (NEUTGMT01), 1309225F1 (COLNFET02)	1841607H1 (COLNNOT07), SBHA03588F1	1852391H1 (LUNGFET03), 734140H1 (TONSNOT01), 1852391F6 (LUNGFET03)	1854555H1 (HNT3AZT01), 2511711H1 (CONUTUT01), 782453R1 (MYOMNOT01), 1854555F6 (HNT3AZT01), 1840675T6 (COLNNOT07), 2109736H1 (BRAITUT03)	1855755H1 (PROSNOT18), 3040236H1 (BRSTNOT16), 1283207F1 (COLNNOT16), 833763T1 (PROSNOT07), 1920926R6 (BRSTTUT01)	1861434H1 (PROSNOT19), 980291R1 (TONGTUT01), 1861434T6 (PROSNOT19), SARA01525F1, SARA02548F1	1872334H1 (LEUKNOT02), 1872334F6 (LEUKNOT02), SBGA03684F1	1877230H1 (LEUKNOT03), 2519841H1 (BRAITUT21), 1877230T6 (LEUKNOT03), 1254693F1 (LUNGFET03), 077020R1 (SYNORAB01), 1232336F1 (LUNGFET03), 1004952R6 (BRSTNOT03), SARA01879F1, SARA02654F1	1877885H1 (LEUKNOT03), 508020F1 (TMLR3DT01), 2751126R6 (THP1AZS08), SARA02571F1	1889269H1 (BLADTUT07), 1915551H1 (PROSTUT04), 629493X12 (KIDNNOT05), 1441289F1 (THYRNOT03), 1215274X34F1 (BRSTTUT01), 1818447F6 (PROSNOT20), 1208463R1 (BRSTNOT02)	1890243H1 (BLADTUT07), SARA01884F1, SATA00046F1, SARA03294F1, SARA02790F1
Library	THPIAZT0!	COLNNOT07	LUNGFET03	HNT3AZT01	PROSNOT18	PROSNOT19	LEUKNOT02	LEUKNOT03	LEUKNOT03	BLADTUT07	BLADTUT07
Clone ID	1831477	1841607	1852391	1854555	1855755	1861434	1872334	1877230	1877885	1889269	1890243
Nucleotide SEQ ID NO:	158	159	160	161	162	163	164	165	991	167	891
Protein SEQ ID NO:	24	25	26	. 27	28	29	30	31	32	33	34



#### **FABLE 1 (cont.**

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	. Clone ID	Library	Fragments
35	169	1900433	BLADTUT06	1900433H1 (BLADTUT06), SATA00396F1, SATA02742F1
36	170	1909441	CONNTUT01	1909441H1 (CONNTUTOI), 139881IF1 (BRAITUT08), 3039939H1 (BRSTNOT16), 3324740H1 (PTHYNOT03), 1442131F6 (THYRNOT03), 2254056H1 (OVARTUT01), 2199453T6 (SPLNFET02), 1692610F6 (COLNNOT23), 1698531H1 (BLADTUT05)
37	171	1932226	COLNNOT16	1932226H1 (COLNNOT16), 2320569H1 (OVARNOT02), 1932226F6 (COLNNOT16), 2469455T6 (THP1NOT03), 2469455F6 (THP1NOT03), 1907140F6 (OVARNOT07), SATA02592F1
38	172	1932647	COLNNOT16	1932647H1 (COLNNOT16), 1492745T1 (PROSNON01), 1492745H1 (PROSNON01), SASA02355F1, SASA00117F1, SASA00192F1
ee -78÷	173	2124245	BRSTNOT07	2124245H1 (BRSTNOT07), 1235393F1 (LUNGFET03), 1402264F6 (LATRTUT02), 1303990F1 (PLACNOT02), 1402264T6 (LATRTUT02)
40	174	2132626	OVARNOT03	2132626H1 (OVARNOT03), 1723432T6 (BLADNOT06), 2132626R6 (OVARNOT03), 1736723T6 (COLNNOT22), 1504738F1 (BRAITUT07)
41	175	2280639	PROSNON01	2280639H1 (PROSNON01), 1435330H1 (PANCNOT08), 1377560F6 (LUNGNOT10)
42	9/1	2292356	BRAINON01	2292356H1 (BRAINON01), 4086827H1 (LIVRNOT06), 1754442F6 (LIVRTUT01), 3571126H1 (HEAPNOT01), 1601305F6 (BLADNOT03)
43	177	2349310	COLSUCT01	2349310H1 (COLSUCT01), 2349310T6 (COLSUCT01)
44	178	2373227	ADRENOT07	2373227H1 (ADRENOT07), 331644H1 (PROSBPT03), 302685R6 (TESTNOT04), SASA02181F1, SASA01923F1, SASA03516F1
45	179	2457682	ENDANOT01	2457682H1 (ENDANOT01), 2457682F6 (ENDANOT01)
46	180	2480426	SMCANOTOI	2480426H1 (SMCANOT01), 2480426F6 (SMCANOT01)

#### [ABLE 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
47	181	2503743	CONUTUTO	2503743H1 (CONUTUT01), 1853909H1 (HNT3AZT01), 1517619F1 (PANCTUT01), 1467896F6 (PANCTUT02), 490031F1 (HNT2AGT01), 1208654R1 (BRSTNOT02), 880544R1 (THYRNOT02)
48	781	2537684	BONRTUTOI	2537684HI (BONRTUT01), 2005493HI (TESTNOT03), 730969HI (LUNGNOT03), 253760IF6 (BONRTUT01), 916487HI (BRSTNOT04), 996135RI (KIDNTUT01), 1920738R6 (BRSTTUT01), 1957710F6 (CONNNOT01)
. 49	183	2593853	OVARTUT02	2593853H1 (OVARTUT02), 807497H1 (STOMNOT02), 914020R6 (STOMNOT02), 889992R1 (STOMTUT01)
50	184	2622354	KERANOT02	2622354H1 (KERANOT02), 2623992H1 (KERANOT02), 1556510F6 (BLADTUT04)
15	185	2641377	FUNGTUTOR	2641377H1 (LUNGTUT08), 4341415H2 (BRAUNOT02), SBCA07049F3
25	981	2674857	KIDNNOTIŞ	2674857H1 (KIDNNOT19), 1872373H1 (LEUKNOT02), 470512R6 (MMLRIDT01), 1728547H1 (PROSNOT14), 3013651F6 (MUSCNOT07), SBCA01366F1, SBCA00694F1
83	187	2758485	THP1AZS08	2758485H1 (THP1AZS08), 3097533H1 (CERVNOT03), 1578959F6 (DUODNOT01)
54	188	2763296	BRSTNOTIZ	2763296H1 (BRSTNOT12), 3486025F6 (KIDNNOT31), SBDA07002F3
55	681	2779436	OVARTUT03.	2779436H1 (OYARTUT03), 2779436F6 (OVARTUT03), SBDA07009F3
56	061	2808528	BLADTUT08.	2808528H1 (BLADTUT08), 2611513F6 (THYMNOT04), SBDA07021T3
22	161	2809230	BLADTUT08	2809230H1 (BLADTUT08), 2213849H1 (SINTFET03), 711706R6 (SYNORAT04), 958323R1 (KIDNNOT05), 030732F1 (THP1NOB01)
28	192	2816821	BRSTNOT14	2816821H1 (BRSTNOT14), 3746964H1 (THYMNOT08), 2816821F6 (BRSTNOT14), 948722T6 (PANCNOT05), 807947R6 (STOMNOT02)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
59	193	2817268	BRSTNOTI	2817268H1 (BRSTNOT14), 3591308H1 (2937F5T01), 419522R1 (BRSTNOT01), 2073028F6 (ISLTNOT01), 1308781F6 (COLNFET02)
09	194	2923165	SININOT04	2923165H1 (SININOT04), 2011630H1 (TESTNOT03), 1457250F1 (COLNFET02), 754668R1 (BRAITUT02), 1406510F6 (LATRTUT02)
19	195	2949822	KIDNFET01	2949822H1 (KIDNFET01), SBDA07078F3
62	961	2992192	KIDNFET02	2992192H1 (KIDNFET02), 2534324H2 (BRAINOT18), 2815255T6 (OVARNOT10), 1551107T6 (PROSNOT06), 1551107R6 (PROSNOT06)
63	197	2992458	KIDNFET02	2992458H1 (KIDNFET02), 2618951H1 (GBLANOT01), 1479252F1 (CORPNOT02), 1879054H1 (LEUKNOT03), 1879054F6 (LEUKNOT03), 2215240H1 (SINTFET03), 1535968T1 (SPLNNOT04)
64	198	3044710	HEAANOT0!	3044710H1 (HEAANOT01), 3741773H1 (MENTNOT01), 859906X42C1 (BRAITUT03), 1534347F1 (SPLNNOT04), 1421122F1 (KIDNNOT09), 1303865F1 (PLACNOT02), 1704452F6 (DUODNOT02), 1251642F1 (LUNGFET03), 1781694R6 (PGANNON02)
65	661	3120415	LUNGTUTI3	3120415H1 (LUNGTUT13), 1360123T1 (LUNGNOT12), 1375015H1 (LUNGNOT10)
66	200	126758	LUNGNOT01	126758H1 (LUNGNOT01), 126758X11 (LUNGNOT01), 811864T1 (LUNGNOT04)
67	201	674760	CRBLNOT01	674760H1 (CRBLNOT01), 3253976H1 (OVARTUN01), SAUA03387F1
68	202	1229438	BRAITUT01	1229438H1 (BRAITUT01), 1230616H1 (BRAITUT01), 1461187R1 (PANCNOT04), 2493039H1 (ADRETUT05), 2891628H1 (LUNGFET04)
69	203	5269221	LUNGFET03	1236935H1 (LUNGFET03), SBAA00983F1, SBAA02057F1, SBAA00170F1
70	204	1359283	LUNGNOT12	1359283H1 (LUNGNOT12), SBAA01213F1, SBAA03934F1
71	205	1450703	PENITUT01	551298FI (BEPINOT01), 551298RI (BEPINOT01), 1450703HI (PENITUT01), 2748715HI (LUNGTUT11)



### FABLE 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone 1D	Library	Fragments
72	206	1910668	CONNTUTO	1269346H1 (BRAINOT09), 1380872F1 (BRAITUT08), 1910668F6 (CONNTUT01), 1910668H1 (CONNTUT01), SATA02800F1, SATA03799F1, SARA02035F1
73	207	1955143	CONNNOTO	1955143F6 (CONNNOT01), 1955143H1 (CONNNOT01)
74	208	1961637	BRSTNOT04	867025H1 (BRAITUT03), 1961637H1 (BRSTNOT04), 2809064T6 (BLADTUT08), 2938714H1 (THYMFET02), 2956402H1 (KIDNFET01), 3808735T6 (CONTTUT01)
75	209	7920661	CORPNOT02	1990762H1 (CORPNOT02), 1990762T3 (CORPNOT02), SBGA04911F1, SBGA01201F1, SBGA02205F1
76	210	1994131	CORPNOT02	1994131H1 (CORPNOT02), 2645984F6 (OVARTUT04)
77	211	1997745	BRSTTUT03	1752307F6 (LIVRTUT01), 1853730H1 (HNT3AZT01), 1997745H1 (BRSTTUT03), SAZA00953F1
78	212	2009035	TESTNOT03	2009035H1 (TESTNOT03), 2009035R6 (TESTNOT03)
- 62	213	2009152	TESTNOT03	2009152H1 (TESTNOT03), 2009152R6 (TESTNOT03), 2783263H1 (BRSTNOT13)
08	214	2061752	OVARNOT03	2061752H1 (OVARNOT03), 2061752T6 (OVARNOT03), 2732805H1 (OVARTUT04), SAZA01310F1, SAZA00830F1
81	215	2061933	OVARNOT03	046580R1 (CORNNOT01), 746061R1 (BRAITUT01), 826996R1 (PROSNOT06), 2061933H1 (OVARNOT03)
82	216	2081422	UTRSNOT08	2081422F6 (UTRSNOT08), 2081422H1 (UTRSNOT08), SBCA04793F1, SBCA05657F1, SBDA00065F1
83	217	2101278	BRAITUT02	2101278H1 (BRAITUT02), SAXA00399F1, SAXA01284F1, SAXA01227F1
84	218	2121353	BRSTNOT07	341437H1 (NEUTFMT01), 687136H1 (UTRSNOT02), 2121353H1 (BRSTNOT07), SASA01311F1

#### ABLE 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
85	219	2241736	PANCTUT02	833263H1 (PROSTUT04), 2241736H1 (PANCTUT02), SAZA01148F1, SASA03299F1, SASA01349F1
86	220	2271935	PROSNON0!	2271935H1 (PROSNON01), 2276774H1 (PROSNON01), 2760171T6 (THP1AZS08)
87	221	2295344	BRSTNOT05	2295344H1 (BRSTNOT05), 3288561F6 (BONRFET01), SBGA01801F1
88	222	2303994	BRSTNOT05	905482T1 (COLNNOT08), 1858636F6 (PROSNOT18), 2303994H1 (BRSTNOT05)
89	223	2497805	ADRETUT05	2497805F6 (ADRETUT05), 2497805H1 (ADRETUT05)
06	224	2646362	LUNGTUTII	1784702H1 (LIVRTUT01), 2640776T6 (LUNGTUT08), 2646362H1 (LUNGTUT11), 3356773H1 (PROSTUT16)
91	225	2657146	LUNGTUT09	2657146F6 (LUNGTUT09), 2657146H1 (LUNGTUT09)
92	226	2755786	THP1AZS08	288436R1 (EOSIHETO2), 1252824F6 (LUNGFET03), 1305549H1 (PLACNOT02), 1364975R1 (SCORNON02), 2018293H1 (THP1NOT01), 2047320H1 (THP1T7T01), 2184537F6 (SININOT01), 2755786H1 (THP1AZS08), 4111022H1 (PROSBPT07)
93	227	2831245	TLYMNOT03	2831245H1 (TLYMNOT03), SBMA01396F1
94	228	3116250	LUNGTUT13	126263FI (LUNGNOT01), 2729942H1 (OVARTUT04), 3116250H1 (LUNGTUT13)
95	229	3129630	LUNGTUTIE	3129630F6 (LUNGTUT12), 3129630H1 (LUNGTUT12), SBDA06436F1
96	230	007632	HMC1NOT01	007632H1 (HMC1NOT01), 007632R6 (HMC1NOT01), 007632T6 (HMC1NOT01)
26	231	1236968	LUNGFET03	1236968H1 (LUNGFET03), SBAA02713F1, SBAA03203F1, SBAA04196F1
86	232	1334153	COLNNOTIS	776410R1 (COLNNOT05), 1334153H1 (COLNNOT13), 1334153T1 (COLNNOT13), 1800085F6 (COLNNOT27), 2701948H1 (OVARTUT10)

Protein SEQ 1D NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
99	233	1396975	BRAITUT08	864113H1 (BRAITUT03), 876139R1 (LUNGAST01), 1268313F1 (BRAINOT09), 1351348T1 (LATRTUT02), 1396975H1 (BRAITUT08), 1485768F6 (CORPNOT02), 1815364F6 (PROSNOT20)
100	234	1501749	SINTBST01	079080R1 (SYNORAB01), 1501749H1 (SINTBST01), 1724970H1 (PROSNOT14)
101	235	1575240	LNODNOT03	081858R1 (SYNORAB01), 1575240H1 (LNODNOT03), 3451462R6 (UTRSNON03)
102	236	1647884	PROSTUT09	1647884H1 (PROSTUT09), 1647884T6 (PROSTUT09), 3998922R6 (HNT2AZS07)
103	237	1661144	BRSTNOT09	720941X17 (SYNOOAT01), 1661144H1 (BRSTNOT09), 2181782H1 (SININOT01)
104	238	1685409	PROSNOT15	755203RI (BRAITUT02), 1226185TI (COLNNOT01), 1300837FI (BRSTNOT07), 1685409HI (PROSNOT15), 1705256HI (DUODNOT02)
105	239	1731419	BRSTTUT08	1731419H1 (BRSTTUT08), 1731419X319T3 (BRSTTUT08), 1731419X322F1 (BRSTTUT08), 1731419X326F1 (BRSTTUT08), 1731419X329F1 (BRSTTUT08), 1733786F6 (BRSTTUT08), SZAH01494F1
106	240	2650265	BRSTNOT14	1680316T6 (STOMFET01), 2650265H1 (BRSTNOT14), 2650265T6 (BRSTNOT14), 2760588R6 (BRAINOS12)
107	241	2677129	KIDNNOT19	1592129H1 (CARGNOT01), 2645962H1 (OVARTUT04), 2677129F6 (KIDNNOT19), 2677129H1 (KIDNNOT19), 2910973H1 (KIDNTUT15), 4571722H1 (PROSTMT02), 4906791H2 (TLYMNOT08)
108	242	3151073	ADRENON04	3150857T6 (ADRENON04), 3151073H1 (ADRENON04), 3151073R6 (ADRENON04)
109	243	3170095	BRSTNOT18.	3170095F6 (BRSTNOT18), 3170095H1 (BRSTNOT18)

-83-

### TABLE 1 (cont.

Fragments	079680F1 (SYNORAB01), 443811T6 (MPHGNOT03), 1509356T6 (LUNGNOT14), 1873596F6 (LEUKNOT02), 2440867H1 (EOSITXT01), 3475168H1 (LUNGNOT27)	446637H1 (MPHGNOT03), 1219376R6 (NEUTGMT01), 3735467F6 (SMCCNOS01), 3836893H1 (DENDTNT01)	2129415T6 (KIDNNOT05), 4072159F6 (KIDNNOT26), 4072159H1 (KIDNNOT26)	620937R6 (PGANNOT01), 1003916H1 and 1003916R6 (BRSTNOT03), 1413623H1 (BRAINOT12), 1435945F1 (PANCNOT08), 1479127F1 (CORPNOT02), 1969146R6 (BRSTNOT04), 2517587F6 (BRAITUT21), 2967848H1 (SCORNOT04)	489651H1 (HNT2AGT01), 1265353T1 (SYNORAT05), 1431505R6 (BEPINON01), 1605237F6 (LUNGNOT15), 2093492H1 and 2093492T6 (PANCNOT04), 4195560H1 (COLITUT02)	2108789H1 and 2108789R6 (BRAITUT03), 2182008T6 (SININOT01), 3255751R6 and 3255751T6 (OVARTUN01)	037241F1 (HUVENOB01), 1821492F6 (GBLATUT01), 2055814T6 (BEPINOT01), 2171401F6 and 2171401H1 (ENDCNOT03), 2668952F6 (ESOGTUT02), 3140313H1 and 3140313T6 (SMCCNOT02), 5031775H1 (EPIBTXT01)	(CORPNOT02), 2062034H1 (OVARNOT01), 919634R6 (RATRNOT02), 1992331H1 (CORPNOT02), 2062034H1 (OVARNOT03), 2212530F6 and 2212530H1 (SINTFET03), 2520479H1 (BRAITUT21), 2878284F6 (THYRNOT10), 2992354H1 (KIDNFET02), 4020719F6 (BRAXNOT02)	2251036H1 and 2251036R6 (OVARTITOI)
Library	LUNGNOT27	DENDINT01	KIDNNOT26	BRSTNOT03	PANCNOT04	BRAITUT03	ENDCNOT03	SINTFET03	OVARTUTO
Clone ID	3475168	3836893	4072159	1003916	2093492	2108789	2171401	2212530	2253036
Nucleotide SEQ ID NO:	244	245	246	247	248	249	250	251	252
Protein SEQ ID NO:	110	111	112	113	114	115	116	117	118

Fragments	482326H1 (HNT2RAT01), 934345H1 (CERVNOT01), 1379358F1 and 1379358T1 (LUNGNOT10), 1438562T1 (PANCNOT08), 1467511F6 (PANCTUT02), 1568138F1 (UTRSNOT05), 1636106T6 (UTRSNOT06), 2134534F6 (ENDCNOT01), 2280161H1 and 2280161X19F1 (PROSNON01), 2789845F6 (COLNTUT16), 3096938H1 (CERVNOT03), 3774621F6 (BRSTNOT25), 4222971H1 (PANCNOT07), 5111983H1 (ENDITXT01), 5324177H1 (FIBPFEN06)	1454588F1 (PENITUT01), 1593332F6 (BRAINOT14), 2287485H1 and 2287485R6 (BRAINON01), 3765992H1 (BRSTNOT24), 4374293H1 (CONFNOT03), 4937931H1 (PROSTUS18), SBCA01722F1	2380344F6 and 2380344H1 (ISLTNOT01), 2888536T3 (LUNGFET04), SASA0364F1, SASA03689F1	956296R1 (KIDNNOT05), 1342250F1 (COLNTUT03), 1468046F1 and 1468046T1 (PANCTUT02), 2383171H1 (ISLTNOT01), SBYA05452U1, SBYA01369U1	2396046F6, 2396046H1 and 2396118T6 (THPIAZT01)	2456587H1 and 2456587T6 (ENDANOT01), 2872569H1 (THYRNOT10), SBCA03778F1, SBDA00115F1, SBCA02401F1, SBCA03351F1, SBCA05164F1, SBCA04783F1, SBCA00155F1, SBCA04141F1	1234970T1 (LUNGFET03), 1338090F6 (COLNNOT13), 2484813H1 (BONRTUT01), SBCA00053F1, SBCA02064F1, SBCA02151F1, SBCA03770F1, SBCA04866F1, SBCA03406F1	2493851H1 (ADRETUTOS), 3805916F6 (BLADTUTO3), 4500439H1 and 4500748H1 (BRAVTXTO2), 5120601H1 (SMCBUNTO1)	603447R1 (BRSTTUT01), 2495719H1 (ADRETUT05), 2917493F6 (THYMFET03),   4647103H1 (PROSTUT20), SBRA04984D1
Library	PROSNONOI	BRAINON01	ISLTNOT01	ISLTNOT01	THP1AZT01	ENDANOT01	BONRTUT01	ADRETUT05	ADRETUT05
Clone 1D	2280161	2287485	2380344	2383171	2396046	2456587	2484813	2493851	2495719
Nucleotide SEQ ID NO:	253	254	255	256	257	258	259	260	261
Protein SEQ ID NO:	119	120	121	122	123	124	125	126	127

Fragments	1833135R6 (BRAINON01), 1966515R6 (BRSTNOT04), 2331103R6 (COLNNOT11), 2614153H1 (GBLANOT01), 2656691F6 (LUNGTUT09), 3951176H1 (DRGCNOT01)	2655184H1 (THYMNOT04), SBDA05215F1, SBDA05213F1, SBDA01516F1	1297974F1 and 1297974T6 (BRSTNOT07), 2630138F6 (COLNTUT15), 2848362H1 (BRSTTUT13)	1541617R1 and 1541617T1 (SINTTUT01), 2684504F6 and 2684504T6 (LUNGNOT23), 2796805H1 (NPOLNOT01), 2849906H1 (BRSTTUT13)	2899137H1 (DRGCNOT01), 3026490F6 and 3026490T6 (HEARFET02), 3483359H1 (KIDNNOT31)	1740227T6 (HIPONON01), 2986229H1 (CARGDIT01)	1754079F6 (LIVRTUT01), 3222081H1 (COLNNON03), 4053813T6 (SPLNNOT13), 4230282H1 (BRAMDIT01), SBDA07029F3
Library	GBLANOT01	THYMNOT04	BRSTTUT13	BRSTTUT13	DRGCNOT01	CARGDIT01	COLNNON03
Clone ID	2614153	2655184	2848362	2849906	2899137	2986229	3222081
Nucleotide SEQ ID NO:	262	263	264	265	266	267	268
Protein SEQ ID NO:	128	129	130	131	132	133	134

#### **TABLE 2**

Identification Analytical Methods	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide
Signature Sequences Ide										
Potential Signa Glycosylation Sites	MI - A21	MI - F28	MI - T18	N58 MI - A29	MI - R24	N34 M1 - N21	M100 M1 - Q20	N60 M1 - A28	M1 - A29	MI - A29
Potential Phosphorylation Sites	T83 S38 T76	S30 S40 T47 T119 W125	T70	S32 T64	T27 S39 S39 S44 S22 T27 S28 S57	T55 S30 S40 T55	\$220 \$70 \$83 T131   N \$134 \$141 T158   Y 123	S62 T123 S142 S189 N	T48	
Amino Acid Residues	88	128	111	110	78	88	227	198	65	154
Protein SEQ ID NO:	-	2	9	4	5	9	7	<b>∞</b>	6	10

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
	237	T116 T26 T79 T85 T182 T188 T194 T206 S60 S123 S176 S213	N128	MI - A19		Signal Peptide HMM
	225	T158 S128	N166	M1 - G27		Signal Peptide HMM
	117	S41		M1 - A23		Signal Peptide HMM
	253	S49 T63 S92 T110 S127 T239	N42 N47 N72 · N207	M1 - T20		Signal Peptide HMM
	171	S43 S94 T114		. M88 - R112		Signal Peptide HMM
	78	S38 S43	N37	MI-G19		Signal Peptide HMM
	11	T64 T67		M1 - C19		Signal Peptide HMM
	188	S36 T58 T133 Y31	N121 N171	MI - A21		Signal Peptide HMM
	80	876		M1-C19	*	Signal Peptide HMM
	80		·	MI - G25	1	Signal Peptide HMM
	84	S39 S53 S60		M1 - G21		Signal Peptide HMM

		22.00	The state of the s			
Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
22	171	S41 T150	٧	M3 - A21		Signal Peptide HMM
23	243	S3 S44 T75 S86 S183 S223 S36 S92 S205 Y40 Y110	N97	M1 - C25		Signal Peptide HMM
. 24	311	T5 S76 T82 T93 T109 S121 T137 T170 S184 S11 T53 S75 S84 T132 S223 S274 Y69	N49 N91 N108 N128 N135 N190	MI - A32	·	Signal Peptide HMM
25	57		*	MI - L29		Signal Peptide HMM
26	82	S46 Y26		MI-S18		Signal Peptide HMM
27	115		,	M1 - G34		Signal Peptide HMM
28	327	S93 S50 S167 S233 S89 T105 T214 S302 T318	N138 N206	M1 - E25		Signal Peptide HMM
59	133	863	N105	M1 - E29		Signal Peptide HMM
30	129	S21 S65 T93		M1 - G20		Signal Peptide HMM

#### **FABLE 2**

	<del></del>	1		Ī	<del></del>			1	T	
Analytical Methods	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide
Identification										
Signature Sequences	MI - A21	MI - F28	MI - TI8	M1 - A29	M1 - R24	MI - N21	M1 - Q20	M1 - A28	MI - A29	MI - A29
Potential Glycosylation - Sites				NS8		N34	N100	N60		
Potential Phosphorylation Sites	T83 S38 T76	S30 S40 T47 T119 W125	170	S32 T64	T27 S39 S39 S44 S22 T27 S28 S57	T55 S30 S40 T55	S220 S70 S83 T131 S134 S141 T158 Y123	S62 T123 S142 S189 S62 T100 Y85	T48	
Amino Acid Residues	88	128	111	110	78	88	227	198	65	154
Protein SEQ ID NO:	-	2	Э.	4	5	9	7	80	6	01

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
Π	237	T116 T26 T79 T85 T182 T188 T194 T206 S60 S123 S176 S213	N128	MI - A19	**	Signal Peptide HMM
12	225	T158 S128	N166	MI - G27		Signal Peptide HMM
13	211	S41		M1 - A23		Signal Peptide HMM
14	253	S49 T63 S92 T110 S127 T239	N42 N47 N72 N207	M1 - T20	·	Signal Peptide HMM
15	171	S43 S94 T114		M88 - R112	•	Signal Peptide HMM
16	78	S38 S43	N37	MI - G19		Signal Peptide HMM
17	7.1	164 T67		MI-C19		Signal Peptide HMM
18	188	S36 T58 T133 Y31	N121 N171	MI - A21		Signal Peptide HMM
61	80	<i>S76</i>		M1 - C19		Signal Peptide HMM
20	80			M1 - G25		Signal Peptide HMM
21	84	S39 S53 S60		M1 - G21		Signal Peptide HMM

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
22	171	S41 T150		M3 - A21		Signal Peptide HMM
23	243	S3 S44 T75 S86 S183 S223 S36 S92 S205 Y40 Y110	N97	MI - C25		Signal Peptide HMM
. 24	311	T5 S76 T82 T93 T109 S121 T137 T170 S184 S11 T53 S75 S84 T132 S223 S274 Y69	N49 N91 N108 N128 N135 N190	MI - A32		Signal Peptide HMM
25	57			M1 - L29		Signal Peptide HMM
26	82	S46 Y26		MI - S18		Signal Peptide HMM
27	115			MI - G34		Signal Peptide . HMM
28	327	S93 S50 S167 S233 S89 T105 T214 S302 T318	N138 N206	M1 - E25		Signal Peptide HMM
29	133	S63	N105	MI - E29		Signal Peptide HMM
30	129	S21 S65 T93		MI - G20		Signal Peptide HMM

TABLE 2 (cont.)

								<del>/</del>
Analytical Methods	Signal Peptide HMM BLAST - GenBank	Signal Peptide HMM	SPScan	Signal Peptide HMM	Signal Peptide HMM	SPScan	Signal Peptide HMM	Signal Peptide HMM
Identification	hematopoietic lineage switch 2 (g3169729)							
Signature Sequences	MI - G20	MI-A18	M1 - G47	_ М9 - G40	MI-A19	MI - E34	M1 - G28	M1 - A21
Potential Glycosylation Sites	N61 N179 N353 N356 N396					N163 N184 N379		N46 N189 N382
Potential Phosphorylation Sites	S164 T32 S42 T141 T154 S155 T235 T262 T271 T334 T376 S402 S421 S435 T441 S19 S29 T327 S378	121	SS7 SS	T6 T14 T135	T15 S58 S66	T7 T76 S150 T224 S228 S257 S358 S474 S529 S539 T186 S219 S368 Y523	T80 S163	T47 T146 S233 S391 S403 T43 S130 S273 S339 S364
Amino Acid Residues	472	66	92	143	68	560	197	437
Protein SEQ ID NO:	31	. 32	33	34	35	36	37	38

								<u> </u>
Analytical Methods	Signal Peptide HMM	Signal Peptide HMM BLAST - GenBank	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM
Identification		receptor-activity-modifying protein (RAMP; g4165368)						
Signature Sequences	MI - G28	MI - R24	MI - V25	MI - S24	MI - T23	MI - G22	M1 - G23	MI-PI8
Potential Glycosylation Sites	N46 N64 N166 N191	N29 N58 N71 N103			and of the		N40	
Potential Phosphorylation Sites	S197 T49 T150 S193 T214 T215 T49 S111 S237	T73 S141	. 678	S89 S165 T174 T182 T83 S155	S54 S29 S98 S50 S57 T104	T29 S106 T120 S161 S195 S37 S47 T51 S136 S223 S230 S281	S21 T63 T63 A146	\$65
Amino Acid Residues	330	148	188	222	111	341	148	87
Protein SEQ ID NO:	39	40	41	42	43	4	45	46

Analytical Methods	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM BLAST - GenBank	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM
Identification						putative involvement in cell wall structure or biosynthesis (g3738170)				
Signature Sequences	MI - P23	MI - L18	M1-A20	MI - C21	MI - G18	M1 - L25	MI - A26	MI - G25	MI - A22	MI - P23
Potential Glycosylation Sites	N93 N207		·	N71	- ·	N250 N321 N463	•	N39		
Potential Phosphorylation Sites	T77 S95 S108 S280 S351 S121 S124 S153 T187	S25 S22	S62	T100 T73 S97 Y48	817 8110	S205 T31 S86 T236 S7 T447	T55 S34 S46 S69 T98 S108 T119 T167 S194 S2 S34 T153	S65 S36 T41 S51 S69 S81	S56	S29
Amino Acid Residues	383	109	185	110	126	488 88	197	84	97	140
Protein SEQ ID NO:	47	48	49	20	. 51	52	53	54	55	56

Analytical Methods	Signal Peptide HMM	Signal Peptide HMM BLAST - GENESEQ	Signal Peptide HMM	SPScan	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM	Signal Peptide HMM
An	Sig	Sig HA BL GE	Sig	g <sub>S</sub>	Sig	Sig FF	Sig	Signal HMM	Signal HMM
Identification		3-acylating enzyme (Q44449)	*						
Signature Sequences	MI - A25	M1 - G28	M1 - C22	MSS - E84B	8ID-IM	MI - G27	MI - G18	MI - G23	MI-A18
Potential Glycosylation Sites	N153	N190			N67			N53 N130 N289	- 1:
Potential Phosphorylation Sites	S53 S108 T216 S253 S277	S62 T166 S62 S71 Y246	S120 T154 T34 T37 S174	S98 T136 T67 S112 S234 S237	168	T21 S117 S120	S107 S97 S146 S339 S440 S245 T303 S304 S399	T145 T214 T16 S24 S35 S45 T145 T269 S297 T300 T314 Y87	S38 S25 S75
Amino Acid Residues	285	262	189	257	82	202	450	322	104
Protein SEQ ID NO:	57	28	. 59	09	. 61	62	63	64	99

Protein SEQ ID NO:	Amino	Potential Phosphorylation Sites	Potential Glycosylation	Signature Sequences	Identification	Analytical
,	Residues		Sites	-		Methods
99	93		*	MI through about S18 - Transmembrane: MI through about Y17		SPscan HMM
67	71	S23 S64	74.2	MI through about A24		SPscan HMM MOTIFS
-97-	394	S392 S393 S31 S127 S179 S334 T338 S358 T383 Y323	N53	M1 through about S31 Transmembrane: about M159 through about F178 about F109 through about S127 about F225 through about V243	·	SPScan HMM MOTIFS
69	72	S29	69N	M1 through about S23 Transmembrane: M1 through about L16		SPscan HMM MOTIFS
70	11	SI 1726		M1 through about Q18		SPscan HMM MOTIFS
71	247	S41 T79		M1 through about S25		SPscan HMM MOTIFS
72	73	S56	i	M1 through about G27		SPscan HMM MOTIFS

F		<del></del>		<del>,</del>				
Analytical Methods	SPscan HMM	SPscan HMM	SPScan	SPscan HMM MOTIFS	SPscan HMM MOTIFS	SPscan HMM MOTIFS	SPscan HMM MOTIFS	SPscan HMM MOTIFS
Identification								
Signature Sequences	M1 through about G20	M1 through about G30	M1 through about G26	M1 through about S19	M1 through about G27 Transmembrane: about W79 through about H97	M1 through about N34	M1 through about C18	M1 through about S30
Potential Glycosylation Sites			3.1			N48		
Potential Phosphorylation Sites				T29 S46 T51	S62 S65		T33 R55	S34
Amino Acid Residues	70	67	16	99	112	54	57	52
Protein SEQ ID NO:	73	74	7.5	76	77	78	62	08

Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
81	49	T43 Y27		M1 through about S41		SPscan HMM MOTIFS
82		S45	·	M1 through about A31 Transmembrane: about L38 through about F55		SPscan HMM MOTIFS
83	56			M1 through about E23		SPscan HMM
8	120	869 S109	89 N95	M1 through about A38 Transmembrane: about L23 through about T41		SPscan HMM MOTIFS
85	67	S28		MI through about K30 Microbodies C-terminal targetting signal: A65KV		SPscan HMM MOTIFS
98	62	S29 S42 S46	N40	M1 through about S29		SPscan HMM MOTIFS
87	75	S25 S46	7.5 - 0	M1 through about L19 Transmembrane: about 13 through about G20		SPscan HMM MOTIFS

1	T		<del></del>	<del></del>		<del></del>	
Analytical Methods	SPscan HMM MOTIFS	SPscan HMM MOTIFS	SPscan HMM MOTIFS	SPscan HMM MOTIFS	SPScan BLOCKS PRINTS MOTIFS	SPscan HMM	SPscan HMM MOTIFS
Identification					,		
Signature Sequences	M1 through about A20	MI through about C48	M1 through about G22	M1 through about P21	M1 through about S18 Tyrosine specific protein phosphatases signature: about V328 through about F340	M1 through about S25	M1 through about S22 Transmembrane: about V3 through about S21
Potential Glycosylation Sites		र १		7.	N226	A VARIONE	antigiam cur a angua aya a
Potential Phosphorylation Sites	128	S11	838	S43	S415 S52 T77 S97 T178 T228 S282 S320 S332 S384 T401 T424 S483 S207 S230 S357 T410 Y263 Y365		839
Amino Acid Residues	08	50	116	67	538	28	119
Protein SEQ ID NO:	88	86	06	~100-	92	93	94

-100-

			1			
Protein SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
56	128	168		MI through about G31 Transmembrane: about F108 through about L126		SPscan HMM MOTIFS
96 .	124	T115 T43 S91		M1-S20 P116-V124 (urotensin II signature)		SPScan HMM Motifs BLOCKS BLAST
26	182	S28 T70 S172 S25 S32 S48 S108 S131		M1-S23, M1-S2 <i>s</i>		SPScan HMM Motifs
86	237	S55 S88 S121 S135	N45 N73 N107 N118 N132 N172 N175 N185	MI-AI6, MI-S21 C40-C198 (cysteine spacing) pattern similar to that of RoBo-1)		SPScan HMM Motifs BLAST
66	160	S36 S59 T143	C C	MI-A27		SPScan HMM Motifs
001	148	T76 S64 Y103		M1-S30, M1-G31		SPScan HMM Motifs
101	170	S78 T4 T30 S130 S25 S29 T122		MI-A23, MI-L28		SPScan HMM Motifs

	<del></del>	<del></del>	<del></del>	<del></del>	<del></del>	<del></del>	<del></del>	
Analytical Methods	SPScan HMM Motifs	SPScan HMM Motifs	SPScan HMM Motifs	SPScan HMM Motifs	SPScan HMM Motifs	SPScan HMM Motifs	SPScan HMM Motifs	SPScan HMM Motifs
Identification								
Signature Sequences	MI-A26, MI-S28	MI-A25, MI-G26	MI-G18, M1-T25	MI-G22, MI-A20	MI-G26, MI-C25	MI-A22	MI-P19, MI-L22	MI-T15, MI-P19
Potential Glycosylation Sites			6		N32 N101	with the second	Į.	N50
Potential Phosphorylation Sites	S50 S78 S91	T57 T80	E .	T29 S40 S72	T115 S38 T41	S53 S217 S240 S283 T224	S88 T73 S84	T82 S52 S77
Amino Acid Residues	150	142	110	120	135	301	103	95
Protein SEQ ID NO:	102	103	104	501	106	107	108	601

	T -		<del></del>	<del></del>	_	<del>-</del>		T
Analytical Methods	SPScan HMM Motifs	SPScan HMM Motifs BLAST - GenBank	SPScan HMM Motifs	SPScan Motifs BLAST	SPScan	HMM Motifs	SPScan Motifs	HMM Motifs
Identification		NK cell activating receptor (g4493702)		Signal Peptide Containing Protein, Homology with KIAA0206	Signal Peptide Containing Protein	Signal Peptide Containing Protein	Signal Peptide Containing Protein	Signal Peptide Containing Protein
Signature Sequences	MI-P19, MI-A24	M1-A20	MI-G30, MI-G27	M1-G26 Signal Peptide	M1-Q29 Signal Peptide	M1-A20 Signal Peptide	M1-G23 Signal Peptide	M1-A24 Signal Peptide
Potential Glycosylation Sites		N146 N191 N194			٠		N280 N384	N87
Potential Phosphorylation Sites	T84 S4	S179 S184 S51 T70 T158 S168 T228 Y29	S39 T61	SSI T46 S191		S29	S143 T156 T227 S235 T271 T293 T436 S453 S117 T148 T213 S263 S417 Y73	S19 S320 S69 S151 T171 T97 S393 Y193 Y378
Amino Acid Residues	113	234	611	200	225	155	468	403
Protein SEQ ID NO:	110	Ξ.	112	113	114	115	116	117

-103-

7	T			<del>,</del>	_
SPScan Motifs	SPScan Motifs HMM BLAST	SPScan Motifs	SPScan MotifS	SPScan Motifs BLAST	SPScan
Signal Peptide Containing Protein	Signal Peptide Containing Protein, Weakly similar to Putative Transmembrane Protein (PTM1) Precursor	Signal Peptide Containing Protein,	Signal Peptide Containing Protein	Signal Peptide Containing Protein, Weakly similar to OXA1L	Signal Peptide Containing Protein
M1-G25 Signal Peptide	M1-P21 Signal Peptide L226-W244, Y402-W422, V375-L392 and Y355-l376 Transmembrane Domains	M1-G24 Signal Peptide	M1-S15 Signal Peptide	M1-L25 Signal Peptide	MI-W16 Signal Peptide
N116	N62 N79 N127 N157 N157 N157 N150	N100 N168 N319			
T131 S24 T79 T118 T123 T127	T176 S192 S196 T220 S344 S369 S476 T501 S529 S541 T548 T553 S48 S115 S121 T386 T424 S500 Y104	T457 T80 S86 T141 T372 T420 S447 S94 T102 S112 T240 S297 S353 S470	T46 S78 T12	S57 T320 S339 S396 S100 S239	
131	556	514	109	431	142
118		120	121	122	123
	131 T131 S24 T79 T118 N116 M1-G25 Signal Peptide Signal Peptide Containing Protein T123 T127	131 S24 T79 T118	131   T131 S24 T79 T118	131   T131 S24 T79 T118	131   T131   S24 T79 T118   N116   M1-G25 Signal Peptide   Signal Peptide Containing Protein

	<del></del>				
Analytical Methods	SPScan Motifs Pfam BLAST	SPScan Motifs	SPScan Motifs PROFILE- SCAN	SPScan Motifs BLAST Pfam PROFILE-	SPScan Motifs BLAST
Identification	Signal Peptide Containing Protein, Thrombospondin Type I Protein	Signal Peptide Containing Protein	Signal Peptide Containing Protein, Glycosyl Hydrolase Protein	Signal Peptide Containing Protein, Ribosomal Protein S18	Signal Peptide Containing Protein, Homology with GTP Binding Protein
Signature Sequences	M1-S28 Signal Peptide, D37-C81, W380-C437, W440- C492 and FS26-C583 Thrombospondin Type 1 Domains	M1-T19 Signal Peptide	M1-R32 Signal Peptide, V4-L53 Glycosyl Hydrolase Family 9 Active Site Signature	M1-S26 Signal Peptide, H79-H123 Ribosomal Protein S18 Signature	MI-S35 Signal Peptide
Potential Glycosylation Sites	N251	N322		1:	N37 N92
Potential Phosphorylation Sites	T8 S28 S77 T169 T199 T235 S252 T320 S402 T413 S414 S58 S22 T25 S56 S62 S120 T184 S329 T423 S475 S574 Y226	S510 T24 T80 S91 T153 T165 S232 S248 S262 T300 T334 S380 S446 S16 T19 T60 S127 S273 T436 T531 S554 T564 Y135 Y489	T62 S27 T36	T105 T47 T56 S158	S112 S131
Amino Acid Residues	643	568	125	196	214
Protein SEQ ID NO:	124	125	126	127	128



<del></del>	T					
Analytical Methods	НММ	SPScan Motifs Pfam	SPScan Motifs	HMM Motifs BLOCKS PRINTS Pfam	SPScan Motifs Pfam	SPScan Motifs BLAST
Identification	Signal Peptide Containing Protein	Signal Peptide Containing Protein, Immunoglobulin Superfamily Protein	Signal Peptide Containing Protein	Signal Peptide Containing Protein, Adrenodoxin Family Iron-Sulfur Binding Protein, and Cytochrome C Family Heme Binding Protein	Signal Peptide Containing Protein, PF00646 F-Box Protein	Signal Peptide Containing Protein, F45G2.10 and Yhr122wp Homology
Signature Sequences	M1-S24 Signal Peptide	M1-A48 Signal Peptide, G59-S142 Immunoglobulin Domain	M1-A30 Signal Peptide	M1-W24 Signal Peptide, E131-K168 and C105-H115 Adrenodoxin Iron-Sulfur Binding Signature, C111-V116 Cytochrome C Heme Binding Signature, N69-A 162 Iron-Sulfur Cluster Binding Domain	M1-G30 Signal Peptide, V28-L74 PF00646 F-Box Domain	M1-A27 Signal Peptide
Potential Glycosylation Sites		NS0 N109	*			in the second second
Potential Phosphorylation Sites		S146 S179 S192 S239 S70 T126 T150	T176 T56 S72 S179 S256 S87	SII T4I T42 S83	S93 T89 Y9	746 T55 S65 S124 T125 T46
Amino Acid Residues	88	260	295	183	113	160
Protein SEQ ID NO:	129	130	131	-106-	133	134

#### ${f TABLE}$ 3

L				
	Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of Fraction)	Vector
	135	Hematopoietic/Immune (1.000)	Inflammation (1.000)	PBLUESCRIPT
	136	Hematopoietic/Immune (0.750) Cardiovascular (0.250)	Inflammation (0.750) Cancer (0.250)	pSPORTI
	137	Nervous (1.000)	Trauma (1.000)	pSPORTI
	138	Musculoskeletal (1.000)	Inflammation (1.000)	pSPORT1
	139	Gastrointestinal (0.714) Cardiovascular (0.143) Reproductive (0.143)	Cancer (0.714) Trauma (0.143)	pSPORT1
	140	Nervous (1.000)	Neurological (0.500) Trauma (0.500)	pSPORTI
	141	Reproductive (0.293) Gastrointestinal (0.146) Hematopoietic/Immune (0.146)	Cancer (0.524) Inflammation (0.256) Fetal (0.146)	pSPORT1
07-	142	Reproductive (0.266) Gastrointestinal (0.170) Nervous (0.138)	Cancer (0.479) Inflammation (0.277) Fetal (0.181)	pINCY
	143	Reproductive (0.417) Nervous (0.292) Developmental (0.125)	Cancer (0.417) Inflammation (0.250) Fetal (0.167)	pINCY
	144	Reproductive (0.321) Cardiovascular (0.143) Developmental (0.143)	Cancer (0.464) Fetal (0.214) Inflammation (0.143)	pINCY
	145	Reproductive (0.600) Gastrointestinal (0.400)	Cancer (0.400) Trauma (0.400) Inflammation (0.200)	pINCY
	146	Cardiovascular (0.400) Dermatologic (0.200) Nervous (0.200)	Cancer (0.600) Fetal (0.600)	pINCY
	147	Developmental (0.667) Gastrointestinal (0.333)	Fetal (0.667) Cancer (0.333)	pINCY
	148	Reproductive (0.256) Nervous (0.248) Cardiovascular (0.137)	Cancer (0.479) Inflammation (0.214) Fetal (0.145)	pINCY
	149	Reproductive (0.244) Nervous (0.178) Hematopoietic/Immune (0.167)	Cancer (0.433) Inflammation (0.322) Fetal (0.156)	pINCY

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of Fraction)	Vector
150	Cardiovascular (0.923) Developmental (0.077)	Cancer (0.692) Fetal (0.154) Inflammation (0.154)	pINCY
151	Reproductive (0.215) Nervous (0.190) Gastrointestinal (0.177)	Cancer (0.494) Inflammation (0.278) Trauma (0.152)	pINCY
152	Reproductive (0.200) Nervous (0.171) Hematopoietic/Immune (0.143)	Inflammation (0.371) Cancer (0.229) Fetal (0.200)	pINCY
153	Reproductive (0.333) Nervous (0.157) Hematopoietic/Immune (0.137)	Cancer (0.549) Inflammation (0.176) Fetal (0.137)	pINCY
154	Gastrointestinal (0.500) Urologic (0.167)	Inflammation (0.667) Cancer (0.167) Trauma (0.167)	pINCY
155	Gastrointestinal (0.429) Reproductive (0.286) Nervous (0.143)	Inflammation (0.429) Cancer (0.286) Trauma (0.143)	pINCY
156	Reproductive (1.000)	Cancer (0.500) Inflammation (0.500)	pINCY
157	Hematopoietic/Immune (0.346) Reproductive (0.154) Gastrointestinal (0.115)	Cancer (0.404) Inflammation (0.404) Fetal (0.212)	pINCY
158	Reproductive (0.236) Hematopoietic/Immune (0.217) Gastrointestinal (0.132)	Cancer (0.415) Inflammation (0.358) Fetal (0.142)	pINCY
159	Gastrointestinal (1.000)	Cancer (1.000)	pSPORT1
160	Developmental (0.500) Hematopoietic/Immune (0.250) Nervous (0.250)	Fetal (0.500) Inflammation (0.250) Trauma (0.250)	pINCY
161	Hematopoietic/Immune (0.250) Reproductive (0.250) Nervous (0.208)	Cancer (0.583) Fetal (0.292) Inflammation (0.250)	pINCY
162	Gastrointestinal (0.412) Reproductive (0.412) Cardiovascular (0.088)	Cancer (0.735) Inflammation (0.176) Fetal (0.029)	pINCY

-108-

Vector	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pSPORTI
Disease/Condition-Specific Expression (Total of Fraction)	Cancer (0.532) Inflammation (0.213) Fetal (0.191)	Cancer (0.667) Inflammation (0.333)	Cancer (0.534) Inflammation (0.284) Fetal (0.091)	Inflammation (0.731) Cancer (0.154) Fetal (0.154)	Cancer (0.672) Inflammation (0.155)	Cancer (0.519) Inflammation (0.370) Fetal (0.259)	Cancer (0.333) Fetal (0.333) Inflammation (0.333)	Cancer (0.643) Inflammation (0.143) Fetal (0.107)	Cancer (0.391) Fetal (0.304) Inflammation (0.217)	Cancer (0.571) Inflammation (0.286) Fetal (0.107)	Cancer (0.387) Inflammation (0.323) Fetal (0.226)	Cancer (0.521) Inflammation (0.312) Trauma (0.146)
Tissue Expression (Fraction of Total)	Reproductive (0.298) Cardiovascular (0.170) Nervous (0.149)	Gastrointestinal (0.333) Hematopoietic/Immune (0.333) Reproductive (0.333)	Reproductive (0.295) Gastrointestinal (0.159) Nervous (0.148)	Hematopoietic/Immune (0.538) Cardiovascular (0.077) Reproductive (0.077)	Reproductive (0.483) Gastrointestinal (0.121) Nervous (0.103)	Gastrointestinal (0.222) Hematopoietic/Immune (0.222) Nervous (0.148)	Urologic (1.000)	Reproductive (0.214) Gastrointestinal (0.179) Nervous (0.143)	Reproductive (0.261) Developmental (0.174) Nervous (0.174)	Reproductive (0.357) Gastrointestinal (0.321) Cardiovascular (0.071)	Reproductive (0.306) Nervous (0.161) Cardiovascular (0.129)	Reproductive (0.229) Nervous (0.188) Cardiovascular (0.167)
Nucleotide SEQ ID NO:	163	164	165	. 166	167	168	169	170	171	172	173	174

Nucleotide SEO ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of	Vector
175	Reproductive (0.444) Developmental (0.167) Cardiovascular (0.111)	Cancer (0.556) Fetal (0.278) Trauma (0.111)	pSPORT1
176	Reproductive (0.294) Gastrointestinal (0.176) Cardiovascular (0.118)	Cancer (0.765) Fetal (0.118) Inflammation (0.118)	pSPORT1
177	Gastrointestinal (1.000)	Cancer (0.667) Inflammation (0.333)	pINCY
178	Reproductive (0.385) Nervous (0.231) Gastrointestinal (0.154)	Cancer (0.385) Inflammation (0.385)	pINCY
179	Reproductive (0.500) Cardiovascular (0.167) Gastrointestinal (0.167)	Cancer (0.667) Fetal (0.167) Inflammation (0.167)	PBLUESCRIPT
180	Cardiovascular (0.231) Reproductive (0.231) Gastrointestinal (0.154)	Cancer (0.615) Inflammation (0.308) Fetal (0.154)	pINCY
181	Reproductive (0.324) Gastrointestinal (0.176) Cardiovascular (0.130)	Cancer (0.519) Inflammation (0.222) Fetal (0.157)	pINCY
182	Reproductive (0.320) Nervous (0.180) Gastrointestinal (0.120)	Cancer (0.580) Inflammation (0.160) Fetal (0.100)	pINCY
183	Gastrointestinal (0.667) Reproductive (0.333)	Cancer (1.000)	pINCY
184	Urologic (0.667) Dermatologic (0.333)	Cancer (0.667) Fetal (0.333)	pSPORTI
185	Cardiovascular (0.500) Reproductive (0.500)	Cancer (1.000)	pINCY
186	Reproductive (0.393) Developmental (0.107) Urologic (0.107)	Cancer (0.607) Fetal (0.179) Inflammation (0.107)	pINCY
187	Cardiovascular (0.400) Reproductive (0.333) Gastrointestinal (0.133)	Inflammation (0.467) Cancer (0.267) Fetal (0.267)	pSPORT1
188	Nervous (0.318) Reproductive (0.227) Urologic (0.136)	Cancer (0.636) Inflammation (0.136) Trauma (0.091)	pINCY

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of Fraction)	Vector
189	Cardiovascular (0.500) Reproductive (0.500)	Cancer (1.000)	pINCY
190	Reproductive (0.318) Nervous (0.227) Hematopoietic/Immune (0.136)	Cancer (0.500) Fetal (0.227) Inflammation (0.227)	pINCY
191	Reproductive (0.253) Cardiovascular (0.158) Gastrointestinal (0.147)	Cancer (0.463) Inflammation (0.232) Fetal (0.200)	pINCY
192	Reproductive (0.333) Gastrointestinal (0.286) Cardiovascular (0.095)	Cancer (0.571) Inflammation (0.333) Fetal (0.095)	pINCY
193	Reproductive (0.304) Cardiovascular (0.217) Gastrointestinal (0.130)	Cancer (0.435) Inflammation (0.391) Fetal (0.174)	pINCY
194	Reproductive (0.312) Nervous (0.188) Cardiovascular (0.125)	Cancer (0.438) Inflammation (0.250) Fetal (0.188)	pINCY
195	Developmental (1.000)	Fetal (1.000)	pINCY
961	Reproductive (0.233) Cardiovascular (0.209) Nervous (0.140)	Cancer (0.605) Fetal (0.186) Inflammation (0.116)	pINCY
161	Reproductive (0.182) Gastrointestinal (0.136) Hematopoietic/Immune (0.136)	Cancer (0.477) Inflammation (0.341) Fetal (0.182)	pINCY
861	Gastrointestinal (0.205) Reproductive (0.205) Cardiovascular (0.114)	Inflammation (0.341) Cancer (0.250) Fetal (0.227)	pINCY
661	Cardiovascular (0.520) Reproductive (0.280) Developmental (0.160)	Cancer (0.720) Fetal (0.200) Inflammation (0.080)	pINCY
200	Lung (0.958) Developmental (0.25) Musculoskeletal (0.042)	Cancer (0.583) Fetal or Proliferating (0.292) Inflammation (0.167)	pBLUESCRIPT
201	Reproductive (0.571) Musculoskeletal (0.143) Nervous (0.143) Urologic (0.143)	Cancer (0.429) Inflammation (0.571)	pSPORTI

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of Fraction)	Vector
202	Endocrine (0.250) Nervous (0.250) Cardiovascular (0.125) Developmental (0.125) Gastrointestinal (0.125) Reproductive (0.125)	Cancer (0.375) Inflammation (0.625) Fetal or Proliferating (0.125)	pSPORT1
203	Lung (1.000)	Fetal or Proliferating (1.000)	pINCY
204	Lung (0.500) Penis (0.500)	Cancer (0.500)	pINCY
205	Cardiovascular (0.231) Dermatologic (0.231) Reproductive (0.231)	Fetal or Proliferating (0.385) Cancer (0.308)	pINCY
206	Nervous (0.596) Reproductive (0.154) Gastrointestinal (0.077)	Cancer (0.442) Neurological (0.192) Inflammation (0.231)	pINCY
207	Gastrointestinal (1.000)	Inflammation (1.000)	pINCY
800 12-	Reproductive (0.300) Hematopoietic/Immune (0.200) Nervous (0.150)	Cancer (0.450) Inflammation (0.400) Fetal or Proliferating (0.250)	pSPORTI
209	Heart (0.500) Brain (0.500)	Neurological (0.500) Inflammation (0.500)	pINCY
210	Nervous (0.625) Reproductive (0.250) Musculoskeletal (0.125)	Cancer (0.750) Fetal or Proliferating (0.250) Neurological (0.125)	pINCY
211	Nervous (0.261) Reproductive (0.304) Gastrointestinal (0.174)	Cancer (0.522) Fetal or Proliferating (0.174) Inflammation (0.130)	pSPORTI
212	Testis (1.000)	Inflammation (1.000)	PBLUESCRIPT
213	Nervous (0.400) Reproductive (0.400) Gastrointestinal (0.200)	Cancer (0.400) Inflammation (0.400) Neurological (0.200)	PBLUESCRIPT
214	Reproductive (0.476) Gastrointestinal (0.286) Cardiovascular (0.095)	Cancer (0.714) Inflammation (0.286) Neurological (0.048)	pSPORTI

Nucleotide SEQ ID NO: 215 216 217 218 219 220 220 221	Tissue Expression (Fraction of Total)  Reproductive (0.284) Gastrointestinal (0.216)  Nervous (0.176) Hematopoietic/Immune (0.108)  Cardiovascular (0.108)  Uterus (0.500) Prostate (0.500)  Nervous (0.429) Cardiovascular (0.143)  Gastrointestinal (0.143) Hematopoietic/Immune (0.143)  Reproductive (0.143)	Disease/Condition-Specific Expression (Total of Fraction)  Cancer (0.486) Inflammation (0.351)  Fetal or Proliferating (0.122)  Cancer (0.500) Inflammation (0.500)  Cancer (0.571) Inflammation (0.429)  Fetal or Proliferating (0.285)  Cancer (0.650) Inflammation (0.200)  Fetal or Proliferating (0.050)	Vector pSPORT1 pINCY pSPORT1
215 216 217 218 219 220 221		Cancer (0.486) Inflammation (0.351)  Fetal or Proliferating (0.122)  Cancer (0.500) Inflammation (0.500)  Cancer (0.571) Inflammation (0.429)  Fetal or Proliferating (0.285)  Cancer (0.650) Inflammation (0.200)  Fetal or Proliferating (0.050)	pSPORT1 plNCY pSPORT1
216 217 218 219 220 221		Cancer (0.500) Inflammation (0.500)  Cancer (0.571) Inflammation (0.429)  Fetal or Proliferating (0.285)  Cancer (0.650) Inflammation (0.200)  Fetal or Proliferating (0.050)	pINCY pSPORT1
218 218 219 220 221		Cancer (0.571) Inflammation (0.429) Fetal or Proliferating (0.285) Cancer (0.650) Inflammation (0.200) Fetal or Proliferating (0.050)	pSPORT1
218 219 220 221 222		Cancer (0.650) Inflammation (0.200) Fetal or Proliferating (0.050)	
	Reproductive (0.450) Hematopoietic/Immune (0.200) Nervous (0.100) Gastrointestinal (0.100)		pINCY
220 221 222	Reproductive (0.364) Cardiovascular (0.182) Nervous (0.182)	Cancer (0.636) Fetal or Proliferating (0.182) Inflammation (0.273)	pINCY
	Prostate (1.000)	Inflammation (1.000)	pSPORTI
	Developmental (0.333) Nervous (0.333) Reproductive (0.333)	Cancer (0.667) Fetal or Proliferating (0.667)	pSPORTI
	Reproductive (0.393) Hematopoietic/Immune (0.180) Nervous (0.098) Cardiovascular (0.098)	Cancer (0.508) Inflammation (0.344) Fetal or Proliferating (0.066)	pSPORTI
223 Endocr	Endocrine (0.333) Gastrointestinal (0.333) Reproductive (0.333)	Cancer (1.000)	pINCY
224 Cardiov Gastroi Urologi	Cardiovascular (0.200) Developmental (0.200) Gastrointestinal (0.200) Reproductive (0.200) Urologic (0.200)	Cancer (0.800) Fetal or Proliferating (0.200)	pINCY
225 Lung (1.000)		Cancer (1.000)	pINCY
226 Reprod	Reproductive (0.302) Hematopoietic/Immune (0.254)  Cardiovascular (0.111)	Cancer (0.381) Inflammation (0.381) Fetal or Proliferating (0.286)	pSPORTI

Vector	pINCY	pINCY	pINCY	PBLUESCRIPT	pINCY	PINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY	pINCY
Disease/Condition-Specific Expression (Total of Fraction)	Inflammation (1.000)	Cancer (0.656) Inflammation (0.250) Fetal or Proliferating (0.094)	Cancer (0.500) Fetal or Proliferating (0.167) Inflammation (0.333)	Cell Proliferation (0.500) Inflammation (0.500)	Cancer (0.500) Cell Proliferation (0.333) Inflammation (0.167)	Cancer (0.500) Inflammation (0.500)	Cancer (0.456) Inflammation (0.235) Trauma (0.147)	Cancer (0.545) Inflammation (0.255) Trauma (0.109)	Cancer (0.538) Inflammation (0.231) Trauma (0.154)	Cancer (1.000)	Cancer (0.571) Cell Proliferation (0.143) Trauma (0.143)	Cancer (0.453) Inflammation (0.241) Cell Proliferation (0.175)	Trauma (0.333) Cancer (0.167) Cell Proliferation (0.167)
Tissue Expression (Fraction of Total)	Lymphocytes (1.000)	Cardiovascular (0.531) Reproductive (0.250) Urologic (0.094)	Reproductive (0.333) Cardiovascular (0.167) Gastrointestinal (0.167) Endocrine (0.167) Hematopoietic/Immune (0.167)	Hematopoietic/Immune (0.500) Reproductive (0.500)	Cardiovascular (0.333) Nervous (0.333) Developmental (0.167)	Gastrointestinal (0.938) Reproductive (0.062)	Nervous (0.324) Reproductive (0.235) Hematopoietic/Immune (0.118)	Nervous (0.255) Reproductive (0.255) Musculoskeletal (0.182)	Musculoskeletal (0.308) Reproductive (0.231) Gastrointestinal (0.154)	Nervous (1.000)	Gastrointestinal (0.429) Hematopoietic/Immune (0.143) Nervous (0.143)	Reproductive (0.254) Gastrointestinal (0.160) Nervous (0.128)	Nervous (0.333) Dermatologic (0.167) Endocrine (0.167)
Nucleotide SEQ ID NO:	227	228	229	. 230	231	232	233	234	235	236	237	238	239

Nucleotide SEQUENCIS         Tissue Expression (Fraction of Total)         Disease/Condition-Specific Expression (Total of Fraction)         Vector           240         Nervous (0.273) Reproductive (0.227)         Cancer (0.4545) Cell Proliferation (0.182)         piNCY           241         Reproductive (0.273)         Cancer (0.4545) Cell Proliferation (0.273)         piNCY           242         Reproductive (1.000)         Trauma (1.000)         Trauma (1.000)         piNCY           243         Reproductive (1.000)         Cancer (1.000)         Cancer (1.000)         piNCY           244         Hematopolicit/Immune (0.182) Cadiovascular (0.091)         Inflammation (0.630) Cancer (0.300)         piNCY           245         Hematopolicit/Immune (0.400)         Inflammation (0.630) Cancer (0.300)         piNCY           246         Urologic (1.000)         Cancer (0.601)         Inflammation (0.630)         piNCY           247         Musculoskeletal (0.125)         Call Proliferation (0.650) Cancer (0.300)         piNCY           248         Hematopoletic/Immune (0.100)         Call Proliferation (0.600) Inflammation/Trauma (0.181)         piNCY           249         Nervous (0.292) Reproductive (0.110)         Cell Proliferation (0.602) Inflammation/Trauma (0.180)         piNCY           250         Cardiovascular (0.130)         Cell Proliferation (0.603) Inflammati				
Nervous (0.273) Reproductive (0.227)   Cancer (0.545) Cell Proliferation (0.182)   Inflammation (0.182)   Inflammation (0.182)   Inflammation (0.182)   Inflammation (0.273)   Hematopoietic/Immune (0.182) Urologic (0.182)   Inflammation (0.273)   Inflammation (0.250)   Infl	Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of Fraction)	Vector
Reproductive (0.273)   Hematopoietic/Immune (0.182) Urologic (0.182)   Inflammation (0.273)   Inflammation (0.273)   Inflammation (0.273)     Reproductive (1.000)   Trauma (1.000)   Cancer (1.000)   Hematopoietic/Immune (0.345)   Inflammation (0.656) Trauma (0.182)   Inflammation (0.656) Trauma (0.182)   Inflammation (0.650) Cancer (0.300)   Hematopoietic/Immune (0.400)   Inflammation (0.650) Cancer (0.300)   Inflammation (0.650) Cancer (0.300)   Inflammation (0.650) Cancer (0.300)   Inflammation (0.620) Inflammation/Trauma (0.181)   Musculoskeletal (0.122)   Reproductive (0.212)   Reproductive (0.212)   Reproductive (0.212)   Developmental (0.132)   Cell Proliferation (0.658) Inflammation/Trauma (0.184)   Nervous (0.500) Gastrointestinal (0.100)   Cell Proliferation (0.603) Inflammation/Trauma (0.265)   Hematopoietic/Immune (0.100)   Cell Proliferation (0.603) Inflammation/Trauma (0.265)   Hematopoietic/Immune (0.104)   Cell Proliferation (0.616) Inflammation/Trauma (0.265)   Hematopoietic/Immune (0.140)   Cell Proliferation (0.616) Inflammation/Trauma (0.265)   Reproductive (1.000)   Cell Proliferation (1.000)   Cell Prolifer	240	Nervous (0.273) Reproductive (0.227) Endocrine (0.136)	Cancer (0.545) Cell Proliferation (0.182) Inflammation (0.182)	pINCY
Reproductive (1.000)	241	_ =	Cancer (0.455) Cell Proliferation (0.273) Inflammation (0.273)	pINCY
Reproductive (1.000)         Cancer (1.000)           Hematopoietic/Immune (0.545)         Inflammation (0.636) Trauma (0.182)           Musculoskeletal (0.182) Cardiovascular (0.091)         Inflammation (0.650) Cancer (0.300)           Musculoskeletal (0.182) Cardiovascular (0.150)         Inflammation (0.650) Cancer (0.300)           Musculoskeletal (0.300) Cardiovascular (0.150)         Cancer (0.500) Cell Proliferation (0.650)           Nervous (0.292) Reproductive (0.222)         Cell Proliferation (0.623) Inflammation/Trauma (0.181)           Musculoskeletal (0.125)         Cell Proliferation (0.658) Inflammation/Trauma (0.184)           Nervous (0.500) Gastrointestinal (0.100)         Cell Proliferation (0.605) Inflammation/Trauma (0.260)           Hematopoietic/Immune (0.100)         Cell Proliferation (0.605) Inflammation/Trauma (0.265)           Hematopoietic/Immune (0.140)         Cell Proliferation (0.616) Inflammation/Trauma (0.265)           Nervous (0.308) Cardiovascular (0.140)         Cell Proliferation (0.616) Inflammation/Trauma (0.265)           Reproductive (1.000)         Cell Proliferation (0.616) Inflammation/Trauma (0.265)	242	Endocrine (1.000)	Trauma (1.000)	pSPORTI
Hematopoletic/Immune (0.545)         Inflammation (0.636) Trauma (0.182)           Musculoskeletal (0.182) Cardiovascular (0.091)         Inflammation (0.650) Cancer (0.300)           Musculoskeletal (0.180)         Cardiovascular (0.150)           Urologic (1.000)         Cancer (0.500) Cell Proliferation (0.625) Inflammation/Trauma (0.181)           Nervous (0.292) Reproductive (0.222)         Cell Proliferation (0.625) Inflammation/Trauma (0.184)           Reproductive (0.211) Developmental (0.132)         Cell Proliferation (0.658) Inflammation/Trauma (0.184)           Nervous (0.500) Gastrointestinal (0.100)         Cell Proliferation (0.605) Inflammation/Trauma (0.260)           Hematopoletic/Immune (0.100)         Cell Proliferation (0.605) Inflammation/Trauma (0.260)           Nervous (0.308) Cardiovascular (0.154)         Cell Proliferation (0.615) Inflammation/Trauma (0.269)           Mervous (0.100)         Cell Proliferation (0.616) Inflammation/Trauma (0.269)           Reproductive (1.000)         Cell Proliferation (0.616) Inflammation/Trauma (0.269)	243	Reproductive (1.000)	Cancer (1.000)	pINCY
Hematopoietic/Immune (0.400)   Musculoskeletal (0.300) Cardiovascular (0.150)   Musculoskeletal (0.300) Cardiovascular (0.150)   Cancer (0.500) Cell Proliferation (0.625) Inflammation/Trauma (0.181)   Musculoskeletal (0.125)   Reproductive (0.211) Developmental (0.132)   Cell Proliferation (0.658) Inflammation/Trauma (0.184)   Nervous (0.500) Gastrointestinal (0.100)   Cardiovascular (0.209) Gastrointestinal (0.140)   Cell Proliferation (0.605) Inflammation/Trauma (0.265)   Hematopoietic/Immune (0.140)   Cell Proliferation (0.616) Inflammation/Trauma (0.256)   Hematopoietic/Immune (0.154)   Cell Proliferation (0.616) Inflammation/Trauma (0.269)   Gastrointestinal (0.154)   Cell Proliferation (0.616) Inflammation/Trauma (0.269)   Reproductive (1.000)   Cell Proliferation (1.000)   Cell P	244		Inflammation (0.636) Trauma (0.182) Cancer (0.091)	pINCY
Urologic (1.000)         Cancer (0.500) Cell Proliferation (0.500)           Nervous (0.292) Reproductive (0.222)         Cell Proliferation (0.625) Inflammation/Trauma (0.181)           Reproductive (0.211) Developmental (0.132)         Cell Proliferation (0.658) Inflammation/Trauma (0.184)           Nervous (0.132)         Cell Proliferation (0.658) Inflammation/Trauma (0.184)           Nervous (0.500) Gastrointestinal (0.100)         Cell Proliferation (0.900) Inflammation/Trauma (0.256)           Hematopoietic/Immune (0.140)         Cell Proliferation (0.616) Inflammation/Trauma (0.256)           Nervous (0.308) Cardiovascular (0.154)         Cell Proliferation (0.616) Inflammation/Trauma (0.269)           Reproductive (1.000)         Cell Proliferation (1.000)	245	Hematopoietic/Immune (0.400) Musculoskeletal (0.300) Cardiovascular (0.150)	Inflammation (0.650) Cancer (0.300)	pINCY
Nervous (0.292) Reproductive (0.222)  Musculoskeletal (0.125)  Reproductive (0.211) Developmental (0.132)  Nervous (0.132)  Nervous (0.500) Gastrointestinal (0.300)  Hematopoietic/Immune (0.100)  Cardiovascular (0.209) Gastrointestinal (0.140)  Nervous (0.308) Cardiovascular (0.154)  Nervous (0.308) Cardiovascular (0.154)  Nervous (0.308) Cardiovascular (0.154)  Nervous (0.308) Cardiovascular (0.154)  Cell Proliferation (0.616) Inflammation/Trauma (0.266)  Gastrointestinal (0.154)  Reproductive (1.000)	246	Urologic (1.000)	Cancer (0.500) Cell Proliferation (0.500)	pINCY
Reproductive (0.211) Developmental (0.132)   Cell Proliferation (0.658) Inflammation/Trauma (0.184)     Nervous (0.132)   Nervous (0.500) Gastrointestinal (0.300)   Cell Proliferation (0.900) Inflammation/Trauma (0.300)     Hematopoietic/Immune (0.100)   Cell Proliferation (0.605) Inflammation/Trauma (0.256)   Hematopoietic/Immune (0.140)   Cell Proliferation (0.616) Inflammation/Trauma (0.256)   Cell Proliferation (0.616) Inflammation/Trauma (0.269)   Cell Proliferation (0.616) Inflammation/Trauma (0.269)   Cell Proliferation (1.000)   Cell Proliferation (1.	247	Nervous (0.292) Reproductive (0.222) Musculoskeletal (0.125)	Cell Proliferation (0.625) Inflammation/Trauma (0.181)	pSPORTI
Nervous (0.500) Gastrointestinal (0.100) Hematopoietic/Immune (0.100) Call Proliferation (0.900) Inflammation/Trauma (0.300) Cardiovascular (0.209) Gastrointestinal (0.140) Hematopoietic/Immune (0.140) Nervous (0.308) Cardiovascular (0.154) Gastrointestinal (0.154) Reproductive (1.000)  Cell Proliferation (0.616) Inflammation/Trauma (0.269) Cell Proliferation (1.000)	248	Reproductive (0.211) Developmental (0.132) Nervous (0.132)	Cell Proliferation (0.658) Inflammation/Trauma (0.184)	pSPORTI
Cardiovascular (0.209) Gastrointestinal (0.140) Hematopoietic/Immune (0.140) Nervous (0.308) Cardiovascular (0.154) Gastrointestinal (0.154) Reproductive (1.000)  Cell Proliferation (0.616) Inflammation/Trauma (0.269) Cell Proliferation (1.000)	249	Nervous (0.500) Gastrointestinal (0.300) Hematopoietic/Immune (0.100)	Cell Proliferation (0.900) Inflammation/Trauma (0.300)	pSPORT1
Nervous (0.308) Cardiovascular (0.154)  Gastrointestinal (0.154)  Reproductive (1.000)  Cell Proliferation (0.616) Inflammation/Trauma (0.269)	250		Cell Proliferation (0.605) Inflammation/Trauma (0.256)	pINCY
Reproductive (1.000)	251	Nervous (0.308) Cardiovascular (0.154) Gastrointestinal (0.154)	Cell Proliferation (0.616) Inflammation/Trauma (0.269)	pINCY
	252		Cell Proliferation (1.000)	pSPORTI

253 Reproductive (0.324) Nervous (0.162) Gastrointestinal (0.113) 254 Reproductive (0.315) Nervous (0.296) Developmental (0.093) 255 Nervous (0.211) Reproductive (0.211) Gastrointestinal (0.158) Reproductive (0.250) Gastrointestinal (0.148) Hematopoietic/Immune (1.000) 257 Hematopoietic/Immune (1.000) 258 Cardiovascular (0.333) Reproductive (0.333) Developmental (0.167) 259 Cardiovascular (0.333) Reproductive (0.250) Developmental (0.167)		Cell Proliferation (0.641) Inflammation/Trauma (0.197) Cell Proliferation (0.630) Inflammation/Trauma (0.278) Cell Proliferation (0.579) Inflammation/Trauma (0.298)	pSPORT1 pSPORT1
255 257 257 258 259		Cell Proliferation (0.630) Inflammation/Trauma (0.278) Cell Proliferation (0.579) Inflammation/Trauma (0.298)	pSPORTI
255 256 257 258 259	- 1	Cell Proliferation (0.579) Inflammation/Trauma (0.298)	pINCY
258 259 259			
	148)	Cell Proliferation (0.705) Inflammation/Trauma (0.193)	pINCY
258 259		Cell Proliferation (0.400) Inflammation/Trauma (0.600)	pINCY
259	133)	Cell Proliferation (0.833) Inflammation/Trauma (0.333)	PBLUESCRIPT
		Cell Proliferation (0.625) Inflammation/Trauma (0.208)	pINCY
	$\vdash$	Cell Proliferation (0.750) Inflammation/Trauma (0.500)	pINCY
261 Reproductive (0.252) Cardiovascular (0.155) Hematopoietic/Immune (0.136)		Cell Proliferation (0.728) Inflammation/Trauma (0.194)	pINCY
262 Reproductive (0.274) Cardiovascular (0.177) Nervous (0.145)		Cell Proliferation (0.742) Inflammation/Trauma (0.210)	pINCY
263 Reproductive (0.267) Cardiovascular (0.160) Hematopoietic/Immune (0.127)		Cell Proliferation (0.654) Inflammation/Trauma (0.193)	pINCY
264 Nervous (0.229) Hematopoietic/Immune (0.200) Reproductive (0.200)		Cell Proliferation (0.743) Inflammation/Trauma (0.286)	pINCY
265 Hematopoietic/Immune (0.333) Gastrointestinal (0.167) Nervous (0.133)		Cell Proliferation (0.600) Inflammation/Trauma (0.333)	pINCY

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease/Condition-Specific Expression (Total of Fraction)	Vector
266	Nervous (0.290) Reproductive (0.258) Cardiovascular (0.129)	Cell Proliferation (0.677) Inflammation/Trauma (0.194)	pINCY
267	Reproductive (0.261) Hematopoietic/Immune (0.217). Cardiovascular (0.087)	Cell Proliferation (0.652) Inflammation/Trauma (0.391)	pINCY
268	Gastrointestinal (0.227) Reproductive (0.193) Hematopoietic/Immune (0.168)	Cell Proliferation (0.731) Inflammation/Trauma (0.227)	pSPORTI

#### TABLE 4

Library Description	The library was constructed using RNA isolated from plastic adherent mononuclear cells isolated from buffy coat units obtained from unrelated male and female donors.	The library was constructed using RNA isolated from peripheral blood granulocytes collected by density, gradient centrifugation through Ficoll-Hypaque. The cells were isolated from buffy coat units obtained from 20 unrelated male and female donors. Cells were cultured in 10 nM GM-CSF for 1 hour before washing and harvesting for RNA preparation.	The library was constructed using RNA isolated from the cerebellum tissue of a 69-year-old Caucasian male who died from chronic obstructive pulmonary disease. Patient history included myocardial infarction, hypertension, and osteoarthritis.	The library was constructed using RNA isolated from the knee synovial membrane tissue of an 82-year-old female with osteoarthritis.	The library was constructed using RNA isolated from ovarian tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology for the associated tumor tissue indicated grade 2 mucinous cystadenocarcinoma. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, cerebrovascular disease, breast cancer, and uterine cancer.	The lighary was constructed using RNA isolated from the brain tissue of a 44-year-old Caucasian male with a cerebral hemorrhage. The tissue, which contained coagulated blood, came from the choroid plexus of the right anterior temporal lobe. Family history included coronary artery disease and mysecardial infarction.
			_			
Library	MPHGNOT03	NEUTGMT01	CRBLNOT0	SYNOOAT0	OVARNOT03	BRAINOT04
Clone ID	443531	632860	670010	726498	795064	924925
Polynucleotide SEQ ID NO:	135	136	137	-118-	139	140

ary Library Description	The library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.	The library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer.	The library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, atherosclerotic coronary artery disease, and type II diabetes.	The library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-cid Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, atherosclerotic coronary artery disease, and type II diabetes.	OT02 The library was constructed using RNA isolated from the placental tissue of a Hispanic female fetus, who was prematurely delivered at 21 weeks' gestation. Serologies of the mother's blood were positive for CMV (extomegalovirus)
Library	BRSTTUT03 The I old C multi quad Patier Patier Famili	MENITUT03 The light of the ligh	BRSTNOT07 The li year-i mildi) Patho adeno	BRSTNOT07 The li year-c year-c mildly Patho adeno coron:	PLACNOT02 The III fetus, positiv
Clone ID	962390	1259405	1297384	1299627	1306026
Polynucleotide SEQ ID NO:	14]	. 142	119- <del>7</del>	144	145

Library Description	The library was constructed using RNA isolated from bladder tumor tissue removed from an 80-year-old Caucasian female during a radical cystectomy and lymph node excision. Pathology indicated grade 3 invasive transitional cell carcinoma. Family history included osteoarthritis and atherosclerosis.	The library was constructed using RNA isolated from the pancreatic tissue of a Caucasian male fetus, who died at 23 weeks' gestation.	The library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease.	The library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, benign neoplasm in the large bowel, and a cataract. Family history included cardiovascular disease, type II diabetes, and stomach cancer.	The library was constructed using RNA isolated from lung tissue removed from a 69-year-old Caucasian male during a segmental lung resection. Pathology for the associated tumor tissue indicated residual grade 3 invasive squamous cell carcinoma. Patient history included acute myocadial infarction, prostatic hyperplasia, and malignant skin neoplasm. Family history included cerebrovascular disease, type I diabetes, acute myocardial infarction, and arteriosclerotic coronary disease.	The library was constructed using RNA isolated from prostate tumor tissue removed from a 60-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 3+4). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included a kidney cyst. Family history included tuberculosis, cerebrovascular disease, and arteriosclerotic coronery artery disease.
Library	BLADTUT02	PANCNOT07	CORPNOT02	PANCTUT01	LUNGNOTIS	PROSTUT08
Clone ID	1316219	1329031	1483050	1514160	1603403	1652303
Polynucleotide SEQ ID NO:	146	147	148	149	150	151

Clone ID Library Library Description	The library was constructed using RNA isolated from diseased colon tissue removed from a 16-year-old Caucasian male during a total colectomy with abdominal/perineal resection. Pathology indicated gastritis and pancolonitis consistent with the acute phase of ulcerative colitis. There was only mild involvement of the ascending and sigmoid colon, and no significant involvement of the cecum, rectum, or terminal ileum. Family history included irritable bowel syndrome.	1707711 DUODNOT02 The library was constructed using RNA isolated from duodenal tissue of a 8-year-old Caucasian female, who died from head trauma. Serology was positive for cytomegalovirus (CMV).	The library was constructed using RNA isolated from colon tissue removed from a 56-year-old Caucasian female with Crohn's disease during a partial resection of the small intestine. Pathology indicated Crohn's disease of the ileum and ileal-colonic anastomosis, causing a fistula at the anastomotic site that extended into pericolonic fat. The ileal mucosa showed linear and puncture ulcers with intervening normal tissue. Previous surgeries included a partial ileal resection and permañent ileostomy. Family history included irritable bowel syndrome.	1749147 STOMTUT02 The library was constructed using RNA isolated from stomach tumor tissue obtained from a 68- year-old Caucasian female during a partial gastrectomy. Pathology indicated a malignant lymphoma of diffuse large-cell type. Patient history included thalassemia. Family history included acute leukemia, malignant neoplasm of the esophagus, malignant stomach neoplasm, and atherosclerotic coronary artery disease.	1817722 The literary was constructed using RNA isolated from diseased prostate tissue removed from a 65-year-old Caucasian male during a radical prostatectomy. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma.	1831290 THP1AZT01 The library was constructed using 1 microgram of polyA RNA isolated from THP-1 promonocyte cells treated for three days with 0.8 micromolar 5-aza-2'-deoxycytidine. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia
Clone ID						
Polynucleotide SEQ ID NO:	152	153	154	155	156	157

<u> </u>	Polynucleotide SEQ ID NO:	Clone ID	Library	Library Description
<u> </u>	166	1877885	LEUKNOT03	The library was constructed using RNA isolated from white blood cells of a 27-year-old female with blood type A+. The donor tested negative for cytomegalovirus (CMV).
	167	1889269	BLADTUT07	The library was constructed using RNA isolated from bladder tumor tissue removed from the anterior bladder wall of a 58-year-old Caucasian male during a radical cystectomy, radical prostat-sctomy, and gastrostomy. Pathology indicated a grade 3 transitional cell carcinoma in the left lateral bladder. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
-12	168	1890243	BLADTUT07	The library was constructed using RNA isolated from bladder tumor tissue removed from the anterior bladder wall of a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, and gastrostomy. Pathology indicated a grade 3 transitional cell carcinoma in the left lateral cladder. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
2	169	1900433	BLADTUT06	The library was constructed using RNA isolated from bladder tumor tissue removed from the posterior bladder wall of a 58-year-old Caucasian male during a radical cyslectomy, radical prostatectomy, and gastrostomy. Pathology indicated grade 3 transitional cell carcinoma in the left lateral bladder wall. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
	170	1909441	CONNTUT01	The library was constructed using RNA isolated from a soft tissue tumor removed from the clival area of the skull of a 30-year-old Caucasian female. Pathology indicated chondroid chordoma with neoplastic cells reactive for keratin.
	171	1932226	COLNNOT16	The library was constructed using RNA isolated from sigmoid colon tissue removed from a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy.
	172	1932647	COLNNOT16	The library was constructed using RNA isolated from sigmoid colon tissue removed from a 62- year-old Caucasian male during a sigmoidectomy and permanent colostomy.

Polynucleotide SEQ ID NO:	Clone ID	Library	Library Description
173	2124245	BRSTNOT07	The library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, atherosclerotic coronary artery disease, and type II diabetes.
	2132626	OVARNOT03	The library was constructed using RNA isolated from ovarian tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology for the associated fumor tissue indicated grade 2 mucinous cystadenocarcinoma. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, cerebrovascular disease, breast cancer, and uterine cancer.
<u>\$2</u>	2280639	PROSNON01	The library was constructed and normalized from 4.4 million independent clones from the PROSNOT11 library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a gunshot wound. The normalization and hybridization conditions were adapted from Soares, M.B. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228-9232, using a longer (?9 hour) reannealing hybridization period.
176	2292356	BRAINON01	The library was constructed and normalized from 4.88 million independent clones from the BRAINCT03 library. Starting RNA was made from brain tissue removed from a 26-year-old Caucasien male during cranioplasty and excision of a cerebral meningeal lesion. Pathology for the associated tumor tissue indicated a grade 4 oligoastrocytoma in the right fronto-parietal part of the brain.
177	2349310	COLSUCTOI	The library was constructed using RNA isolated from diseased sigmoid colon tissue obtained from a 70-year-fold Caucasian male during colectomy with permanent ileostomy. Pathology indicated chronic ulcerative colitis. Patient history included benign neoplasm of the colon. Family history included atherosclerotic coronary artery disease and myocardial infarctions.
178	2373227	ADRENOT07	The library was constructed using RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands.

-124-

cleotide Clone ID Library Library Library Description	The library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.	80 2480426 SMCANOT01 The library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.	The library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-ophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites.	2537684 BONRTUT01 The library was constructed using RNA isolated from rib tumor tissue removed from a 16-year-old Caucasian male during a rib osteotomy and a wedge resection of the lung. Pathology indicated a metastatic grade 3 (of 4) osteosarcoma, forming a mass involving the chest wall.	The library was constructed using RNA isolated from ovarian tumor tissue removed from a 51- year-old Caucasian female during an exploratory laparotomy, total abdominal hysterectomy, salpingo-oophorectomy, and an incidental appendectomy. Pathology indicated mucinous cystadenoma presenting as a multiloculated neoplasm involving the entire left ovary. The right ovary contained a follicular cyst and a hemorrhagic corpus luteum. The uterus showed proliferative endometrium and a single intramural leiomyoma. The peritoneal biopsy indicated benign glandular inclusions consistent with endosalpingiosis. Family history included atherosclerotic coronary artery diseasts, benign hypertension, breast cancer, and uterine cancer.	2622354 KERANOT02 The library was constructed using RNA isolated from epidermal breast keratinocytes (NHEK).
Polynucleotide SFO ID NO:	621	180	181	182	₩	184

<u> </u>		<del></del>	<del></del>	
Library Description	The library was constructed using RNA isolated from ovarian tumor tissue removed from the left ovary of a 52-year-old mixed ethnicity female during a total abdominal hysterectomy, bilateral salpingo-ophorectomy, peritoneal and lymphatic structure biopsy, regional lymph node excision, and peritoneal tissue destruction. Pathology indicated an invasive grade 3 (of 4) seroanaplastic carcinoma forming a mass in the left ovary. The endometrium was atrophic. Multiple (2) leiomyomata were identified, one subserosal and 1 intramural. Pathology also indicated a metastatic grade 3 seroanaplastic carcinoma involving the omentum, cul-de-sac peritoneum, left broad ligament peritoneum, and mesentery colon. Patient history included breast cancer, chronic peptic ulcer, and joint pain. Family history included colon cancer, cerebrovascular disease, breast cancer, type 11 diabetes, esophagus cancer, and depressive disorder.	The lighary was constructed using RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma in the right bladder base. Family history included myocardial infarction, cerebrovascular disease, brain cancer, and myocardial infarction.	The library was constructed using RNA isolated from bladder tumor tissue removed from a 72-year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma in the right bladder base. Patient history included pure hypercholesterolemia and tobacco abuse. Family history included myocardial infarction, cerebrovascular disease, brain cancer, and myocardial infarction.	The library was constructed using RNA isolated from breast tissue removed from a 62-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor-dissue indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma, ductal type. Ductal carcinoma in situ, comedo type, comprised 60% of the tumor mass. Metastatic adenocarcinoma was identified in one (of 14) axillary lymph nodes with no perinodal extension. The tumor cells were strongly positive for estrogen receptors and weakly positive for progesterone receptors. Patient history included a benign colon neoplasm, hyperlipidemia, and cardiac dysrhythmia. Family history included atherosclerotic coronary artery disease, myocardial infarction, colon cancer. June cancer. and cerebrovascular disease.
Library	OVARTUT03	BLADTUT08	BLADTUT08	BRSTNOT14
Clone ID	2779436	2808528	2809230	2816821
Polynucleotide SEQ ID NO:	188	190	191	192
<u> </u>		-127-		

Pelynucleotide Clone ID Library The library was constructed using RNA isolated from breast tissue removed from a 62-year-old Cauciasian: female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 (of 3) nuclear grade 3 (of 3) adenocarcinoma, dural tissue indicated an invasive grade 3 (of 4) anches grade 1 (of 3) adenocarcinoma, dural tissue indicated an invasive grade 3 (of 4) anches grade 1 (of 3) adenocarcinoma, dural tissue indicated an invasive grade 3 (of 4) anches grade 1 (of 3) adenocarcinoma, detailed upon 60 (of 1) audillary lymph nodes with no perindal extension. The timor calls were strongly positive for estrogen receptors and weakly positive for progesterone cereptors. Patient history included a benign colon neophasm, hyperlipidemia, and cardiac of synthylinia. Emily history included a benign colon neophasm, hyperlipidemia, and cardiac of synthylinia. Emily history included a benign colon neophasm, hyperlipidemia, and cardiac of synthylinia. Emily history included a benign colon neophasm, hyperlipidemia, and cardiac of synthylinia. Emily history included a benign colon neophasm, hyperlipidemia, and cardiac of synthylinia. Emily history included a benign colon neophasm. Permanent colostomy, permanent colostomy, and an incidental appendence on the synthylinia of the small intestine.  195 2949822 KIDNFET01 The library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus, who died at 17 weeks gestation from anemored from a caucasian male fetus, who died at 17 weeks gestation from an entrephalus.  198 3044710 HEAANOT01 The library was constructed using RNA isolated from kidney tissue removed from a caucasian male fetus, who was stillborn with a hypoplastic left heart and died at 23 weeks gestation.  198 3044710 HEAANOT01 The library was constructed using RNA isolated from might coronary and right circumparatory or the library was constructed using RNA isolated from might coronary and right circumparat			<del></del>	<del>,</del>	<del></del>		<del></del>
2817268 2923165 2949822 1 2992192 P		The library was constructed using RNA isolated from breast tissue removed from a 62-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma, ductal type. Ductal carcinoma in situ, comedo type, comprised 60% of the tumor mass. Metastatic adenocarcinoma was identified in one (of 14) axillary lymph nodes with no perinodal extension. The tumor cells were strongly positive for estrogen receptors and weakly positive for progesterone receptors. Patient history included a benign colon neoplasm, hyperlipidemia, and cardiac dysrhythmia. Family history included atherosclerotic coronary artery disease, myocardial infarction, colon gancer, ovarian cancer, lung cancer, and cerebrovascular disease.	The library was constructed using RNA isolated from diseased ileum tissue obtained from a 26-year-old Caucasian male during a partial colectomy, permanent colostomy, and an incidental appendectomy. Pathology indicated moderately to severely active Crohn's disease. Family history included enteritis of the small intestine.	The library was constructed using RNA isolated from kidney tissue removed from a Caucasian female fetus, who died at 17 weeks' gestation from anencephalus.	The library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart and died at 23 weeks' gestation.	The library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus, who was stillborn with a hypoplastic left heart and died at 23 weeks' gestation.	The library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old Caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, and left ventricular dysfunction. Previous surgeries included cardiac cathererization. Eamily history included at heacel and a surgeries.
	Library	BRSTNOT14	SININOT04	KIDNFET01	KIDNFET02	KIDNFET02	HEAANOT01
Polynucleotide SEQ ID NO: 193 195 196 197 198	Clone ID	2817268	2923165	2949822	2992192	2992458	3044710
	Polynucleotide SEQ ID NO:	193	194	195	196	197	198

Polynucleotide	Library Description	The library was constructed using RNA isolated from tumorous lung tissue removed from the right upper libe of a 47-year-old Caucasian male during a segmental lung resection. Pathology indicated invasive grade 3 (of 4) adenocarcinoma. Family history included atherosclerotic coronary artery disease, and type II diabetes.	The library was constructed at Stratagene using RNA isolated from the lung tissue of a 72-year-old male.	The library was constructed using RNA isolated from the cerebellum tissue of a 69-year-old Caucasian male who died from chronic obstructive pulmonary disease. Patient history included myocardial infarction, hypertension, and osteoarthritis.	The library was constructed using RNA isolated from brain tumor tissue removed from a 50-year-old Caucasian female during a frontal lobectomy. Pathology indicated recurrent grade 3 oligosizrocytoma with focal necrosis and extensive calcification. Patient history included a speech disturbance and epilepsy. The patient's brain had also been irradiated with a total dose of 5,082 cyg (Fraction 8). Family history included a brain tumor.	The library was constructed using RNA isolated from lung tissue removed from a Caucasian feniale fetus who died at 20 weeks' gestation.	The library was constructed using RNA isolated from lung tissue removed from a 78-year-old Caucasian male during a segmental lung resection and regional lymph node resection. Pathology indicated fibrosis pleura was puckered, but not invaded. Pathology for the associated tumor tissue indicated an invasive pulmonary grade 3 adenocarcinoma. Patient history included cerebrovascular disease, arteriosclerotic coronary artery disease, thrombophlebitis, chronic obstructive pulmonary disease, and asthma. Family history included intracranial hematoma, cerebrovascular disease, arteriosclerotic coronary artery disease, and type I diabetes.
	Library	LUNGTUTI3	LUNGNOT01	•*•		,	
Polynucleotide SEQ ID NO: 199 200 202 203 203	Clone ID	3120415	126758	674760	1229438	1236935	1359283
	Polynucleotide SEQ ID NO:	661	200	. 201	202	203	204

Library Description	The library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-cld Caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.	The library was constructed using RNA isolated from a soft tissue tumor removed from the clival area of the skull of a 30-year-old Caucasian female. Pathology indicated chondroid chordoma with neoplastic cells reactive for keratin.	The library was constructed using RNA isolated from mesentery fat tissue obtained from a 71-year-old Caprasian male during a partial colectomy and permanent colostomy. Family history included atherosclerotic coronary artery disease, myocardial infarction, and extrinsic asthma.	The library was constructed using RNA isolated from breast tissue removed from a 62-year-old East Indian female during a unilateral extended simple mastectomy. Pathology for the associated tumor thissue indicated an invasive grade 3 ductal carcinoma. Patient history included benign hypertension, hyperlipidemia, and hematuria. Family history included cerebrovascular and cardiovascular disease, hyperlipidemia, and liver cancer.	The lineary was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease.	The library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease
Library	PENITUT01 The year 4 so per per dissipation of the year 1 decision o	CONNTUTO! The	CONNNOT01 The old athe	BRSTNOT04 The East tum hyp card	CORPNOT02 The from	CORPNOT02 The
Clone ID	1450703	1910668	1955143	1961637	1990762	1994131
Polynucleotide SEQ ID NO:	205	206	207	208	209	210

Library Description	g RNA isolated fre illateral extended to ular carcinoma. The ules were found in cer, rheumatic hear ascular disease, co artery disease, and	/A RNA isok m liver diseas	NA isola rer diseas	ed fro pian tu adenoc ily hisi	ed from the state of the state
	The library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant; and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.	The library was constructed using polyA RNA isolated from testicular tissue removed from a 37-year-old Caucasian male who died from liver disease. Patient history included cirrhosis, jaundice, and live: failure.	The library was constructed using polyA RNA isolated from testicular tissue removed from a 37-year-old Caucasian male who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.	The library was constructed using RNA isolated from ovarian tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology for the associated tumor tissue indicated grade 2 mucinous cystadenocarcinoma. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.	The library was constructed using RNA isolated from ovarian tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology for the associated tumor tissue indicated grade 2 mucinous cystadenocarcinoma. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine
Library	BRSTTUT03	TESTNOT03	TESTNOT03	OVARNOT03	OVARNOT03
Clone ID	1997745	2009035	2009152	2061752	2061933
Polynucleotide SEQ ID NO:	211	. 212	213	214	215

ry Library Description	The library was constructed using RNA isolated from uterine tissue removed from a 35-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated that the endometrium was secretory phase with a benign endometrial polyp 1 cm in diameter. The cervix showed mild chronic cervicitis. Family history included atherosclerotic coronary artery disease and type 11 diabetes.	The library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney.	The library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes.	The library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia and atheresclerotic coronary artery disease.	This normalized prostate library was constructed from 4.4 M independent clones from the PROSNOT11 library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a self-inflicted gunshot wound. The normalization and hybridization conditions were adapted from Soares, M.B. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228-9232, using a labeled from hybridization pariod.
Library	UTRSNOT08 C	BRAITUT02 Ti lo in cs cs	BRSTNOT07 17	PANCTUT02 TH	PROSNON01 TP
Clone ID	2081422	2101278	2121353	2241736	2271935
Polynucleotide SEQ ID NO:	216	217	8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	219	220

-132-

	r-old riated uded ed	ld ted ed	old na.	ed an odes and and sease,	F bic
Library Description	The library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, ostcoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes.	The library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes.	The ligrary was constructed RNA isolated from adrenal tumor tissue removed from a 52-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated a pheochromocytoma.	The library was constructed using RNA isolated from lung tumor tissue removed from the right lower lobe a 57-year-old Caucasian male during a segmental lung resection. Pathology indicated an infiltrating grade 4 squamous cell carcinoma. Multiple intrapulmonary peribronchial lymph nodes showed metastatic squamous cell carcinoma. Patient history included a benign brain neoplasm and tobacco abuse. Family history included spinal cord cancer, type II diabetes, cerebrovascular disease, and malignant prostate neoplasm.	The lithery was constructed using RNA isolated from lung tumor tissue removed from a 68-year-old Caucasian male during segmental lung resection. Pathology indicated invasive grade 3 squamous cell carcinoma and a metastatic tumor. Patient history included type II diabetes, thyroid disorder, depressive disorder, hyperlipidemia, esophageal ulcer, and tobaccourse.
Library	BRSTNOT05	BRSTNOT05	ADRETUT05	LUNGTUTII	LUNGTUT09
Ciolle 1D	2295344	2303994	2497805	2646362	2657146
SEQ ID NO:	221	222	223	224	225
		2295344 BRSTNOT05	2295344 BRSTNOT05 2303994 BRSTNOT05	2295344 BRSTNOT05 2303994 BRSTNOT05 2497805 ADRETUT05	221 2295344 BRSTNOT05 222 2303994 BRSTNOT05 223 2497805 ADRETUT05 224 2646362 LUNGTUT11

Library Description	This subtracted THP-1 promonocyte cell line library was constructed using 5.76 million clones from a 5-aza-2'-deoxycytidine (AZ) treated THP-1 cell library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. The hybridization probe for subtraction was derived from a similarly constructed library, made from RNA isolated from untreged THP-1 cells. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NÁR (1991) 19:1954, and Bonaldo et al., Genome Research (1996) 6:791. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia.	The library was constructed using RNA isolated from nonactivated Th1 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-12 and B7-transfected COS cells.	The library was constructed using RNA isolated from tumorous lung tissue removed from the right upper lobe of a 47-year-old Caucasian male during a segmental lung resection. Pathology indicated invasive grade 3 (of 4) adenocarcinoma. Family history included atherosclerotic coronary artery disease, and type II diabetes.	The library was constructed using RNA isolated from tumorous lung tissue removed from a 70-year-old Caucasian female during a lung lobectomy of the left upper lobe. Pathology indicated grade & (of 4) adenocarcinoma and vascular invasion. Patient history included tobacco abuse, depressive disorder, anxiety state, and skin cancer. Family history included cerebrovascular disease, congestive heart failure, colon cancer, depressive disorder, and primary liver.	The library was constructed using RNA isolated from the HMC-1 human mast cell line derived from a \$2-year-old female. Patient history included mast cell leukemia.	The library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus who died at 20 weeks' gestation.	The literary was constructed using RNA isolated from ascending colon tissue of a 28-year-old
Library	THPI AZS08	TLYMNOT03	LUNGTUTI3	בטאפדטדונ	HMC1NOT01	LUNGFET03	COLNNOTI3
Clone ID	2755786	2831245	3116250	3129630	007632	1236968	1334153
Polynucleotide SEQ ID NO:	226	227	228	529	230	231	232

Polynucleotide	Clone ID	Library	Library Description
SEQ ID NO:			
	1396975	BRAITUT08	The library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 47-year-old Caucasian male during excision of cerebral meningeal tissue. Pathology indicated grade 4 fibrillary astrocytoma with focal tumoral radionecrosis. Patient history included cerebrovascular disease, deficiency anemia, hyperlipidemia, epilepsy, and tobacco use. Family history included cerebrovascular disease and malignant prostate neoplasm.
	1501749	SINTBST01	The library was constructed using RNA isolated from ileum tissue removed from an 18-year-old Caucasian female during bowel anastomosis. Pathology indicated Crohn's disease of the ileum. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
	1575240	LNODNOT03	The library was constructed using RNA isolated from lymph node tissue removed from a 67-year-old Caucasian male during a segmental lung resection and bronchoscopy. This tissue was extensively necrotic with 10% viable tumor. Pathology for the associated tumor tissue indicated invasive grade 3-4 squamous cell carcinoma. Patient history included hemangioma. Family history included hemangioma. Family history included atherosclerotic coronary artery disease, benign hypertension, and congestive heart failure.
	1647884	PROSTUT09	The library was constructed using RNA isolated from prostate tumor tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology indicated grade 3 transitional cell carcinoma. Patient history included lung neoplasm, and benton hypertension. Family history included malignant breast neoplasm, tuberculosis, cerebrovascular disease, atherosclerotic coronary artery disease, and lung cancer.
	1661144	BRSTNOT09	The lighary was constructed using RNA isolated from breast tissue removed from a 45-year-old Caucasian female during unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated invasive nuclear grade 2-3 adenocarcinoma. Patient history included valvuiopiasty of mirral valve and rheumatic heart disease. Family history included cardiovascular disease and type II diabetes.

Library Description	The library was constructed using RNA isolated from diseased prostate tissue removed from a 66-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 2+3). The patient presented with elevated prostate specific antigen (PSA). Family history included prostate cancer, secondary bone cancer, and benign hyperension.	The library was constructed using RNA isolated from breast tumor tissue removed from a 45-year-old Caucasian female during unilateral extended simple mastectomy. Pathology indicated invasive nuclear grade 2-3 adenocarcinoma. Patient history included valvuloplasty of mitral valve and rheumgiric heart disease. Family history included cardiovascular disease and type II diabetes.	The liprery was constructed using RNA isolated from breast tissue removed from a 62-year-old Caucastan female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma. Patient history included a benign colon neoplasm, hyperlipidemia, cardiac dysrhythmia, and obesity. Family history included cardiovascular and cerebrovascular disease and colon, ovary and lung cances.	The library was constructed using RNA isolated from kidney tissue removed a 65-year-old Cauczajan male during an exploratory laparotomy and nephroureterectomy. Pathology for the associated tumor tissue indicated grade 1 renal cell carcinoma within the upper pole of the left kidney. Patient history included malignant melanoma of the abdominal skin, benign neoplasm of colon, corebrovascular disease, and umbilical hernia. Family history included myocardial infarction, atherosclerotic coronary artery disease, cerebrovascular disease, and prostate cancer.	The normalized adrenal gland library was constructed from 1.36 x 1e6 independent clones from an adrenal issue library. Starting RNA was made from adrenal gland tissue removed from a 20-year-old Caucasian male who died from head trauma. The library was normalized in two rounds using conditions adapted from Soares et al. (PNAS (1994) 91:9228-9232) and Bonaldo et al. (Genome Res (1996) 6: 791-806) using a significantly longer (48-hours/round) reannealing hybridization period.	
Library	PROSNOT15	BRSTTUT08	BRSTNOT14	KIDNNOT19	ADRENON04	
Clone ID	1685409	1731419	2650265	2677129	3151073	
Polynucleotide SEQ ID NO:	238	239	240	241	242	

Polynucleotide SEO ID NO:	Clone ID	Library	Library Description
243	3170095	BRSTNOT18	The library was constructed using RNA isolated from diseased breast tissue removed from a 57-year-old Caucasian female during a unilateral simple extended mastectomy. Pathology indicated mildly proliferative breast disease. Patient history included breast cancer and osteoarthritis. Family history included type II diabetes, gallbladder and breast cancer, and chronic lymphocytic leukemia.
244	3475168	LUNGNOT27	The library was constructed using RNA isolated from lung tissue removed from a 17-year-old Hispanic female.
245	3836893	DENDTNT01	The library was constructed using RNA isolated from treated dendritic cells from peripheral blood.
246	4072159	KIDNNOT26	The library was constructed using RNA isolated from left kidney medulla and cortex tissue removed from a 53-year-old Caucasian female during a nephroureterectomy. Pathology for the associated tumor tissue indicated grade 2 renal cell carcinoma involving the lower pole of the kidnes. Patient history included hyperlipidemia, cardiac dysrhythmia, menorrhagia, cerebrovascular disease, atherosclerotic coronary artery disease, and tobacco abuse. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
247	9168001	BRSTNOT03	The library was constructed using RNA isolated from diseased breast tissue removed from a 54-year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Patient history included kidney infection and condyloma acuminatum. Family history included benign hypergesion, hyperlipidemia and a malignant neoplasm of the colon.
248	2093492	PANCNOT04	The library was constructed using RNA isolated from the pancreatic tissue of a 5-year-old Caucasian male who died in a motor vehicle accident.
249	2108789	BRAITUT03	The library was constructed using RNA isolated from brain tumor tissue removed from the left frontal tobe a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small-cell astrocytoma. Family history included benign hypertension and cerebrovascular disease.
250	2171401	ENDCNOT03	The library was constructed using RNA isolated from dermal microvascular endothelial cells removed from a neonatal Caucasian male.

Polynucleotide SEQ ID NO:	Clone ID	Library	Library Description
251	2212530	SINTFET03	The library was constructed using RNA isolated from small intestine tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation.
252	2253036	OVARTUT01	The library was constructed using RNA isolated from ovarian tumor tissue removed from a 43-year-old-Caucasian female during removal of the fallopian tubes and ovaries. Pathology indicated grade 2 mucinous cystadenocarcinoma involving the entire left ovary. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.
253	2280161	PROSNON01	The normalized prostate library was constructed from 4.4 M independent clones from the PROSNOT11 library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a self-inflicted gunshot wound. The normalization and hybridization conditions were adapted from Soares, M.B. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228-9232, using â longer (19 hour) reannealing hybridization period.
254	2287485	BRAINON01	The library was constructed and normalized from 4.88 million independent clones from the BRAINOT03 library. RNA was made from brain tissue removed from a 26-year-old Caucasian male during cranioplasty and excision of a cerebral meningeal lesion. Pathology for the associated tumor tissue indicated a grade 4 oligoastrocytoma in the right fronto-parietal part of the brain.
255	2380344	ISLTNOT01	The library was constructed using RNA isolated from a pooled collection of pancreatic islet cells.
256	2383171	ISLTNOT01	The liprary was constructed using RNA isolated from a pooled collection of pancreatic islet cells.
257	2396046	THP1AZT01	The library was constructed using RNA isolated from THP-1 promonocyte cells treated for three days with 0.8 micromolar 5-aza-2'-deoxycytidine. THP-1 (ATCC TIB 202)is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia.
258	2456587	ENDANOT01	The library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.

Polynucleotide SEQ ID NO:	Clone ID	Library	Library Description
259	2484813	BONRTUT01	The library was constructed using RNA isolated from rib tumor tissue removed from a 16-year-old Caucasian male during a rib osteotomy and a wedge resection of the lung. Pathology indicated a metasiatic grade 3 (of 4) osteosarcoma, forming a mass involving the chest wall.
260	2493851	ADRETUT05	The fibrary was constructed RNA isolated from adrenal tumor tissue removed from a 52-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated a pheochromocytoma.
261	2495719	ADRETUT05	The library was constructed RNA isolated from adrenal tumor tissue removed from a 52-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated a pheochromocytoma.
262	2614153	GBLANOT01	The library was constructed using RNA isolated from diseased gallbladder tissue removed from a 53-year-old Caucasian female during a cholecystectomy. Pathology indicated mild chronic cholecystitis and cholelithiasis with approximately 150 mixed galistones. Family history included benign hypertension.
263	2655184	THYMNOT04	The library was constructed using RNA isolated from thymus tissue removed from a 3-year-old Caucastan male, who died from anoxia. Serologies were negative. The patient was not taking any medications.
264	2848362	BRSTTUT13	The library was constructed using RNA isolated from breast tumor tissue removed from the right breast of a 46-year-old Caucasian female during a unilateral extended simple mastectomy with breast reconstruction. Pathology indicated an invasive grade 3 adenocarcinoma, ductal type with apocrine features and greater than 50% intraductal component. Patient history included breast cancer.
265	2849906	BRSTTUT13	The library was constructed using RNA isolated from breast tumor tissue removed from the right breast of a 46-year-old Caucasian female during a unilateral extended simple mastectomy with breast reconstruction. Pathology indicated an invasive grade 3 adenocarcinoma, ductal type with apocrine features and greater than 50% intraductal component. Patient history included breast cancer.

		<del></del>	T
Library Description	The litrary was constructed using RNA isolated from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.	The library was constructed using RNA isolated from diseased cartilage tissue. Patient history included osteoarthritis.	The normalized colon library was constructed from 2.84x10° independent clones from the COLNNOT07 library. Starting RNA was made from colon tissue removed from a 60-year-old Caucasian male during a left hemicolectomy. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9228-9232), Swaroop et al. (Nucl. Acids Res. (1991) 19:1954) and Bonaldo et al. (Genome Res (1996) 6: 791-806), using a significantly longer (48 hour) reannealing hybridization period.
Library	DRGCNOT01	CARGDIT01	COLNNON03
Clone ID	2899137	2986229	3222081
Polynucleotide SEQ ID NO:	266	267	268

#### Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and synotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequetices.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. s. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or les
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, tfastx, and sserrch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTx: fasta E value=1.06E-6 Assembled ESTs: fasta Identity- 95% or greater and Match length=200 bases or greater; fast E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
ВLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

-141-

## Table 5 (cont.)

Parameter Threshold	; Score≃ 4.0 or greater eic		Score= 120 or greater; Match S. length= 56 or greater		Score=5 or greater	
Reference	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186- 194.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Bairoch et al. <u>supra;</u> Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, W1.
Description	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence pattems defined in Prosite.	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	A graphical tool for viewing and editing Phragassemblies	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	A program that searches amino acid sequences for patterns that matched those defined in Prosite.
Program	ProfileScan	Phred	Phrap	Consed	SPScan	Motifs

**FABLE 6** 

1 Lagurent	
	443531HI
	1406807F6   7
	SBBA00451F1
	SBBA00676F1
	632860H1
	784715R3
	509590H1
	670010H1
	669971RI
	726498H1
	726498R6
	866599R3
	795064H1
	4339458H1
	937605R3
	2381151F6 : .
	1466346F6
	924925H1
	3268330H1
	759120R3
	907958F6
	023569F1
	167282F1
	1309211F1

TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of
SEQ ID NO:		SEQ ID NO	Fragment	Fragment
		1259405H1	46	277
		2472425H1	331	354
		774303R1	061	743
142	1259405	1520779F1	418	1001
		1693833F6	914	1467
		1831858T6.comp	1336	1742
		1527737T6.comp	1386	1829
		1297384HI	402	641
		1269310F6	_	492
143	1297384	1457367FI	792	1380
		415587R1	1358	1712
		SANA02967F1	1143	614
		1299627H1		250
		1359140F6	1004	1573
144	1299627	1349224F1	1330	1731
		SBAA01431F1	46	397
		SBAA02909F1	868	262
		SBAA01156F1	106	1266
		1306026H1		223
145	1306026	1464088R6	302	829
		SBAA02496F1	92	568
		SBAA04305F1	366	883
		1316219H1	246	491
146	1316219	2458603F6	_	402
-		2504756T6	086	380
	7	1329031H1	-	264
147	1329031	1329031T6	505	
		1329031F6	1	523

TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of
SEQ ID NO:		SEQ ID NO	Fragment	Fragment
		1483050H1	722	931
		855049H1	_	267
		077017F1	6901	619
148	1483050	1483050F6	722	1215
		1480024T6	2063	1315
		1483050T6	2068	1535
		759486R1	1762	2089
		1514160H1	1640	1838
		1866765T7	2383	2210
		782676R1	1652	1875
149	1514160	008055X4	1090	1804
		008055X5	1316	1952
		1866765F6	2209	2391
		SAOA03127F1	2129	1703
		1603403H1	7	224
150	1603403	372910F1	420	44
		733299R7	219	420
		1652303H1	4	256
		1671806H1		224
		1341743T1	2069	1900
	,	3803812H1	389	269
151	1652303	1878546F6	747	1344
		1428640F1	1081	1664
		2058609R6	1715	2098
		1331621F1	1780	2096
		1306331T1	1897	2098

LABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Unding Muslostide of	Γ
SEQ ID NO:		SEQ ID NO	Fragment	Fragment	
		1693358HI	41	125	Т
		2498265H1	_	252	
152	1693358	1867125F6	205	373	
		1693358T6	1094	416	
		2245848R6	737	1103	
		1H1177071	408	626	Т
		1484609T1	2165	1855	
		1707711F6	408	286	_
153	170711	1267959F1	1721	2182	
		1484609F1	1855	2178	
		SAJA00930F1	544	1132	
		SAJA01300R1	1675	1212	
		SAJA00999R1	1675	1142	
		1738735H1	L	236	_
154	1738735	SAJA00944R1	393	Ś	
		SAJA00137F!	913	685	
		SAJA03629F1	435	42	
155		1749147HI	-	276	т —
155	1749147	1749147F6	47	457	
155		1749147T6	479	_	
156	1817722	1817722H1		268	_
		2011085H1	344	545	
		1831290HI	10	257	<del></del>
		3473958H1	70	242	
		1972268F6	163	617	
157	1831290	1301277F1	413	852	
		1521574F1	1024	1602	
		1561690T6	1729	1058	
		891461RI	1261	1738	

TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of	
SEQ ID NO:		SEQ ID NO	Fragment	Fragment	
		1831477HI	59	337	П
		1582867HI	_	199	
-		1336769T1	1986	1639	
		1933092H1	525	789	
158	1831477	1519909F1	841	1296	
		1220946H1	1901	1318	
		809556T1	1983	1687	
		1217559TI	2002	1445	
		1309225F1	1747	2001	
159	1841607	1841607HI	13	192	Г
		SBHA03588FI	13	172	
		1852391HI	86	367	Г
160	1852391	734140H1		225	
		1852391F6	86	542	
		1854555H1		265	Т
		2511711H1	37	. 28	
191	1854555	782453R1	223	712	
		185455F6	_	346	
		1840675T6	1046	098	
		2109736H1	938	1054	
		1855755HI	17	224	$\overline{}$
		3040236HI	-	179	
162	1855755	1283207F1	306	816	
		833763T1	1148	835	
		1920926R6	854	1161	
		1861434HI	13	253	
163	1861434	1861434T6	872	261	
		SARA01525F1	. 426	808	
		SARA02548F1	587	889	

TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of
SEQ ID NO:		SEQ ID NO	Fragment	Fragment
		1872334H1		229
164	1872334	1872334F6	· · ·	424
*		SBGA03684F1	358	425
		1877230H1	1405	1677
		2519841H1		251
		1877230T6	1903	1405
		1254693F1	335	716
165	1877230	077020R1	682	1414
		1232336F1	906	1507
		1004952R6	1451	1904
		SARA01879F1	1545	1921
		SARA02654F1	1545	1923
		1877885H1	89	323
166	1877885	508020F1	499	51
		2751126R6	219	516
		SARA02571F1	407	499
		1889269H1	757	1020
		1915551H1		161
		629493X12	481	865
167	1889269	1441289F1 🧢 🍇	693	865
		1215274X34F1	1106	1631
		1818447F6	1307	1540
		1208463R1	1372	1493
		1890243H1	6	268
1		SARA01884F1	521	168
891	1890243	SATA00046F1	1057	851
		SARA03294F1	1329	910
		SARA02790F1	1138	1535

TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of
SEQ ID NO:		SEQ ID NO	Fragment	Fragment
		1900433H1		242
169	1900433	SATA00396F1	409	124
		SATA02742F1	-	294
		1909441H1	786	1048
		1398811F1	_	550
		3039939H1	209	876
170	1909441	3324740H1	685	944
		1442131F6	787	1232
		2254056H1	1423	1522
		2199453T6	1955	1351
		1698531H1	1968	1796
		1932226H1	294	510
		2320569H1	_	266
		1932226F6	294	685
171	1932226	2469455T6	1475	1071
		2469455F6	1034	1492
		1907140F6	1158	1482
		SATA02592F1	857	518
		1932647H1	17	246
		1492745T1	1582	1418
172	1932647	1492745H1	1418	1599
		SASA02355F1	386	61
		SASA00117F1	250	569
		SASA00192F1	515	816
		2124245H1	45	190
-		1235393F1	495	895
173	2124245	1402264F6	323	925
		1303990F1	682	1240
		1402264T6	1613	950

ABLE 6 (cont.)

Ending Nucleotide of Fragment	651	746	904	857	1320	303	777	896	275	577	808	1464	236	2	524	1053	1496	-	466	1249	226	554	213	105
Starting Nucleotide of Fragment	406	1299	406	1292	898	28	261	417		232	497	808		682	298	801	1141	577	963	1102		-	_	-
Fragment of SEQ ID NO	2132626Н1	1723432T6	2132626R6	1736723T6	1504738F1	2280639H1	1377560F6	2292356HI	4086827H1	1754442F6	3571126H1	1601305F6	2349310HI	2349310T6	2373227HI	3316444HI	302685R6	SASA02181F1	SASA01923F1	SASA03516F1	2457682H1	2457682F6	2480426H1	2480426F6
Clone ID			2132626			2280639				2292356			2349310				2373227				2457682		2480426	
Nucleotide SEQ ID NO:			174		-	175				176			177				178				179		081	



TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of
SEQ ID NO:		SEQ ID NO	Fragment	Fragment
		2503743HI	9	222
		1853909H1		272
		1517619F1	172	830
181	2503743	1467896F6	540	1112
		490031F1	1647	8901
		1208654R1	1382	1633
		880544R1	1450	1648
		2537684HI	434	682
		2005493H1	_	194
		730969H1	307	547
182	2537684	916487HI	723	686
		996135R1	1 666	1598
		1920738R6	1306	1692
		1957710F6	1472	1692
		2593853H!		252
183	2593853	807497H1	7	217
		914020R6	284	740
		889992RI	416	729
		2622354H1	3	266
184	2622354	2623992H1		246
		1556510F6	81	258
		2641377H1	126	369
185	2641377	4341415H2	01	345
	,	SBCA07049F3	126	599

EABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of	Г
SEQ ID NO:		SEQ ID NO	Fragment	Fragment	
		2674857H1	681	393	Γ
		1872373H1		270	
		470512R6	1486	1502	
186	2674857	1728547H1	1285	1508	
		3013651F6	1423	1987	
		SBCA01366F1	819	385	
		SBCA00694F1	973	1198	
		2758485HI	20	267	Τ
187	2758485	3097533HI	_	158	
		1578959F6	291	771	
		2763296H1	63	301	Τ
188	2763296	3486025F6	<b>p</b>	130	
		SBDA07002F3	63	687	
		2779436HI		233	Т
189	2779436	2779436F6	_	577	
		SBDA07009F3	-	809	
		2808528HI	25	335	Π
061	2808528	2611513F6	2	489	
		SBDA07021T3	1058	443	
		2809230H1	409	630	Т
,		2213849H1		133	
161	2809230	711706R6	396	169	
		958323R1	407	800	
		030732FI	1366	623	
		2816821HI	210	501	Т
192	2816821	3746964H1		307	
		2816821F6	210	682	
		948722T6	959	527	



TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of
SEQ ID NO:		SEQ ID NO	Fragment	Fragment
		2817268HI	42	282
		3591308HI	13	264
193	2817268	419522R1	179	808
		2073028F6	446	924
		1308781F6	698	1112
		2923165H1	8	295
		2011630H1	1.8	238
194	2923165	1457250F1	268	856
		754668R1	327	878
		1406510F6	558	106
195	2949822	2949822HI		280
		SBDA07078F3		909 ·
		2992192HI	25	321
		2534324H2		240
961	2992192	2815255T6	069	219
		1551107T6	893	471
		1551107R6	471	069
		2992458HI	48	362
		2618951H1		247
		1479252F1	163	610
197	2992458	1879054H1	563	840
		1879054F6	563	9601
		2215240H1	951	1202
		1535968T1	1729	1173

TABLE 6 (cont.)

Nucleotide	Clone ID	Fragment of	Starting Nucleotide of	Ending Nucleotide of	_
SEQ ID NO:		SEQ ID NO	Fragment	Fragment	
		3044710H1	652	952	_
		3741773HI	_	283	
		859906X42CI	94	192	
		1534347F1	06	268	
198	3044710	1421122F1	830	1392	
		1303865F1	1033	1487	
		1704452F6	1432	1934	
		1251642F1	2006	1544	
		1781694R6	1894	2017	
		3120415H1	72	363	
199	3120415	1360123T1	523	141	
		1375015H1	380	. 526	
					,

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ 5 ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEO ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEO ID NO:26, SEO ID NO:27, SEO ID NO:28, SEO ID NO:29, SEO ID NO:30, SEO 10 ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, 15 SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID 20 NO:84; SEO ID NO:85; SEO ID NO:86; SEO ID NO:87, SEO ID NO:88, SEO ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID 25 NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134 (SEQ ID 30 NO:1-134), and fragments thereof.

2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.

An isolated and purified polynucleotide encoding the polypeptide of claim

- 4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
- 5 S. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
  - 6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
- 7. A method for detecting a polynucleotide, the method comprising the steps 10 of:
  - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
  - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.

- 8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
- 9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:135, SEQ ID NO:136, SEQ 20.5 IID NO.137, SEQ ID NO.133, SEQ ID NO.139, SEQ ID NO.140, SEQ ID NO.141, SEQ . ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ 25 ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ

ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:223, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:257, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268 (SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268 (SEQ ID NO:135-268), and fragments thereof.

10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

15

- 11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
- 12. An expression vector comprising at least a fragment of the polynucleotide
  - 13. A host cell comprising the expression vector of claim 12.
  - 14. A method for producing a polypeptide, the method comprising the steps of:
  - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
    - b) recovering the polypeptide from the host cell culture.
  - 15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
    - 16. A purified antibody which specifically binds to the polypeptide of claim 1.
    - 17. A purified agonist of the polypeptide of claim 1.
- 30 18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of HSPP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

20. A method for treating or preventing a disorder associated with increased expression or activity of HSPP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

## SEQUENCE LISTING

```
<110> INCYTE PHARMACEUTICALS, INC.
      LAL, Preeti
      TANG, Y. Tom
      GORGONE, Gina A.
      CORLEY, Neil C.
      GUEGLER, Karl J.
      BAUGHN, Mariah R.
      AKERBLOM, Ingrid E.
      AU-YOUNG, Janice
      YUE, Henry
      PATTERSON, Chandra
      REDDY, Roopa
      HILLMAN, Jennifer L.
      BANDMAN, Olga
<120> HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS
<130> PF-0541 PCT
<140> To Be Assigned
<141> Herewith
<150> 60/090,762; 60/094,983; 60/102,686; 60/112,129
<151> 1998-06-26; 1998-07-31; 1998-10-01; 1998-12-11
<160> 268
<170> PERL Program
<210> L
<211> 88
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 443531
<400> 1
Met Ser Trp Trp Leu Cys Leu Pro Leu Gly Leu Phe Gly Ser Cys
                  5
Leu Ala Pro Ala Ala Ala Ala Leu Ser Glu Phe Thr Gln Glu
                20
Gln His Asp Gly Ala Gln Pro Ser Pro Lys Cys Leu Ala Glu Glu
                35
                                     40
Leu Gly Asp Ala Trp Thr Ile Gln Ile Glu Ala Asn Trp Lys Tyr
                50
                                     55
Arg Ala Val Asn Thr Asn Gln Arg Gly Lys Leu Leu Ala Ser Glu
                65
                                    70
Thr Trp Lys Gly Arg Arg Asn Thr Phe Phe Leu Pro
                80
```

```
<210> 2
<211> 128
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 632860
<400> 2
Met Trp Pro Ala Gly Leu Gly Arg Ser Leu Leu Ala Gln Pro Ala
Leu Cys Ser Phe Met Gly Pro Gln Trp Ile Leu Gln Phe Cys Ser
                 20
Trp Leu Glu Pro Arg Gln Leu Arg Trp Ser Trp Thr Glu Pro Pro
                 35
Phe Thr Leu Leu Asp Ser Leu Gly Leu Arg Ala Ala Gln Asp Ser
                 50
Cys Ser Phe Thr Thr Leu Val Pro Leu Thr Leu Asp Ser Ser Phe
                 65
Met Thr Val Asn Val Val Pro Phe Val Trp Thr Ser Ser Phe Phe
                 80
                                     85
Arg Ala Phe Gln Tyr Pro Val Thr Ser Pro Cys Arg Thr Lys Asn
                 95
                                    100
Thr Pro Leu Leu Ile Asp Gly Val Thr Arg Ile Gln Ala Thr Trp
               110
Pro Glu Ala Arg Ser Gln His Glu
                125
<210> 3
<211> 111
```

<212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 670010 <400> 3 Met Gly Leu Leu Leu Val Leu Phe Leu Ser Leu Leu Pro Val 10 Ala Tyr Thr Ile Met Ser Leu Pro Pro Ser Phe Asp Cys Gly Pro 20 25 Phe Arg Cys Arg Val Ser Val Ala Arg Glu His Leu Pro Ser Arg 35 40 Gly Ser Leu Leu Arg Gly Pro Arg Pro Arg Ile Pro Val Leu Val 55 Ser Cys Gln Pro Val Lys Gly His Gly Thr Leu Gly Glu Ser Pro 70 Met Pro Phe Lys Arg Val Phe Cys Gln Asp Gly Asn Val Arg Ser 80 85 Phe Cys Val Cys Ala Val His Phe Ser Ser His Gln Pro Pro Val Ala Val Glu Cys Leu Lys

<210> 5

```
<210> 4
<211> 110
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 726498
<400> 4
Met Trp Arg Leu Arg Arg Asn Leu Ala Leu Pro Pro Gly Lys Leu
                                     10
Ala Trp Leu Tyr Leu Ser Val Phe Ser Gln Gly Ser Arg Ala Met
                 20
                                     25
Met Ser Leu Thr Glu Ile Arg Leu Lys His Met Leu Glu Ile Trp
                 35
                                     40
His Gly Arg Gln Ala Arg Ala Cys Glu Asn Leu Arg Asn Gln Thr
                 50
                                     55
Arg Val Ala Thr Lys Val Glu Pro Gln Lys Gly Arg Ser Thr Glu
                 65
                                     70
Ile Cys Cys Leu Ala Val Val Pro Leu Asn Glu Val Val Gln Ser
                 80
                                     85
Ser Ile Leu Trp Trp Val Trp Ser Cys Cys Gln His Gln Glu Asp
                 95
                                                        105
Lys Leu Gly Ala Lys
                110
```

```
<211> 78
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 795064
<400> 5
Met Ala Glu Ser Gly Leu Thr Ser Leu Pro Gly Thr Ala Ser Trp
                                     10
Phe Cys Phe Leu Pro Val Ser Gln Arg Lys Ala Thr Ser Lys Lys
                 20
                                     25
Leu Leu Leu Lys Ala Arg Lys Lys Ser Gly Phe Glu Leu Ser Val
                 35
                                     40
Thr Asp Ser Ser Glu Cys Phe Arg Val Thr Ala Ser Val Arg Gly
                 50
                                     55
Met Lys Asn Arg His Ala Lys Gly Asn Gly Cys Thr Arg Asp Pro
Cys Phe Gly
```

```
<210> 6
 <211> 88
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc feature
 <223> Incyte Clone No: 924925
 <400> 6
Met Trp Pro Ser Gln Val Pro Leu Leu Ala Phe Cys Phe Leu Leu
                                      10
Val Lys Ser Thr Ser Asn Ile Asn Leu Pro Thr Pro Pro Ser
                                     25
Ser Leu Glu Asn Ser Ser Phe Val Val Ser Gln Arg Gly Asn Leu
                                      40
Ile Val Phe Gly Gly Gln Lys Lys Ala Thr Phe Arg Tyr His Phe
                                     55
Tyr Leu Asp Arg Met Pro Phe Tyr Ser Gln Ile Ser Val Tyr Phe
                                     70
Val Asn Gly Phe Arg Val Asn Gly Tyr Leu Cys Asn Asn
<210> 7
<211> 227
<212> PRT
<213> Homo sapiens
<220>
<221> mise_feature .v., .
<223> Incyte Clone No: 962390
<400> 7
Met Gly Arg Pro Leu Leu Leu Pro Leu Leu Leu Leu Gln Pro
                                     10
Pro Ala Phe Leu Gln Pro Gly Gly Ser Thr Gly Ser Gly Pro Ser
                                     25
Tyr Leu Tyr Gly Val Thr Gln Pro Lys His Leu Ser Ala Ser Met
                                     40
Gly Gly Ser Val Glu Ile Pro Phe Ser Phe Tyr Tyr Pro Trp Glu
Leu Ala Ile Val Pro Asn Val Arg Ile Ser Trp Arg Arg Gly His
                                     70
Phe His Gly Gln Ser Phe Tyr Ser Thr Arg Pro Pro Ser Ile His
                                     85
Lys Asp Tyr Val Asn Arg Leu Phe Leu Asn Trp Thr Glu Gly Gln
```

100

Glu Ser Gly Phe Leu Arg Ile Ser Asn Leu Arg Lys Glu Asp Gln

Ser Val Tyr Phe Cys Arg Val Glu Leu Asp Thr Arg Arg Ser Gly

Arg Gln Gln Leu Gln Ser Ile Lys Gly Thr Lys Leu Thr Ile Thr

PCT/US99/14484 WO 00/00610

```
140
Gln Ala Val Thr Thr Thr Thr Trp Arg Pro Ser Ser Thr Thr
Thr Ile Ala Gly Leu Arg Val Thr Glu Ser Lys Gly His Ser Glu
Ser Trp His Leu Ser Leu Asp Thr Ala Ile Arg Val Ala Leu Ala
Val Ala Val Leu Lys Thr Val Ile Leu Gly Leu Leu Cys Leu Leu
Leu Leu Trp Trp Arg Arg Arg Lys Gly Ser Arg Ala Pro Ser Ser
Asp Phe
```

<210> 8 <211> 198 <212> PRT <213> Homo sapiens

<220>

<221> misc feature <223> Incyte Clone No: 1259405

<400> 8 Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala Gln Leu Ser Asp Ala Ala Lys Asn Phe Glu Asp Val Arg Cys Lys Cys Ile Cys Pro Pro Tyr Lys Glu Asn Ser Gly His Ile Tyr Asn Lys Asn The Sar Shodys Asp Cys Asp Cys Leu His Val Val Glu Pro Met 70 Pro Val Arg Gly Pro Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu 85 Cys Lys Tyr Glu Glu Arg Ser Ser Val Thr Ile Lys Val Thr Ile 100 Ile Ile Tyr Leu Ser Ile Leu Gly Leu Leu Leu Tyr Met Val 115 Tyr Leu Thr Leu Val Glu Pro Ile Leu Lys Arg Arg Leu Phe Gly 130 His Ala Gln Leu Ile Gln Ser Asp Asp Ile Gly Asp His Gln 145 Pro Phe Ala Asn Ala His Asp Val Leu Ala Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Ala Gln Gln Arg Trp Lys 175

Leu Gln Val Gln Glu Gln Arg Lys Ser Val Phe Asp Arg His Val 190

Val Leu Ser

```
<210> 9
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1297384
<400> 9
Met Met Pro Arg Leu Leu Gly Leu Gly Leu Phe Ser Phe Gly
 1
                 5
                                    10
Gly Leu Pro Leu Leu Leu Phe Phe Gln Arg Ser Arg Ala Ser
                20
                                    25
Leu Ala Ser Ser Ser Thr Gly Leu Trp Ile Asn Gln Leu Pro Lys
                35
                                   40
Gly Cys Thr Cys Arg Val Val Trp Ala Cys Ile Pro Asp Val Leu
                50
Glu Tyr Ala Trp Met
```

<210> 10 <211> 154 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1299627

:400> 10

Met Asp. Alg. Pro Arg. Leu Pro Val. Arg. Pro Gly Val Leu Leu Pro 5 10 15 Lys Leu Val Leu Leu Phe Val Tyr Ala Asp Asp Cys Leu Ala Gln Cys Gly Lys Asp Cys Lys Ser Tyr Cys Cys Asp Gly Thr Thr Pro 35 40 Tyr Cys Cys Ser Tyr Tyr Ala Tyr Ile Gly Asn Ile Leu Ser Gly 50 Thr Ala Ile Ala Gly Ile Val Phe Gly Ile Val Phe Ile Met Gly Val Ile Ala Gly Ile Ala Ile Cys Ile Cys Met Cys Met Lys Asn His Arg Ala Thr Arg Val Gly Ile Leu Arg Thr Thr His Ile Asn 95 Thr Val Ser Ser Tyr Pro Gly Pro Pro Pro Tyr Gly His Asp His 110 Glu Met Glu Tyr Cys Ala Asp Leu Pro Pro Pro Tyr Ser Pro Thr 125 130 Pro Gln Gly Pro Ala Gln Arg Ser Pro Pro Pro Pro Tyr Pro Gly Asn Ala Arg Lys

```
<210> 11
<211> 237
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1306026
<400> 11
Met Lys Pro Leu Val Leu Leu Val Ala Leu Leu Leu Trp Pro Ser
                                   10
Ser Val Pro Ala Tyr Pro Ser Ile Thr Val Thr Pro Asp Glu Glu
                20
                                   25
Gln Asn Leu Asn His Tyr Ile Gln Val Leu Glu Asn Leu Val Arg
                35
                                   40
Ser Val Pro Ser Gly Glu Pro Gly Arg Glu Lys Lys Ser Asn Ser
                50
                                   55
Pro Lys His Val Tyr Ser Ile Ala Ser Lys Gly Ser Lys Phe Lys
                65
                                   70
Glu Leu Val Thr His Gly Asp Ala Ser Thr Glu Asn Asp Val Leu
                80
                                   85
Thr Asn Pro Ile Ser Glu Glu Thr Thr Thr Phe Pro Thr Gly Gly
                95
                                 100
Phe Thr Pro Glu Ile Gly Lys Lys His Thr Glu Ser Thr Pro
               110
                                  115
Phe Trp Ser Ile Lys Pro Asn Asn Val Ser Ile Val Leu His Ala
               125
                                  130
Glu Glu Pro Tyr Ile Glu Asn Glu Glu Pro Glu Pro Glu Pro Glu
               140
                                  145
Pro Ala Ala Lys Gln Thr Glu Ala Pro Arg Met Leu Pro Val Val
               155
                                  160
The Glu Ser Ser The Ser Pro Tyr Val The Ser Tyr Lys Ser Pro
               170
                                  175
Val Thr Thr Leu Asp Lys Ser Thr Gly Ile Glu Ile Ser Thr Glu
               185
                                   190
Ser Glu Asp Val Pro Gln Leu Ser Gly Glu Thr Ala Ile Glu Lys
                                   205
Pro Glu Ser Trp Lys His Gln Arg Val Gly Tyr Asp Ala Phe Glu
                                   220
Lys Asn Leu Val Leu Ile Thr Met His Arg His Phe
<210> 12
```

```
<211> 225
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1316219
<400> 12
```

```
Met Thr Pro Glu Gly Val Gly Leu Thr Thr Ala Leu Arg Val Leu
                                    10
Cys Asn Val Ala Cys Pro Pro Pro Pro Val Glu Gly Gln Gln Lys
                                    25
Asp Leu Lys Trp Asn Leu Ala Val Ile Gln Leu Phe Ser Ala Glu
                 35
                                    40
Gly Met Asp Thr Phe Ile Arg Val Leu Gln Lys Leu Asn Ser Ile
                                    55
Leu Thr Gln Pro Trp Arg Leu His Val Asn Met Gly Thr Thr Leu
                 65
                                    70
His Arg Val Thr Thr Ile Ser Met Ala Arg Cys Thr Leu Thr Leu
                 80
                                . 85
Leu Lys Thr Met Leu Thr Glu Leu Leu Arg Gly Gly Ser Phe Glu
                95
                                   100
Phe Lys Asp Met Arg Val Pro Ser Ala Leu Val Thr Leu His Met
                110
                                . 112
Leu Leu Cys Ser Ile Pro Leu Ser Gly Arg Leu Asp Ser Asp Glu
                125
                                  130
Gln Lys Ile Gln Asn Asp Ile Ile Asp Ile Leu Leu Thr Phe Thr
                140
                                  145
Gln-Gly Val Asn Glu Lys Leu Thr Ile Ser Glu Glu Thr Leu Ala
                155
                                   160
Asn Asn Thr Trp Ser Leu Met Leu Lys Glu Val Leu Ser Ser Ile
                170
                                   175
Leu Lys Val Pro Glu Gly Phe Phe Ser Gly Leu Ile Leu Leu Ser
                185
                                   190
Glu Leu Leu Pro Leu Pro Leu Pro Met Gln Thr Thr Gln Val Ser
                200
                                   205
Leu Pro Tyr Asn Met His Leu Ile Asn Asp Cys Ser Asn Thr Phe
```

```
<216> 43 . . .
<211> 117
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1329031
<400> 13
Met Pro Ser Pro Gly Thr Val Cys Ser Leu Leu Leu Gly Met
                 .5
Leu Trp Leu Asp Leu Ala Met Ala Gly Ser Ser Phe Leu Ser Pro
Glu His Gln Arg Val Gln Gln Arg Lys Glu Ser Lys Lys Pro Pro
Ala Lys Leu Gln Pro Arg Ala Leu Ala Gly Trp Leu Arg Pro Glu
Asp Gly Gly Gln Ala Glu Gly Ala Glu Asp Glu Leu Glu Val Arg
Phe Asn Ala Pro Phe Asp Val Gly Ile Lys Leu Ser Gly Val Gln
Tyr Gln Gln His Ser Gln Ala Leu Gly Lys Phe Leu Gln Asp Ile
```

95 100 105 Leu Trp Glu Glu Ala Lys Glu Ala Pro Ala Asp Lys 110 115

<210> 14 <211> 253 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1483050 <400> 14 Met Asp Asn Arg Phe Ala Thr Ala Phe Val Ile Ala Cys Val Leu 10 Ser Leu Ile Ser Thr Ile Tyr Met Ala Ala Ser Ile Gly Thr Asp 20 25 Phe Trp Tyr Glu Tyr Arg Ser Pro Val Gln Glu Asn Ser Ser Asp 35 40 Leu Asn Lys Ser Ile Trp Asp Glu Phe Ile Ser Asp Glu Ala Asp 50 55 Glu Lys Thr Tyr Asn Asp Ala Leu Phe Arg Tyr Asn Gly Thr Val 65 70 Gly Leu Trp Arg Arg Cys Ile Thr Ile Pro Lys Asn Met His Trp 80 85 Tyr Ser Pro Pro Glu Arg Thr Glu Ser Phe Asp Val Val Thr Lys 100 Cys Val Ser Phe Thr Leu Thr Glu Gln Phe Met Glu Lys Phe Val 115 Asp Pro Gly Asn Mis Asn Ser Gly Ile Asp Leu Leu Arg Thr Tyr : 125 130 135 Leu Trp Arg Cys Gln Phe Leu Leu Pro Phe Val Ser Leu Gly Leu 140 145 Met Cys Phe Gly Ala Leu Ile Gly Leu Cys Ala Cys Ile Cys Arg 155 Ser Leu Tyr Pro Thr Ile Ala Thr Gly Ile Leu His Leu Leu Ala 170 175 Gly Leu Cys Thr Leu Gly Ser Val Ser Cys Tyr Val Ala Gly Ile 185 Glu Leu Leu His Gln Lys Leu Glu Leu Pro Asp Asn Val Ser Gly 200 Glu Phe Gly Trp Ser Phe Cys Leu Ala Cys Val Ser Ala Pro Leu 215 220 Gln Phe Met Ala Ser Ala Leu Phe Ile Trp Ala Ala His Thr Asn 230

Arg Lys Glu Tyr Thr Leu Met Lys Ala Tyr Arg Val Ala

245

<210> 15 <211> 171

```
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1514160
<400> 15
Met Ser Leu Pro Ile Pro Trp Leu Ser Leu Pro Pro Cys Pro Ile
 1
                  5
                                     10
Leu Gly Gln Pro Ala Gly Leu Leu Trp Leu Phe Arg Pro Phe
                 20
                                     25
Ser Gln Cys Cys Gln Cys Pro Trp Glu Gly Arg Ala Ser Leu Arg
                 35
                                     40
His Pro Asn Gly Pro Ser Gly Cys Arg Glu Ala Glu Ala Trp Pro
                 50
                                    55
Gln Arg Ser Leu Leu Arg Gln Gln Leu Gln Gln Ala His Pro Leu
                 65
                                     70
Pro Thr Leu Pro Thr Pro Glu Arg Leu Pro Glu Gln Met Leu Phe
                 80
                                     85
                                                         90
Pro Ser Ser Ser Lys Pro Phe Ser Leu Leu Ser Leu Thr Ile
                 95
                                    100
Trp Ala Arg Leu Val Gly Arg Leu Thr Asn Arg Ile Cys Pro Val
                110
                                    115
Pro Pro Gly Ser Val Ala Ser Ser Met Ser Leu Gln Ala Gly Arg
                125
                                    130
                                                        135
Cys Gly Asn Pro Val Val Leu Pro Gln Pro Met Pro Pro Gly Leu
                                    145
Leu Cys Met Asn Glu Cys Ser Leu Val Pro Gly Leu Gly Arg Gly
Gln Val Asn Ser Arg Val
                170
```

```
<211> 78
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1603403
<400> 16
Met Gly Ser Gly Leu Pro Leu Val Leu Leu Leu Thr Leu Leu Gly
                  5
                                     10
Ser Ser His Gly Thr Gly Pro Gly Met Thr Leu Gln Leu Lys Leu
Lys Glu Ser Phe Leu Thr Asn Ser Ser Tyr Glu Ser Ser Phe Leu
                                     40
                                                          45
Glu Leu Leu Glu Lys Leu Cys Leu Leu Leu His Leu Pro Ser Gly
                                                          60
Thr Ser Val Thr Leu His His Ala Arg Ser Gln His His Val Val
Cys Asn Thr
```

<210> 16

```
<210> 17
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1652303
<400> 17
Met Lys Leu Leu Ser Cys Leu Leu Phe Leu Lys Ala Pro Leu Tyr
                                     10
Pro Thr Leu Cys Ser Lys Asp Pro Arg Ala Gly His Ser Leu Ile
                 20
                                     25
Cys Gly Gln Ala Gly Gln Ile Pro Glu Ala Gln Leu Gly Phe Ser
                 35
                                     40
Ser Asp Phe Lys Leu Cys Trp Cys Trp Asp Gln Gln Lys Ala Asn
                 50
                                     55
Val Gln Pro Thr His Arg Thr Val Arg Gly Leu
<210> 18
<211> 188
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
42235 Incyte Clone No: 1693358
<400> 18
Met Val Pro Gly Ala Ala Gly Trp Cys Cys Leu Val Leu Trp Leu
Pro Ala Cys Val Ala Ala His Gly Phe Arg Ile His Asp Tyr Leu
Tyr Phe Gln Val Leu Ser Pro Gly Asp Ile Arg Tyr Ile Phe Thr
Ala Thr Pro Ala Lys Asp Phe Gly Gly Ile Phe His Thr Arg Tyr
                 50
                                                         60
Glu Gln Ile His Leu Val Pro Ala Glu Pro Pro Glu Ala Cys Gly
                 65
Glu Leu Ser Asn Gly Phe Phe Ile Gln Asp Gln Ile Ala Leu Val
                 80
Glu Arg Gly Gly Cys Ser Phe Leu Ser Lys Thr Arg Val Val Gln
                 95
Glu His Gly Gly Arg Ala Val Ile Ile Ser Asp Asn Ala Val Asp
                110
                                    115
Asn Asp Ser Phe Tyr Val Glu Met Ile Gln Asp Ser Thr Gln Arg
                125
                                    130
```

145

Thr Ala Asp Ile Pro Ala Leu Phe Leu Leu Gly Arg Asp Gly Tyr

140

135

<211> 80 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1707711 <400> 19 Met Lys Ala Gln Pro Leu Glu Ala Leu Leu Leu Val Ala Leu Val 10 Leu Ser Phe Cys Gly Val Trp Phe Glu Asp Trp Leu Ser Lys Trp 25 Arg Phe Gln Cys Ile Phe Gln Leu Ala His Gln Pro Ala Leu Val 40 Asn Ile Gln Phe Arg Gly Thr Val Leu Gly Ser Glu Thr Phe Leu 55 Gly Ala Glu Glu Asn Ser Ala Asp Val Arg Ser Trp Gln Thr Leu Ser Tyr Phe Glu Leu

<210> 20 <211> 80 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1738735

<210> 19

80

```
<210> 21
<211> 84
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1749147
<400> 21
Met Gln Arg Pro Phe Leu Ser Val Pro Cys Leu Leu Leu Pro
                                    10
Ala Arg Val Val Trp Gly Cys Trp Cys Phe Leu Pro Gly Glu Asp
                20
                                    25
Gly Gly Cys Pro Thr Pro Ser Ser Gly Arg Ile Lys Leu Leu
                35
                                    40
Gln Gln Cys Leu Leu His Pro Ser Leu Arg Ser Ile Thr Val Ser
                                    55
Arg Arg Ser Ala Gln Leu Leu Cys Arg Leu Lys Leu Gln Asn His
                                    70
Ile Pro Lys Val Pro Gly Lys Asn Val
                80
```

<221> misc\_feature

<223> Incyte Clone No: 1817722

<400> 22

 Met
 His
 Met
 Ile
 Leu
 Lys
 Val
 Leu
 Thr
 Thr
 Ala
 Leu
 Leu
 Leu
 15

 Ala
 Ala
 Ser
 Ala
 Leu
 Ala
 Asn
 Tyr
 Ile
 His
 Phe
 Ser
 Ser
 Tyr
 Ser
 30

 Lys
 Asp
 Gly
 Ile
 Gly
 Val
 Pro
 Phe
 Met
 Gly
 Ser
 Leu
 Ala
 Glu
 Phe

 Asp
 Gly
 Ile
 Gly
 Val
 Pro
 Phe
 Met
 Gly
 Ser
 Leu
 Ala
 Glu
 Phe

 Phe
 Asp
 Ile
 Ala
 Ser
 Gln
 Ile
 Ala
 Met
 Ile
 Ile
 Ala
 Ile
 Ala
 Ile
 Ile

, · .,

<210> 23 <211> 243 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1831290 <400> 23 Met Ser Ser Gly Thr Glu Leu Leu Trp Pro Gly Ala Ala Leu Leu 10 Val Leu Leu Gly Val Ala Ala Ser Leu Cys Val Arg Cys Ser Arg 25 Pro Gly Ala Lys Arg Ser Glu Lys Ile Tyr Gln Gln Arg Ser Leu Arg Glu Asp Gln Gln Ser Phe Thr Gly Ser Arg Thr Tyr Ser Leu Val Gly Gln Ala Trp Pro Gly Pro Leu Ala Asp Met Ala Pro Thr 75 Arg Lys Asp Lys Leu Leu Gln Phe Tyr Pro Ser Leu Glu Asp Pro 90 Ala Ser Ser Ang Tyr Glin Asa Phe Ser Lys Cly Ser Ang This Gly 95 100 105 Ser Glu Glu Ala Tyr Ile Asp Pro Ile Ala Met Glu Tyr Tyr Asn 110 Trp Gly Arg Phe Ser Lys Pro Pro Glu Asp Asp Ala Asn Ser 130 Tyr Glu Asn Val Leu Ile Cys Lys Gln Lys Thr Thr Glu Thr Gly 140 Ala Gln Gln Glu Gly Ile Gly Gly Leu Cys Arg Gly Asp Leu Ser 155 Leu Ser Leu Ala Leu Lys Thr Gly Pro Thr Ser Gly Leu Cys Pro 170 Ser Ala Ser Pro Glu Glu Asp Glu Glu Ser Glu Asp Tyr Gln Asn 185 190 Ser Ala Ser Ile His Gln Trp Arg Glu Ser Arg Lys Val Met Gly 205 Gln Leu Gln Arg Glu Ala Ser Pro Gly Pro Val Gly Ser Pro Asp 220 Glu Glu Asp Gly Glu Pro Asp Tyr Val Asn Gly Glu Val Ala Ala Thr Glu Ala

<210> 24

```
<211> 311
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1831477
Met Gly Val Pro Thr Ala Pro Glu Ala Gly Ser Trp Arg Trp Gly
                                   10
Ser Leu Leu Phe Ala Leu Phe Leu Ala Ala Ser Leu Gly Pro Val
                20
                                   25
Ala Ala Phe Lys Val Ala Thr Pro Tyr Ser Leu Tyr Val Cys Pro
                35
                                   40
Glu Gly Gln Asn Val Thr Leu Thr Cys Arg Leu Leu Gly Pro Val
                50
                                   55
Asp Lys Gly His Asp Val Thr Phe Tyr Lys Thr Trp Tyr Arg Ser
                65
Ser Arg Gly Glu Val Gln Thr Cys Ser Glu Arg Arg Pro Ile Arg
                80
                                   85
Asn Leu Thr Phe Gln Asp Leu His Leu His His Gly Gly His Gln
                95
                                  100
Ala Ala Asn Thr Ser His Asp Leu Ala Gln Arg His Gly Leu Glu
               110
                                  115
Ser Ala Ser Asp His His Gly Asn Phe Ser Ile Thr Met Arg Asn
               125
                                  130
Leu Thr Leu Leu Asp Ser Gly Leu Tyr Cys Cys Leu Val Val Glu
               140
                                  145
Ile Arg His His Ser Glu His Arg Val His Gly Ala Met Glu
               155
                                  160
Leu Glr Val Gln Thr Gly Lys Asp Ala Pro Ser Asn Cys Val Val
 170
                        175
Tyr Pro Ser Ser Ser Gln Glu Ser Glu Asn Ile Thr Ala Ala Ala
               185
                                  190
Leu Ala Thr Gly Ala Cys Ile Val Gly Ile Leu Cys Leu Pro Leu
               200
                                   205
Ile Leu Leu Val Tyr Lys Gln Arg Gln Ala Ala Ser Asn Arg
               215
                                  220
Arg Ala Gln Glu Leu Val Arg Met Asp Ser Asn Ile Gln Gly Ile
               230
                                  235
Glu Asn Pro Gly Phe Glu Ala Ser Pro Pro Ala Gln Gly Ile Pro
               245
                                  250
Glu Ala Lys Val Arg His Pro Leu Ser Tyr Val Ala Gln Arg Gln
Pro Ser Glu Ser Gly Arg His Leu Leu Ser Glu Pro Ser Thr Pro
               275
                                   280
Leu Ser Pro Pro Gly Pro Gly Asp Val Phe Phe Pro Ser Leu Asp
               290
Pro Val Pro Asp Ser Pro Asn Phe Glu Val Ile
```

```
<210> 25
<211> 57
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1841607
<400> 25
Met Ala Ser Ser Cys Phe Ser Leu Ser Phe Pro Pro Leu Ser Leu
 1
                 5
                                    10
Ala Gly Ser Leu Ala Leu Trp Gly His Cys Cys Val Arg Leu Gly
                ,20
                                   25
Cys Ser Phe Trp Ser Val Ser Ala Met Ala Gln Arg Leu Pro Ser
                                  40
                35
Gln Asn Thr Tyr Asn Pro Pro Leu Cys Trp Ala Trp
<210> 26
<211> 82
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1852391
<400> 26
Met Phe Ser Leu Phe Ser Cys Leu Leu Ala Cys Leu Leu Asp Leu
1 5 10
Lieu Lieu Ser Argi Val Ala Asp Glu Ala The Tyr Lys Gln Pro Phe
 · . . . .
                                   25
Ala Asp Val Ile Gly Tyr Val Tyr Val Ala Lys Leu Ile Pro Phe
                                   40
Ser Thr Ser Asp Ser Phe Tyr Phe Cys Leu Glu Leu Met Leu Leu
                                   55
Leu Cys His Gln Leu Leu Cys Phe Leu Asn Tyr Phe Lys Leu Ala
                65
Leu Trp Gly Leu Pro Lys Asn
                80
<210> 27
<211> 115
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1854555
```

```
<400> 27
Met Ala Gly Thr Val Leu Gly Val Gly Ala Gly Val Phe Ile Leu
                 5
Ala Leu Leu Trp Val Ala Val Leu Leu Cys Val Leu Leu Ser
Arg Ala Ser Gly Ala Ala Arg Phe Ser Val Ile Phe Leu Phe Phe
                                    40
Gly Ala Val Ile Ile Thr Ser Val Leu Leu Phe Pro Arg Ala
                                    55
Gly Glu Phe Pro Ala Pro Glu Val Glu Val Lys Ile Val Asp Asp
                                    70
                                                        75
Phe Phe Ile Gly Arg Tyr Val Leu Leu Ala Phe Leu Ser Ala Ile
                                   85
Phe Leu Gly Gly Leu Phe Leu Val Leu Ile His Tyr Val Leu Glu
                                   100
Pro Ile Tyr Ala Lys Pro Leu His Ser Tyr
```

<210> 28
<211> 327
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 1855755

Met Ala Glu Leu Pro Gly Pro Phe Leu Cys Gly Ala Leu Leu Gly 10 Phe Leu Cys Leu Ser Gly Leu Ala Val Glu Val Lys Val Pro Thr 20 Glu Pro Leu Ser Thr Pro Leu Gly Lys Thr Ala Glu Leu Thr Cys 35 40 Thr Tyr Ser Thr Ser Val Gly Asp Ser Phe Ala Leu Glu Trp Ser Phe Val Gln Pro Gly Lys Pro Ile Ser Glu Ser His Pro Ile Leu Tyr Phe Thr Asn Gly His Leu Tyr Pro Thr Gly Ser Lys Ser Lys 85 Arg Val Ser Leu Leu Gln Asn Pro Pro Thr Val Gly Val Ala Thr 100 Leu Lys Leu Thr Asp Val His Pro Ser Asp Thr Gly Thr Tyr Leu 115 Cys Gln Val Asn Asn Pro Pro Asp Phe Tyr Thr Asn Gly Leu Gly 125 130 Leu Ile Asn Leu Thr Val Leu Val Pro Pro Ser Asn Pro Leu Cys 145 Ser Gln Ser Gly Gln Thr Ser Val Gly Gly Ser Thr Ala Leu Arg 155 160 Cys Ser Ser Ser Glu Gly Ala Pro Lys Pro Val Tyr Asn Trp Val 170 175 Arg Leu Gly Thr Phe Pro Thr Pro Ser Pro Gly Ser Met Val Gln 185 190

```
Asp Glu Val Ser Gly Gln Leu Ile Leu Thr Asn Leu Ser Leu Thr
                200
Ser Ser Gly Thr Tyr Arg Cys Val Ala Thr Asn Gln Met Gly Ser
                215
                                    220
Ala Ser Cys Glu Leu Thr Leu Ser Val Thr Glu Pro Ser Gln Gly
                                    235
Arg Val Ala Gly Ala Leu Ile Gly Val Leu Leu Gly Val Leu Leu
Leu Ser Val Ala Ala Phe Cys Leu Val Arg Phe Gln Lys Glu Arg
                                   265
                                                        270
Gly Lys Lys Pro Lys Glu Thr Tyr Gly Gly Ser Asp Leu Arg Glu
                                   280
Asp Ala Ile Ala Pro Gly Ile Ser Glu His Thr Cys Met Arg Ala
               290
                                   295
Asp Ser Ser Lys Gly Phe Leu Glu Arg Pro Ser Ser Ala Ser Thr
               305
                                  . 310
Val Thr Thr Lys Ser Lys Leu Pro Met Val Val
               320
```

<210> 29
<211> 133
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 1861434

<400> 29 Met Arg Met Ser Leu Ala Gln Arg Val Leu Leu Thr Trp Leu Phe 5 Thr Leuvley, Phe Leu Ile Met Leu Val Lauslys: Leu Asp Slu Lys \* Ala Pro Trp Asn Trp Phe Leu Ile Phe Ile Pro Val Trp Ile Phe 40 Asp Thr Ile Leu Leu Val Leu Leu Ile Val Lys Met Ala Gly Arg 55 Cys Lys Ser Gly Phe Asp Pro Arg His Gly Ser His Asn Ile Lys 70 Lys Lys Ala Trp Tyr Leu Ile Ala Met Leu Leu Lys Leu Ala Phe Cys Leu Ala Leu Cys Ala Lys Leu Glu Gln Phe Thr Thr Met Asn 95 100 Leu Ser Tyr Val Phe Ile Pro Leu Trp Ala Leu Leu Ala Gly Ala 115 Leu Thr Glu Leu Gly Tyr Asn Val Phe Phe Val Arg Asp

<210> 30
<211> 129
<212> PRT

<213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1872334 <400> 30 Met Gly Leu Thr Leu Leu Leu Leu Leu Leu Gly Leu Glu Gly 1 Gln Gly Ile Val Gly Ser Leu Pro Glu Val Leu Gln Ala Pro Val 20 25 Gly Ser Ser Ile Leu Val Gln Cys His Tyr Arg Leu Gln Asp Val 35 40 Lys Ala Gln Lys Val Trp Cys Arg Phe Leu Pro Glu Gly Cys Gln 50 55 Pro Leu Val Ser Ser Ala Val Asp Arg Arg Ala Pro Ala Gly Arg 65 70 Arg Thr Phe Leu Thr Asp Leu Gly Gly Gly Leu Leu Gln Val Glu 80 85 Met Val Thr Leu Gln Glu Glu Asp Ala Gly Glu Tyr Gly Cys Met 95 100 Val Asp Gly Ala Arg Gly Pro Gln Ile Leu His Arg Val Ser Leu 110 115 Asn Ile Leu Pro Pro Gly Glu Leu Ser 125 <210> 31 <211> 472 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1877230 Met Lys Phe Leu Ile Phe Ala Phe Phe Gly Gly Val His Leu Leu 10 Ser Leu Cys Ser Gly Lys Ala Ile Cys Lys Asn Gly Ile Ser Lys 25 Arg Thr Phe Glu Glu Ile Lys Glu Glu Ile Ala Ser Cys Gly Asp 40 Val Ala Lys Ala Ile Ile Asn Leu Ala Val Tyr Gly Lys Ala Gln

PCT/US99/14484

```
<210> 32
<211> 93
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte Clone No: 1877885

Met Ile His Leu Gly His Ile Leu Phe Leu Leu Leu Pro Val 10 Ala Ala Ala Gln Thr Thr Pro Gly Glu Arg Ser Ser Leu Pro Ala 20 25 Phe Tyr Pro Gly Thr Ser Gly Ser Cys Ser Gly Cys Gly Ser Leu 35 40 Ser Leu Pro Leu Leu Ala Gly Leu Val Ala Ala Asp Ala Val Ala 50 55 Ser Leu Leu Ile Val Gly Ala Val Phe Leu Cys Ala Arg Pro Arg 65 70 Arg Ser Pro Ala Gln Glu Asp Gly Lys Val Tyr Ile Asn Met Pro 85 Gly Arg Gly

<210> 33 <211> 92 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1889269 <400> 33 Met Asn Arg Pro Ser Ala Arg Asn Ala Leu Gly Asn Val Phe Val Ser Glu Leu Leu Glu Thr Leu Ala Gln Leu Arg Glu Asp Arg Gln 25 Val Ary Val Lea Let Phe Arg Ser Gly Val Lys Gly Val Phe Cys . 35 40 Ala Gly Ala Asp Leu Lys Glu Arg Glu Gln Met Ser Glu Ala Glu 50 Val Gly Val Phe Val Gln Arg Leu Arg Gly Leu Met Asn Asp Ile 65 Gly Glu Asp Leu Gly Val Gly Trp Arg Arg Gly Phe Gly Gly Pro

<210> 34 <211> 143 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1890243 <400> 34

Cys Arg

Met Trp Ile Lys Gly Thr Met Lys Met Arg Gly Gly Lys Thr Ser 10 Arg Ser Ala Val Leu Pro Val Ala Gln Leu Thr Leu Ile Ala Ser 25 Cys Phe Pro Asn Ser Gln Thr Val Leu Gly Thr Glu Gly Thr Leu 40 Asp Val Glu Ser Ser Pro Leu Ala Leu Leu Thr Gly Leu Trp Ala 55 Ser Pro Glu Ser Leu Ser Leu Tyr Leu Val Thr Leu Leu Cys Val 70 Cys Pro Ala Leu Gln Ser Cys Gln Gly Gln Gln Ala Asp Val Thr 85 Leu Ala Pro Cys Glu Ile Phe Ile Pro Gln Thr Leu Ala Cys Glu 95 100 Pro Phe Pro Ser Gln Trp Arg Ala Leu Lys Gly Ala Ser Leu Glu 110 115 Ser Ser Ser Val Leu Trp Val Ala Pro Cys Arg Trp Pro Leu Thr 125 130 Leu Arg Cys Ser Arg Val His Leu 140

<210> 35
<211> 89
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 1900433

<400> 35 Met Glu Arg Val Thr Leu Ala Leu Leu Leu Leu Ala Gly Leu Thr 1 5 10 Ala Leu Glu Ala Asn Asp Pro Phe Ala Asn Lys Asp Asp Pro Phe 20 25 Tyr Tyr Asp Trp Lys Asn Leu Gln Leu Ser Gly Leu Ile Cys Gly 35 40 Gly Leu Leu Ala Ile Ala Gly Ile Ala Ala Val Leu Ser Gly Lys 55 Cys Lys Tyr Lys Ser Ser Gln Lys Gln His Ser Pro Val Pro Glu 65 70 Lys Ala Ile Pro Leu Ile Thr Pro Gly Ser Ala Thr Thr Cys

<210> 36 <211> 560 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1909441

<400> 36 Met Ala Lys Lys Leu Thr Glu Met Ile Pro Leu Cys Asn His Pro Ala Ser Phe Val Lys Leu Phe Val Ala Leu Gly Pro Ile Ala Gly Pro Glu Glu Lys Lys Gln Leu Lys Ser Thr Met Leu Leu Met Ser Glu Asp Leu Thr Gly Glu Gln Ala Leu Ala Val Leu Gly Ala Met Gly Asp Met Glu Ser Arg Asn Ser Cys Leu Ile Lys Arg Val Thr Ser Val Leu His Lys His Leu Asp Gly Tyr Lys Pro Leu Glu Leu Leu Lys Ile Thr Gln Glu Leu Thr Phe Leu His Phe Gln Arg Lys Glu Phe Phe Ala Lys Leu Arg Glu Leu Leu Ser Tyr Leu Lys Asn Ser Phe Ile Pro Thr Glu Val Ser Val Leu Val Arg Ala Ile Ser Leu Leu Pro Ser Pro His Leu Asp Glu Val Gly Ile Ser Arg Ile Glu Ala Val Leu Pro Gln Cys Asp Leu Asn Asn Leu Ser Ser Phe Ala Thr Ser Val Leu Arg Trp Ile Gln His Asp His Met Tyr Leu Asp Asn Met Thr Ala Lys Gln Leu Lys Leu Leu Gln Lys Leu Asp His Tyr Gly Arg Cln Arg Leu Gln His Ser Asn Ser Leu Asp Leu Leu Arg Lys Glu Leu Lys Ser Leu Lys Gly Asn Thr Phe Pro Glu Ser bev Leu Glu Glu Met Jie Ala Thr Leu Gln His Phe Met Asp Asp Ile Asn Tyr Ile Asn Val Gly Glu Ile Ala Ser Phe Ile Ser Ser Thr Asp Tyr Leu Ser Thr Leu Leu Leu Asp Arg Ile Ala Ser Val Ala Val Gln Gln Ile Glu Lys Ile His Pro Phe Thr Ile Pro Ala Ile Ile Arg Pro Phe Ser Val Leu Asn Tyr Asp Pro Pro Gln Arg Asp Glu Phe Leu Gly Thr Cys Val Gln His Leu Asn Ser Tyr Leu Gly Ile Leu Asp Pro Phe Ile Leu Val Phe Leu Gly Phe Ser Leu Ala Thr Leu Glu Tyr Phe Pro Glu Asp Leu Leu Lys Ala Ile Phe Asn Ile Lys Phe Leu Ala Arg Leu Asp Ser Gln Leu Glu Ile Leu Ser Pro Ser Arg Ser Ala Arg Val Gln Phe His Leu Met Glu Leu Asn Arg Ser Val Cys Leu Glu Cys Pro Glu Phe Gln Ile Pro Trp Phe His Asp Arg Phe Cys Gln Gln Tyr Asn Lys Gly 

```
Ile Gly Gly Met Asp Gly Thr Gln Gln Gln Ile Phe Lys Met Leu
                410
                                    415
Ala Glu Val Leu Gly Gly Ile Asn Cys Val Lys Ala Ser Val Leu
                425
                                    430
Thr Pro Tyr Tyr His Lys Val Asp Phe Glu Cys Ile Leu Asp Lys
                440
                                    445
Arg Lys Lys Pro Leu Pro Tyr Gly Ser His Asn Ile Ala Leu Gly
                455
                                    460
Gln Leu Pro Glu Met Pro Trp Glu Ser Asn Ile Glu Ile Val Gly
                470
                                    475
Ser Arg Leu Pro Pro Gly Ala Glu Arg Ile Ala Leu Glu Phe Leu
                485
                                    490
Asp Ser Lys Ala Leu Cys Arg Asn Ile Pro His Met Lys Gly Lys
                500
                                    505
Ser Ala Met Lys Lys Arg His Leu Glu Ile Leu Gly Tyr Arg Val
                515
                                    520
Ile Gln Ile Ser Gln Phe Glu Trp Asn Ser Met Ala Leu Ser Thr
                530
                                    535
Lys Asp Ala Arg Met Asp Tyr Leu Arg Glu Cys Ile Phe Gly Glu
                545
                                    550
Val Lys Ser Cys Leu
                560
```

```
<210> 37
<211> 197
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1932226
<400> 37
Met Gly Val Pro Leu Gly Leu Gly Ala Ala Trp Leu Leu Ala Trp
 1
Pro Gly Leu Ala Leu Pro Leu Val Ala Met Ala Ala Gly Gly Arg
Trp Val Arg Gln Gln Gly Pro Arg Val Arg Arg Gly Ile Ser Arg
                 35
Leu Trp Leu Arg Val Leu Leu Arg Leu Ser Pro Met Ala Phe Arg
                 50
                                     55
Ala Leu Gln Gly Cys Gly Ala Val Gly Asp Arg Gly Leu Phe Ala
                 65
Leu Tyr Pro Lys Thr Asn Lys Asp Gly Phe Arg Ser Arg Leu Pro
                 80
```

95

110

125

140

130

145

Val Pro Gly Pro Arg Arg Arg Asn Pro Arg Thr Thr Gln His Pro

Leu Ala Leu Leu Ala Arg Val Trp Val Leu Cys Lys Gly Trp Asn

Trp Arg Leu Ala Arg Ala Ser Gln Gly Leu Ala Ser His Leu Pro

Pro Trp Ala Ile His Thr Leu Ala Ser Trp Gly Leu Leu Arg Gly

Glu Arg Pro Thr Arg Ile Pro Arg Leu Leu Pro Arg Ser Gln Arg

```
155 160 165

Gln Leu Gly Pro Pro Ala Ser Arg Gln Pro Leu Pro Gly Thr Leu
170 175 180

Ala Gly Arg Arg Ser Arg Thr Arg Gln Ser Arg Ala Leu Pro Pro
185 190 195

Trp Arg
```

```
<210> 38
<211> 437
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1932647
<400> 38
Met Ser Ala Val Leu Leu Leu Ala Leu Leu Gly Phe Ile Leu Pro
Leu Pro Gly Val Gln Ala Leu Leu Cys Gln Phe Gly Thr Val Gln
                                     25
His Val Trp Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys
Asn Thr Ser Cys Asp Ser Gly Leu Gly Cys Gln Asp Thr Leu Met
                 50
                                     55
Leu Ile Glu Ser Gly Pro Gln Val Ser Leu Val Leu Ser Lys Gly
                 65
Cys Thr Glu Ala Lys Asp Gln Glu Pro Arg Val Thr Glu His Arg
                 80
Met Gly Pro Gly Leu Ser Leu Ile Ser Tyr Thr Phe Val Cys Arg
                 95
Cln Glu Asp Phe Cys Asn Asn Leu Val Asn Ser Leu Pro Leu Trp
                110
Ala Pro Gln Pro Pro Ala Asp Pro Gly Ser Leu Arg Cys Pro Val
                125
                                    130
Cys Leu Ser Met Glu Gly Cys Leu Glu Gly Thr Thr Glu Glu Ile
                140
                                    145
Cys Pro Lys Gly Thr Thr His Cys Tyr Asp Gly Leu Leu Arg Leu
                155
                                    160
Arg Gly Gly Gle Phe Ser Asn Leu Arg Val Gln Gly Cys Met
                170
                                    175
Pro Gln Pro Gly Cys Asn Leu Leu Asn Gly Thr Gln Glu Ile Gly
                185
                                    190
Pro Val Gly Met Thr Glu Asn Cys Asn Arg Lys Asp Phe Leu Thr
                200
                                    205
Cys His Arg Gly Thr Thr Ile Met Thr His Gly Asn Leu Ala Gln
                215
                                    220
Glu Pro Thr Asp Trp Thr Thr Ser Asn Thr Glu Met Cys Glu Val
                230
                                    235
Gly Gln Val Cys Gln Glu Thr Leu Leu Leu Ile Asp Val Gly Leu
                245
                                    250
Thr Ser Thr Leu Val Gly Thr Lys Gly Cys Ser Thr Val Gly Ala
                260
                                    265
Gln Asn Ser Gln Lys Thr Thr Ile His Ser Ala Pro Pro Gly Val
```

```
275
                                  280
Leu Val Ala, Ser Tyr Thr His Phe Cys Ser Ser Asp Leu Cys Asn
                                  295
               290
Ser Ala Ser Ser Ser Ser Val Leu Leu Asn Ser Leu Pro Pro Gln
               305
                                  310
Ala Ala Pro Val Pro Gly Asp Arg Gln Cys Pro Thr Cys Val Gln
                                  325
               320
Pro Leu Gly Thr Cys Ser Ser Gly Ser Pro Arg Met Thr Cys Pro
                                  340
               335
Arg Gly Ala Thr His Cys Tyr Asp Gly Tyr Ile His Leu Ser Gly
               350
                                  355
Gly Gly Leu Ser Thr Lys Met Ser Ile Gln Gly Cys Val Ala Gln
                                   370
               365
Pro Ser Ser Phe Leu Leu Asn His Thr Arg Gln Ile Gly Ile Phe
               380
                                   385
Ser Ala Arg Glu Lys Arg Asp Val Gln Pro Pro Ala Ser Gln His
               395
                                  400
Glu Gly Gly Gly Ala Glu Gly Leu Glu Ser Leu Thr Trp Gly Val
               410
                                  415
Gly Leu Ala Leu Ala Pro Ala Leu Trp Trp Gly Val Val Cys Pro
               425
Ser Cys
```

<210> 39 <211> 330 <212> PRT <213> Homo sapiens

<220>
<221> misc\_feature

<223> Inmyte Clone No. 2124245

<400> 39

Met Glu Gly Ala Pro Pro Gly Ser Leu Ala Leu Arg Leu Leu Leu 10 Phe Val Ala Leu Pro Ala Ser Gly Trp Leu Thr Thr Gly Ala Pro Glu Pro Pro Pro Leu Ser Gly Ala Pro Gln Asp Gly Ile Arg Ile 35 40 Asn Val Thr Thr Leu Lys Asp Asp Gly Asp Ile Ser Lys Gln Gln 50 55 Val Val Leu Asn Ile Thr Tyr Glu Ser Gly Gln Val Tyr Val Asn 70 65 Asp Leu Pro Val Asn Ser Gly Val Thr Arg Ile Ser Cys Gln Thr 80 85 Leu Ile Val Lys Asn Glu Asn Leu Glu Asn Leu Glu Glu Lys Glu 95 100 Tyr Phe Gly Ile Val Ser Val Arg Ile Leu Val His Glu Trp Pro 110 115 Met Thr Ser Gly Ser Ser Leu Gln Leu Ile Val Ile Gln Glu Glu 125 130 Val Val Glu Ile Asp Gly Lys Gln Val Gln Gln Lys Asp Val Thr 140 145 Glu Ile Asp Ile Leu Val Lys Asn Arg Gly Val Leu Arg His Ser

```
155
                                    160
Asn Tyr Thr Leu Pro Leu Glu Glu Ser Met Leu Tyr Ser Ile Ser
                170
                                    175
Arg Asp Ser Asp Ile Leu Phe Thr Leu Pro Asn Leu Ser Lys Lys
                185
                                    190
Glu Ser Val Ser Ser Leu Gln Thr Thr Ser Gln Tyr Leu Ile Arg
                200
                                    205
Asn Val Glu Thr Thr Val Asp Glu Asp Val Leu Pro Gly Lys Leu
                215
                                    220
Pro Glu Thr Pro Leu Arg Ala Glu Pro Pro Ser Ser Tyr Lys Val
                230
                                    235
Met Cys Gln Trp Met Glu Lys Phe Arg Lys Asp Leu Cys Arg Phe
                245
                                    250
Trp Ser Asn Val Phe Pro Val Phe Phe Gln Phe Leu Asn Ile Met
                260
                                    265
Val Val Gly Ile Thr Gly Ala Ala Val Val Ile Thr Ile Leu Lys
                275
                                    280
Val Phe Phe Pro Val Ser Glu Tyr Lys Gly Ile Leu Gln Leu Asp
                290
                                    295
Lys Val Asp Val Ile Pro Val Thr Ala Ile Asn Leu Tyr Pro Asp
                305
                                    310
Gly Pro Glu Lys Arg Ala Glu Asn Leu Glu Asp Lys Thr Cys Ile
                320
```

<210> 40 <211> 148 <212> PRT <213> Homo sapiens

<220>

<221> misc\_feature <223> Incyte Clone Nor 2132626

<400> 40

Met Glu Thr Gly Ala Leu Arg Arg Pro Gln Leu Leu Pro Leu Leu 10 Leu Leu Cys Gly Gly Cys Pro Arg Ala Gly Gly Cys Asn Glu Thr Gly Met Leu Glu Arg Leu Pro Leu Cys Gly Lys Ala Phe Ala 40 Asp Met Met Gly Lys Val Asp Val Trp Lys Trp Cys Asn Leu Ser 55 Glu Phe Ile Val Tyr Tyr Glu Ser Phe Thr Asn Cys Thr Glu Met 70 Glu Ala Asn Val Val Gly Cys Tyr Trp Pro Asn Pro Leu Ala Gln 85 Gly Phe Ile Thr Gly Ile His Arg Gln Phe Phe Ser Asn Cys Thr 100 Val Asp Arg Val His Leu Glu Asp Pro Pro Asp Glu Val Leu Ile 115 Pro Leu Ile Val Ile Pro Val Val Leu Thr Val Ala Met Ala Gly 125 130 Leu Val Val Trp Arg Ser Lys Arg Thr Asp Thr Leu Leu 140 145

```
<210> 41
<211> 188
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2280639
<400> 41
Met Ala Pro Pro Pro Pro Ser Pro Gln Leu Leu Leu Ala Ala
                                     10
Leu Ala Arg Leu Leu Gly Pro Ser Glu Val Met Ala Gly Pro Ala
                                     25
Glu Glu Ala Gly Ala His Cys Pro Glu Ser Leu Trp Pro Leu Pro
                                     40
Pro Gln Val Ser Pro Arg Val Thr Tyr Thr Arg Val Ser Pro Gly
                                     55
Gln Ala Glu Asp Val Thr Phe Leu Tyr His Pro Cys Ala His Pro
                                     70
Trp Leu Lys Leu Gln Leu Ala Leu Leu Ala Tyr Ala Cys Met Ala
                 80
                                     85
Asn Pro Ser Leu Thr Pro Asp Phe Ser Leu Thr Gln Asp Arg Pro
                 95
                                    100
Leu Val Leu Thr Ala Trp Gly Leu Ala Leu Glu Met Ala Trp Val
                110
                                    115
Glu Pro Ala Trp Ala Ala His Trp Leu Met Arg Arg Arg Arg Arg
                125
                                    130
Lys Gln Arg Lys Lys Lys Ala Trp Ile Tyr Cys Glu Ser Leu Ser
                140
                                    145
                                                        150
Gly Pro Ala Pro Ser Clu Pro Thr Pro Gly Arg Cly Arg Leu Cys
               155
                                   160
Arg Arg Gly Cys Val Gln Ala Leu Ala Leu Ala Phe Ala Leu Arg
               170
                                   175
                                                        180
Thr Gly Gly Pro Leu Ala Gln Arg
```

```
Pro Trp Lys Glu Ala Leu Val Arg Pro Pro Gly Ser Tyr Ser Ser
                 35
                                     40
Ser Ser Asn Ser Gly Asp Trp Gly Trp Asp Leu Ala Ser Asp Gln
                 50
                                     55
Ser Ser Pro Ser Thr Pro Ser Pro Pro Leu Pro Pro Glu Ala Ala
                 65
                                     70
His Phe Leu Phe Gly Glu Pro Thr Leu Arg Lys Arg Lys Ser Pro
                 80
Ala Gln Val Met Phe Gln Cys Leu Trp Lys Ser Cys Gly Lys Val
                 95
                                    100
Leu Ser Thr Ala Ser Ala Met Gln Arg His Ile Arg Leu Val His
                110
                                    115
Leu Gly Cys Gly Gly Ala Trp Gly Ala Ala Gly Pro Ala Gly Trp
                125
                                   130
Leu Gly Leu Leu Gly Pro Ala Arg Pro Pro Leu Gln Leu Pro Leu
                140
                                   145
Ala Gly Cys Val Ser Arg Arg Gln Ala Glu Pro Glu Gln Ser
                155
                                   160
Asp Gly Glu Glu Asp Phe Tyr Tyr Thr Glu Leu Asp Val Gly Val
                170
                                   175
Asp Thr Leu Thr Asp Gly Leu Ser Ser Leu Thr Pro Val Phe Pro
                185
                                   190
Glu Gly Phe His Ala Ser Leu Pro Ser Pro Ala Leu Lys Leu Arg
               200
                                   205
Arg Leu Gly Gly Thr Arg Gln Pro Arg Gln Tyr Pro
                215
```

```
<211> 111
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2349310
<400> 43
Met Gly Pro Ser Ser Cys Leu Leu Leu Ile Leu Ile Pro Leu Leu
                                     10
Gln Leu Ile Asn Leu Gly Ser Thr Gln Cys Ser Leu Asp Ser Val
Met Asp Lys Lys Ile Lys Asp Val Leu Asn Ser Leu Glu Tyr Ser
Pro Ser Pro Ile Ser Lys Lys Leu Ser Cys Ala Ser Val Lys Ser
                                     55
Gln Gly Arg Pro Ser Ser Cys Pro Ala Gly Met Ala Val Thr Gly
Cys Ala Cys Gly Tyr Gly Cys Gly Ser Trp Asp Val Gln Leu Glu
                                     85
Thr Thr Cys His Cys Gln Cys Ser Val Val Asp Trp Thr Thr Ala
                 95
Arg Cys Cys His Leu Thr
```

<210> 43

```
<210> 44
<211> 341
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2373227
<400> 44
Met Val Pro Ala Ala Gly Ala Leu Leu Trp Val Leu Leu Leu Asn
                                   10
Leu Gly Pro Arg Ala Ala Gly Ala Gln Gly Leu Thr Gln Thr Pro
Thr Glu Met Gln Arg Val Ser Leu Arg Phe Gly Gly Pro Met Thr
                                   40
Arg Ser Tyr Arg Ser Thr Ala Arg Thr Gly Leu Pro Arg Lys Thr
                50
Arg Ile Ile Leu Glu Asp Glu Asn Asp Ala Met Ala Asp Ala Asp
                65
                                   70
Arg Leu Ala Gly Pro Ala Ala Glu Leu Leu Ala Ala Thr Val
                80
                                   85
Ser Thr Gly Phe Ser Arg Ser Ser Ala Ile Asn Glu Glu Asp Gly
                95
                                 100
Ser Ser Glu Glu Gly Val Val Ile Asn Ala Gly Lys Asp Ser Thr
               110
                                  115
Ser Arg Glu Leu Pro Ser Ala Thr Pro Asn Thr Ala Gly Ser Ser
                                   130
Ser Thr Arg Phe Ile Ala Asn Ser Gln Glu Pro Glu Ile Arg Leu
Thr Ser Ser Leu Pro Arg Ser Pro Gly Arg Ser Thr Glu Asp Leu
               155 160
Pro Gly Ser Gin Ala Thr Len Set Gine Trp Ser Thr Pro Gly Ser
               170
                                   175
Thr Pro Ser Arg Trp Pro Ser Pro Ser Pro Thr Ala Met Pro Ser
                           190
               185
Pro Glu Asp Leu Arg Leu Val Leu Met Pro Trp Gly Pro Trp His
                                   205
Cys His Cys Lys Ser Gly Thr Met Ser Arg Ser Arg Ser Gly Lys
               215
                                   220
Leu His Gly Leu Ser Gly Arg Leu Arg Val Gly Ala Leu Ser Gln
               230
                                   235
Leu Arg Thr Glu His Lys Pro Cys Thr Tyr Gln Gln Cys Pro Cys
               245
Asn Arg Leu Arg Glu Glu Cys Pro Leu Asp Thr Ser Leu Cys Thr
                                   265
Asp Thr Asn Cys Ala Ser Gln Ser Thr Thr Ser Thr Arg Thr Thr
               275
Thr Thr Pro Phe Pro Thr Ile His Leu Arg Ser Ser Pro Ser Leu
               290
                                   295
Pro Pro Ala Ser Pro Cys Pro Ala Leu Ala Phe Trp Lys Arg Val
                                   310
Arg Ile Gly Leu Glu Asp Ile Trp Asn Ser Leu Ser Ser Val Phe
               320
Thr Glu Met Gln Pro Ile Asp Arg Asn Gln Arg
```

<210> 45

335

340

```
<211> 148
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2457682
Met Ala Gly Leu Ala Ala Arg Leu Val Leu Leu Ala Gly Ala Ala
Ala Leu Ala Ser Gly Ser Gln Gly Asp Arg Glu Pro Val Tyr Arg
                20
Asp Cys Val Leu Gln Cys Glu Glu Gln Asn Cys Ser Gly Gly Ala
Leu Asn His Phe Arg Ser Arg Gln Pro Ile Tyr Met Ser Leu Ala
Gly Trp Thr Cys Arg Asp Asp Cys Lys Tyr Glu Cys Met Trp Val
                                    70
Thr Val Gly Leu Tyr Leu Gln Glu Gly His Lys Val Pro Gln Phe
                                    85
His Gly Lys Trp Pro Phe Ser Arg Phe Leu Phe Phe Gln Glu Pro
                                   100
Ala Ser Ala Val Ala Ser Phe Leu Asn Gly Leu Ala Ser Leu Val
                                   115
Met Leu Cys Arg Tyr Arg Thr Phe Val Pro Ala Ser Ser Pro Met
               125
                                   130
Tyr Him Thr Cys Val Ala Phe Ala Trp Leu Ser Gly Arg
           . 140
                                   145
```

<210> 46 <211> 87 <212> PRT <213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone No: 2480426

<400> 46

Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu Ile Arg Val Pro Pro
65 70 75
Leu Ser Asp Ala Pro Leu Pro Ser Thr Ala Cys Trp
80 85

<210> 47
<211> 383
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature

<223> Incyte Clone No: 2503743

<400> 47 Met Ala Gly Ile Pro Gly Leu Leu Phe Leu Leu Phe Phe Leu Leu Cys Ala Val Gly Gln Val Ser Pro Tyr Ser Ala Pro Trp Lys Pro Thr Trp Pro Ala Tyr Arg Leu Pro Val Val Leu Pro Gln Ser Thr Leu Asn Leu Ala Lys Pro Asp Phe Gly Ala Glu Ala Lys Leu Glu Val Ser Ser Ser Cys Gly Pro Gln Cys His Lys Gly Thr Pro Leu Pro Thr Tyr Glu Glu Ala Lys Gln Tyr Leu Ser Tyr Glu Thr Leu 85 Tyr Ala Asn Gly Ser Arg Thr Glu Thr Gln Val Gly Ile Tyr Ile 100 95 Leu Ser Ser Ser Gly Asp Gly Ala Gln His Arg Asp Ser Gly Ser : 1.15 110 Ser Gly Lys Ser Arg Arg Lys Arg Gln fle Tyr Gly Tyr Asp Ser 125 130 Arg Phe Ser Ile Phe Gly Lys Asp Phe Leu Leu Asn Tyr Pro Phe 140 145 Ser Thr Ser Val Lys Leu Ser Thr Gly Cys Thr Gly Thr Leu Val 155 160 Ala Glu Lys His Val Leu Thr Ala Ala His Cys Ile His Asp Gly 170 175 Lys Thr Tyr Val Lys Gly Thr Gln Lys Leu Arg Val Gly Phe Leu 185 190 Lys Pro Lys Phe Lys Asp Gly Gly Arg Gly Ala Asn Asp Ser Thr 200 205 Ser Ala Met Pro Glu Gln Met Lys Phe Gln Trp Ile Arg Val Lys 215 220 Arg Thr His Val Pro Lys Gly Trp Ile Lys Gly Asn Ala Asn Asp 235 Ile Gly Met Asp Tyr Asp Tyr Ala Leu Leu Glu Leu Lys Lys Pro 250 His Lys Arg Lys Phe Met Lys Ile Gly Val Ser Pro Pro Ala Lys 265 Gln Leu Pro Gly Gly Arg Ile His Phe Ser Gly Tyr Asp Asn Asp 280 275 Arg Pro Gly Asn Leu Val Tyr Arg Phe Cys Asp Val Lys Asp Glu

```
| 290 | 295 | 300 | 315 | 315 | 316 | 316 | 317 | 317 | 318 | 318 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319 | 319
```

<211> 109 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 2537684 <400> 48 Met Leu Leu Pro Ala Leu Cys Ala Trp Leu Leu Trp Val Pro Trp Cys Leu Leu Val Ala Gly Ser Gly Arg Ser Gly Gly Glu Leu Cys 20 25 30 Cys Ser Ser Tyr Gly Val Ser Val Ile Ser Val Trp Ser Lys Cys 35 40 45 Ser Val Cys Arg Cys Leu Met Gly Ser Val Pro Arg Ile Phe Phe 50 60 Ala Phe Tyr Pro Ile Ala Trp Leu Pro Leu Pro Gly Ser Gln Gly 65 Cys Trp Ser Arg Ser Trp Glu Trp Pro Leu Val Glu Pro Ala Ser

Cys Leu Val Cys Leu Cys Phe Thr Phe Gly Val Leu Ser Gly Val

<210> 48

Val Ala Val Lys

<210> 49
<211> 185
<212> PRT
<213> Homo sapiens

<220>
<221> misc\_feature
<223> Incyte Clone No: 2593853

<400> 49
Met Lys Phe Thr Ile Val Phe Ala Gly Leu Leu Gly Val Phe Leu

```
10
Ala Pro Ala Leu Ala Asn Tyr Asn Ile Asn Val Asn Asp Asp Asn
                                     25
Asn Asn Ala Gly Ser Gly Gln Gln Ser Val Ser Val Asn Asn Glu
                                     40
His Asn Val Ala Asn Val Asp Asn Asn Gly Trp Asp Ser Trp
                                     55
Asn Ser Ile Trp Asp Tyr Gly Asn Gly Phe Ala Ala Thr Arg Leu
                 65
                                     70
Phe Gln Lys Lys Thr Cys Ile Val His Lys Met Asn Lys Glu Val
                 80
                                     85
Met Pro Ser Ile Gln Ser Leu Asp Ala Leu Val Lys Glu Lys Lys
                 95
                                    100
Leu Gln Gly Lys Gly Pro Gly Gly Pro Pro Pro Lys Gly Leu Met
                110
                                    115
Tyr Ser Val Asn Pro Asn Lys Val Asp Asp Leu Ser Lys Phe Gly
                125
                                    130
Lys Asn Ile Ala Asn Met Cys Arg Gly Ile Pro Thr Tyr Met Ala
                140
                                    145
Glu Glu Met Gln Glu Ala Ser Leu Phe Phe Tyr Ser Gly Thr Cys
                155
                                    160
Tyr Thr Thr Ser Val Leu Trp Ile Val Asp Ile Ser Phe Cys Gly
                170
                                    175
Asp Thr Val Glu Asn
```

```
<210> 50
<211> 110
<212> PRT
<213> Homo sapiens
```

<220> →

<221> misc\_feature

<223> Incyte Clone No: 2622354

110

<400> 50

Met Ala Pro Arg Gly Cys Ile Val Ala Val Phe Ala Ile Phe Cys 10 Ile Ser Arg Leu Leu Cys Ser His Gly Ala Pro Val Ala Pro Met 20 Thr Pro Tyr Leu Met Leu Cys Gln Pro His Lys Arg Cys Gly Asp Lys Phe Tyr Asp Pro Leu Gln His Cys Cys Tyr Asp Asp Ala Val 55 Val Pro Leu Ala Arg Thr Gln Thr Cys Gly Asn Cys Thr Phe Arg 65 Val Cys Phe Glu Gln Cys Cys Pro Trp Thr Phe Met Val Lys Leu 80 85 Ile Asn Gln Asn Cys Asp Ser Ala Arg Thr Ser Asp Asp Arg Leu 95 100 Cys Arg Ser Val Ser

```
<210> 51
<211> 126
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2641377
<400> 51
Met Trp Leu Gly Ser Trp Leu Thr Ser Leu Leu Ser Pro Tyr
                                     10
Gly Ser Gly Trp Glu Lys Val Pro Cys Cys Val Thr Gly His Leu
                20
                                     25
Arg Ser Cys Ser Cys Cys Leu Leu Gly Leu Ala Gly Val Gln Ser
                 35
                                     40
Asp His Phe Ser Glu Gly Phe Phe Ser Glu Tyr Ser Ser Asp Val
                                     55
Leu Pro Trp Gly Arg Arg Ser Phe Leu Pro Gln Gly Asp Ala Ser
Leu Leu Ala Cys Glu Cys Phe Leu His Leu Gln Val Val Trp Gly
                 80
                                     85
Gln Phe Cys Leu Leu Glu Ala Trp Ala Gly Phe Thr Glu Gly Ser
                 95
                                    100
Met Pro Ala Pro Ser Cys Arg Val His Phe Trp Cys Arg Val Asn
                110
Thr Cys Ala Phe Met Ser
<210> 52
<211> 468
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2674857
<400> 52
Met Ala Gly Lys Gly Ser Ser Gly Arg Arg Pro Leu Leu Gly
                                     10
Leu Leu Val Ala Val Ala Thr Val His Leu Val Ile Cys Pro Tyr
                 20
                                     25
Thr Lys Val Glu Glu Ser Phe Asn Leu Gln Ala Thr His Asp Leu
                35
                                     40
Leu Tyr His Trp Gln Asp Leu Glu Gln Tyr Asp His Leu Glu Phe
```

50

65

80

55

70

85

100

Pro Gly Val Val Pro Arg Thr Phe Leu Gly Pro Val Val Ile Ala

Val Phe Ser Ser Pro Ala Val Tyr Val Leu Ser Leu Leu Glu Met

Ser Lys Phe Tyr Ser Gln Leu Ile Val Arg Gly Val Leu Gly Leu

```
Gly Val Ile Phe Gly Leu Trp Thr Leu Gln Lys Glu Val Arg Arg
                110
                                   115
His Phe Gly Ala Met Val Ala Thr Met Phe Cys Trp Val Thr Ala
                125
                                    130
Met Gln Phe His Leu Met Phe Tyr Cys Thr Arg Thr Leu Pro Asn
                140
                                    145
Val Leu Ala Leu Pro Val Val Leu Leu Ala Leu Ala Ala Trp Leu
                155
                                    160
Arg His Glu Trp Ala Arg Phe Ile Trp Leu Ser Ala Phe Ala Ile
                170
                                    175
Ile Val Phe Arg Val Glu Leu Cys Leu Phe Leu Gly Leu Leu
                185
                                    190
Leu Leu Ala Leu Gly Asn Arg Lys Val Ser Val Val Arg Ala Leu
                200
Arg His Ala Val Pro Ala Gly Ile Leu Cys Leu Gly Leu Thr Val
                215
                                  · 220
Ala Val Asp Ser Tyr Phe Trp Arg Gln Leu Thr Trp Pro Glu Gly
                230
                                   235
Lys Val Leu Trp Tyr Asn Thr Val Leu Asn Lys Ser Ser Asn Trp
                245
                                   250
Gly Thr Ser Pro Leu Leu Trp Tyr Phe Tyr Ser Ala Leu Pro Arg
                260
                                    265
Gly Leu Gly Cys Ser Leu Leu Phe Ile Pro Leu Gly Leu Val Asp
               . 275
                                    280
Arg Arg Thr His Ala Pro Thr Val Leu Ala Leu Gly Phe Met Ala
                                    295
Leu Tyr Ser Leu Leu Pro His Lys Glu Leu Arg Phe Ile Ile Tyr
                                    310
Ala Phe Pro Met Leu Asn Ile Thr Ala Ala Arg Gly Cys Ser Tyr
Leu Leu Asn Asn Tyr Lys Lys Ser Trp Leu Tyr Lys Ala Gly Ser
                                    340
Leu Leu Val Ile Gly His Leu Val Val Asn Ala Ala Tyr Ser Ala
Thr Ala Leu Tyr Val Ser His Phe Asn Tyr Pro Gly Gly Val Ala
Met Gln Arg Leu His Gln Leu Val Pro Pro Gln Thr Asp Val Leu
Leu His Ile Asp Val Ala Ala Ala Gln Thr Gly Val Ser Arg Phe
Leu Gln Val Asn Ser Ala Trp Arg Tyr Asp Lys Arg Glu Asp Val
Gln Pro Gly Thr Gly Met Leu Ala Tyr Thr His Ile Leu Met Glu
                425
                                    430
Ala Ala Pro Gly Leu Leu Ala Leu Tyr Arg Asp Thr His Arg Val
                440
                                    445
Leu Ala Ser Val Val Gly Thr Thr Gly Val Ser Leu Asn Leu Thr
                455
                                    460
Gln Leu Pro Pro Phe Asn Val His Leu Gln Thr Lys Leu Val Leu
                470
                                    475
Leu Glu Arg Leu Pro Arg Pro Ser
                485
```

```
<211> 197
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2758485
Met Ser Pro Arg Arg Thr Leu Pro Arg Pro Leu Ser Leu Cys Leu
Ser Leu Cys Leu Cys Leu Cys Leu Ala Ala Leu Gly Ser Ala
Gln Ser Gly Ser Cys Arg Asp Lys Lys Asn Cys Lys Val Val Phe
Ser Gln Gln Glu Leu Arg Lys Arg Leu Thr Pro Leu Gln Tyr His
Val Thr Gln Glu Lys Gly Thr Glu Ser Ala Phe Glu Gly Glu Tyr
                65
                                    70
Thr His His Lys Asp Pro Gly Ile Tyr Lys Cys Val Val Cys Gly
                80
                                    85
Thr Pro Leu Phe Lys Ser Glu Thr Lys Phe Asp Ser Gly Ser Gly
                95
                                   100
Trp Pro Ser Phe His Asp Val Ile Asn Ser Glu Ala Ile Thr Phe
               110
                                   115
Thr Asp Asp Phe Ser Tyr Gly Met His Arg Val Glu Thr Ser Cys
               125
                                   130
Ser Gln Cys Gly Ala His Leu Gly His Ile Phe Asp Asp Gly Pro
                                   145
Arg Pro Thr Gly Lys Arg Tyr Cys Ile Asn Ser Ala Ala Leu Ser
Phe Thr Pro Ala Asp Ser Ser Gly Thr Ala Glu Gly Gly Ser Gly
               170
                                   175
Val Ala Ser Pro Ala Gln Ala Asp Lys Ala Asp Ser Glu Ser Asn
               185
                                 1.90
                                                       -195
Gly Glu
<210> 54
<211> 84
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2763296
```

```
50 55 60

Ser Pro Leu Lys Ser Asn Ser Asp Ser Ala Arg Leu Pro Ile Ser
65 70 75

Ser Gly Ser Thr Ser Ser Ser Arg Ile
80
```

```
<210> 55
<211> 97
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
.<223> Incyte Clone No: 2779436
<400> 55
Met Gln Leu Gly Thr Gly Leu Leu Leu Ala Ala Val Leu Ser Leu
  1
                                     10
Gln Leu Ala Ala Ala Glu Ala Ile Trp Cys His Gln Cys Thr Gly
Phe Gly Gly Cys Ser His Gly Ser Arg Cys Leu Arg Asp Ser Thr
His Cys Val Thr Thr Ala Thr Arg Val Leu Ser Asn Thr Glu Asp
Leu Pro Leu Val Thr Lys Met Cys His Ile Gly Cys Pro Asp Ile
Pro Ser Leu Gly Leu Gly Pro Tyr Val Ser Ile Ala Cys Cys Gln
Thr Ser Leu Cys Asn His Asp
                 95
```

35

<210> 56

Gln Glu Met Lys Thr Leu Phe Leu Asn Thr Glu Tyr Leu Met Pro

<210> 57 <211> 285 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 2809230 <400> 57 Met Glu Val Pro Pro Pro Ala Pro Arg Ser Phe Leu Cys Arg Ala 1 5 10 Leu Cys Leu Phe Pro Arg Val Phe Ala Ala Glu Ala Val Thr Ala Asp Ser Glu Val Leu Glu Glu Arg Gln Lys Arg Leu Pro Tyr Val 40 Pro Glu Pro Tyr Tyr Pro Glu Ser Gly Trp Asp Arg Leu Arg Glu 50 55 Leu Phe Gly Lys Asp Glu Gln Gln Arg Ile Ser Lys Asp Leu Ala Asn Ile Cys Lys Thr Ala Ala Thr Mla Gly Ile Ile Gly Trp Val 85 Tyr Gly Gly Ile Pro Ala Phe Ile His Ala Lys Gln Gln Tyr Ile 95 100 Glu Gln Ser Gln Ala Glu Ile Tyr His Asn Arg Phe Asp Ala Val 110 115 Gln Ser Ala His Arg Ala Ala Thr Arg Gly Phe Ile Arg Tyr Gly 125 130 Trp Arg Trp Gly Trp Arg Thr Ala Val Phe Val Thr Ile Phe Asn 145 Thr Val Asn Thr Ser Leu Asn Val Tyr Arg Asn Lys Asp Ala Leu 155 160 Ser His Phe Val Ile Ala Gly Ala Val Thr Gly Ser Leu Phe Arg 170 175 Ile Asn Val Gly Leu Arg Gly Leu Val Ala Gly Gly Ile Ile Gly 185 190 Ala Leu Leu Gly Thr Pro Val Gly Gly Leu Leu Met Ala Phe Gln 205 Lys Tyr Ser Gly Glu Thr Val Gln Glu Arg Lys Gln Lys Asp Arg 215 220 Lys Ala Leu His Glu Leu Lys Leu Glu Glu Trp Lys Gly Arg Leu 230 235 Gln Val Thr Glu His Leu Pro Glu Lys Ile Glu Ser Ser Leu Gln

<210> 58 <211> 262 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 2816821 <400> 58 Met Thr Gln Pro Val Pro Arg Leu Ser Val Pro Ala Ala Leu Ala 10 Leu Gly Ser Ala Ala Leu Gly Ala Ala Phe Ala Thr Gly Leu Phe 20 25 Leu Gly Arg Arg Cys Pro Pro Trp Arg Gly Arg Arg Glu Gln Cys 35 40 Leu Leu Pro Pro Glu Asp Ser Arg Leu Trp Gln Tyr Leu Leu Ser 50 55 Arg Ser Met Arg Glu His Pro Ala Leu Arg Ser Leu Arg Leu Leu 65 70 Thr Leu Glu Gln Pro Gln Gly Asp Ser Met Met Thr Cys Glu Gln 85 Ala Gln Leu Leu Ala Asn Leu Ala Arg Leu Ile Gln Ala Lys Lys 100 Ala Leu Asp Leu Gly Thr Phe Thr Sly Tyr Ser Ala Leu Ala Leu 115 Ala Leu Ala Leu Pro Ala Asp Gly Arg Val Val Thr Cys Glu Val 125 130 Asp Ala Gln Pro Pro Glu Leu Gly Arg Pro Leu Trp Arg Gln Ala 140 145 Glu Ala Glu His Lys Ile Asp Leu Arg Leu Lys Pro Ala Leu Glu 155 160 Thr Leu Asp Glu Leu Leu Ala Ala Gly Glu Ala Gly Thr Phe Asp 170 175 Val Ala Val Val Asp Ala Asp Lys Glu Asn Cys Ser Ala Tyr Tyr 185 190 195 Glu Arg Cys Leu Gln Leu Leu Arg Pro Gly Gly Ile Leu Ala Val 200 205 Leu Arg Val Leu Trp Arg Gly Lys Val Leu Gln Pro Pro Lys Gly 215 220 Asp Val Ala Ala Glu Cys Val Arg Asn Leu Asn Glu Arg Ile Arg 230 235 Arg Asp Val Arg Val Tyr Ile Ser Leu Leu Pro Leu Gly Asp Gly 245 250 255 Leu Thr Leu Ala Phe Lys Ile

WO 00/00610

PCT/US99/14484

```
<210> 59
<211> 189
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2817268
Met Ala Leu Leu Ser Arg Pro Ala Leu Thr Leu Leu Leu Leu
                                     10
Met Ala Ala Val Val Arg Cys Gln Glu Gln Ala Gln Thr Thr Asp
                                     25
Trp Arg Ala Thr Leu Lys Thr Ile Arg Asn Gly Val His Lys Ile
                 35
                                     40
Asp Thr Tyr Leu Asn Ala Ala Leu Asp Leu Leu Gly Gly Glu Asp
                 50
                                     55
Gly Leu Cys Gln Tyr Lys Cys Ser Asp Gly Ser Lys Pro Phe Pro
                 65
                                     70
Arg Tyr Gly Tyr Lys Pro Ser Pro Pro Asn Gly Cys Gly Ser Pro
                 80
                                     85
Leu Phe Gly Val His Leu Asn Ile Gly Ile Pro Ser Leu Thr Lys
                95
                                    100
Cys Cys Asn Gln His Asp Arg Cys Tyr Glu Thr Cys Gly Lys Ser
               110
                                    115
Lys Asn Asp Cys Asp Glu Glu Phe Gln Tyr Cys Leu Ser Lys Ile
                125
                                    130
Cys Arg Asp Val Gln Lys Thr Leu Gly Leu Thr Gln His Val Gln
               140
                                    145
Ala Cys Glu Thr Thr Val Glu Leu Leu Phe Asp Ser Val Ile His
               155
                                   160
Lou Gly Cys Lys Pro Tyr Leu Asp Ser Glm Amg Ala Ala Cys Arg
              370
                                   175
                                                        180
Cys His Tyr Glu Glu Lys Thr Asp Leu
               185
```

```
Leu Leu Ile Ser Ser Leu Val Trp Phe Met Ala Arg Val Ile Ile
                 50
                                     55
Asp Asn Lys Asp Gly Pro Thr Gln Lys Tyr Leu Leu Ile Phe Gly
                 65
                                     70
Ala Phe Val Ser Val Tyr Ile Gln Glu Met Phe Arg Phe Ala Tyr
                 80
                                     85
Tyr Lys Leu Leu Lys Lys Ala Ser Glu Gly Leu Lys Ser Ile Asn
                 95
                                    100
Pro Gly Glu Thr Ala Pro Ser Met Arg Leu Leu Ala Tyr Val Ser
                110
                                    115
Gly Leu Gly Phe Gly Ile Met Ser Gly Val Phe Ser Phe Val Asn
                125
                                    130
Thr Leu Ser Asp Ser Leu Gly Pro Gly Thr Val Gly Ile His Gly
                140
                                    145
Asp Ser Pro Gln Phe Phe Leu Tyr Ser Ala Phe Met Thr Leu Val
                155
                                    160
Ile Ile Leu Leu His Val Phe Trp Gly Ile Val Phe Phe Asp Gly
                170
                                    175
Cys Glu Lys Lys Trp Gly Ile Leu Leu Ile Val Leu Leu Thr
                185
                                    190
His Leu Leu Val Ser Ala Gln Thr Phe Ile Ser Ser Tyr Tyr Gly
                200
                                    205
Ile Asn Leu Ala Ser Ala Phe Ile Ile Leu Val Leu Met Gly Thr
                215
                                    220
Trp Ala Phe Leu Ala Ala Gly Gly Ser Cys Arg Ser Leu Lys Leu
                230
                                    235
Cys Leu Leu Cys Gln Asp Lys Asn Phe Leu Leu Tyr Asn Gln Arg
                245
                                    250
Ser Arg
```

<210> 61 <211> 52 <212> PRT <213> Homo sapiens <220> <221> misc feature

<223> Incyte Clone No: 2949822

<400> 61

 Met
 Pro
 Phe
 Ser
 Trp
 Met
 Val
 Ile
 Leu
 Gly
 Phe
 Leu
 Cys
 Gly

 1
 5
 10
 10
 15
 15
 15
 15
 15
 15
 16
 16
 16
 16
 16
 16
 16
 15
 15
 15
 15
 15
 15
 15
 15
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16
 16

```
<210> 62
<211> 202
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2992192
<400> 62
Met Ala Ala Pro Trp Arg Arg Trp Pro Thr Gly Leu Leu Ala Val
                                     10
Leu Arg Pro Leu Leu Thr Cys Arg Pro Leu Gln Gly Thr Thr Leu
                 20
                                     25
Gln Arg Asp Val Leu Leu Phe Glu His Asp Arg Gly Arg Phe Phe
                 35
                                     40
Thr Ile Leu Gly Leu Phe Cys Ala Gly Gln Gly Val Phe Trp Ala
                 50
                                     55
Ser Met Ala Val Ala Ala Val Ser Arg Pro Pro Val Pro Val Gln
                 65
                                     70
Pro Leu Asp Ala Glu Val Pro Asn Arg Gly Pro Phe Asp Leu Arg
                 80
Ser Ala Leu Trp Arg Tyr Gly Leu Ala Val Gly Cys Gly Ala Ile
                 95
                                    100
Gly Ala Leu Val Leu Gly Ala Gly Leu Leu Phe Ser Leu Arg Ser
                110
                                    115
Val Arg Ser Val Val Leu Arg Ala Gly Gly Gln Gln Val Thr Leu
                125
                                    130
Thr Thr His Ala Pro Phe Gly Leu Gly Ala His Phe Thr Val Pro
                140
                                    145
Leu Lys Gln Val Ser Cys Met Ala His Arg Gly Glu Val Pro Ala
                155
                                    160
                                                         165
Met Leu Pro Leu Lys Val Lys Gly Arg Arg Phe Tyr Phe Leu Leu
                170
                                    175
                                                        130
Asp Lys Thr Gly His Phe Pro Asn Thr Lys Leu Phe Asp Asn Thr
                185
                                    190
Val Gly Ala Tyr Arg Ser Leu
                200
```

Arg Ala Cys Ser Asn Pro Ser Phe Leu Arg Phe Gln Leu Asp Phe Tyr Gln Val Tyr Phe Leu Ala Leu Ala Ala Asp Trp Leu Gln Ala Pro Tyr Leu Tyr Lys Leu Tyr Gln His Tyr Tyr Phe Leu Glu Gly Gln Ile Ala Ile Leu Tyr Val Cys Gly Leu Ala Ser Thr Val Leu Phe Gly Leu Val Ala Ser Ser Leu Val Asp Trp Leu Gly Arg Lys Asn Ser Cys Val Leu Phe Ser Leu Thr Tyr Ser Leu Cys Cys Leu Thr Lys Leu Ser Gln Asp Tyr Phe Val Leu Leu Val Gly Arg Ala Leu Gly Gly Leu Ser Thr Ala Leu Leu Phe Ser Ala Phe Glu Ala Trp Tyr Ile His Glu His Val Glu Arg His Asp Phe Pro Ala Glu Trp Ile Pro Ala Thr Phe Ala Arg Ala Ala Phe Trp Asn His Val Leu Ala Val Val Ala Gly Val Ala Ala Glu Ala Val Ala Ser Trp Ile Gly Leu Gly Pro Val Ala Pro Phe Val Ala Ala Ile Pro Leu Leu Ala Leu Ala Gly Ala Leu Ala Leu Arg Asn Trp Gly Glu Asn Tyr Asp Arg Gln Arg Ala Phe Ser Arg Thr Cys Ala Gly Gly Leu Arg Cys Leu Leu Ser Asp Arg Arg Val Leu Leu Leu Gly Thr Ile Gln Ala Leu Phe Glu Ser Val Ile Phe Ile Phe Val Phe Leu Trp Thr Pro Val Leu Asp Pro His Gly Ala Pro Leu Gly Ile Ile Phe Ser Ser Phe Met Ala Ala Ser Leu Leu Gly Ser Ser Leu Tyr Arg Ile Ala Thr Ser Lys Arg Tyr His Leu Gln Pro Met His Leu Leu Ser Leu Ala Val Leu Ile Val Val Phe Ser Leu Phe Met Leu Thr Phe Ser Thr Ser Pro Gly Gln Glu Ser Pro Val Glu Ser Phe Ile Ala Phe Leu Leu Ile Glu Leu Ala Cys Gly Leu Tyr Phe Pro Ser Met Ser Phe Leu Arg Arg Lys Val Ile Pro Glu Thr Glu Gln Ala Gly Val Leu Asn Trp Phe Arg Val Pro Leu His Ser Leu Ala Cys Leu Gly Leu Leu Val Leu His Asp Ser Asp Arg Lys Thr Gly Thr Arg Asn Met Phe Ser Ile Cys Ser Ala Val Met Val Met Ala Leu Leu Ala Val Val Gly Leu Phe Thr Val Val Arg His Asp Ala Glu Leu Arg Val Pro Ser Pro Thr Glu Glu Pro Tyr Ala Pro Glu Leu 

<210> 64

```
<211> 322
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 3044710
<400> 64
Met Ala Arg Cys Phe Ser Leu Val Leu Leu Leu Thr Ser Ile Trp
                                     10
Thr Thr Arg Leu Leu Val Gln Gly Ser Leu Arg Ala Glu Glu Leu
                 20
                                     25
Ser Ile Gln Val Ser Cys Arg Ile Met Gly Ile Thr Leu Val Ser
                 35
                                     40
Lys Lys Ala Asn Gln Gln Leu Asn Phe Thr Glu Ala Lys Glu Ala
                 50
                                     55
Cys Arg Leu Leu Gly Leu Ser Leu Ala Gly Lys Asp Gln Val Glu
Thr Ala Leu Lys Ala Ser Phe Glu Thr Cys Ser Tyr Gly Trp Val
                                     85
                 80
Gly Asp Gly Phe Val Val Ile Ser Arg Ile Ser Pro Asn Pro Lys
                 95
                                    100
Cys Gly Lys Asn Gly Val Gly Val Leu Ile Trp Lys Val Pro Val
                110
                                    115
Ser Arg Gln Phe Ala Ala Tyr Cys Tyr Asn Ser Ser Asp Thr Trp
                125
                                    130
Thr Asn Ser Cys Ile Pro Glu Ile Ile Thr Thr Lys Asp Pro Ile
               140
                                    145
Phe Asn Thr Gln Thr Ala Thr Gln Thr Thr Glu Phe Ile Val. Ser
                155
                                    366 .
Asp Sem Thr Tyr Ser Val Ala Ser Pro Tyr Ser Thr Tie Pro Ala
               170
                                   175
Pro Thr Thr Pro Pro Ala Pro Ala Ser Thr Ser Ile Pro Arg
                                   190
Arg Lys Lys Leu Ile Cys Val Thr Glu Val Phe Met Glu Thr Ser
                200
                                    205
Thr Met Ser Thr Glu Thr Glu Pro Phe Val Glu Asn Lys Ala Ala
                215
                                    220
Phe Lys Asn Glu Ala Ala Gly Phe Gly Gly Val Pro Thr Ala Leu
                230
                                    235
Leu Val Leu Ala Leu Leu Phe Phe Gly Ala Ala Ala Gly Leu Gly
                245
                                    250
Phe Cys Tyr Val Lys Arg Tyr Val Lys Ala Phe Pro Phe Thr Asn
                260
                                    265
Lys Asn Gln Gln Lys Glu Met Ile Glu Thr Lys Val Val Lys Glu
                275
                                    280
Glu Lys Ala Asn Asp Ser Asn Pro Asn Glu Glu Ser Lys Lys Thr
                290
                                    295
Asp Lys Asn Pro Glu Glu Ser Lys Ser Pro Ser Lys Thr Thr Val
                305
Arg Cys Leu Glu Ala Glu Val
```

```
<210> 65
<211> 104
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 3120415
<400> 65
Met Lys Leu Ala Ala Leu Leu Gly Leu Cys Val Ala Leu Ser Cys
                                     10
Ser Ser Ala Ala Ala Phe Leu Val Gly Ser Ala Lys Pro Val Ala
                 20
                                     25
Gln Pro Val Ala Ala Leu Glu Ser Ala Ala Glu Ala Gly Ala Gly
                 35
                                     40
Thr Leu Ala Asn Pro Leu Gly Thr Leu Asn Pro Leu Lys Leu Leu
                 50
                                     55
Leu Ser Ser Leu Gly Ile Pro Val Asn His Leu Ile Glu Gly Ser
                 65
                                     70
Gln Lys Cys Val Ala Glu Leu Gly Pro Gln Ala Val Gly Ala Val
                 80
                                     85
Lys Ala Leu Lys Ala Leu Leu Gly Ala Leu Thr Val Phe Gly
                 95
```

<210> 66 <211> 93 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 126758 <400> 66 Met Lys Leu Val Thr Ile Phe Leu Leu Val Thr Ile Ser Leu Cys 10 Ser Tyr Ser Ala Thr Ala Phe Leu Ile Asn Lys Val Pro Leu Pro 20 25 Val Asp Lys Leu Ala Pro Leu Pro Leu Asp Asn Ile Leu Pro Phe 35 40 Met Asp Pro Leu Lys Leu Leu Lys Thr Leu Gly Ile Ser Val 55 Glu His Leu Val Glu Gly Leu Arg Lys Cys Val Asn Glu Leu Gly 65 70 Pro Glu Ala Ser Glu Ala Val Lys Lys Leu Leu Glu Ala Leu Ser 85 His Leu Val

```
<210> 67
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 674760
<400> 67
Met Thr Ala Gly Gln Phe Pro Ala Leu Val Ser Leu Ala Leu Leu
Leu Asp Gly Gly Arg Arg Ala Ser Ala Arg Arg Asn Arg Gly His
                 20
Leu Trp Val Phe Cys Thr Ser Phe Leu Leu Ala Pro Trp Glu Val
                 35
                                     40
Glu Asp Val Gly Trp Lys Lys Gly Leu Asp Leu Pro Pro Ser Ser
                 50
                                     55
Ser Pro Pro Ser Pro Lys Glu Leu Ala Leu Gln
```

<211> 394 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1229438

<210> 68

<400× 68

Met Lys Arg Gln Asn Val Arg The Leu Ala Leu Ile Val Cys Thr 10 Phe Thr Tyr Leu Leu Val Gly Ala Ala Val Phe Asp Ala Leu Glu 20 25 Ser Glu Pro Glu Leu Ile Glu Arg Gln Arg Leu Glu Leu Arg Gln 35 40 Gln Glu Leu Arg Ala Arg Tyr Asn Leu Ser Gln Gly Gly Tyr Glu 50 55 Glu Leu Glu Arg Val Val Leu Arg Leu Lys Pro His Lys Ala Gly 65 70 Val Gln Trp Arg Phe Ala Gly Ser Phe Tyr Phe Ala Ile Thr Val 85 Ile Thr Thr Ile Gly Tyr Gly His Ala Ala Pro Ser Thr Asp Gly 95 100 Gly Lys Val Phe Cys Met Phe Tyr Ala Leu Leu Gly Ile Pro Leu 110 115 Thr Leu Val Met Phe Gln Ser Leu Gly Glu Arg Ile Asn Thr Leu 125 130 Val Arg Tyr Leu Leu His Arg Ala Lys Lys Gly Leu Gly Met Arg 140 145 Arg Ala Asp Val Ser Met Ala Asn Met Val Leu Ile Gly Phe Phe 155 160 Ser Cys Ile Ser Thr Leu Cys Ile Gly Ala Ala Ala Phe Ser His

```
175
Tyr Glu His Trp Thr Phe Phe Gln Ala Tyr Tyr Tyr Cys Phe Ile
                                   190
Thr Leu Thr Thr Ile Gly Phe Gly Asp Tyr Val Ala Leu Gln Lys
Asp Gln Ala Leu Gln Thr Gln Pro Gln Tyr Val Ala Phe Ser Phe
Val Tyr Ile Leu Thr Gly Leu Thr Val Ile Gly Ala Phe Leu Asn
                230
                                   235
Leu Val Val Leu Arg Phe Met Thr Met Asn Ala Glu Asp Glu Lys
                245
                                   250
Arg Asp Ala Glu His Arg Ala Leu Leu Thr Arg Asn Gly Gln Ala
                260
                                   265
Gly Gly Gly Gly Gly Gly Ser Ala His Thr Thr Asp Thr Ala
               275
                                  280
Ser Ser Thr Ala Ala Ala Gly Gly Gly Phe Arg Asn Val Tyr
               290
                                   295
Ala Glu Val Leu His Phe Gln Ser Met Cys Ser Cys Leu Trp Tyr
               305
                                   310
Lys Ser Arg Glu Lys Leu Gln Tyr Ser Ile Pro Met Ile Ile Pro
               320
                                  325
Arg Asp Leu Ser Thr Ser Asp Thr Cys Val Glu Gln Ser His Ser
               335
                                   340
Ser Pro Gly Gly Gly Arg Tyr Ser Asp Thr Pro Ser Arg Arg
               350
                                   355
Cys Leu Cys Ser Gly Ala Pro Arg Ser Ala Ile Ser Ser Val Ser
               365
                                  370
Thr Gly Leu His Ser Leu Ser Thr Phe Arg Gly Leu Met Lys Arg
                380
                                   385
Arg Ser Ser Val
```

```
<210> 69
<211> 72
<212> PRT
<213> Homo sapiens
```

<220>

<221> misc\_feature <223> Incyte Clone No: 1236935

<400> 69

```
<210> 70
<211> 71
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1359283
<400> 70
Met Arg Leu Thr Gly Leu Thr Leu Leu Leu Ser Leu Met Glu Ser
                                     10
Leu Gly Gln Val Glu Asp Arg Phe Phe Ser Thr His Arg Arg Phe
                                     25
Pro His His Thr Pro Ile Ser Gly Leu Leu Cys Arg Glu Phe Ser
                                     40
Leu Pro Lys Arg Ser Gly Val Pro Trp Thr Arg Val Leu Ile Ser
                 50
                                     55
Cys Ile Trp Arg Ser Gly Ala Gly Lys Arg Met
```

<210> 71 <211> 247 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1450703

<490> 71 Met His Leu Ala Arg Leu Val Gly Ser Cys Ser Leu Leu Leu Leu 10 Leu Gly Ala Leu Ser Gly Trp Ala Ala Ser Asp Asp Pro Ile Glu 25 Lys Val Ile Glu Gly Ile Asn Arg Gly Leu Ser Asn Ala Glu Arg 35 40 Glu Val Gly Lys Ala Leu Asp Gly Ile Asn Ser Gly Ile Thr His 55 Ala Gly Arg Glu Val Glu Lys Val Phe Asn Gly Leu Ser Asn Met 70 Gly Ser His Thr Gly Lys Glu Leu Asp Lys Gly Val Gln Gly Leu 85 Asn His Gly Met Asp Lys Val Ala His Glu Ile Asn His Gly Ile 100 Gly Gln Ala Gly Lys Glu Ala Glu Lys Leu Gly His Gly Val Asn 110 115 Asn Ala Ala Gly Gln Ala Gly Lys Glu Ala Asp Lys Ala Val Gln 125 130 Gly Phe His Thr Gly Val His Gln Ala Gly Lys Glu Ala Glu Lys 140 145 Leu Gly Gln Gly Val Asn His Ala Ala Asp Gln Ala Gly Lys Glu 155 160 Val Glu Lys Leu Gly Gln Gly Ala His His Ala Ala Gly Gln Ala

```
<210> 72
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1910668
<400> 72
Met Thr Cys Trp Met Leu Pro Pro Ile Ser Phe Leu Ser Tyr Leu
                                    10
Pro Leu Trp Leu Gly Pro Ile Trp Pro Cys Ser Gly Ser Thr Leu
                 20
                                     25
Gly Lys Pro Asp Pro Gly Val Trp Pro Ser Leu Phe Arg Pro Trp
                 35
                                     40
Asp Ala Ala Ser Pro Gly Asn Tyr Ala Leu Ser Arg Gly Glu Asn
                 50
                                     55
Gln Tyr Glu Lys Trp Gly Gln Gly Thr His Ser Ser Leu
                . 65
```

50

<210> 73

Ser Pro Tyr Pro Thr Asp Pro Ile His Leu 65 70

<210> 74 <211> 67 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 1961637

<210> 75
<211> 91
<212> PRT
<213> None sapiens
<220>

<220>
<221> misc\_feature
<223> Incyte Clone No: 1990762

```
<210> 76
<211> 56
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1994131
<400> 76
Met Asn Glu Trp Trp Leu Leu Leu Leu His Leu His Pro Pro
                 5
                                     10
Arg Val Ile Ser Pro Phe Trp Phe Ile Val Ser Val Leu Thr Ala
                 20
                                     25
Cys Asp Asn Arg Lys Tyr Ile Leu Leu Arg Thr Val Pro Val Phe
                 35
                                     40
Ser Phe Pro Glu Asn Thr Tyr Phe Asp Val Gly
                 50
<210> 77
<211> 112
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1997745
<400> 77
Met Pro Leu Phe Leu Ser Ile Pro Ser Leu Phe Leu Thr Leu Ser
                                     J.C
Gly Leu Gly Leu Ala Val Gln Ser Pro Ala Gly Gly Cys Trp Gly
                20
                                     25
Leu Ser Leu Cys Arg His Cys Val Phe Leu Arg Gly Cys Pro Gln
                35
                                     40
Asn Thr Pro Pro Ala Pro Trp Gly Ser Ser Gly Ser His Phe Ser
                 50
                                     55
Trp Ser Leu Arg Ser Gln Lys Gln Leu Leu Gln Glu Ala Lys Lys
                65
                                     70
Arg Leu Gly Trp Leu Leu Val Leu Met Met Ala Phe Ile Leu Leu
                80
                                     85
Gly His Phe Gly Tyr Ile His Gly His Cys Phe His Leu Ser Phe
                95
                                   100
Leu Pro Val Pro Pro Leu Pro
               110
```

<210> 78 <211> 54 <212> PRT <213> Homo sapiens

<220>

```
<221> misc feature
<223> Incyte Clone No: 2009035
<400> 78
Met Met Leu Gln Pro Val Asp Leu Leu Gln Ser Tyr Leu Leu Leu
                 5
                                    10
Leu Tyr Cys Trp Ser Phe Ser Leu Leu Phe Thr Leu Leu Cys Asn
                 20
                                     25
Ala Val Arg Asn Asp Phe Phe His Lys Leu Phe Ser Ile Tyr Trp
                 35
                                     40
Met Tyr Asn Leu Thr His Ser Lys His
                 50
<210> 79
<211> 57
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2009152
Met Lys Phe Tyr Ala Val Leu Leu Ser Ile Cys Leu Leu Ser
                                    10
Cys Trp Cys Ala Cys His Val Arg Asp Cys Asn Leu Ile Cys Leu
                 20
                                    25
Phe Ser Thr Val Lys Ala Ile Thr Arg Glu Leu Leu Gln Leu Pro
                 35
                                    40
Ser Tyr Val Lys Arg Phe Phe Phe Ash Ser Leu Arg.
                 50
                                    55
<210> 80
<211> 52
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2061752
<400> 80
Met Gln Arg Leu Gly Lys Ala Pro Gly Thr Trp Gln Ala Ile Ser
                 5
Lys Cys Trp Leu Leu Leu Leu Ser Leu Pro Phe Ser Gln Ser
                20
                                    25
Ile Ile Ile Ser Leu Arg Ala Gly Thr Met Ser Tyr Leu Pro Leu
                35
Tyr Phe Pro Gln Tyr Phe Pro
```

WO 00/00610

```
<210> 81
<211> 64
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2061933
Met Lys Leu Leu Leu Lys Leu Asp Phe Phe Ile Leu Leu Gly
                 5
                            . 10
Ser Glu Glu Ser Arg Cys Leu Val Asp Val Gln Tyr Val Ile Phe
                 20
                                    25
Phe Leu Ile Glu Cys Val His Leu Lys Ser Ser Leu Thr Phe Leu
                 35
                                    40
Glu Arg Leu Leu Ser Ile Asn Asn Gly Ile Leu Glu Glu Lys Trp
                 50
                                    55
Phe Phe Lys Ser
<210> 82
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2081422
<400> 82
Met Lys Pro Leu Ile Pro Phe Leu Ser Pro Pro Pro Leu Leu Pro
                                    10
Leu Thr Phe Phe Leu Ser Ser Leu Leu Leu Ser Pro Leu Cys Arg
                20
                                    25
Ala Leu Gly Thr Ser Gln Ala Val Pro Pro Leu Arg Ala Leu Ser
                35
                                    40
Val Thr Asp Ala His Gly Ser Leu Leu Leu His Pro Lys Thr Leu
                                    55
Ala Cys Pro Cys Leu
<210> 83
<211> 56
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte Clone No: 2101278

<210> 84 <211> 120 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 2121353 Met Pro Ala Leu Pro Pro Gly Phe Ser Gln Ala Gly Ser Cys Val 10 Pro Thr Gly Ser Ser Leu Val Leu Cys Leu Leu Ala Ala Ser Leu 20 25 Leu Leu Phe Val Pro Thr Leu Ala Leu Leu Thr Gly Ala Thr Thr 35 40 Cys Trp Cys Leu His Asn Lys Arg Leu Ala Leu Arg Pro Leu Ala 50 55 . Two Gam Gly how Try Gly Lew Wal Ser Thr Arg Lew Ser Sis Gly 70 Arg Thr Ser Phe Tyr Phe Asn Ser Leu Pro Leu Gln Thr Asn Ser 85 Ser Thr Cys Gln Asn His Ser Trp Asp Ser Gly Ala Arg Ala Thr 95 100 Ala Leu Ala Ser Gly Arg Thr Gln Glu Gly Gly Val Gly Ser Val 115

```
Lys Asp Cys Val Leu Leu Phe Ala Met Ser Lys Val Ser Gln Lys 30 Gln Lys Val Leu Gly Pro Phe Gly Ser Pro Glu Leu Glu Ser Leu 45 Gly Ile Gly Pro Arg Tyr Leu His Phe His Arg Phe Leu Val Gly 60 Asp Phe Leu Gln Ala Lys Val 65
```

```
<210> 86
<211> 62
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2271935
<400> 86
Met Ala Trp Leu Ser Phe Ala Ala Val Glu Met Thr Leu Leu Leu
                                    10
His Ser Ser Ser Leu Leu Ser Phe Ala Lys Val Val Leu Ser Leu
                 20
                                    25
Pro Glu Ile Arg Pro Phe Gly Asp Gly Asn Phe Ser Leu Lys Gln
                35
                                    40
Ser Ser Lys Gln Asn Pro Asn Pro Ala Arg Val Gly Arg Lys Ser
                                    55
Met Phe
```

<210> 87 <211> 75 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 2295344

<400> 87

 Met
 Met
 Ile
 Leu
 Leu
 Ser
 Leu
 Leu
 Val
 Ala
 Leu
 Ile
 Ser
 Val
 Ser

 Leu
 Val
 Phe
 Ser
 Leu
 Val
 Arg
 Phe
 Ser
 Arg
 Glu
 Asp
 Phe
 Ser
 30

 Phe
 Pro
 Leu
 Trp
 Arg
 Glu
 Lys
 Ala
 Phe
 Trp
 Gln
 His
 Ser
 Ser
 Ser

 Ser
 Val
 Gly
 Glu
 Arg
 Leu
 Gln
 Ala
 Leu
 Arg
 Lys
 His
 Ala
 Phe
 Thr
 Fr
 60

 Leu
 Phe
 Gly
 Gly
 Tr
 Ile
 Pro
 Leu
 Leu
 Val
 Tr
 Val
 Pro
 Gly
 Tr

 Leu
 Phe
 Gly
 Tr
 Ile
 Pro
 Leu
 Leu
 Val
 Tr

 Leu
 Phe
 Gly
 Tr
 Tr
 <td

```
<210> 88
<211> 80
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2303994
Met Asn Ser Ile Phe Phe Leu Ser Leu Cys Leu Pro Leu Trp Val
                                     10
Ser Leu Leu Trp Ala Lys Pro Leu Glu Met His Lys Thr Ser Arg
                 20
                                     25
His Gly Phe Trp Gln Lys Leu His Asp Phe Lys Leu Ala Leu Leu
                 35
                                     40
Leu Leu Thr Phe His Arg Glu Lys Ile Phe Pro Leu Lys Lys Thr
                 50
                                     55
Gly Leu Val Ile Phe Ser Leu Val Ala Leu Ser Arg Asp Ile Ser
                 65
                                     70
Ala Leu His Tyr Thr
                 80
<210> 89
<211> 50
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2497805
Met Arg Pro Ala Arg Leu Gly Pro Arg Cys Ser Asp Leu Asp Phe
                 5
                                    10
Gly Leu Val Leu Ser Ser Trp Leu Arg Leu Ala Arg Cys Pro Leu
                 20
                                     25
Glu Ser Ser Phe Gly Phe Ala Phe Phe Val Cys Leu Phe Ser Pro
                 35
                                     40
                                                         45
Asn Phe Cys Gln Thr
<210> 90
<211> 116
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2646362
```

```
<400> 90
Met Trp Trp Ala Leu Cys Ser Met Leu Pro Leu Leu Gly Cys Ala
                                     10
Cys Ser Ser Gly Cys Trp Gly Ser Gly Pro Thr Pro Leu Leu Ala
                 20
                                     25
Glu Pro Thr Phe Leu Cys Val Ser Ser Arg Pro His Asn Pro Leu
                 35
                                     40
Ser Phe Leu Ser Val Leu Pro Cys Ser Arg Gly Pro Gly Pro Ser
                 50
                                     55
Gly Leu Gln Gly Asp Gly Ala Gly Leu Pro Ala His Leu Gly Pro
                 65
                                     70
Leu Ser Cys Ile Cys Leu Pro Ser Leu Leu Cys Asp Leu Gly Glu
                 80
                                     85
Arg Gln Cys Pro Leu Trp Ala Val Arg Ser Thr Gln Cys Leu Ile
                 95
                                    100
Ala Gly Lys Lys Val Leu Gln Arg Leu Cys Pro
                110
                                    115
```

```
<210> 91
<211> 67
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2657146
<400> 91
Met Ile Cys Gln Cys Leu Arg Leu Leu Leu Val Leu Val Thr Leu
 1
                  5
Leu Ile Cys Phe Ser Pro Asp Arg Leu Thr Cys Pro Leu Asn Ser
                 20
                                     25
Ala Val Val Leu Ala Ser Tyr Ala Val Gln Cys Lys Ser Gln Arg
                 35
                                     40
Glu His Phe Thr Asp Gly Gln Val Val Leu Ile Ser Val Trp Arg
                 50
                                     55
Lys Ser Leu Val Pro Pro Ala
```

Ser Ala Ser Ser Gly Asn Gln Pro Pro Gln Glu Leu Gly Leu Gly Glu Leu Leu Glu Glu Phe Ser Arg Thr Gln Tyr Arg Ala Lys Asp 40 Gly Ser Gly Thr Gly Gly Ser Lys Val Glu Arg Ile Glu Lys Arg 55 Cys Leu Glu Leu Phe Gly Arg Asp Tyr Cys Phe Ser Val Ile Pro 70 Asn Thr Asn Gly Asp Ile Cys Gly His Tyr Pro Arg His Ile Val 85 Phe Leu Glu Tyr Glu Ser Ser Glu Lys Glu Lys Asp Thr Phe Glu 100 Ser Thr Val Gln Val Ser Lys Leu Gln Asp Leu Ile His Arg Ser 110 115 Lys Met Ala Arg Cys Arg Gly Arg Phe Val Cys Pro Val Ile Leu 125 130 Phe Lys Gly Lys His Ile Cys Arg Ser Ala Thr Leu Ala Gly Trp 140 145 Gly Glu Leu Tyr Gly Arg Ser Gly Tyr Asn Tyr Phe Phe Ser Gly 155 160 Gly Ala Asp Asp Ala Trp Ala Asp Val Glu Asp Val Thr Glu Glu 175 Asp Cys Ala Leu Arg Ser Gly Asp Thr His Leu Phe Asp Lys Val 190 Arg Gly Tyr Asp Ile Lys Leu Leu Arg Tyr Leu Ser Val Lys Tyr 200 205 Ile Cys Asp Leu Met Val Glu Asn Lys Lys Val Lys Phe Gly Met 215 220 Asn Val Thr Ser Ser Glu Lys Val Asp Lys Ala Gln Arg Tyr Ala 230 235 Asp Phe Thr Leu Leu Ser Ile Pro Tyr Pro Gly Cys Glu Phe Phe 245 250 Lys Glu Tyr Lys Asp Arg Asp Tyr Met Ala Glu Gly Leu Ile Phe 260 265 Asm Trp Lys Glu Asp Tyr Val Asp Ala Pro Leu Ser Ile Pro Asp 275 280 Phe Leu Thr His Ser Leu Asn Ile Asp Trp Ser Gln Tyr Gln Cys 290 295 Trp Asp Leu Val Gln Gln Thr Gln Asn Tyr Leu Lys Leu Leu Leu 310 Ser Leu Val Asn Ser Asp Asp Ser Gly Leu Leu Val His Cys 325 Ile Ser Gly Trp Asp Arg Thr Pro Leu Phe Ile Ser Leu Leu Arg 335 340 Leu Ser Leu Trp Ala Asp Gly Leu Ile His Thr Ser Leu Lys Pro 350 355 Thr Glu Ile Leu Tyr Leu Thr Val Ala Tyr Asp Trp Phe Leu Phe 365 370 Gly His Met Leu Val Asp Arg Leu Ser Lys Gly Glu Glu Ile Phe 380 385 Phe Phe Cys Phe Asn Phe Leu Lys His Ile Thr Ser Glu Glu Phe 395 400 Ser Ala Leu Lys Thr Gln Arg Arg Lys Ser Leu Pro Ala Arg Asp 410 415 Gly Gly Phe Thr Leu Glu Asp Ile Cys Met Leu Arg Arg Lys Asp 425 430 Arg Gly Ser Thr Thr Ser Leu Gly Ser Asp Phe Ser Leu Val Met

```
445
Glu Ser Ser Pro Gly Ala Thr Gly Ser Phe Thr Tyr Glu Ala Val
                455
                                    460
Glu Leu Val Pro Ala Gly Ala Pro Thr Gln Ala Ala Trp Leu Ala
                470
                                    475
Ala Leu Ser Asp Arg Glu Thr Arg Leu Gln Glu Val Arg Ser Ala
                485
                                    490
Phe Leu Ala Ala Tyr Ser Ser Thr Val Gly Leu Arg Ala Val Ala
                500
                                   505
Pro Ser Pro Ser Gly Ala Ile Gly Gly Leu Leu Glu Gln Phe Ala
                515
                                    520
Arg Gly Val Gly Leu Arg Ser Ile Ser Ser Asn Ala Leu
                530
                                    535
```

```
<210> 93
<211> 58
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2831245
<400> 93
Met Glu Met Lys Gly Ser Arg Val Trp Leu Leu Leu Phe Met
                                    10
Trp Lys Ala Arg Pro Thr Phe Phe Gln Ser Cys Val Val Pro Phe
                 20
                                     25
Ile Leu Ser Pro Gln Asn Cys Val Gln Thr His Ser Leu Gly Pro
                 35
                                     40
Gly Val Tap Leu Gly Val Phe Pro Ser Gly Ser Leu His.
```

50

50

<210> 94

<211> 119 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 3116250 <400> 94 Met Lys Val Leu Ile Ser Ser Leu Leu Leu Leu Pro Leu Met 5 10 Leu Met Ser Met Val Ser Ser Ser Leu Asn Pro Gly Val Ala Arg 20 25 Gly His Arg Asp Arg Gly Gln Ala Ser Arg Arg Trp Leu Gln Glu 35 40

Gly Gly Gln Glu Cys Glu Cys Lys Asp Trp Phe Leu Arg Ala Pro

55

<210> 95 <211> 128 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 3129630 <400> 95 Met Ala Tyr Ser Thr Val Gln Arg Val Ala Leu Ala Ser Gly Leu Val Leu Ala Leu Ser Leu Leu Leu Pro Lys Ala Phe Leu Ser Arg 20 25 30 Gly Lys Arg Gln Glu Pro Pro Pro Thr Pro Glu Gly Lys Leu Gly 35 40 Arg Phe Pro Pro Met Met His His His Gln Ala Pro Ser Asp Gly 50 55 Gln Thr Pro Gly Ala Arg Phe Gln Arg Ser His Leu Ala Glu Ala Phe Ala Lys Ala Lys Gly Ser Gly Gly Gly Ala Gly Gly Gly . 30 🕓 - 35 90 Ser Gly Arg Gly Leu Met Gly Gln Ile Ile Pro Ile Tyr Gly Phe 100 95 Gly Ile Phe Leu Tyr Ile Leu Tyr Ile Leu Phe Lys Val Ser Arg 110 115 Ile Ile Leu Ile Ile Leu His Gln

<210> 96
<211> 124
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 007632

125

```
25
Phe Gln Leu Ser Ala Pro His Glu Asp Ala Arg Leu Thr Pro Glu
                                     40
Glu Leu Glu Arg Ala Ser Leu Leu Gln Ile Leu Pro Glu Met Leu
                 50
                                     55
Gly Ala Glu Arg Gly Asp Ile Leu Arg Lys Ala Asp Ser Ser Thr
                 65
                                     70
Asn Ile Phe Asn Pro Arg Gly Asn Leu Arg Lys Phe Gln Asp Phe
                                     85
Ser Gly Gln Asp Pro Asn Ile Leu Leu Ser His Leu Leu Ala Arg
                 95
                                    100
Ile Trp Lys Pro Tyr Lys Lys Arg Glu Thr Pro Asp Cys Phe Trp
                                    115
Lys Tyr Cys Val
```

<210> 97 <211> 182 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1236968 <400> 97 Met Trp Pro Leu Ser Ser Asp Ser Ser Trp Ser Leu Trp Ile Ser 10 Thr Gly Met Ala Pro Ala Pro Ser Ser Ser Thr Arg Ser Phe Ser 25 Glu Ser Leu Lys Gln Lys Leu Val Arg Val Leu Glu Glu Asn Leu 40 The Leu Ser GTu Lys The GIn Gln ben Glu Glu Gly Ala Ala Ile 50 55 Ser Ile Val Ser Gly Gln Gln Ser His Thr Tyr Asp Asp Leu Leu 65 70 His Lys Asn Gln Gln Leu Thr Met Gln Val Ala Cys Leu Asn Gln 80 85 Glu Leu Ala Gln Leu Lys Lys Leu Glu Lys Thr Val Ala Ile Leu 95 100 His Glu Ser Gln Arg Ser Leu Val Val Thr Asn Glu Tyr Leu Leu 110 115 Gln Gln Leu Asn Lys Glu Pro Lys Gly Tyr Ser Gly Lys Ala Leu 125 130 Leu Pro Pro Glu Lys Gly His His Leu Gly Arg Ser Ser Pro Phe 140 145 Gly Lys Ser Thr Leu Ser Ser Ser Pro Val Ala His Glu Thr 155 160 Gly Gln Tyr Leu Ile Gln Ser Val Leu Asp Ala Ala Pro Glu Pro

Gly Leu

```
<210> 98
<211> 237
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1334153
<400> 98
Met Lys Gly Ile Leu Val Ala Gly Ile Thr Ala Val Leu Val Ala
Ala Val Glu Ser Leu Ser Cys Val Pro Cys Asn Ser Trp Glu Lys
                                      25
Ser Cys Val Asn Ser Ile Ala Ser Glu Cys Pro Ser His Ala Asn
                 35
                                      40
Thr Ser Cys Ile Ser Ser Ser Ala Ser Ser Ser Leu Glu Thr Pro
                                     55
Val Arg Leu Tyr Gln Asn Met Phe Cys Ser Ala Glu Asn Cys Ser
                 65
                                     70
Glu Glu Thr His Ile Thr Ala Phe Thr Val His Val Ser Ala Glu
                                     85
Glu His Phe His Phe Val Ser Gln Cys Cys Gln Gly Lys Glu Cys
                                    100
Ser Asn Thr Ser Asp Ala Leu Asp Pro Pro Leu Lys Asn Val Ser
                                    115
Ser Asn Ala Glu Cys Pro Ala Cys Tyr Glu Ser Asn Gly Thr Ser
                125
                                    130
Cys Arg Gly Lys Pro Trp Lys Cys Tyr Glu Glu Glu Gln Cys Val
                140
                                    145
Phe Leu Val Ala Glu Leu Lys Asn Asp Ile Glu Ser Lys Ser Leu
                155
                                    160
Val Leu Lys Gly Cys Ser Asn Val Ser Asn Ala Thr Cys Gln Phe
                2.70
                                   . 175
Leu Ser Gly Glu Asn Lys Thr Leu Gly Gly Val Ile Phe Arg Lys
                185
Phe Glu Cys Ala Asn Val Asn Ser Leu Thr Pro Thr Ser Ala Pro
                200
                                    205
Thr Thr Ser His Asn Val Gly Ser Lys Ala Ser Leu Tyr Leu Leu
                215
                                    220
Ala Leu Ala Ser Leu Leu Leu Arg Gly Leu Leu Pro
```

```
<210> 99
<211> 160
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone No: 1396975

<400> 99
Met Arg Pro Gly Pro Met Leu Gln Ala Arg Val Ser Ile Pro Ala
```

```
5
                                     10
Ala Leu Gly Thr Leu Phe Pro Arg Pro Gly Trp Ala Pro Gly Glu
                 20
                                    25
Val Ser Ser Glu Ile Ser Ser Arg Asp Leu Leu Asn Pro His Pro
                 35
                                     40
Ser Thr Pro Ser Cys Cys Ser Gln Ser Trp Ser Pro Met Ser Val
                 50
                                     55
Leu Glu Pro Asp Ser Arg Gly Pro Pro Pro Ile Ser Leu Thr His
                 65
                                     70
Thr Gly Ile His Thr Pro Gln Lys Thr Ser Gln Met Arg Pro Asp
                 80
                                    85
Ser Gly Ser Arg Gly Met Cys Phe Cys Pro Cys Lys Gly Phe Gly
                 95
                                    100
                                                        105
Glu Gly Gly Asn Ile Val Glu Ala Gly Lys Ser Pro Gln Thr Cys
                110
                                    115
                                                        120
Ala His Ala Pro Pro Ala Leu Arg Phe His Ser Ala Phe Ser Glu
                125
                                   130
Cys Pro Cys Cys Thr Gln Thr Thr Gly Gln Glu Arg Pro Ser Leu
                140
                                    145
Pro Leu Gln Pro Leu Ser Leu Pro Phe Asn
                155
```

<210> 100 <211> 148 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 1501749

<400 = 100

Met Ala Ala Ser Pro Ala Arg Pro Ala Val Leu Ala Leu Thr Gly 10 Leu Ala Leu Leu Leu Leu Cys Trp Gly Pro Gly Gly Ile Ser 20 25 Gly Asn Lys Leu Lys Leu Met Leu Gln Lys Arg Glu Ala Pro Val 35 40 Pro Thr Lys Thr Lys Val Ala Val Asp Glu Asn Lys Ala Lys Glu 55 Phe Leu Gly Ser Leu Lys Arg Gln Lys Arg Gln Leu Trp Asp Arg 70 Thr Arg Pro Glu Val Gln Gln Trp Tyr Gln Gln Phe Leu Tyr Met 85 Gly Phe Asp Glu Ala Lys Phe Glu Asp Asp Ile Thr Tyr Trp Leu 100 Asn Arg Asp Arg Asn Gly His Glu Tyr Tyr Gly Asp Tyr Tyr Gln 115 Arg His Tyr Asp Glu Asp Ser Ala Ile Gly Pro Arg Ser Pro Tyr 125 130 Gly Phe Arg His Gly Ala Ser Val Asn Tyr Asp Asp Tyr 140 145

```
<210> 101
<211> 170
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1575240
<400> 101
Met Thr Pro Thr Lys Arg Glu Pro Pro Ala Ala Pro Leu Leu Leu
                                    10
Arg Val Leu Pro Gln Leu Ser Ala Met Ser Leu Arg Leu Ser Thr
                 20
                                     25
Arg Arg Glu Asp Met Ile Gly Gln Thr Ser Gly Met Cys Ser Phe
                                     40
Cys Ser Phe Gln Asn Met Arg Gly Glu Ser Ile Trp Leu Leu Cys
                 50
                                     55
Leu Glu Glu Gly Ala Gly Leu Cys Gln Asn Ser Leu Asp Lys
                 65
                                     70
Arg Phe Ser Gln Lys Glu Gly Cys Ser Asp Asp Lys Ser Pro Leu
                 80
                                    85
His His Phe Pro Trp Leu Ser Asp Ala Pro Pro Ser Ser His Ala
                 95
                                   100
Arg Thr Ser Glu Ile Arg Leu Pro Pro Asp Ile Thr Gln Pro Cys
               110
                                   115
Leu Thr Lys Arg Gln Trp Phe Ile Pro Ser Leu Gly Glu Lys Arg
               125
                                   130
                                                        135
Gly Asn Ala Lys Leu Leu His Gln Leu Leu Ile Leu Leu Pro Ala
               140
                                   145
Arg Asn Pro Gly Tyr Leu Gln Val Ser Leu Pro Leu Val Trp Ser
               155
                                   160
Trp Leu Ser Leu Phe
               170
<210> 102
```

<211> 150

```
Ala Thr Pro Gln Met Arg Pro Glu Thr Pro Ser Gln Val Gln Glu
                                     70
Arg Thr Ser Glu Arg Asp Gly Ala Cys Ser Ser Pro Leu Cys Leu
                 80
                                     85
Ser Cys Lys Gly Thr Glu Gly Pro Thr Cys Pro Thr Phe His Leu
                 95
                                    100
Thr Asp Glu Lys Thr Glu Ala Gly Arg Gly Tyr Val Thr Cys Leu
               110
                                    115
Arg Ser Lys Pro Val Gln Gly Pro Val Asn Gly Val Ser Gly Ala
               125
                                    130
Gly Leu Asp Val Thr Asp Pro Arg Trp Leu Leu Val Ile Phe His
                                    145
```

```
<210> 103
<211> 142
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1661144
<400> 103
Met Gly Cys Leu Val Trp Gly Pro Ser Trp Pro Pro Leu Ser Leu
                                     10
Leu Ala Ser Leu Leu His Ser Gly Ile Ala Gly Arg Cys Leu Leu
                 20
                                     25
Cys Leu Phe Lys Gly Leu Ala Ala Ala Ala Ser Leu Gln Ile Arg
                 35
                                     40
Asp Leu Ala Ser Arg Leu Thr Thr Gly Pro Arg Thr Cys Arg Val
                 50
                                     55
Gln Pro Pro Pro His Pro Gln Ser Ser Pro Pro Trp Pro Gly Pro
                 65
                                     70
Pro Gly Ala Glu Thr Cys Arg Pro Leu Ser Arg Thr Val Gly Gly
                 80
                                     85
Val Cys Pro Ser Asp Trp Pro Val Ser Trp Leu Leu Pro Pro
                 95
                                    100
Leu Pro Glu Val Val Thr Cys Ser Cys Pro Arg Ile Lys Ala Arg
                110
                                    115
Pro Glu Arg Thr Pro Glu Leu Leu Cys Ala Trp Gly Gly Arg Gly
               125
                                    130
Lys His Ser Gln Leu Val Ala
```

<210> 104 <211> 110 <212> PRT <213> Homo sapiens <220> <221> misc\_feature

<223> Incyte Clone No: 1685409

<400> 104 Met Glu Thr Gly Arg Leu Leu Ser Leu Ser Ser Leu Pro Leu Val 10 Leu Leu Gly Trp Glu Tyr Ser Ser Gln Thr Leu Asn Leu Val Pro 20 25 Ser Thr Ser Ile Leu Ser Phe Val Pro Phe Ile Pro Leu His Leu 40 Val Leu Phe Ala Leu Trp Tyr Leu Pro Val Pro His His Leu Tyr 55 Pro Gln Gly Leu Gly Asp His Ala Ala Glu Ala Glu Lys Gly Lys 65 70 Arg Glu Glu Gly Gly Thr Gln Val Ala Leu Trp Leu Arg Val Gln 85 Pro Ser Cys Pro Ser Pro Val Cys Leu Glu Pro Val Pro Pro Arg 100 Ser Arg Phe Leu Leu

<210> 105 <211> 120 <212> PRT <213> Homo sapiens

<220>
<221> misc\_feature
<223> Incyte Clone No: 1731419

<400> 105 Met Ser Arg Ala Gly Met Leu Gly Val Val Cys Ala Leu Leu Val 10 Trp Ala Tyr Leu Ala Val Gly Lys Leu Val Val Arg Met Thr Phe 20 25 Thr Glu Leu Cys Thr His His Pro Trp Ser Leu Arg Cys Glu Ser 35 40 Phe Cys Arg Ser Arg Val Thr Ala Cys Leu Pro Ala Pro Ala Pro 50 55 Trp Leu Arg Pro Phe Leu Cys Pro Met Leu Phe Ser Asp Arg Asn 65 70 Pro Val Glu Cys His Leu Phe Gly Glu Ala Val Ser Asp Pro Val 80 85 Cys Lys Gly Leu Leu Pro His Tyr Phe Trp His Pro Thr Phe Phe 95 100 Pro Val Lys Ala Asn Cys Leu Val Ser Phe Cys Pro Thr Thr Val 110 115

<210> 106 <211> 135 <212> PRT <213> Homo sapiens

<221> misc\_feature <223> Incyte Clone No: 2650265 <400> 106 Met Ala Arg Phe Trp Val Cys Val Ala Gly Ala Gly Phe Phe Leu 10 Ala Phe Leu Val Leu His Ser Arg Phe Cys Gly Ser Pro Val Leu 20 25 Arg Asn Phe Thr Phe Ala Val Ser Trp Arg Thr Glu Lys Ile Leu 35 40 Tyr Arg Leu Asp Val Gly Trp Pro Lys His Pro Glu Tyr Phe Thr 50 55 Gly Thr Thr Phe Cys Val Ala Val Asp Ser Leu Asn Gly Leu Val 65 70 Tyr Ile Gly Gln Arg Gly Asp Asn Ile Pro Lys Ile Leu Val Phe 80 85 Thr Glu Asp Gly Tyr Phe Leu Arg Ala Trp Asn Tyr Thr Val Asp 95 100 Thr Pro His Gly Ile Phe Ala Ala Ser Thr Leu Tyr Glu Gln Ser 110 115 Val Trp Ile Thr Asp Val Gly Ser Gly Met Tyr Ser Asn Ile Tyr . 125 130

<210> 107 <211> 301 <212> PRT <213> Homo sapiens

<221> misc\_feature

<223> Incyte Clone No: 2677129 \*\*\*

<400> 107

<220>

Met Leu Met Ile Ile Ile Glu Pro Phe Ser Val Leu Ile Leu 10 Phe Lys Ser Gly Ile Leu Ala Asp Phe Phe Ala Leu Leu Leu Leu 25 Ile Asn Phe Phe Leu Val Ser, Phe Phe Leu Ala Tyr Pro Leu Phe 40 Asn Asn Gln Ile Asn Ser Arg Ser Met Asn Glu Ile Lys Asn Leu 50 55 Gln Tyr Leu Pro Arg Thr Ser Glu Pro Arg Glu Val Leu Phe Glu 65 70 Asp Arg Thr Arg Ala His Ala Asp His Val Gly Gln Gly Phe Asp 85 Trp Gln Ser Thr Ala Ala Val Gly Val Leu Lys Ala Val Gln Phe 100 Gly Glu Trp Ser Asp Gln Pro Arg Ile Thr Lys Asp Val Ile Cys 110 115 Phe His Ala Glu Asp Phe Thr Asp Val Val Gln Arg Leu Gln Leu 125 130 Asp Leu His Glu Pro Pro Val Ser Gln Cys Val Gln Trp Val Asp 140 145 150

Glu Ala Lys Leu Asn Gln Met Arg Arg Glu Gly Ile Arg Tyr Ala 155 160 Arg Ile Gln Leu Cys Asp Asn Asp Ile Tyr Phe Ile Pro Arg Asn 170 175 Val Ile His Gln Phe Lys Thr Val Ser Ala Val Cys Ser Leu Ala 185 190 Trp His Ile Arg Leu Lys Gln Tyr His Pro Val Val Glu Ala Thr 200 205 Gln Asn Thr Glu Ser Asn Ser Asn Met Asp Cys Gly Leu Thr Gly 215 220 Lys Arg Glu Leu Glu Val Asp Ser Gln Cys Val Arg Ile Lys Thr 230 235 Glu Ser Glu Glu Ala Cys Thr Glu Ile Gln Leu Leu Thr Thr Ala 245 250 Ser Ser Ser Phe Pro Pro Ala Ser Glu Leu Asn Leu Gln Gln Asp 260 265 Gln Lys Thr Gln Pro Ile Pro Val Leu Lys Val Glu Ser Arg Leu 275 280 Asp Ser Asp Gln Gln His Asn Leu Gln Glu His Ser Thr Thr Ser 290 295 Val

<210> 108 <211> 103 <212> PRT <213> Homo sapiens <220>

<220>
<221> misc\_feature
<223> Incyte Clone No: 3151073

<400> 108

Met Ser Phe Val Pro Gly Leu Leu Leu Cys Phe Val Leu Leu Leu 10 Cys Val Ser Pro Val Tyr Leu Pro Ser Arg Ser Pro Ser Thr Phe 20 25 Pro Ile Ser Glu Pro Leu Ser Phe Ile Gly Met Ser Ala Trp Pro 35 40 Gln Cys Ser Pro Ile Tyr Ser Gln Thr Pro Gly Leu Ala Tyr Glu 50 55 Pro Ser Ser Phe Pro Lys Arg Arg Tyr Trp Val Cys Thr Leu His 65 70 Glu Ile Lys Trp Glu Cys Pro Arg Ser Arg Arg Thr Ser Asp Ala 80 85 90 Val His Ala Asn Lys Leu Gly Leu Pro Leu Lys Ile Ile 95 100

<210> 109 <211> 95 <212> PRT <213> Homo sapiens

<221> misc feature <223> Incyte Clone No: 3170095 <400> 109 Met Lys Phe Leu Leu Val Leu Ala Ala Leu Gly Phe Leu Thr 5 10 Gln Val Ile Pro Ala Ser Ala Gly Gly Ser Lys Cys Val Ser Asn 20 25 Thr Pro Gly Tyr Cys Arg Thr Cys Cys His Trp Gly Glu Thr Ala 35 40 Leu Phe Met Cys Asn Ala Ser Arg Lys Cys Cys Ile Ser Tyr Ser 50 55 Phe Leu Pro Lys Pro Asp Leu Pro Gln Leu Ile Gly Asn His Trp 65 70 Gln Ser Arg Arg Arg Asn Thr Gln Arg Lys Asp Lys Lys Gln Gln 80 85 Thr Thr Val Thr Ser

<210> 110 <211> 113 <212> PRT <213> Homo sapiens <220>

<221> misc\_feature

<220>

<223> Incyte Clone No: 3475168

Met Ser Pro Ser Pro Arg Trp Gly Phe Leu Cys Val Leu Phe Thr 5 10 Ala Val His Pro Ala Pro Ser Thr Ala Pro Val Gln Asp Lys Cys 20 25 Pro Val Asn Thr Trp Glu Ala Met Gln Ala Ser Ser Gln Gln Leu 35 40 Leu Gln Thr Asp Pro Arg Pro Lys Pro Phe Leu Leu Pro Pro Leu 50 55 Pro Pro Leu Leu Leu Ile Ser Ala Gly Thr Glu Val Ser Ser Leu 65 70 Val Phe Gln Lys Ser Pro Leu His Thr Gln Pro Glu Gly Ala Ile 80

Lys Thr Ala Gly Gln Pro Thr Ser Val His Ser Lys Val Leu Ser
95 100 105

Lys Gly Ser Leu Leu Leu Gly Glu

110

<210> 111 <211> 234 <212> PRT <213> Homo sapiens

```
<221> misc_feature
<223> Incyte Clone No: 3836893
<400> 111
Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp Met Leu Phe Val
                                     10
Ser Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu Lys Tyr Glu
Leu Lys Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr Thr Leu
Glu Lys Phe Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg Asp
Gly Glu Met Pro Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys
                                     70
Asn Ser His Pro Val Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr
His Asp His Gly Leu Leu Arg Val Arg Met Val Asn Leu Gln Val
                                    100
Glu Asp Ser Gly Leu Tyr Gln Cys Val Ile Tyr Gln Pro Pro Lys
                                    115
Glu Pro His Met Leu Phe Asp Arg Ile Arg Leu Val Val Thr Lys
                125
                                    130
Gly Phe Ser Gly Thr Pro Gly Ser Asn Glu Asn Ser Thr Gln Asn
                140
                                    145
Val Tyr Lys Ile Pro Pro Thr Thr Lys Ala Leu Cys Pro Leu
                155
                                    160
Tyr Thr Ser Pro Arg Thr Val Thr Gln Ala Pro Pro Lys Ser Thr
                170
                                    175
Ala Asp Val Ser Thr Pro Asp Ser Glu Ile Asn Leu Thr Asn Val
                185
                                    190
Thr Asp Ile Ile Arg Val Pro Val Phe Asn Ile Val Ile Leu Leu
                200
                                    205
Ala Gly Gly Phe Leu Ser Lys Ser Leu Val Phe Ser Val Leu Phe
                215
                                    220
Ala Val Thr Leu Arg Ser Phe Val Pro
                230
```

<210> 112 <211> 119 <212> PRT <213> Homo sapiens

<220>
<221> misc\_feature
<223> Incyte Clone No: 4072159

<400> 112

<220>

 Met Val Leu Pro Leu Pro Trp Leu Ser Arg Tyr His Phe Leu Arg
 1
 5
 10
 15

 Leu Leu Leu Pro Ser Trp Ser Leu Ala Pro Gln Gly Ser His Gly
 20
 25
 30

 Cys Cys Ser Gln Asn Pro Lys Ala Ser Met Glu Glu Gln Thr Asn
 35
 40
 45

```
<210> 113
<211> 200
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1003916
<400> 113
Met Ala Ser Ser Leu Thr Cys Thr Gly Val Ile Trp Ala Leu Leu
                 5
                                    10
Ser Phe Leu Cys Ala Ala Thr Ser Cys Val Gly Phe Phe Met Pro
                 20
Tyr Trp Leu Trp Gly Ser Gln Leu Gly Lys Pro Val Ser Phe Gly
                 35
Thr Phe Arg Arg Cys Ser Tyr Pro Val His Asp Glu Ser Arg Gln
                 50
                                     55
Met Met Val Met Val Glu Glu Cys Gly Arg Tyr Ala Ser Phe Gln
                 65
                                     70
Gly Ile Pro Ser Ala Glu Trp Arg Ile Cys Thr Ile Val Thr Gly
                 80
                                     85
Leu Gly Cys Gly Leu Leu Leu Val Ala Leu Thr Ala Leu Met
                95
                                   100
Gly Cys Cys Val Ser Asp Leu Ile Ser Arg Thr Val Gly Arg Val
                110
                                   115
Ala Gly Gly Ile Gln Phe Leu Gly Gly Leu Leu Ile Gly Ala Gly
               125
                                   130
Cys Ala Leu Tyr Pro Leu Gly Trp Asp Ser Glu Glu Val Arg Gln
               140
                                   145
Thr Cys Gly Tyr Thr Ser Gly Gln Phe Asp Leu Gly Lys Cys Glu
               155
                                   160
Ile Gly Trp Ala Tyr Tyr Cys Thr Gly Ala Gly Ala Thr Ala Ala
               170
                                   175
Met Leu Leu Cys Thr Trp Leu Ala Cys Phe Ser Gly Lys Lys Gln
               185
                                   190
Lys His Tyr Pro Tyr
               200
```

```
<211> 225
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2093492
 <400> 114
Met Gly Phe Arg Leu Glu Gly Ile Phe Pro Ala Ala Leu Leu Pro
                  5
                                      10
Leu Leu Leu Thr Met Ile Leu Phe Leu Gly Pro Leu Met Gln Leu
                 20
Ser Met Asp Cys Pro Cys Asp Leu Ala Asp Gly Leu Lys Val Val
                 35
                                     40
Leu Ala Pro Arg Ser Trp Ala Arg Cys Leu Thr Asp Met Arg Trp
                 50
                                      55
Leu Arg Asn Gln Val Ile Ala Pro Leu Thr Glu Glu Leu Val Phe
                 65
                                     70
Arg Ala Cys Met Leu Pro Met Leu Ala Pro Cys Met Gly Leu Gly
                 80
Pro Ala Val Phe Thr Cys Pro Leu Phe Phe Gly Val Ala His Phe
                 95
His His Ile Ile Glu Gln Leu Arg Phe Arg Gln Ser Ser Val Gly
                110
                                    115
Asn Ile Phe Leu Ser Ala Ala Phe Gln Phe Ser Tyr Thr Ala Val
                125
                                    130
Phe Gly Ala Tyr Thr Ala Phe Leu Phe Ile Arg Thr Gly His Leu
                140
                                    145
Ile Gly Pro Val Leu Cys His Ser Phe Cys Asn Tyr Met Gly Phe
                155
                                    160
Pro Ala Val Cys Ala Ala Leu Glu His Pro Gln Arg Arg Pro Leu
                170
                                    175
Leu Ala Gly Tym Ala Leu Gly Val Gly Leu Phe Leu Leu Leu
                185
                                    190
Gln Pro Leu Thr Asp Pro Lys Leu Tyr Gly Ser Leu Pro Leu Cys
                200
                                    205
Val Leu Leu Glu Arg Ala Gly Asp Ser Glu Ala Pro Leu Cys Ser
                215
                                    220
<210> 115
<211> 155
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2108789
<400> 115
Met Ser Gly Leu Leu Ile Pro Pro Leu Pro Gly Trp Val Leu Gly
```

10

25

Pro Leu Met Trp Ala Cys Arg Pro Pro Gln Asp Glu Pro Ser Gly

Thr Asp Pro Pro Pro Pro Arg Leu Gln Pro His His Val Ser Gly 35 Leu Gly Leu Gly Gln Ala Trp Ala Gln Ser Trp Ala Pro Arg Gly 55 Ser Pro Pro Leu Thr Trp Leu Leu Pro Thr Leu Pro Leu Lys Asp 65 70 Gly Pro Ala Ala Arg Leu Pro Pro Pro Pro His Thr Leu Gly 80 85 Gly Leu Ser His Pro Pro Gln Pro Arg Ser Ala Gln Thr Asp Pro 95 100 His Ser Ile Pro Arg Pro Ala Ala Gln Val Arg Gly Pro Val Leu 110 115 Pro Gly Ala Trp Ala Thr Pro Tyr Ala Ile Ser Ser Glu Gln Pro 125 130 Gly Pro Thr Asp Pro His Ala Leu Ser Tyr Val Pro Phe Ser Pro 140 145 Asp Phe Phe Cys Thr

<210> 116 <211> 468 <212> PRT <213> Homo sapiens <220> <221> misc\_feature

<223> Incyte Clone No: 2171401

<400> 116

Met Gly Arg Gly Trp Gly Phe Leu Phe Gly Leu Leu Gly Ala Val 10 Trp Leu Leu Ser Ser Gly His Gly Glu Glu Gln Pro Pro Glu Thr 20 25 Ala Ala Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp 35 40 Cys Thr Cys Asp Val Glu Thr Ile Asp Arg Phe Asn Asn Tyr Arg 50 55 Leu Phe Pro Arg Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg 70 Tyr Tyr Lys Val Asn Leu Lys Arg Pro Cys Pro Phe Trp Asn Asp 80 85 Ile Ser Gln Cys Gly Arg Arg Asp Cys Ala Val Lys Pro Cys Gln 100 Ser Asp Glu Val Pro Asp Gly Ile Lys Ser Ala Ser Tyr Lys Tyr 110 115 Ser Glu Glu Ala Asn Asn Leu Ile Glu Glu Cys Glu Gln Ala Glu 125 130 Arg Leu Gly Ala Val Asp Glu Ser Leu Ser Glu Glu Thr Gln Lys 140 145 Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser Ser Asp Asn Phe 155 160 Cys Glu Ala Asp Asp Ile Gln Ser Pro Glu Ala Glu Tyr Val Asp 170 175 Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly Pro Asp

```
185
                                    190
Ala Trp Lys Ile Trp Asn Val Ile Tyr Glu Glu Asn Cys Phe Lys
                200
                                    205
Pro Gln Thr Ile Lys Arg Pro Leu Asn Pro Leu Ala Ser Gly Gln
                215
                                    220
Gly Thr Ser Glu Glu Asn Thr Phe Tyr Ser Trp Leu Glu Gly Leu
                230
                                    235
Cys Val Glu Lys Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His
                245
                                    250
Ala Ser Ile Asn Val His Leu Ser Ala Arg Tyr Leu Leu Gln Glu
                260
                                    265
Thr Trp Leu Glu Lys Lys Trp Gly His Asn Ile Thr Glu Phe Gln
                275
                                    280
Gln Arg Phe Asp Gly Ile Leu Thr Glu Gly Glu Gly Pro Arg Arg
                290
                                    295
Leu Lys Asn Leu Tyr Phe Leu Tyr Leu Ile Glu Leu Arg Ala Leu
                305
                                    310
Ser Lys Val Leu Pro Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe
                320
                                    325
Thr Gly Asn Lys Ile Gln Asp Glu Glu Asn Lys Met Leu Leu Leu
                335
                                    340
Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu His Phe Asp Glu
                350
                                    355
Asn Ser Phe Phe Ala Gly Asp Lys Lys Glu Ala His Lys Leu Lys
                365
                                    370
Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile Met Asp
                380
                                    385
Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln Thr
                395
                                    400
Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu
                410
                                    415
Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe His Leu
                425
                                    430
Thr Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile
                440
                                    445
Ser Thr Ser Val Lys Glu Leu Glu Asn Phe Arg Asn Leu Leu Gln
                                    460
Asn Ile His
```

```
<210> 117
<211> 403
<212> PRT
<213> Homo sapiens
```

<220>

<221> misc feature

<223> Incyte Clone No: 2212530

<400> 117

 Met Ser Thr Ser Thr Ser Pro Ala Ala Met Leu Leu Arg Arg Leu

 1
 5
 10
 15

 Arg Arg Leu Ser Trp Gly Ser Thr Ala Val Gln Leu Phe Ile Leu
 20
 25
 30

 Thr Val Val Thr Phe Gly Leu Leu Ala Pro Leu Ala Cys His Arg

```
40
Leu Leu His Ser Tyr Phe Tyr Leu Arg His Trp His Leu Asn Gln
Met Ser Gln Glu Phe Leu Gln Gln Ser Leu Lys Glu Gly Glu Ala
Ala Leu His Tyr Phe Glu Glu Leu Pro Ser Ala Asn Gly Ser Val
Pro Ile Val Trp Gln Ala Thr Pro Arg Pro Trp Leu Val Ile Thr
Ile Ile Thr Val Asp Arg Gln Pro Gly Phe His Tyr Val Leu Gln
Val Val Ser Gln Phe His Arg Leu Leu Gln Gln Cys Gly Pro Gln
                                    130
Cys Glu Gly His Gln Leu Phe Leu Cys Asn Val Glu Arg Ser Val
               140
                                    145
Ser His Phe Asp Ala Lys Leu Leu Ser Lys Tyr Val Pro Val Ala
               155
                                    160
Asn Arg Tyr Glu Gly Thr Glu Asp Asp Tyr Gly Asp Asp Pro Ser
                170
                                    175
Thr Asn Ser Phe Glu Lys Glu Lys Gln Asp Tyr Val Tyr Cys Leu
               185
                                    190
Glu Ser Ser Leu Gln Thr Tyr Asn Pro Asp Tyr Val Leu Met Val
               200
                                    205
Glu Asp Asp Ala Val Pro Glu Glu Gln Ile Phe Pro Val Leu Glu
               215
                                    220
His Leu Leu Arg Ala Arg Phe Ser Glu Pro His Leu Arg Asp Ala
                230
                                    235
Leu Tyr Leu Lys Leu Tyr His Pro Glu Arg Leu Gln His Tyr Ile
                                    250
                245
Asn Pro Glu Pro Met Arg Ile Leu Glu Trp Val Gly Val Gly Met
                260
                                    265
Leu Leu Gly Pro Leu Leu Thr Trp Ile Tyr Met Arg Phe Ala Ser
               275
                                    280
arg Pro Gly Phe Ser Trp Pro Val Met Leu Phe Phe Ser Leu Tyr
               290
                                    295
Ser Met Gly Leu Val Glu Leu Val Gly Arg His Tyr Phe Leu Glu
               305
                                    310
Leu Arg Arg Leu Ser Pro Ser Leu Tyr Ser Val Val Pro Ala Ser
               320
                                    325
Gln Cys Cys Thr Pro Ala Met Leu Phe Pro Ala Pro Ala Ala Arg
               335
                                    340
Arg Thr Leu Thr Tyr Leu Ser Gln Val Tyr Cys His Lys Gly Phe
               350
                                    355
Gly Lys Asp Met Ala Leu Tyr Ser Leu Leu Arg Ala Lys Gly Glu
               365
                                    370
Arg Ala Tyr Val Val Glu Pro Asn Leu Val Lys His Ile Gly Leu
                                    385
Phe Ser Ser Leu Arg Tyr Asn Phe His Pro Ser Leu Leu
```

<210> 118

<211> 131

<212> PRT

<213> Homo sapiens

100

<221> misc\_feature <223> Incyte Clone No: 2253036 <400> 118 Met Glu Arg Cys Phe His Cys Phe Pro Val His Leu Val Phe Asn 10 Leu Val Gln Ser Phe Ser Pro Ile Ser Gly Val Glu Ser Cys Leu 20 25 Leu Pro Gln Cys Asp Lys Cys Trp Pro Met Val Tyr Arg Ser Cys 35 40 Asp Ala Ser Arg Gly Leu Val Asn Ala Cys Ile Leu Gly Phe Val 50 55 Leu Leu Glu Cys Ser Phe Val Gly Ala Leu Asn Asn Tyr Val Arg 65 70 Ser Leu Ala Thr Leu Leu Glu Arg Thr His Gly Gly Lys Arg Leu 80 85 Lys Leu Cys Glu Glu Ser Gln Ala Ser His Pro Ser Phe Ser Ala

Glu Pro Arg His Gln Pro Thr Cys Gln Leu Asn Ala Thr Val Arg

Val Ile Thr Ser Lys Ile Thr Arg Lys Thr Thr
125 130

95

<210> 119 <211> 556 <212> PRT <213> Homo sapiens

<220>
<221> misc\_feature .
<223> Incyte Clone No. 2280161

<400> 119

<220>

Met Ala Ala Ala Trp Leu Gln Val Leu Pro Val Ile Leu Leu 10 Leu Leu Gly Ala His Pro Ser Pro Leu Ser Phe Phe Ser Ala Gly 25 Pro Ala Thr Val Ala Ala Ala Asp Arg Ser Lys Trp His Ile Pro 40 Ile Pro Ser Gly Lys Asn Tyr Phe Ser Phe Gly Lys Ile Leu Phe 55 Arg Asn Thr Thr Ile Phe Leu Lys Phe Asp Gly Glu Pro Cys Asp 70 Leu Ser Leu Asn Ile Thr Trp Tyr Leu Lys Ser Ala Asp Cys Tyr 85 Asn Glu Ile Tyr Asn Phe Lys Ala Glu Glu Val Glu Leu Tyr Leu 100 Glu Lys Leu Lys Glu Lys Arg Gly Leu Ser Gly Lys Tyr Gln Thr 110 115 Ser Ser Lys Leu Phe Gln Asn Cys Ser Glu Leu Phe Lys Thr Gln 125 130 135 Thr Phe Ser Gly Asp Phe Met His Arg Leu Pro Leu Leu Gly Glu 140 145

Lys	Gln	Glu	Ala	Lys 155	Glu	Asn	Gly	Thr	Asn 160	Leu	Thr	Phe	Ile	Gly 165
Asp	Lys	Thr	Ala	Met 170	His	Glu	Pro	Leu	Gln 175	Thr	Trp	Gln	Asp	Ala 180
Pro	Tyr	Ile	Phe	Ile 185	Val	His	Ile	Gly	Ile 190	Ser	Ser	Ser	Lys	Glu 195
Ser	Ser	Lys	Glu	Asn 200	Ser	Leu	Ser	Asn	Leu 205	Phe	Thr	Met	Thr	Val 210
Glu	Val	Lys	Gly	Pro 215	Tyr	Glu	Tyr	Leu	Thr 220	Leu	Glu	Asp	Tyr	Pro 225
Leu	Met	Ile	Phe	Phe 230	Met	Val	Met	Суѕ	Ile 235	Val	Tyr	Val	Leu	Phe 240
Gly	Val	Leu	Trp	Leu 245	Ala	Trp	Ser	Ala	Суs 250	Tyr	Trp	Arg	Asp	Leu 255
Leu	Arg	Ile	Gln	Phe 260	Trp	Ile	Gly	Ala	Val 265	Ile	Phe	Leu	Gly	Met 270
				275					Phe 280					285
Lys	Gly	Glu	Ser	Val 290	Gln	Gly	Ala	Leu	Ile 295	Leu	Ala	Glu	Leu	Leu 300
			_	305				_	Thr 310					315
				320					Arg 325					330
	_			335		_			Tyr 340					345
				350					Tyr 355			_		360
				365					Ala 370		_		_	375
				380					Gln 385			_		390
	,			395					Ser 400		,			405
		•		410					Ala 415					420
	_			425	_				Val 430		•			435
_				440		_			11e 445	_	_			450
,				455					Leu 460	_				465
				470					Leu 475 Lys					480
				485					490 Pro					495
				500					505 Lys					510
				515					520					525
				530		_			Leu 535 Phe					540
Glu	roh	GIU	GIU	545	1.1C.C	TTE	1117	mrs	550	GIU	ътA	ae1	ռչ	мес 555
Jiu														

<210> 120

```
<211> 514
 <212> PRT
 <213> Homo sapiens
 <220>
<221> misc_feature
 <223> Incyte Clone No: 2287485
<400> 120
Met Ser Trp Pro Arg Arg Leu Leu Leu Arg Tyr Leu Phe Pro Ala
                                      10
Leu Leu His Gly Leu Gly Glu Gly Ser Ala Leu Leu His Pro
                 20
                                      25
Asp Ser Arg Ser His Pro Arg Ser Leu Glu Lys Ser Ala Trp Arg
                 35
                                      40
Ala Phe Lys Glu Ser Gln Cys His His Met Leu Lys His Leu His
                 50
                                      55
Asn Gly Ala Arg Ile Thr Val Gln Met Pro Pro Thr Ile Glu Gly
                 65
                                      70
His Trp Val Ser Thr Gly Cys Glu Val Arg Ser Gly Pro Glu Phe
                 80
                                      85
Ile Thr Arg Ser Tyr Arg Phe Tyr His Asn Asn Thr Phe Lys Ala
                 95
                                    100
Tyr Gln Phe Tyr Tyr Gly Ser Asn Arg Cys Thr Asn Pro Thr Tyr
                110
                                    115
Thr Leu Ile Ile Arg Gly Lys Ile Arg Leu Arg Gln Ala Ser Trp
                125
                                    130
Ile Ile Arg Gly Gly Thr Glu Ala Asp Tyr Gln Leu His Asn Val
                140
                                    145
                                                         150
Gln Val Ile Cys His Thr Glu Ala Val Ala Glu Lys Leu Gly Gln
                155
                                    160
                                                         165
Gln Val Asn Arg Thy Cys Pro Gly Phe Leu Ala Asp Gly Gly Pro
                170
                                    175
                                                         180
Trp Val Gln Asp Val Ala Tyr Asp Leu Trp Arg Glu Glu Asn Gly
                185
                                    190
Cys Glu Cys Thr Lys Ala Val Asn Phe Ala Met His Glu Leu Gln
                200
                                    205
Leu Ile Arg Val Glu Lys Gln Tyr Leu His His Asn Leu Asp His
                215
                                    220
Leu Val Glu Glu Leu Phe Leu Gly Asp Ile His Thr Asp Ala Thr
                230
                                    235
Gln Arg Met Phe Tyr Arg Pro Ser Ser Tyr Gln Pro Pro Leu Gln
                245
                                    250
Asn Ala Lys Asn His Asp His Ala Cys Ile Ala Cys Arg Ile Ile
                260
                                    265
Tyr Arg Ser Asp Glu His His Pro Pro Ile Leu Pro Pro Lys Ala
                275
                                    280
Asp Leu Thr Ile Gly Leu His Gly Glu Trp Val Ser Gln Arg Cys
                290
                                    295
Glu Val Arg Pro Glu Val Leu Phe Leu Thr Arg His Phe Ile Phe
                305
                                    310
His Asp Asn Asn Asn Thr Trp Glu Gly His Tyr Tyr His Tyr Ser
               320
                                    325
                                                         330
Asp Pro Val Cys Lys His Pro Thr Phe Ser Ile Tyr Ala Arg Gly
                335
                                    340
                                                         345
```

```
Arg Tyr Ser Arg Gly Val Leu Ser Ser Arg Val Met Gly Gly Thr
                350
                                    355
Glu Phe Val Phe Lys Val Asn His Met Lys Val Thr Pro Met Asp
                365
                                    370
                                                        375
Ala Ala Thr Ala Ser Leu Leu Asn Val Phe Asn Gly Asn Glu Cys
                380
                                    385
                                                        390
Gly Ala Glu Gly Ser Trp Gln Val Gly Ile Gln Gln Asp Val Thr
                395
His Thr Asn Gly Cys Val Ala Leu Gly Ile Lys Leu Pro His Thr
                410
Glu Tyr Glu Ile Phe Lys Met Glu Gln Asp Ala Arg Gly Arg Tyr
Leu Leu Phe Asn Gly Gln Arg Pro Ser Asp Gly Ser Ser Pro Asp
Arg Pro Glu Lys Arg Ala Thr Ser Tyr Gln Met Pro Leu Val Gln
Cys Ala Ser Ser Fro Arg Ala Glu Asp Leu Ala Glu Asp Ser
Gly Ser Ser Leu Tyr Gly Arg Ala Pro Gly Arg His Thr Trp Ser
                                    490
Leu Leu Leu Ala Ala Leu Ala Cys Leu Val Pro Leu Leu His Trp
                                    505
                                                        510
Asn Ile Arg Arg
```

<210> 121 <211> 109 <212> PRT <213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone No: 2380344

<400> 121

Met Leu Trp Trp Leu Val Leu Leu Leu Pro Thr Leu Lys Ser 10 Val Phe Cys Ser Leu Val Thr Ser Leu Tyr Leu Pro Asn Thr Glu 25 Asp Leu Ser Leu Trp Leu Trp Pro Lys Pro Asp Leu His Ser Gly 40 Thr Arg Thr Glu Val Ser Thr His Thr Val Pro Ser Lys Pro Gly 50 55 Thr Ala Ser Pro Cys Trp Pro Leu Ala Gly Ala Val Pro Ser Pro 65 70 Thr Val Ser Arg Leu Glu Ala Leu Thr Arg Ala Val Gln Val Ala 85 Glu Pro Leu Gly Ser Cys Gly Phe Gln Gly Gly Pro Cys Pro Gly 100 105 Arg Arg Arg Asp

<211> 431

```
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2383171
<400> 122
Met Ser Trp Val Gln Ala Thr Leu Leu Ala Arg Gly Leu Cys Arg
Ala Trp Gly Gly Thr Cys Gly Ala Ala Leu Thr Gly Thr Ser Ile
Ser Gln Val Pro Arg Arg Leu Pro Arg Gly Leu His Cys Ser Ala
                                 . 40
Ala Ala His Ser Ser Glu Gln Ser Leu Val Pro Ser Pro Pro Glu
Pro Arg Gln Arg Pro Thr Lys Ala Leu Val Pro Phe Glu Asp Leu
Phe Gly Gln Ala Pro Gly Gly Glu Arg Asp Lys Ala Ser Phe Leu
Gln Thr Val Gln Lys Phe Ala Glu His Ser Val Arg Lys Arg Gly
                 95
His Ile Asp Phe Ile Tyr Leu Ala Leu Arg Lys Met Arg Glu Tyr
Gly Val Glu Arg Asp Leu Ala Val Tyr Asn Gln Leu Leu Asn Ile
                125
Phe Pro Lys Glu Val Phe Arg Pro Arg Asn Ile Ile Gln Arg Ile
                                    145
Phe Val His Tyr Pro Arg Gln Gln Glu Cys Gly Ile Ala Val Leu
Glu Gln Met Glu Asn His Gly Val Met Pro Asn Lys Glu Thr Glu
                170
Phe Leu Leu Ile Gln Ile Phe Gly Arg Lys Ser Tyr Pro Met Leu
                185
                                  190
                                         A second second
Lys Leu Val Arg Leu Lys Leu Trp Phe Pro Arg Phe Met Asn Val
                200
                                    205
Asn Pro Phe Pro Val Pro Arg Asp Leu Pro Gln Asp Pro Val Glu
                215
                                    220
Leu Ala Met Phe Gly Leu Arg His Met Glu Pro Asp Leu Ser Ala
                230
                                    235
Arg Val Thr Ile Tyr Gln Val Pro Leu Pro Lys Asp Ser Thr Gly
                245
                                    250
Ala Ala Asp Pro Pro Gln Pro His Ile Val Gly Ile Gln Ser Pro
                260
                                    265
Asp Gln Gln Ala Ala Leu Ala Arg His Asn Pro Ala Arg Pro Val
                275
                                    280
Phe Val Glu Gly Pro Phe Ser Leu Trp Leu Arg Asn Lys Cys Val
                290
                                    295
Tyr Tyr His Ile Leu Arg Ala Asp Leu Leu Pro Pro Glu Glu Arg
                305
                                    310
Glu Val Glu Glu Thr Pro Glu Glu Trp Asn Leu Tyr Tyr Pro Met
                320
                                    325
Gln Leu Asp Leu Glu Tyr Val Arg Ser Gly Trp Asp Asn Tyr Glu
                335
                                    340
Phe Asp Ile Asn Glu Val Glu Glu Gly Pro Val Phe Ala Met Cys
                350
                                    355
```

```
        Met
        Ala
        Gly
        Ala
        His
        Asp
        Gln
        Ala
        Thr
        Met
        Ala
        Lys
        Trp
        Ile
        Gln

        Gly
        Leu
        Gln
        Glu
        Thr
        Asn
        Pro
        Thr
        Leu
        Ala
        Gln
        Ile
        Pro
        Val
        Val
```

<210> 123
<211> 142
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 2396046
<400> 123
Met Leu Leu Gly Val Arg Ala Va

Met Leu Leu Gly Val Arg Ala Val Pro Leu Cys Ser Ala Trp Gln Gly Ala Val Gly Leu Val Ser Leu Ala Ile Ser Ile Cys Lys His 20 Gly Leu Ser Ser Gln Gln Asn Leu Val Pro Gly Lys Ser Asn Val 35 40 Pro Lys Ala Ser Asp Met Pro Arg Cys Pro Pro Val Phe Gln Ser 50 55 Pro Asn Leu Thr Pro Phe Pro His His Thr Lys His Thr Ser Gln 65 70 Gly Ser His Leu Gly Val Pro Pro Pro Ala Pro Met Pro Trp Cys 80 85 Pro Gln Ala Gln Gly Phe Gly Leu Ser Cys Gln Ser Leu Asp Ala 100 Phe Glu Gly Gln Leu Gly Cys Gly Trp Gly Val Gln Ala Ala Gly 110 115 120 Glu Pro Arg Leu Arg Ile Ile His Thr Leu Leu Phe Gly Ala Phe 125 135 Val Glu Val Ser Arg Ile Pro

<210> 124
<211> 643
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 2456587

<400> 124 Met Glu Cys Cys Arg Arg Ala Thr Pro Gly Thr Leu Leu Leu Phe Leu Ala Phe Leu Leu Ser Ser Arg Thr Ala Arg Ser Glu Glu Asp Arg Asp Gly Leu Trp Asp Ala Trp Gly Pro Trp Ser Glu Cys Ser Arg Thr Cys Gly Gly Gly Ala Ser Tyr Ser Leu Arg Arg Cys Leu Ser Ser Lys Ser Cys Glu Gly Arg Asn Ile Arg Tyr Arg Thr 70 Cys Ser Asn Val Asp Cys Pro Pro Glu Ala Gly Asp Phe Arg Ala Gln Gln Cys Ser Ala His Asn Asp Val Lys His His Gly Gln Phe 100 Tyr Glu Trp Leu Pro Val Ser Asn Asp Pro Asp Asn Pro Cys Ser 110 Leu Lys Cys Gln Ala Lys Gly Thr Thr Leu Val Val Glu Leu Ala 125 130 Pro Lys Val Leu Asp Gly Thr Arg Cys Tyr Thr Glu Ser Leu Asp 140 145 Met Cys Ile Ser Gly Leu Cys Gln Ile Val Gly Cys Asp His Gln 160 Leu Gly Ser Thr Val Lys Glu Asp Asn Cys Gly Val Cys Asn Gly 170 175 Asp Gly Ser Thr Cys Arg Leu Val Arg Gly Gln Tyr Lys Ser Gln 185 190 Leu Ser Ala Thr Lys Ser Asp Asp Thr Val Val Ala Ile Pro Tyr 200 205 Gly Ser Arg His Ile Arg Leu Val Leu Lys Gly Pro Asp His Leu 215 220 Tyr Leu Glu Thr Lys Thr Leu Gln Gly Thr Lys Gly Glu Asn Ser 230 235 Leu Ser Ser Thr Gly Thr Phe Leu Val Asp Asn Ser Ser Val Asp 245 250 Phe Gln Lys Phe Pro Asp Lys Glu Ile Leu Arg Met Ala Gly Pro 260 265 Leu Thr Ala Asp Phe Ile Val Lys Ile Arg Asn Ser Gly Ser Ala 275 280 Asp Ser Thr Val Gln Phe Ile Phe Tyr Gln Pro Ile Ile His Arg 290 295 Trp Arg Glu Thr Asp Phe Phe Pro Cys Ser Ala Thr Cys Gly Gly 305 310 Gly Tyr Gln Leu Thr Ser Ala Glu Cys Tyr Asp Leu Arg Ser Asn 320 325 Arg Val Val Ala Asp Gln Tyr Cys His Tyr Tyr Pro Glu Asn Ile 335 340 Lys Pro Lys Pro Lys Leu Gln Glu Cys Asn Leu Asp Pro Cys Pro 350 355 Ala Ser Asp Gly Tyr Lys Gln Ile Met Pro Tyr Asp Leu Tyr His 365 370 Pro Leu Pro Arg Trp Glu Ala Thr Pro Trp Thr Ala Cys Ser Ser 380 385 Ser Cys Gly Gly Ile Gln Ser Arg Ala Val Ser Cys Val Glu 395 400 Glu Asp Ile Gln Gly His Val Thr Ser Val Glu Glu Trp Lys Cys 410

```
Met Tyr Thr Pro Lys Met Pro Ile Ala Gln Pro Cys Asn Ile Phe
                425
                                    430
Asp Cys Pro Lys Trp Leu Ala Gln Glu Trp Ser Pro Cys Thr Val
                440
                                    445
Thr Cys Gly Gln Gly Leu Arg Tyr Arg Val Val Leu Cys Ile Asp
                455
                                    460
His Arg Gly Met His Thr Gly Gly Cys Ser Pro Lys Thr Lys Pro
                470
                                    475
His Ile Lys Glu Glu Cys Ile Val Pro Thr Pro Cys Tyr Lys Pro
                485
                                    490
Lys Glu Lys Leu Pro Val Glu Ala Lys Leu Pro Trp Phe Lys Gln
                500
                                    505
Ala Gln Glu Leu Glu Glu Gly Ala Ala Val Ser Glu Glu Pro Ser
                515
                                    520
Phe Ile Pro Glu Ala Trp Ser Ala Cys Thr Val Thr Cys Gly Val
                530
                                    535
Gly Thr Gln Val Arg Ile Val Arg Cys Gln Val Leu Leu Ser Phe
                545
                                    550
Ser Gln Ser Val Ala Asp Leu Pro Ile Asp Glu Cys Glu Gly Pro
                560
                                    565
Lys Pro Ala Ser Gln Arg Ala Cys Tyr Ala Gly Pro Cys Ser Gly
                575
                                    580
Glu Ile Pro Glu Phe Asn Pro Asp Glu Thr Asp Gly Leu Phe Gly
                590
                                    595
Gly Leu Gln Asp Phe Asp Glu Leu Tyr Asp Trp Glu Tyr Glu Gly
                605
                                    610
Phe Thr Lys Cys Ser Glu Ser Cys Gly Gly Gly Val Gln Glu Ala
                620
                                    625
Val Val Ser Cys Leu Asn Lys Gln Thr Arg Glu Pro Cys
```

```
<210> 125
<211> 568
<212> PRT
<213> Homo sapiens
```

<220>
<221> misc\_feature
<223> Incyte Clone No: 2484813

<400> 125

```
Met Val Leu Leu His Trp Cys Leu Leu Trp Leu Leu Phe Pro Leu
                                     10
Ser Ser Arg Thr Gln Lys Leu Pro Thr Arg Asp Glu Glu Leu Phe
                                     25
Gln Met Gln Ile Arg Asp Lys Ala Phe Phe His Asp Ser Ser Val
                                     40
Ile Pro Asp Gly Ala Glu Ile Ser Ser Tyr Leu Phe Arg Asp Thr
                 50
                                     55
Pro Lys Arg Tyr Phe Phe Val Val Glu Glu Asp Asn Thr Pro Leu
                 65
                                     70
Ser Val Thr Val Thr Pro Cys Asp Ala Pro Leu Glu Trp Lys Leu
                 80
                                     85
Ser Leu Gln Glu Leu Pro Glu Asp Arg Ser Gly Glu Gly Ser Gly
```

λen	T.a.ı	Glu	Pro	95 Leu		Cl n	C1 n	Tara	100		77.	T7.	Asn	105
nsp	Deu	GIU		110		GIII	GIN	гра	115		rre	TTE	Asn	GIU 120
Glu	Gly	Thr	Glu	Leu 125		Ser	Tyr	Lys		Asn	Asp	Val	Glu	Tyr 135
Phe	Ile	Ser	Ser	Ser		Pro	Ser	Gly		Tyr	Gln	Leu	Asp	Leu 150
Leu	Ser	Thr	Glu		Asp	Thr	His	Phe			Tyr	Ala	Thr	Thr
Thr	Pro	Glu	Ser	_	Gln	Pro	Tyr	Pro		Leu	Pro	Tyr	Asp	
Arg	Val	ĄsĄ	Val			Leu	Gly	Arg		Thr	Val	Thr	Leu	180 Ala 195
Trp	Lys	Pro	Ser		Thr	Ala	Ser	Leu		Lys	Gln	Pro	Ile	
Tyr	Cys	Val	Val		Asn	Lys	Glu	His		Phe	Lys	Ser	Leu	Cys 225
Ala	Val	Glu	Ala		Leu	Ser	Ala	Asp		Ala	Phe	Met	Met	
Pro	Lys	Pro	Gly	Leu 245	Asp	Phe	Ser	Pro		Asp	Phe	Ala	His	
Gly	Phe	Pro	Ser	Asp 260	Asn	Ser	Gly	Lys		Arg	Ser	Phe	Gln	
Lys	Pro	Ser	Pro	Lys 275	Leu	Gly	Arg	His	Val 280	Tyr	Ser	Arg	Pro	
Val	Asp	Ile	Gln	Lys 290	Ile	Cys	Ile	Gly	Asn 295	Lys	Asn	Ile	Phe	
				305					310				Val	315
				320					325				Gly	330
				335					340				Glu	345
				350					355			_	Gly	360
				365					370				Val	375
				380					385				Val	390
				395					400				Ile	405
				410					415				Val	420
				425					430				Leu	435
				440					445				Glu	450
				455					460				Ser	465
				470					475				Cys	480
				485					490				Lys	495
				500					505				Lys	510
Glu	Lys	Val	Leu	Cys 515	Lys	Tyr	Phe	His	Ser 520	Gln	Asn	Leu	Gln	Lys 525

```
Ala Val Thr Thr Glu Thr Ile Lys Gly Leu Gln Pro Gly Lys Ser 530

Tyr Leu Leu Asp Val Tyr Val Ile Gly His Gly Gly His Ser 555

Lys Tyr Gln Ser Lys Val Val Lys Thr Arg Lys Phe Cys 560
```

```
<210> 126
 <211> 125
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 2493851
 <400> 126
 Met Trp Leu Val Gly Pro Ser Phe Leu Ser Cys Pro Leu Gly Lys
 Val Pro Pro Ala Gly Leu Leu Leu Ala Gly Ser Ser Gly Arg Gly
                 20
Ala Arg Arg Pro Ala Thr Pro Arg His Trp Ser Ser Thr Thr Pro
                 35
                                     40
Gly Leu Arg Leu Glu Ala Pro Leu Cys Gln Leu Cys Pro Leu Gly
                 50
                                     55
Gly Thr Arg Gln Asp Cys Gln Pro Leu Ser Trp Gln Val Thr Ser
                 65
                                     70
Ala Phe Lys Leu Thr Val Pro Ser Pro Phe His Ala Pro Pro Arg
                 80
                                     85
Ser Trp Ser Cys Leu Leu Gly Ile Phe Pro Gly Gln Ala Leu
                 95
                                   100
Ala Leu Glu Pro Trp His Leu Phe Leu Gly Ser Met Leu Pro Arg
                110
                                   115
Cys Asp Gly Glu Cys
```

<210> 127
<211> 196
<212> PRT
<213> Homo sapiens

<220>
<221> misc\_feature
<223> Incyte Clone No: 2495719

<400> 127

```
Thr Thr Ile Ile Glu Gly Arg Ile Thr Ala Thr Pro Lys Glu Ser
                 50
                                     55
Pro Asn Pro Pro Asn Pro Ser Gly Gln Cys Pro Ile Cys Arg Trp
                 65
Asn Leu Lys His Lys Tyr Asn Tyr Asp Asp Val Leu Leu Leu Ser
                 80
                                     85
Gln Phe Ile Arg Pro His Gly Gly Met Leu Pro Arg Lys Ile Thr
                 95
                                    100
Gly Leu Cys Gln Glu Glu His Arg Lys Ile Glu Glu Cys Val Lys
                                    115
Met Ala His Arg Ala Gly Leu Leu Pro Asn His Arg Pro Arg Leu
                125
                                    130
Pro Glu Gly Val Val Pro Lys Ser Lys Pro Gln Leu Asn Arg Tyr
                                    145
Leu Thr Arg Trp Ala Pro Gly Ser Val Lys Pro Ile Tyr Lys Lys
                                    160
Gly Pro Arg Trp Asn Arg Val Arg Met Pro Val Gly Ser Pro Leu
                170
                                    175
Leu Arg Asp Asn Val Cys Tyr Ser Arg Thr Pro Trp Lys Leu Tyr
                                    190
His
```

<210> 128
<211> 214
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 2614153

<400> 128 Met Val Leu Gly Gly Cys Pro Val Ser Tyr Leu Leu Leu Cys Gly 10 Gln Ala Ala Leu Leu Gly Asn Leu Leu Leu His Cys Val 25 Ser Arg Ser His Ser Gln Asn Ala Thr Ala Glu Pro Glu Leu Thr 35 40 Ser Ala Gly Ala Ala Gln Pro Glu Gly Pro Gly Gly Ala Ala Ser 55 Trp Glu Tyr Gly Asp Pro His Ser Pro Val Ile Leu Cys Ser Tyr 65 70 Leu Pro Asp Glu Phe Ile Glu Cys Glu Asp Pro Val Asp His Val 80 85 Gly Asn Ala Thr Ala Ser Gln Glu Leu Gly Tyr Gly Cys Leu Lys 95 100 Phe Gly Gly Gln Ala Tyr Ser Asp Val Glu His Thr Ser Val Gln 110 115 Cys His Ala Leu Asp Gly Ile Glu Cys Ala Ser Pro Arg Thr Phe 125 130 Leu Arg Glu Asn Lys Pro Cys Ile Lys Tyr Thr Gly His Tyr Phe 140 145 Ile Thr Thr Leu Leu Tyr Ser Phe Phe Leu Gly Cys Phe Gly Val

```
      Asp
      Arg
      Phe
      Cys
      Leu
      Gly
      His
      Thr
      Gly
      Thr
      Ala
      Val
      Gly
      Leu
      Leu

      Leu
      Thr
      Leu
      Gly
      Leu
      Gly
      Ile
      Trp
      Trp
      Phe
      Val
      Asp
      Leu
      Ile

      Leu
      Leu
      Ile
      Thr
      Gly
      Gly
      Leu
      Met
      Pro
      Ser
      Asp
      Gly
      Ser
      Asn
      Trp

      Leu
      Thr
      Val
      Tyr
      T
```

<211> 88 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte Clone No: 2655184 <400> 129 Met Ala Cys Phe Ser Phe Phe Leu Cys Phe Leu Val His Leu Leu Ile Lys Met Asn Pro Val Thr Glu Ser Pro Ser Cys Leu Phe Ser 20 25 Pro Pro Ser Glu Ser Ala Leu Ala Ser Gln Leu Ala Leu Ser Ala 35 40 Ser Cys Asp Gln Arg Ala Pro Phe Ser Leu Ala Gly Val Val Ser 50 55 His Asp Pro Gly Trp Pro Val Val Arg Leu His Arg Pro Leu Val 65 70 Pro Glu His Ala Val Phe Ser Gln Pro Ser Leu Gln Pro

<210> 130 <211> 260 <212> PRT <213> Homo sapiens <220> <221> misc\_feature <223> Incyte Clone No: 2848362

50

<210> 129

. 85

```
Arg Arg Lys Ala Trp Cys Arg Gln Leu Gly Glu Lys Gly Pro Cys
                 80
Gln Arg Val Val Ser Thr His Asn Leu Trp Leu Leu Ser Phe Leu
                 95
                                    100
Arg Arg Trp Asn Gly Ser Thr Ala Ile Thr Asp Asp Thr Leu Gly
                110
                                    115
Gly Thr Leu Thr Ile Thr Leu Arg Asn Leu Gln Pro His Asp Ala
                                    130
Gly Leu Tyr Gln Cys Gln Ser Leu His Gly Ser Glu Ala Asp Thr
                                    145
Leu Arg Lys Val Leu Val Glu Val Leu Ala Asp Pro Leu Asp His
                                    160
Arg Asp Ala Gly Asp Leu Trp Phe Pro Gly Glu Ser Glu Ser Phe
                170
                                   175
Glu Asp Ala His Val Glu His Ser Ile Ser Arg Ser Leu Leu Glu
                                    190
Gly Glu Ile Pro Phe Pro Pro Thr Ser Ile Leu Leu Leu Leu Ala
                200
                                    205
Cys Ile Phe Leu Ile Lys Ile Leu Ala Ala Ser Ala Leu Trp Ala
                                    220
Ala Ala Trp His Gly Gln Lys Pro Gly Thr His Pro Pro Ser Glu
                230
                                    235
Leu Asp Cys Gly His Asp Pro Gly Tyr Gln Leu Gln Thr Leu Pro
                245
                                    250
Gly Leu Arg Asp Thr
                260
```

```
<210> 131
<211> 295
<212> PRT
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2849906
<400> 131
Met Gly Leu Pro Val Ser Trp Ala Pro Pro Ala Leu Trp Val Leu
                  5
                                     10
Gly Cys Cys Ala Leu Leu Leu Ser Leu Trp Ala Leu Cys Thr Ala
                 20
                                     25
Cys Arg Arg Pro Glu Asp Ala Val Ala Pro Arg Lys Arg Ala Arg
                 35
                                     40
Arg Gln Arg Ala Arg Leu Gln Gly Ser Ala Thr Ala Ala Glu Ala
                 50
                                     55
Ser Leu Leu Arg Arg Thr His Leu Cys Ser Leu Ser Lys Ser Asp
                 65
                                     70
Thr Arg Leu His Glu Leu His Arg Gly Pro Arg Ser Ser Arg Ala
                 80
                                     85
Leu Arg Pro Ala Ser Met Asp Leu Leu Arg Pro His Trp Leu Glu
                 95
                                    100
Val Ser Arg Asp Ile Thr Gly Pro Gln Ala Ala Pro Ser Ala Phe
                110
```

Pro His Gln Glu Leu Pro Arg Ala Leu Pro Ala Ala Ala Thr 125 130 Ala Gly Cys Ala Gly Leu Glu Ala Thr Tyr Ser Asn Val Gly Leu 140 145 Ala Ala Leu Pro Gly Val Ser Leu Ala Ala Ser Pro Val Val Ala 155 160 Glu Tyr Ala Arg Val Gln Lys Arg Lys Gly Thr His Arg Ser Pro 170 175 Gln Glu Pro Gln Gln Gly Lys Thr Glu Val Thr Pro Ala Ala Gln 185 190 Val Asp Val Leu Tyr Ser Arg Val Cys Lys Pro Lys Arg Arg Asp 200 205 Pro Gly Pro Thr Thr Asp Pro Leu Asp Pro Lys Gly Gln Gly Ala 215 220 Ile Leu Ala Leu Ala Gly Asp Leu Ala Tyr Gln Thr Leu Pro Leu 230 235 Arg Ala Leu Asp Val Asp Ser Gly Pro Leu Glu Asn Val Tyr Glu 245 250 Ser Ile Arg Glu Leu Gly Asp Pro Ala Gly Arg Ser Ser Thr Cys 260 265 Gly Ala Gly Thr Pro Pro Ala Ser Ser Cys Pro Ser Leu Gly Arg 275 280 Gly Trp Arg Pro Leu Pro Ala Ser Leu Pro 290

<210> 132 <211> 183 <212> PRT <213> Homo sapiens

<220>
<221> misc\_feature
<223> Incyte Clone No: 2899137

<400> 132

Met Ala Ala Ser Met Ala Arg Gly Gly Val Ser Ala Arg Val Leu 10 Leu Gln Ala Ala Arg Gly Thr Trp Trp Asn Arg Pro Gly Gly Thr 20 25 Ser Gly Ser Gly Glu Gly Val Ala Leu Gly Thr Thr Arg Lys Phe 35 40 Gln Ala Thr Gly Ser Arg Pro Ala Gly Glu Glu Asp Ala Gly Gly 50 55 Pro Glu Arg Pro Gly Asp Val Val Asn Val Val Phe Val Asp Arg 65 70 Ser Gly Gln Arg Ile Pro Val Ser Gly Arg Val Gly Asp Asn Val 80 85 Leu His Leu Ala Gln Arg His Gly Val Asp Leu Glu Gly Ala Cys 95 100 Glu Ala Ser Leu Ala Cys Ser Thr Cys His Val Tyr Val Ser Glu 110 115 Asp His Leu Asp Leu Leu Pro Pro Pro Glu Glu Arg Glu Asp Asp 125 130 Met Leu Asp Met Ala Pro Leu Leu Gln Glu Asn Ser Arg Leu Gly

 Met
 Trp
 Arg
 Lys
 Pro
 Asp
 Val
 Leu
 Tyr
 Ser
 Val
 Ile
 Pro
 Val
 Thr

 Ser
 Leu
 Phe
 Phe
 Leu
 Leu
 Ala
 Leu
 Asn
 Leu
 Pro
 Asp
 Val
 Phe
 Phe
 Gly

 Leu
 Val
 Val
 Leu
 Bu
 Leu
 Leu
 Leu
 Asp
 Ile
 Phe
 Arg
 Leu

 Leu
 Asp
 Val
 Arg
 Ser
 Val
 Leu
 Ser
 Leu
 Arg
 Ile
 Phe
 Arg
 Arg

 Leu
 Asp
 Val
 Arg
 Arg

<210> 134
<211> 160
<212> PRT
<213> Homo sapiens
<220>
<221> misc\_feature
<223> Incyte Clone No: 3222081

Val Val Gly Phe Phe Cys Cys Lys

```
50
                                      55
Val Val Ser Glu Ser Cys Val Glu Val Gln Glu Ile Asn Glu Glu
                 65
                                      70
Glu Tyr Leu Val Ile Ile Arg Phe Thr Pro Thr Val Pro His Cys
                 80
                                      85
                                                          90
Ser Leu Ala Thr Leu Ile Gly Leu Cys Leu Arg Val Lys Leu Gln
                 95
                                    100
                                                         105
Arg Cys Leu Pro Phe Lys His Lys Leu Glu Ile Tyr Ile Ser Glu
                110
                                    115
                                                         120
Gly Thr His Ser Thr Glu Glu Asp Ile Asn Lys Gln Ile Asn Asp
                125
                                    130
                                                         135
Lys Glu Arg Val Ala Ala Ala Met Glu Asn Pro Asn Leu Arg Glu
                140
Ile Val Glu Gln Cys Val Leu Glu Pro Asp
                155
<210> 135
<211> 865
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 443531
<400> 135
attecteaat tttccagtet eeettgaget aagtgtggee etatgaetea ettecageea 60
tgaaaacaag tgcaaatctg ttaggagtat gttctggggc aatttttgct ctcctgatga 120
agacaaaggc tgttgatcca ctgaacccac ccagacacta tgtggtttct tgaatgtcct 180
acgtacattt tgatggatta cccaaggact atctgatgaa gaataataga gacatataaa 240
tacatatggg ctacatettg geaaaataaa gtaateetga aggaaattet aaggatgtte 300
tgaattgaca cetettaage acaacegaat gteetggtgg etttgeetee cactgggget 360
ttttggetet tgtttggece cageggetge tgcagetetg tetgaattea cacaggagea 420
acatgatggt gctcagccct cgccgaagtg tcttgctgaa gagttgggag atgcttggac 480
tattcagata gaagccaact ggaagtacag ggcagtcaac acaaaccaga gaggcaaact 540
tttggccagt gagacatgga aagggagaag aaatacattc ttcttctcc cctagagtga 600
ggaccaacct gagtcccagt cacctggaat cccctcagac gagcgtccct tgagatccag 660
cacatggcag ccagcgtgct gacgattect tectgectae tggeteette ttatttetge 720
ctccgtggaa ctgtattctc taatcaatat tagcacatac atattgcccc agactgtacc 780
teetgggaac ccaggataaa gcactateta aacattttgt ettggaattg taataaactt 840
caaaagaaaa atacaaaaaa aaaaa
<210> 136
<211> 706
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 11, 12
```

<223> a or g or c or t, unknown, or other

<220>

```
<221> misc feature
<223> Incyte Clone No: 632860
<400> 136
cggaccgtgg nnttggtaaa gcccatttcc gaggatttta gggagaccta ggtggggcag 60
acactagaag tgtccagcct ccaagcccaa gagatgtggc cggcagggct gggcaggtcc 120
ttgctggctc agcctgctct ttgctccttc atgggacccc agtggatcct gcagttctgc 180
tettggetgg aaccaegeca gettegetgg agetggaetg ageegeettt tacattattg 240
gacteteteg ggttgagage tgeecaggae teetgeagtt teaceacect tgtteetttg 300
actettgact catcattcat gaccgttaac gtggttccat ttgtatggac ttettettte 360
ttcagagcat ttcagtatcc tgttacctcc ccatgcagaa caaagaatac tccacttttg 420
atagatgggg ttaccaggat tcaggctaca tggcctgagg caaggtcaca acatgagtga 480
cagaatgtgt cetggaagee aggeateete tggggtgtat ttggggeget caacaagget 540
tgatcgagct ttgggggtag atctagctat tccatgggga ttcttttcag aattgctgtt 600
ttcggtaact aattccatga ccaggtccat ggcattggat gacattgcgc tacactgttg 660
ctcacccggg tcacccgtcc tcacaggttg gatggcaagc atgttg
<210> 137
<211> 801
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 670010
<400> 137
acttetacat gggcetectg etgetggtge tettecteag ceteetgeeg gtggcetaca 60
ccatcatgtc ceteccaece teetttgact gegggeegtt caggtgcaga gtetcagttg 120
eccgggagca ceteceetee egaggeagte tgeteagagg geeteggeee agaatteeag 180
ttctggtttc atgccagcct gtaaaaggcc atggaacttt gggtgaatca ccgatgccat 240
ttaagagggt tttctgccag gatggaaatg ttaggtcgtt ctgtgtctgc gctgttcatt 300
teagtayeea ecagecaeet guggeegttg agtgettgaa atgaggaaet gagaaaatta 360
attroceatg tattricte attrattat taattritaa etgatagttg tacatatttg 420
ggggtacatg tgatatttgg atacatgtat acaatatata atgatcaaat cagggtaact 480
gggatateca teacateaaa catttatttt ttattetttt tagacagagt eteactetgt 540
cacccagget ggagtgcagt ggtgccatet cagettactg caacctetge ctgccaggtt 600
caagcgattc tcatgcctcc acctcccaag tagctgggac tacaggcatg caccacaatg 660
cccaactaat ttttgtattt ttagtagaga cggggttttg ccatgttgcc caggctggcc 720
ttgaactcct ggcctcaaac aatccacttg cctcggcctc ccaaagtgtt atgattacag 780
gcgtgagcca ccgtgcctgg g
<210> 138
<211> 664
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 505, 518, 527, 540, 565, 566
<223> a or g or c or t, unknown, or other
<220>
<221> misc_feature
<223> Incyte Clone No: 726498
```

```
<400> 138
cggacgcgtg ggctggaagg agctctggag tcggaatcag gatgtggagg ctgagaagaa 60
atctggctct accacctggg aaactggcat ggttgtattt gtcagtgttc agtcagggga 120
gcagagccat gatgagtctt acggaaataa ggttaaaaca tatgcttgaa atttggcatg 180
gcagacaagc cagagettgt gaaaatctaa gaaaccaaac acgtgtagcc accaaagtgg 240
aaccacaaaa gggaagatct acagaaattt gttgccttgc tgtagttcca ttaaatgagg 300
ttgtgcagtc aagcatcttg tggtgggtct ggagctgttg ccagcatcag gaagacaagc 360
tgggtgctaa gtgaagaaat acacaatgta gaaactgtca ggcatctctg cccctggact 420
teaceatate tgatgatgtt eteagagtea gggeaetget teactttteg etteeaaate 480
tcacacaaaa ttetetgtta ggcaneecca gettaganee ttacaantga gggggatean 540
ggaaatggag tacccagata cccanngtga tatactttta tgccctcagt ttcttatctt 600
tcagtgggga taatatcctc ggatacaaaa gagtgtacat atataccctg tatttggtaa 660
acta
<210> 139
<211> 1241
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 795064
<400> 139
ccaggcaata tctcaggata tggaagtttc tgggtttatt tacccctcag tgcccagagt 60
taaagtttca gaagagactt gtgcacataa gggcttcatc tcaagtgtat tgcagtaatg 120
gctgaatcgg ggttaacatc ccttccaggc acagcgagtt ggttctgctt tttgcctgta 180
agccaaagaa aagccacatc taaaaagcta ctactaaaag ccagaaagaa aagtggattt 240
gaactcagtg tcacagactc ttctgagtgt tttagggtca cagctagtgt aagaggcatg 300
aagaatagac atgcaaaagg gaacgggtgc accagagacc cctgttttgg ctgacagacc 360
atatgtccca ccagctgggg aatctgacaa gaggacatag gtggcactct ttttttaaag 420
ctatttattg tatctattt taaataaaat tgcccatcct cattcagctc ttagaacaaa 480
agcaaaaaac cotgtaaatc aggagatata agcacatotg cacccagaaq aggccqatat 540
gatagggcaa ccctgagctt aaacaatgac atcttcaagg gtagaactaa tctgaaaccc 600
cettecagec tetggaagac actggeetge atcagttaga gteagageaa gtgteaette 660
acagggaaaa gaaggattat atagacttcc tatccctaga gtttataaat gtcaactata 720
taaaaaaagc tcaaaaacagt gttaaaggaa tgaacagtag aattttaata ggctgtccaa 780
agaagecagg tetgetgtgg geaagtatag eetaaceeta gtettgtaaa ataagecaga 840
aagggttact gagccacctt aagctagtac ctatatagta ggcaaaaagt acagaaatag 900
atgcaataag tgtggtgagt ctttgagcct acgagtcatg ccaccagcca taagttgacc 960
tatcacttga gaacctcctc agcaaagatg ccagaaaaca ttcaatcaag ttggcaaatg 1020
acacagggag ctggccctct gaccatcttc ctggcaaacc tggactggaa gggccatttg 1080
cagcactgtc ctggagctaa tacactgttt cactgcctct gccatataat gatgccagca 1140
ctagccagct ggtgggtatt tggaggaatc ctgcatgagg attgcccaat aaggggcagg 1200
tacacatacc tggcaaagtg atgatgatgt gaattgtttc c
<210> 140
<211> 750
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 570, 641
<223> a or g or c or t, unknown, or other
```

```
<220>
<221> misc feature
<223> Incyte Clone No: 924925
<400> 140
tggagtgggg agaagagcat acgccaggag cetectgeet caaagtgete ecctaaqtet 60
tetteeteet gtgetgaeet eagggtggte tgaeeettee eteggtgtgg gggatgtgge 120
cctctcaggt gcccctactt gctttctgct tccttctggt gaagtccacc tccaacatta 180
acctgcccac cccacccccg tcatccctgg agaattccag ctttgtcgta tctcagagag 240
ggaatctaat tgtttttggg gggcaaaaga aagcaacgtt taggtatcac ttctacttgg 300
accgcatgcc tttttatagc caaatttctg tgtatttcgt aaatggattt cqcqttaatq 360
gatatttatg taataactag acttctcaga ttattgtgag aagggtcagg ttggaagggg 420
tgtaggaaga cgggtgaggg gtagttttt tctgtcctag ttttttttt ttttattgtc 480
atetetgagg tggaetttgt eacetgtggt tattggggee aagtggaete ageteegggg 540
gagaaggett etetgeeatt teggteeaan ggtgaetgae acaggegtae tttttgggae 600
tgtggaagca tcagatgcca gcactgactt cagaccagca nttcgggcta gaggaagatg 660
ggacetttea ggatggaaat acettggact ttettttggt ceeteggaaa ettgggettt 720
ctctaccgac ttgcccagat ttcatttcac
<210> 141
<211> 1235
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 962390
ccctcaggca gcccctccac aggacccctc tcctgcctgg acagetctgc tggtctcccc 60
gteccetgga gaagaacaag gecatgggte ggeecetget getgeecetg etgeteetge 120
tgcagccgcc agcathtctg cagcctggtg gctccacagg atctggtcca agctaccttt, 180
atgougtone teadecassa caestetess sefecatogg togetetes gasatecet 210
teteetteta: ttacccetgg gagttageca tagtteecaa egtgagaata teetggagae 300
ggggccactt ccacgggcag tccttctaca gcacaaggcc gccttccatt cacaaggatt 360
atgtgaaccg getetttetg aactggacag agggteagga gageggette etcaggatet 420
caaacctgcg gaaggaggac cagtctgtgt atttctgccg agtcgagctg gacacccgga 480
gatcagggag gcagcagttg cagtccatca aggggaccaa actcaccatc acccaggctg 540
tcacaaccac caccacctgg aggeccagea gcacaaccac catagccggc ctcagggtca 600
cagaaagcaa agggcactca gaatcatggc acctaagtct ggacactgcc atcagggttg 660
cattggctgt cgctgtgctc aaaactgtca ttttgggact gctgtgcctc ctcctcctgt 720
ggtggaggag aaggaaaggt agcagggcgc caagcagtga cttctgacca acagagtgtg 780
gggagaaggg atgtgtatta gccccggagg acgtgatgtg agacccgctt gtgagtcctc 840
cacactegtt ceccattggc aagatacatg gagagcacec tgaggacett taaaaggcaa 900
agccgcaagg cagaaggagg ctgggtccct gaatcaccga ctggaggaga gttacctaca 960
agageettea teeaggagea teeacaetge aatgatatag gaatgaggte tgaacteeac 1020
tgaattaaac cactggcatt tgggggctgt ttattatagc agtgcaaaga gttcctttat 1080
cctccccaag gatggaaaaa tacaatttat tttgcttacc atacacccct tttctcctcq 1140
tecacatttt ecaatetgta tggtggetgt ettetatgge agaaggtttt ggggaataaa 1200
tagcgtgaaa tgctgctgac acttaaaaaa aaaaa
<210> 142
<211> 1834
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
              <223> Incyte Clone No: 1259405
              <400> 142
             gacggaagtg cgggcggagg atccccagcc gggtcccaag cctgtgcctg tgcctgagcc 60
             tgagcctgag cctgagcccg agccgggagc cggtcgcggg ggctccgggc tgtgggaccg 120
             ctgggccccc agcgatggcg accctgtggg gaggcettet teggettgge teettgetca 180
             gcctgtcgtg cctggcgctt tccgtgctgc tgctggcgca gctgtcagac gccgccaaga 240
             atttcgagga tgtcagatgt aaatgtatct gccctcccta taaagaaaat tctgggcata 300
             tttataataa gaacatatct cagaaagatt gtgattgcct tcatgttgtg gagcccatgc 360
             ctgtgcgggg gcctgatgta gaagcatact gtctacgctg tgaatgcaaa tatgaagaaa 420
             gaagetetgt cacaateaag gttaceatta taatttatet etecattttg ggeeêtetae 480
             ttctgtacat ggtatatctt actctggttg agcccatact gaagaggcgc ctctttggac 540
             atgcacagtt gatacagagt gatgatgata ttggggatca ccagcctttt gcaaatgcac 600
             acgatgtgct agcccgctcc cgcagtcgag ccaacgtgct gaacaaggta gaatatgcac 660
             agcagegetg gaagetteaa gtecaagage agegaaagte tgtetttgae eggeatgttg 720
             tcctcagcta attgggaatt gaattcaagg tgactagaaa gaaacaggca gacaactgga 780
             aagaactgac tgggttttgc tgggtttcat tttaatacct tgttgatttc accaactgtt 840
             gctggaagat tcaaaactgg aagcaaaaac ttgcttgatt ttttttctt gttaacgtaa 900
             taatagagac atttttaaaa gcacacagct caaagtcagc caataagtct tttcctattt 960
             gtgactttta ctaataaaaa taaatctgcc tgtaaattat cttgaagtcc tttacctgga 1020
             acaagcactc tctttttcac cacatagttt taacttgact ttcaagataa ttttcagggt 1080
             agtggttaac aactttttc aagtcacttt actaaacaaa cttttgtaaa tagaccttac 1200
             cttctatttt cgagtttcat ttatattttg cagtgtagcc agcctcatca aagagctgac 1260
             ttactcattt gacttttgca ctgactgtgt tatctgggta tctgctgtgt ctgcacttca 1320
             tggtaaacgg gatctaaaat gcctggtggc ttttcacaaa aagcagattt tcttcatgta 1380
             ctgtgatgtc tgatgcaatg catcctagaa caaactggcc atttgctagt ttactctaaa 1440
             gactaaacat agtottggtg tgtgtggtct tactcatctt ctagtacctt taaggacaaa 1500
             tcctaaggac ttggacactt gcaataaaga aattttattt taaacccaag cctccctgga 1560
             ttgataatat atacacattt gtcagcattt ccggtcgtgg tgagaggcag ctgtttgagc 1620
             tecaatgtgt geagetttga actagggetg gggttgtggg tgeetsttet gaaaggteta 1680
Minimakka i mangabbat ba galanotggo bitubbetug etettiggaa i tgiaacaata aaaataitti 1740i...
             ttgaaacatc catcagtgta tctatctatg tctcctagtt ttttcctcct ccctcttttq 1800
             ctgtataatg agagagaaga tctgatgaga taac
             <210> 143
             <211> 1722
             <212> DNA
             <213> Homo sapiens
             <220>
             <221> misc feature
             <223> Incyte Clone No: 1297384
             <400> 143
             tacgagaccc ggccgcaccc cgagtcacac aggcccccgg ggccacggcg ttcgtctctc 60
             etgtgetgte etcaggeete egeteetgtt ttggtggeee aggeteteee etgeeceate 120
             ctegeteece caceteettg ggteatgeec acceaecett teetgeetee teegtgtgaa 180
             gacatccaac atccacgtga cttttccagc tccattttta aacagtgact gagattctag 240
             aaaaactggc tgctaactgg cctgagccag gcaacactga ttccaatccc tcctctttt 300
             ttaagttatt tgatggaaga ctcacctaat ttgtgacctg aaactgttga agaaatagag 360
             ctaggttact gggtttgggg ggattgtttt cttttggggg ccttcccctt ttactccttt 480
             tettecagag ateaagaget tetettgeat ettetteeae tgggetetgg attaateaat 540
```

PCT/US99/14484

## WO 00/00610

```
tacccaaagg ctgcacctgc cgtgttgtct gggcttgcat cccagatgtg ttggagtatg 600
catggatgta gtgcttttta gaggagccac tgggcaaggc caccaagaac aaatgcatga 660
cattttatag ccaaggacgc ctcgctaaag tcttatgggc gtcccctggg gttggggggg 720
cacaaggttt tggaggaaga agacaacttc cetcatteca teatcaccat etettetca 780
ctaggttctt tctagttttc aagcaatagt tctagcctgc cttggacaag ggggccccag 840
ttaaacaaac tacccatcca tgaggtgcca ggcagtcaaa aacagaagct tccccgactt 900
gtgagtccct gagatgtgct cttgttgttt ggcatttggg gtgacaggga gtgacccaqa 960
ggccaccact gcttttcatg caggagttac agacactggt ttcttggaaa atggagagaa 1020
gegeactiting cacagaegic gicaattaag teecaatting ceacting to tingaptacae 1080
tggaccctga ccactggctc ttgggcaaac gtccttcctc acggggcgcc tccgccaagc 1140
eggeecaget geacceetee etteetggag ggatggeeag ggaaggagaa aacagagaac 1200
tgacaccttt gaaaccacag aatgtgttac atgcagactc gctcaagggc ataagttatt 1260
gtgaacgttt ttgccaatca ctgctcaaca gccctgctag attttgtatg atgctgaatt 1320
attatgcaga ctaattccac ccagttgaga cacaccatgc ttgttcactt gtatttattg 1380
aaactgtgga ttcttgcccg tgctgtccct tgtatttact ttaagcactg atcacttatc 1440
atteattegg tatggtttte cetgteeett gtacacatte tggtatgaat ttgtaaaaat 1500
aacctgctac aaattggttg aatgtttctg tctgtggtgc gaaccagcat taacggatgg 1560
ggcacgtgcc caactgagga acaggagaag aaatcaccaa tttgggctct cagagctaag 1620
acacacttat tgattctgtt gcacattttg cactggttta tggcgattgt tttcttggac 1680
ggatagtgta aaataaactt ctctgttctc taaaaaaaaa aa
```

<210> 144 <211> 1741 <212> DNA <213> Homo sapiens <220> <221> misc feature

<223> Incyte Clone No: 1299627

## <400> 144

tgtggcaaag attgcaaatc ttactgctgt gatggaacca cgccctactg ttgctcctac 180 tacgettata ttgggaatat ceteteggge aetgeaattg egggeattgt ttttggaata 240 gtatttatca tgggggtcat tgctgggatt gccatatgca tctgcatgtg catgaagaac 300 cacagggega ceegegtggg cateeteagg acgaeteaca teaacacegt etecteetat 360 cetggaccac caccetacgg teacgaccae gagatggaat actgtgcaga ettgcetect 420 ccatactccc ccaccccaca gggtccagca cagcgttctc caccccctcc ttatcctgga 480 aacgcaagga aataatctat ctcccagaac agaacatgtg ccaatgggcg atcttgcctg 540 gaataaaatg cetetaetea gaaacaggea ggaaagaatt geteeaagga ataetttttg 600 gggtcagata atgtgtcagg tggaatatee etgetaggag atataggatt tetaetetge 660 tcaaagctga ccccatctgg agtattaatg tttggttcta tggaaccaca ttttaagaga 720 tetgetgate cacctaagea catteaggga agagtaatgt aattgacaaa atatetgata 780 atcatgttgt ttaagggcta ggtgaagaaa gtttcagtat tgatcctgga aaaaaagaag 840 atctaagtag gatgggagaa tgatttggcc cacacaagga agcaacttta ttctatatag 900 ctttaaaagt cagaactaga attgttcatt ctttcattca tcaataaatg tattttgagt 960 gcctaagagt ttactatgtg cctagcactg tttgaggtcc tgatggaagt tacaggatgg 1020 gtactctggt tttagtacaa gaaagagcaa tgactagatt gctttgtgaa gctcttggta 1080 gagacacgct ccagaaggga taacaaaatc aaatagtaga tgggttcatt gggcctcaga 1140 agttetgete gtattttagg tgggtgtgaa gtgaatttet atatgtecag gagtgaatae 1200 aacagaaaga gttggatctt atttatttaa ttagggagtt aaaacaagac caaaaagact 1260 caacagccgc ttgaagccaa gaactcttca atgccagcta ctgccaccta aaaatcatct 1320 ggctttatag tggatcagaa taaaggttat tctaactgtg gggagaaaaa aaaaattgta 1380 tcaagttcca caggtagcag acacttcact tccaagtaaa agatgagaaa tcaattattc 1440 ccacaggatt ttaggtcagg gagcaaaaat ctcagaactt gaccatgaag atacacaaca 1500

```
gactogcaaa aataaagtgg gaaatgaagt toagattooc ttotgtagat ttoottaaaa 1560
ctattatttt tttcttcttc gtaaaatttt gataatctgt tctcttaaaa aagttaatga 1620
cacaattaag atactgacat caaattgttg ccttttacca aaatgcaaat tttatgaagt 1680
а
<210> 145
<211> 997
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 973
<223> a or g or c or t, unknown, or other
<220>
<221> misc_feature
<223> Incyte Clone No: 1306026
<400> 145
ggacaaccgt tgctgggtgt cccagggcct gaggcaggac ggtactccgc tgacaccttc 60
cettteggee ttgaggttee cageetggtg geeccaggae gtteeggteg catqqeaqaq 120
tgctacggac gacgcctatg aagcccttag tccttctagt tgcgcttttg ctatggcctt 180
cgtctgtgcc ggcttatccg agcataactg tgacacctga tgaagagcaa aacttgaatc 240
attatataca agttttagag aacctagtac gaagtgttcc ctctggggag ccaggtcgtg 300
agaaaaaatc taactctcca aaacatgttt attctatagc atcaaaggga tcaaaattta 360
aggagetagt tacacatgga gaegetteaa etgagaatga tgttttaace aateetatea 420
gtgaagaaac tacaactttc cctacaggag gcttcacacc ggaaatagga aagaaaaaac 480
acacggaaag taccccattc tggtcgatca aaccaaacaa tgtttccatt gttttgcatg 540
cagaggaacc ttatattgaa aatgaagagc cagagccaga gccggagcca gctgcaaaac 600
aaactgaggc accaagaatg ttgccagttg ttactgaarc atctacaagt ccatatgtta 660
cctcatacaa-gtcacctgtc,accactttag-ataagagcac tggcattgag.atctctacag-7207
aatcagaaga tgttcctcag ctctcaggtg aaactgcgat agaaaaaccc gagagttgga 780
agcaccagag agtgggatat gatgcatttg aaaaaaattt agtattaatc acaatgcaca 840
ggcacttcta gtgacacagc acccagctat agagagatat gaaggggtac gagctcgaat 900
togaatcatg toatagotgt ttootgtgtg aattggtato gotcacaatg cacacacata 960
cgagcggaag ctnaattggt aagcgggggt gccatqa
                                                                997
<210> 146
<211> 981
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1316219
<400> 146
gttttaaatt tacttaataa atataaaata ttgtatgttc ttaacttgaa gctcatattt 60
tcaagtaatt ccttgtctgg aattttctgt tgatctcatg ggtactaaga aacgaaatat 120
tetgtteatt tteattttta aagaatateg ataaettgat gaccecagaa ggagttggee 180
ttaccactgc cttacgtgtt ctctgtaatg ttgcatgccc accacctcct gttgaaggtc 240
aacagaaaga tetgaaatgg aatettgeeg ttatteaget tttttetget gaaggaatgg 300
acacgtttat tegagttetg caaaaattga acagtattet gaeteageet tggaggetee 360
```

```
atgtcaacat ggggactacc cttcacagag ttactactat ttcaatggct cgctgcacac 420
 tcactcttct taaaactatg ttaacggaac tcctgagagg tggatccttt gagtttaagg 480
 acatgogtgt teetteageg ettgttaett tacatatget eetgtgetet atececetet 540
 caggtcgttt ggatagtgat gaacagaaaa ttcagaatga tatcattgat attttactga 600
 cttttacaca aggagttaat gaaaaactca caatctcaga agagactctg gccaataata 660
 cttggtcttt aatgttaaaa gaagttcttt cttcaatctt gaaggttcct gaaggatttt 720
tttetggaet catacteett teagagetge tgeetettee attgeecatg caaacaacte 780
 aggtatcact tecatataac atgeatetta taaatgactg cagtaacact ttttaaaaag 840
ccagtgattt tgttaaaaaa caaaaaccct catctccctt cctcccaaaa agacataaaa 900
taaccggatg agggggagat aaaactgaaa caagttggtc attgaggaaa tatgggggta 960
aaaattttaa ataaattttt q
<210> 147
<211> 526
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1329031
<400> 147
ctgcaggccc acctgtctgc aacccagctg aggccatgcc ctccccaggg accgtctgca 60
geeteetget eeteggeatg etetggetgg aettggeeat ggeaggetee agetteetga 120
gecetgaaca ecagagagte cageagagaa aggagtegaa gaageeacca gecaagetge 180
ageceegage tetageagge tggeteegee eggaagatgg aggteaagea gaaggggeag 240
aggatgaact ggaagtccgg ttcaacgccc cctttgatgt tggaatcaag ctgtcagggg 300
ttcagtacca gcagcacage caggecetgg ggaagtttet tcaggacate etetgggaag 360
aggecaaaga ggececagee gacaagtgat egeceacaag cettaeteac etetetetaa 420
gtttagaagc gctcatctgg cttttcgctt gcttctgcag caactcccac gactgttgta 480
caagctcagg aggcgaataa atgttccaac ctggtaaaaa aaaaaa
                                                                   526
                                                              La College College College
<210> 148
<211> 2090
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1483050
gaggcgcggg gagagtaggg tgctgtggtc tgagctagag ggtgaagctg gcggagcagg 60
aggatgggcg tatgcaggtg atagactaga gaacaagacc tctgtctccg tagcatcctg 120
gagcagtetg aatgccagaa tggataaccg ttttgctaca gcatttgtaa ttgcttgtgt 180
gettageete atttecacca tetacatgge ageetecatt ggeacagaet tetggtatga 240
atategaagt ecagtteaag aaaatteeag tgatttgaat aaaageatet gggatgaatt 300
cattagtgat gaggcagatg aaaagactta taatgatgca ctttttcgat acaatggcac 360
agtgggattg tggagacggt gtatcaccat acccaaaaac atgcattggt atagcccacc 420
agaaaggaca gagtcatttg atgtggtcac aaaatgtgtg agtttcacac taactgagca 480
gttcatggag aaatttgttg atcccggaaa ccacaatagc gggattgatc tccttaggac 540
ctatetttgg cgttgeeagt teettttace ttttgtgagt ttaggtttga tgtgetttgg 600
ggetttgate ggaetttgtg ettgeatttg eegaagetta tateecacea ttgeeaeggg 660
cattetecat etecttgeag gtetgtgtae aetgggetea gtaagttgtt atgttgetgg 720
aattgaacta ctccaccaga aactagagct ccctgacaat gtatccggtg aatttggatg 780
```

```
qtccttctgc ctggcttgtg tctctgctcc cttacagttc atggcttctg ctctcttcat 840
etgggetget cacaccaacc ggaaagagta cacettaatg aaggeatate gtgtggeatg 900
agcaagaaac tgcctgcttt acaattgcca tttttatttt tttaaaaataa tactgatatt 960
ttccccacct ctcaattgtt tttaattttt atttgtggat ataccatttt attatgaaaa 1020
tctattttat ttatacacat tcaccactaa atacacactt aataccacta aaatttatgt 1080
ggtttacttt aagcgatgcc atctttcaaa taaactaatc taggtctaga cagaaagaaa 1140
tggatagaga cttgacacaa atttatgaaa gaaaattggg agtaggaatg tgaccgaaaa 1200
caagttgtgc taatgtctgt tagacttttc agtaaaacta aagtaactgt atctgttcaa 1260
ctaaaaactc tatattagtt tctttgggaa acctctcatc gtcaaaactt tatgttcact 1320
ttgctgttgt agatagccag tcaaccagca gtattagtgc tgttttcaaa gatttaagct 1380
ctataaaatt gggaaattat ctaagatcat tttccctaag cattgacaca tagcttcatc 1440
tgaggtgaga tatggcagct gtttgtatct gcactgtgtc tgtctacaaa aagtgaaaaa 1500
tacagtgttt acttgaaatt ttaactttgt aactgcaaga attccagttc agccgggcga 1560
ggattagtat tatttttaac teteegtaag atttteagta eeaccaaatt gttttggatt 1620
tttttttttt cctcttcaca taccagggtt attaaaagtg tgctttcttt ttacattata 1680
ttacagttac aaggtaaaat tcctcaactg ctatttattt attccagccc agtactataa 1740
agaacgtttc accataatga ccctccagag ctgggaaacc taccacaaga tctaaagttc 1800
tggctgtcca ttaacctcca actatggtct ttatttcttg tggtaatatg atgtgccttt 1860
ccttgcctaa atcccttcct ggtgtgtatc aacattattt aatgtcttct aattcagtca 1920
tttttttata agtatgtcta taaacattga actttaaaaa acttatttat ttattccact 1980
actgtagcaa ttgacagatt aaaaaaatgt aacttcataa tttcttacca taacctcaat 2040
2090
<210> 149
<211> 2403
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1514160
gggagagagc agcagagacc tcatcagcag accaaggaag tggtgggtgc tccccctccc 60
taageteeag ggteeetgaa tettetgaaa teteaaatga gtggaggeet eetggggtgg 120
cctgtcctgc aggggccctg gaatgggggc aagcagctgg gtgggcagaa tgcagagtag 180
acteggggga ggateettte acttteeget teecettetg atgeatggag gatggtgtga 240
gettttcagc aggcccggaa aggtacgcag gtgacgcctt agcagccccg cagctggtgc 300
tetgeecege ggtactggeg ecateaggge etecettgee egeetgagag cageagcagt 360
ctctgtcatc ccgtcgcccc ttacccccca ccccaggcca ctgggcccct cccacaccac 420
ctggggagct gagaagagga ggctggagta agggaggact tgatcatcca agaaatactt 480
tttattgetg ggagtettet gaaceteace aaactgagge cagagetgag eteetggggg 540
agttaattca gaggggagag gccagcacct ccctcctcca tcgctcgctg tgtgccttaa 600
actocatote atgtecetec ccatecoetg getttecete ceteettgee ccatectggg 660
ccagccagca gggeteetee tetggetett cagacettte agecagtget gteagtgeec 720
ctgggaggga agggcatece tgaggcaece gaatggteee teagggtgea gggaggeaga 780
agectggeca cagaggagec tectaaggea geagetgeag caagegeace etetececae 840
tetececacg ccagagegge ttecagagea gatgetgttt ccateeteet egteaaaace 900
attetegetg etgagettga caatetggge aaggettgtg gggegettga caaacagaat 960
ctgccctgtg ccgcctggtt ccgtggcctc cagcatgagc ctgcaggcag ggcgctgcgg 1020
gaacccagtt gtgctgcccc agcccatgcc tccgggtctg ctgtgcatga atgagtgctc 1080
acttgtcccg ggtttaggac gtggtcaagt gaacagcagg gtctaactgt gcttacttag 1140
cccagttcaa acagaacaaa ggaaaaatat agaaagcaac atctgttgat catttaggtt 1200
tttttttaaa ccaccatgtc actttgagtc cttcatgggt ttttgaacag catttatcaa 1260
gaagaaaatg tgggcttttt cccctctccc gtgttttgtt tgtcctgtag atagagggag 1320
```

gaaagccgtg cagtggcagg cgggaccccc tctggtggcg ggaccccctc ttgcggtggt 1380

```
cttgegggge cageegggae etgteaettt attatttaag gagtgtgtgt gtagagtege 1440
tggcttatta acagtattgt gtgtgggttg ggtttttagt ttgttccttc tttttgaagt 1500
cccttcattt caatccttga etetetetee ccttcccttg cccagetetg ttgaatgetg 1560
ctgtgcgcgt gtgagggccg ctctgcacac agggcccttg ggttgtgtga actgaaattc 1620
tccctgtatt tgtgagactc gcaggagtcc ccatctgtag cacaggcaat gccagtgcca 1680
tgctgcagcc tcagaaacca ggcctctcac tccagcagca ggcagaaccg tgtctgtggt 1740
cgggtgctgt ccacagetet gtctgccttg ttcttgggct tgagctggat agaggtgggg 1800
tetetteace tteeetgaat teagaacaga eeetgtgeet ggeeceagtg tgeecaggea 1860
attececagg cecteattgg gagecettgg tgttetgage ageagggeee aggeageaea 1920
tgagcagtgc ccaggggctc cctgcgtgag gacggcaagg tgcgatgtat gtctaactta 1980
ttgatggcag gcagccccct gtgcccccta agcctggccc tggttattgc tgagctctgt 2040
geteagtget geggeetgge egtggetegt etgtteettt ggggggeeeg ggegggttgt 2100
gggaatcagt cttcacagac agacgtgagc caggcggagg actcgttcct tgcagaggtc 2160
agtectcacc tgcaggtgtc ggggtggggg ggggcaagga ggggcaggca cacaccatgt 2220
ctgacctgaa cccgattctg gggagcatct tcccgctccg gccccacgac ctccacaggg 2280
ttacattgta atatatatgc cccagctaac ctgtctgatg gtggcatctt cctgcagaca 2340
tttcaaacat gtaactttta tatgaaaaaa aataaacaca gatgaaagct gaaaaaaaa 2400
aaa
                                                                  2403
<210> 150
<211> 431
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1603403
<400> 150
ggccaccggg acttcagtgt ctcctccatc ccaggagege agtggccact atggggtctg 60
ggctgcccct tgtcctcctc ttgaccctcc ttggcagctc acatggaaca gggccgggta 120
tgaetttgca actgaagetg aaggagtett ttetgaeaaa tteeteetat gagtegaget 180
togtsgaaftysgttgaaaag ctotseptoctsgaactor coortcaggg accagegtose240 '* %'
ccctccacca tgcaagatct caacaccatg ttgtctgcaa cacatgacag ccattgaagc 300
ctqtgtcctt cttggcccgg gcttttgggc cggggatgca ggaggcaggc cccgaccctg 360
tettteagea ggeececace etectgagtg gcaataaata aaatteggta tgetgaatte 420
aaaaaaaaa a
                                                                  431
<210> 151
<211> 2109
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1652303
<400> 151
tttgtagcca agtgggagct attttctttt ttgtgcatat agatatttct taaatgaagc 60
tgetttettg tettttattt etaaaageee eettataeee eaetttgtge ageaaagate 120
cccgtgcagg tcacagcctg atttgtggcc aggctggaca aattcctgag gcacaacttg 180
getteagtte agattteaag etgtgttggt gttgggacea geagaaggea aaegteeage 240
caacacacag gactgtaaga ggactctgag ctacgtgccc tgtgaaqacc cccaqqcttt 300
gtcataggag gtcgttcagc ttccccaaag tcagaggtga tttgatttgg ggaagactga 360
atattcacae ctaagtcgtg agcatatect gagttttact teettatgge ttgeeeteea 420
```

```
agttetetet eteatacaea cacacacet tgetecagaa teaccagaca eetecatgge 480
tecagetatg ggaacagetg cattgggget geetttetgt ttggettagg aacttetgtg 540
ettettgtgg etecaetege gaggeagete ggaggtgtgg acteegattg ggetgeagge 600
agetetggga eggeacaggg egggegetet gateageteg tgtaaaacae acegtettet 660
tggcctcctg gccagtcttt ctgcgaatag tcctctccct ggccagttga atgggggaag 720
ctgctggcac aggaaggaga ggcgatcccg gctgaggctt aggaaattgc tggagccggc 780
tccaagcaga taattcactg gggaggtttt cagagtcaaa catcattctg cctgtgttgg 840
gggccaggtg tgtcacacaa gcatctcaaa gtcaaaagcc atctggggct gctgcttctc 900
tttctcaggc tctggggaaa ggaatctccc tctcctctca cttgattcca agtgtggttg 960
aattgtctgg agcactggga ctttttttct cttttccttg atggaccaac agtgcaaatg 1020
caatetegee atttaaettt eaggtegatt teettteetg ateagacate tttgtgeece 1080
ctttaggaag gaaaagaata cacctacgat gtgccaggca ctgtgttagg cgcttttata 1140
tagatecteg ttaggatgag actaagggat gaggacatet etttataaaa ggeceetaag 1200
taatggataa acagaaacac ttagaggtga gaaggtctgt cttcaagatc caaggtaaga 1260
ttgccttcag tctgatgttt gttctcaagg acttatcccc tacaatattc tcccactcca 1320
tactteteet tetaceccae catgtgetee egtgeactee teagatggte agaggggtaa 1380
cccaagtcct tagagaattt ggggaccaat agaatatgtg atgtgtgaat tttctttaaa 1440
aaacttaagg agtctttgct accttctgct tgttgagttg ttttggcatt catattaaaa 1500
gccagcatct cactatttat tgacaggttg ggctgtgtgt gtgcgcatgt gtgtatacat 1560
ttccaggcgt gcctgtgtcc tgtagctttt taaaaggaaa cccagtcatc ccactatgaa 1620
tetggcatet tettatgett etagtgtttt ggccatacat caaccaaggg gtttaattta 1680
tccaatgett gacgacatgt tcaggagggg ctggatcaaa ttttgagagg gttaťgggaa 1740
agggaggggg agaagaaatt gacatttatt ttattattta ttttaaatgt ttacatcttc 1800
tttatgttgt atcaageetg aatagaaact gatageatta aaatacteeg tteetetete 1860
tetteteget teettittt tittittaa attiaggata acacattitt gittetaaag 1920
tgatttgtga tttgtgctgt ataaactgta taaaaggttc tgtttttaaa ggtggatttt 1980
catteetetg gggacagtgg tegecaagae atetacattg taagagaaca cagtggaaga 2040
teetgteetg atteteaaaa attattttet etgtatgatt aaaagtttat teeatttaaa 2100
aaaaaaaa
                                                                 2109
<210> 152
<211> 1114
<212> DNA ...
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1693358
<400> 152
aacgcggcgc cgggccgggc cgggccctgg agatggtccc cggcgccgcg ggctggtgtt 120
gtetegtget etggeteece gegtgegteg eggeceaegg etteegtate catgattatt 180
tgtactttca agtgctgagt cetggggaca ttcgatacat cttcacagcc acacctgcca 240
aggaetttgg tggtatettt cacacaaggt atgagcagat teacettgte ceegetgaac 300
ctccagaggc ctgcggggaa ctcagcaacg gtttcttcat ccaggaccag attgctctgg 360
tggagagggg gggctgctcc ttcctctcca agactcgggt ggtccaggag cacggcgggc 420
gggcggtgat catctctgac aacgcagttg acaatgacag cttctacgtg gagatgatcc 480
aggacagtac ccagegeaca getgacatee eegecetett eetgetegge egagaegget 540
acatgateeg eegetetetg gaacageatg ggetgeeatg ggecateatt tecateeeag 600
tcaatgtcac cagcatcccc acctttgagc tgctgcaacc gccctggacc ttctggtaga 660
agagtttgtc ccacattcca gccataagtg actctgagct gggaagggga aacccaggaa 720
ttttgctact tggaatttgg agatagcatc tggggacaag tggagccagg tagaggaaaa 780
gggtttgggc gttgctaggc tgaaagggaa gccacaccac tggccttccc ttccccaggg 840
cccccaaggg tgtctcatgc tacaagaaga ggcaagagac aggccccagg gcttctggct 900
agaacccgaa acaaaaggag ctgaaggcag gtggcctgag agccatctgt gacctgtcac 960
```

```
actcacctgg ctccagcctc ccctacccag ggtctctgca cagtgacctt cacagcagtt 1020
gttggagtgg tttaaagagc tggtgtttgg ggactcaata aaccctcact gactttttag 1080
caataaagct tctcatcagg gttaaaaaaa aaaa
<210> 153
<211> 2192
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1707711
<400> 153
ggaactcatg agccaacagc tgaagaaacc cattgctaca gcttccagtt gaatgccggg 60
gagaaacctg tccaatttta gcaggtttga agggaggatc ttcttcagtt gtagtttgga 120
aggttccttg gtgtggctca tgaaatcaca gagctcagag ataccatctt gagaaatcct 180
cettggtate atgaaactgg agcagaggaa ttgcaattta gcaggaggte etetactggt 240
gataccetca cettggggta atggtectaa eccagaceca gggtetggaa gettaatgtt 300
gagttggtga ctccagcctc tttctcctgg aggtcacaag atgatgattg cgtagatgtt 360
gcctggtgca aagtgcccca aacagcaata gaaaggcata tgtataacca aactccaagt 420
gataaccaga cccatctctc ctccaccttg acaaaagcag attatagtat acaaggtagg 480
aattootgto otatttgaga tgaactatat ootgtacoto tgtgototgt gtotgcatga 540
aggeteagee tttagaggea eteettetag ttgeattagt aetgtettte tgtggagttt 600
ggtttgaaga etggeteage aagtggaggt tteaatgtat tttteagttg geteateage 660
cagcattggt gaatattcag tttaggggaa cagttctagg gagtgagaca tttttgggag 720
cagaggaaaa ctctgctgat gttcggtcct ggcaaacatt gagttatttt gagctgtgaa 780
ggcagtcgtc tctgttacac agtggcagct cttgagttat gcactgtgaa gaatgagaag 840
ggaaaagcaa aaattateet tgtgaaatat etgetgattg tgeeetaete ttttgeaeetg 900
actititecta gitgicetgg tgctaacaca ggagctacac citgatecte teetggcatg 960
aaaataaaac aaaggttttc gttgttgttg ttccattgcc catttccccc atgttgtctt 1020
treettgget galgestect etgggteaca tigettelta testgaadad tigecadett (1086 /
gaggskagaawkinagogitti: ggttittacchiptogagoata hyctgtitoge tatgtgaggginiaki. "We
tttcagtaca aatgctgctg tctatttctg tgcacttaac aatggaaccc aaacagaaga 1200
gaataaagcc ttgataccaa aattgggaaa gaacatgtgt ccatttqqac caaacqttqt 1260
tggtttttaa aaaattttat tttgtttttt tgtttttgtt tttqtttttt ttcatcttaa 1320
tatgtaccag tggcacttaa ccaaaagata cagtgatata qccatqtact qtqqqtqqqa 1380
cagatacagt ctccttggcc tataatgaaa ccactaggac tttatacagt tttccttaat 1440
ttgttgacat ataaatggta aattatattt aggettatee tgttttgaaa tgatggtagt 1500
catctttctt actgctactt tcatgttgct ttctagaaaa cagcatttca ttccaaaata 1560
actaggatet geatttagaa eaagaateat tatttgteet gaeettttea gteetaeaga 1620
gacgcatctg tggttctttt gtacttgcca tagatgtaac ctaaaaagtt ttggcatatt 1680
taggtcagcc tagcggaact tttttttca tttaaatgga gctgaataat ggagattttg 1740
tgtctgcaaa attcctgaga tcattgaaaa agtaacaagc tgttccttgt ttctgataca 1800
taaaaattatt ttaagcattt tatcaatcat taaaaatttac tgccagttgt gagtggcttt 1860
ttaattaact tgtctttcat tgcacttcac tctgcctgtt ttcaagggga gtaagattgg 1920
taacatttgg ggagactgta tctgtctact tagcgtggct gttttgaggg actgtcccat 1980
cagtgaacaa actgcatggc cttggagaga gactctgggc tcttggctca qatqtqttca 2040
teaaatacte ettteagage tgttgtgggt gtaagtgaca tgatqtqqce aaaaatecaa 2100
actgtgcagt tgcgttgtga caaacatgca atgtgctqta aaaattcaat acaqtttaaa 2160
taaaatctct atattagtgc tgaaaaaaaa aa
                                                                  2192
<210> 154
<211> 913
<212> DNA
```

```
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1738735
<400> 154
ctcgagcggc tcgagagcgg ggcaaactgc ttggcacctc ttcaataggt gacattcaat 60
gatagatete tggetteetg etetgtttgt tetggttgee etggaaagee tgetgeteag 120
cccatgccc gggacttcct ccaccctcac caggacattc tttccatctc ttgtctcctg 180
tgtgcaagtc cetttetect ggatteeatg tettgaatgt ttettaattt aetteeteat 240
tttggcagag gatgtcctcc agttgttttc tgggaatgct aatatgcaag tgaaccagtg 300
acctgcagtt ctgcccacac agggttaata accaatcaga ttctctcttt tcaagatggt 360
taacataaca gacaccaaga aagggaagag gagccgacag cagaggggga agctgaaaag 420
acgcacaaag aatggccata aaagatatga gcaaccccag ctttccagac agtcactttt 480
eccaptggte atacetggte tggaagatte eccateatet egaataaage tgttgttget 540
tttaactcca tggagagacc gaatggagtg agcccagcag ggcatgctgg gcaagagagg 600
tecceegagt eccaaataag aattteaact agtataaaac gaggeagega acceacacgt 660
ggaagtetga taccgettge agaagggaat tgaatagatg tetecetatt ggtaaggatg 720
tggttttatt gacttgaaat aacaaagccc gcaagcaaca actgatcatc cgcgggatgc 780
tgccacaagg aataattgag cactcattca gacacagggg aaaccactgc ctctttcagt 840
ctttctccca gattccaaca gtcagtgtta cagcatttca ccttgttcac ctccctgaga 900
agacgttgca ggg
<210> 155
<211> 480
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1749147
<400> 155
cttctgttca ggctgggatt acaggtgtga gccgctgcgc tcggccttct ttgattttat 60
attattagga gcaaaagtaa atgaagccca ggaaaacacc tttgggaaca aactcttcct 120
ttgatggaaa atgcagagge eetteetete tgtgeegtge ttgeteetet taeetgeeeg 180
ggtggtttgg gggtgttggt gtttcctccc tggagaagat gggggaggct gtcccactcc 240
cagetetqqe agaateaage tgttgeagea gtgeettett cateetteet taegateaat 300
cacaqtetee agaagateag etcaattget gtgeaggtta aaactacaga accacatece 360
aaaggtacct ggtaagaatg tttgaaagat cttccatttc taggaacccc agtcctgctt 420
ctccgcaatg gcacatgctt ccactccatc catactgcag tcgtcaaata aacagatatg 480
<210> 156
<211> 545
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1817722
<400> 156
caggetatta agaaaggegg acceatgeac atgattttaa aggttetgac aactgeattg 60
ctgttacaag ctgcttcagc tttagctaat tacattcatt tctccagtta ctccaaagat 120
```

```
ggaatagggg taccatttat gggaagtttg gcagaatttt ttgacatcgc ttcccaaatt 180
cagatgttat acttactttt gagtctatgc atgggttgga caatagtcag aatgaagaag 240
teteaaagea gaceteteea gtgggattet acaeetgeat ecaetggeat tgeagtatte 300
attgtcatga cacagagtgt tttgctactt tggggaacagt ttgaagatat cagtcatcat 360
agetaccatt cacaccacaa cttagcaggg atcctcctaa ttgttctaag aatttgccta 420
gcattgtcat taggctgtgg actctatcag atcatcacag tggagagaag tacactcaaa 480
agggagttct acatcacatt tgccaaagta tgggtttgga aagaaaatgg tttattctga 540
ttatc
                                                                  545
<210> 157
<211> 1746
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1831290
<400> 157
ttggcatcag cttgggcagg tgtgcgggct caggatgggg cggccgtggt gaggaaccct 60
ggacteteag cateacaaga ggeaacacca ggageeaaca tgageteggg gaetgaactg 120
ctgtggcccg gagcagcgct gctggtgctg ttgggggtgg cagccagtct gtgtgtgcgc 180
tgctcacgcc caggtgcaaa gaggtcagag aaaatctacc agcagagaag tctgcgtgag 240
gaccaacaga getttaeggg gteeeggace taeteettgg tegggeagge atggeeagga 300
cccctggcgg acatggcacc cacaaggaag gacaagctgt tgcaattcta ccccagcctg 360
gaggatccag catcttccag gtaccagaac ttcagcaaag gaagcagaca cgggtcggag 420
gaageetaca tagaceecat tgecatggag tattacaact gggggeggtt etegaageec 480
ccagaagatg atgatgccaa ttcctacgag aatgtgctca tttgcaagca gaaaaccaca 540
gagacaggtg cccagcagga gggcataggt ggcctctgca gaggggacct cagcctgtca 600
ctggccctga agactggccc cacttctggt ctctgtccct ctgcctcccc ggaagaagat 660
gaggaatctg aggattatca gaactcagca tccatccatc agtggcgcga gtccaggaag 720
gtcatggggc aactocagag agaagcated detagedngg tgggaagede agacgaggag 780--
gacggggaas cggattacgt gaatgggggg stggcageen cagaagccta-gggcagacca 840
agaagaaagg agccaaggca aagagggacc actgtqctca tggacccatc gctgccttcc 900
aaggaccatt teccagaget acteaacttt taageeeetg eeatggttge teetggaagg 960
agaaccagcc accetgagga ccacetggcc atgegtgcac ageetgggaa aagacagtta 1020
ctcacgggag ctgcaggccc gtcaccaagc cctctcccga cccaggcttt gtggggcagg 1080
cacctggtac caagggtaac ccggctcctg gtatggacgg atgcgcagga tttaggataa 1140
gctgtcaccc agtccccata acaaaaccac tgtccaacac tggtatctgt gttcttttgt 1200
gctatgaatt tggatteeta attgctattg ttggttgctg gggttttaaa tgattgataa 1260
gcttgtacag ttaacttata gagggggagc catatttaac attctggatt tcagagtaga 1320
gatttctgtg ttgtctccta gaaagcatta catgtagttt atttcagcat ccttgttggg 1380
tggggccttg gctetettec cetttggtgq qaceteceet ttetttqqqc tteaqttcac 1440
tcaggaagaa atgaggctgt cgccatcttt atgtqcttcc aqtqqaaatq tcacttqcta 1500
cagacaatag tgcatgagag tctagagaag tagtgaccag aacagggcag agtaggtccc 1560
etecatggee etgaateete etetgeteea gggetggeet etgeagaget gattaaacag 1620
tgttgtgact gtctcatggg aagagctggg gcccagaggg accttgagtc agaaatgttg 1680
ccagaaaaag tateteetee aaccaaaaca teteaataaa accattttag ttgaaaaaaa 1740
aaaaaa
                                                                  1746
<210> 158
<211> 2011
<212> DNA
```

<213> Homo sapiens

```
<220>
 <221> misc feature
 <223> Incyte Clone No: 1831477
 <400> 158
 ggagcacggc gctggggccg cccgcagcgc tcactcgctc gcactcagtc gcgggaggct 60
 teccegegee ggeegegtee egeeegetee eeggeaceag aagtteetet gegegteega 120
 cggcgacatg ggcgtcccca cggccccgga ggccggcagc tggcgctggg gatccctgct 180
 cttcgctctc ttcctggctg cgtccctagg tccggtggca gccttcaagg tcgccacgcc 240
gtattccctg tatgtctgtc ccgagggca gaacgtcacc ctcacctgca ggctcttggg 300
ccctgtggac aaagggcacg atgtgacctt ctacaagacg tggtaccgca gctcgagggg 360
cgaggtgcag acctgctcag agegccggcc catccgcaac ctcacgttcc aggaccttca 420
cetgeaceat ggaggecace aggetgecaa caccagecac gacetggete agegecacgg 480
getggagteg geeteegace accatggeaa ettetecate accatgegea acetgaceet 540
getggatage ggeetetaet getgeetggt ggtggagate aggeaceaec aeteggagea 600
cagggtecat ggtgecatgg agetgeaggt geagacagge aaagatgeac cateeaactg 660
tgtggtgtac ccatceteet eccaggagag tgaaaacate acggetgeag ecctggetac 720
gggtgcctgc atcgtaggaa tcctctgcct ccccctcatc ctgctcctgg tctacaagca 780
aaggcaggca gcctccaacc gccgtgccca ggagctggtg cggatggaca gcaacattca 840
agggattgaa aacceegget ttgaagcete accacetgee caggggatae eegaggeeaa 900
agtcaggcac cccctgtcct atgtggccca gcggcagcct tctgagtctg ggcggcatct 960
gettteggag cecageacce ceetgtetee tecaggeece ggagaegtet tetteceate 1020
cetggaccet gtecetgact etecaaactt tgaggtcate tageceaget gggggacagt 1080
gggetgttgt ggetgggtet ggggeaggtg catttgagee agggetgget etgtgagtgg 1140
cctccttggc ctcggccctg gttccctccc tcctgctctg ggctcagata ctgtgacatc 1200
ccagaageee ageeeeteaa eccetetgga tgetacatgg ggatgetgga eggeteagee 1260
cctgttccaa ggattttggg gtgctgagat tctcccctag agacctgaaa ttcaccagct 1320
acagatgeca aatgaettae atettaagaa gteteagaae gteeageeet teageagete 1380
tcgttctgag acatgagcct tgggatgtgg cagcatcagt gggacaagat ggacactggg 1440
ccaccetece aggeaceaga cacagggeae ggtggagaga etteteceee gtggeegeet 1500
tggctccccc gttttgcccg aggctgctct tctgtcagac ttcctctttg taccacagtg 1560
getetgggge caggeetgee tgeccactgg ccategeeac etteccage tgecteetac 1620
cagcagttte tetgaagate tgtcaacagg ttaagtcaat etggggette cactgeetge 1680
attoragues congagotts stagetoresa, ancessande acatactors gentigues in 40 ...
ctccgtgagc aaatggtgtc ttgggcaatc tgaggccagg acagatgttg ccccacccac 1800
tggagatggt gctgagggag gtgggtgggg ccttctggga aggtgagtgg agaggggcac 1860
ctgccccccg ccctccccat cccctactcc cactgctcag cgcgggccat tgcaagggtg 1920
ccacacaatg tettgtccac cetgggacac ttetgagtat gaagegggat getattaaaa 1980
actacatggg gaaacaggtg caaaaaaaa a
                                                                  2011
<210> 159
<211> 480
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 440
<223> a or g or c or t, unknown, or other
<221> misc_feature
<223> Incyte Clone No: 1841607
<400> 159
cccacgcgtc cgaaaagaaa agaaaaaaga aaatggcctc atcttgtttc agcctcagtt 60
```

```
ttoctoccot cagtotggot gggagottag ototttgggg toattgotgt gtcaggotgg 120
gttgtteett ttggtetgtt tetgeeatgg eecagegeet teeeteteag aatacataca 180
atcccccct ctgctgggcg tggtgactca tgtctataat cccagctctt tgggaggcca 240
gggcgggtgg atcacttgag cctaggagtt cgaaaccagc ctgagcaaca tggtgaaagc 300
ccatetetae gaaaaatgca aaagttagee aggeatggtg gtgcaegtet gtagaeeeag 360
ctacttggga ggctgaggca ggaggatect tgageceagg aggeagaage tgeagtgage 420
tgtgategea ceaetgeten teageetgge gacagagega gatteeetea aaaaaaaaa 480
<210> 160
<211> 542
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1852391
<400> 160
ttgaatcaac ataatgtatg tgaaagggct tagtccatga ttgggtgctt aatatgcccg 60
tgttgctggg gtgagccaaa gggatgaagt tggcagtgct tgctctgtcg tggagcagtc 120
cccacqtggg aaggccagcg ggaaaccagg cctgctgaag tctccagcgc tggaagcctc 180
acgggggtta ggaaggagcc ttgggagcag ctcctcagag cacagttgta cctcaattgt 240
ggattttaga tgtttetget teteaatgtt etetettttt teetgeetge ttgeetgeet 300
tttggacete ttgctgtcta gggtggcaga tgaagettte tacaaacaac cettegetga 360
cgtgattggt tatgtgtatg ttgcaaaact aattcetttt tetacatetg attettteta 420
cttttgttta gagttaatgc teettttatg teaccagttg etttgetttt taaattattt 480
caaattggca ctttgggggc tgcctaagaa ttgataagcg gggtatgatc tgttgatgaa 540
tc
<210> 161
<211> 1066
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1854555
<400> 161
ttaggettte tgtatttgte tgaatgettt caegggagtg tgtegcaetg gageacagag 60
gacactegat egtgeggege geagggeggg gggeegeege tgeeteeeeg egggatgget 120
ggcactgtgc tcggagtcgg tgcgggcgtg ttcatcttag ccctgctctg ggtggcagtg 180
etgetgetgt gtgtgetget gtecagagee teeggggegg egaggttete tgteattttt 240
ttattcttcg gtgctgtgat catcacatca gttctgttgc ttttcccgcg agctggtgaa 300
ttcccagccc cagaagtgga agttaagatt gtggatgact ttttcattgg ccgctatgtc 360
ctgctggctt tccttagtgc catcttcctt ggaggcctct tcttggtttt aatccattat 420
gttctggagc cgatctatgc caaaccactg cactcctact gaccactctt caggaaaacg 480
aaaacctgtt ctctccttca ttgtgatgac attgatgagc aggaaggcac tattcagagc 540
cttgttttga cagccctcat gccttaaggt tagaggagta tctgtccatc actaagacaa 600
atctctggag tcctggcttc cagaaacagg attgccaaat tgtccctgtg gggctagatt 660
cttaccagct taagaaggat attgctatct tcttagtacc cgtaccttag gatttccaac 720
tgttttgaaa gggaaatagt aacagtgatc tgcttagagt ggattttcac tcaagtcctt 780
agtaagtgga tttttggggaa aaaagcacat gggcttctgg ttctttttga taatatataa 840
aattattcat tatgaggttg cagttgtttg caaaggagag gcactcaaat ttgaaaggtt 900
attttaatgt gataatttgg aagacttact cagatgttgg tcattgacca ctctgtgcat 960
```

```
atatttetge agagetetgt gaaggeaatg agtgteaett eeetetgete taataaagea 1020
ataaataata gctaaagggc tgactttcac ttcgaaaaaa aaaaaa
<210> 162
<211> 1173
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1855755
<400> 162
gtetegetee tgeeeagece gggeggetge cettgggtge tecetteeet geeegacaec 60
cagacegace ttgacegece acetggcagg ageaggacag gaeggeegga egeggeeatg 120
geogagetee eggggeeett tetetgeggg geeetgetag getteetgtg cetgagtggg 180
ctggccgtgg aggtgaaggt acccacagag ccgctgagca cgcccctggg gaagacagcc 240
gagetgaeet geacetacag eacgteggtg ggagaeaget tegecetgga gtggagettt 300
gtgcagcctg ggaaacccat ctctgagtcc catccaatcc tgtacttcac caatggccat 360
ctgtatccaa ctggttctaa gtcaaagcgg gtcagcctgc ttcagaaccc ccccacagtg 420
ggggtggcca cactgaaact gactgacgtc caccctcag atactggaac ctacctctgc 480
caagtcaaca acceaceaga tttctacace aatgggttgg ggctaatcaa ccttactgtg 540
ctggttcccc ccagtaatcc cttatgcagt cagagtggac aaacctctgt gggaggctct 600
actgcactga gatgcagctc ttccgagggg gctcctaagc cagtgtacaa ctgggtgcgt 660
cttggaactt ttcctacacc ttctcctggc agcatggttc aagatgaggt gtctggccag 720
cteattetea ceaacetete cetgacetee tegggeacet acegetgtgt ggecaecaac 780
cagatgggca gtgcatcctg tgagctgacc ctctctgtga ccgaaccctc ccaaggccga 840
gtggccggag ctctgattgg ggtgctcctg ggcgtgctgt tgctgtcagt tgctgcgttc 900
tgcctggtca ggttccagaa agagagggg aagaagccca aggagacata tgggggtagt 960
gacetteggg aggatgeeat egeteetggg atetetgage acaettgtat gagggetgat 1020
tetageaagg ggtteetgga aagaceeteg tetgeeagea eegtgaegae caccaagtee 1080
aageteeeta tggtegtgtg actteteeeg ateeetgagg geggtgaggg ggaatateaa 1140
taattaasgt gigtgggtad caaaaaaaaaa, aab 🦠 🛒 👝 🧢 🦠
                                                                 1375
<210> 163
<211> 890
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1861434
<400> 163
ctcgagccgg agagatcctc taccgcagtc gtttgaggag gcggaactga agttttttct 60
taattatcat gtgacgggtt ctggatttaa tggggggaaa agggcggaaa aggacaagga 120
tccaaactgg cgaatttgct gatcttegcg tccctctccg ctttccggcc ggcagcgctg 180
ccagggtata tttccttttt tccgatcctg caacagcctc tttaaactgt ttaaatgaga 240
atgtccttgg ctcagagagt actactcacc tggcttttca cactactctt cttgatcatg 300
ttggtgttga aactggatga gaaagcacct tggaactggt tcctcatatt cattccagtc 360
tggatatttg atactateet tettgteetg etgattgtga aaatggetgg geggtgtaag 420
totggotttg accotogaca tggatcacac aatattaaaa aaaaagcotg gtacctcatt 480
gcaatgttac ttaaattagc cttctgcctc gcactctgtg ctaaactgga acagtttact 540
accatgaate tateetatgt etteatteet ttatgggeet tgetggetgg ggetttaaca 600
gaacteggat ataatgtett ttttgtgaga gactgactte taagtacate ateteettte 660
```

```
tattgctgtt caacaagtta ccattaaagt gttctgaatc tgtcaagctt caagaatacc 720
agagaactga gggaaaatac caaatgtagt tttatactac ttccataaaa caggattggt 780
gaatcacgga cttctagtca acctacagct taattattca gcatttgagt tattgagatc 840
<210> 164
<211> 806
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1872334
tgcatcagtg cccaggcaag cccaggagtt gacatttctc tgcccagcca tgggcctcac 60
cetgetettg etgetgetee tgggaetaga aggteaggge atagttggea geeteeetga 120
ggtgctgcag gcacccgtgg gaagetccat tetggtgcag tgccactaca ggetccagga 180
tgtcaaagct cagaaggtgt ggtgccggtt cttgccggag gggtgccagc ccctggtgtc 240
ctcagctgtg gatcgcagag ctccagcggg caggcgtacg tttctcacag acctgggtgg 300
gggcctgctg caggtggaaa tggttaccct gcaggaagag gatgctggcg agtatggctg 360
catggtggat ggggccaggg ggccccagat tttgcacaga gtctctctga acatactgcc 420
cecaggtgag ttatectagg ccagetacca eccettagae etaccetece caececegee 480
tattgccagg gctcatgggt tcttgaggag tgggggcccc tggggaggag gcattccaag 540
gagatatect ettgacaget etgeagggag eggaaaceaa aetgggtègg aagtetgaga 600
taaatcagct gaaaaccatc cetttecccc ttccacacta ctgcgcttcc ccacaggaag 660
gcatgteett eccaeteeag ggaettggee tettetteea geatttteaa eataettgat 720
gctaacttat tttttaatta gaaatatttt aaacaatgtt gaatctgagt gtataaaaca 780
gaataatttt tgtageteea gtgttt
<210> 165
<211> 1923
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1877230
<400> 165
tggccggcaa gcagggctgc agtcacgggg cggcgcggag ggccccagcc cagtcagggg 60
tgtggccgcc gccaccgtaa ggctaggccg cgagcttagt cctgggagcc gcctccgtcg 120
cegeegteag ageegeeeta teagattate ttaacaagaa aaccaactgg aaaaaaaaat 180
gaaatteett atettegeat titteggigg tgiteaeett tiateeeigt geieigggaa 240
agctatatgc aagaatggca tctctaagag gacttttgaa gaaataaaag aagaaatagc 300
cagctgtgga gatgttgcta aagcaatcat caacctagct gtttatggta aagcccagaa 360
cagatectat gagegattgg cacttetggt tgatactgtt ggacecagae tgagtggete 420
caagaaceta gaaaaageca tecaaattat gtaecaaaae etgeageaag atgggetgga 480
gaaagttcac ctggagccag tgagaatacc ccactgggag agggggagaag aatcagctgt 540
gatgctggag ccaagaattc ataagatagc catcctgggt cttggcagca gcattgggac 600
tectecagaa ggcattacag cagaagttet ggtggtgace tetttegatg aactgcagag 660
aagggcctca gaagcaagag ggaagattgt tgtttataac caacettaca tcaactactc 720
aaggacggtg caataccgaa cgcagggggc ggtggaagct gccaaggttg gggctttggc 780
atototoatt ogatoogtgg cotoottoto catotacagt cotoacacag gtattcagga 840
ataccaggat ggcgtgccca agattccaac agcctgtatt acggtggaag atgcagaaat 900
```

```
gatgtcaaga atggcttctc atgggatcaa aattgtcatt cagctaaaga tgggggcaaa 960
gacctaccca gatactgatt cetteaacac tgtagcagag atcactggga gcaaatatec 1020
agaacaggtt gtactggtca gtggacatct ggacagctgg gatgttgggc agggtgccat 1080
ggatgatggc ggtggagcct ttatatcatg ggaagcactc tcacttatta aagatcttgg 1140
getgegteca aagaggaete tgeggetggt getetggaet geagaagaae aaggtggagt 1200
tggtgccttc cagtattatc agttacacaa ggtaaatatt tccaactaca gtctggtgat 1260
ggagtetgae geaggaacet tettaceeae tgggetgeaa tteaetggea gtgaaaagge 1320
cagggecate atggaggagg ttatgageet getgeageec etcaatatea etcaggteet 1380
gagccatgga gaagggacag acatcaactt ttggatccaa gctggagtgc ctggagccag 1440
tetaettgat gaettataea agtatttett etteeateae teeeaeggag acaceatgae 1500
tgtcatggat ccaaagcaga tgaatgttgc tgctgctgtt tgggctgttg tttcttatgt 1560
tgttgcagac atggaagaaa tgctgcctag gtcctagaaa cagtaagaaa gaaacgtttt 1620
catgettetg gecaggaate etgggtetge aactttggaa aacteetett cacataacaa 1680
tttcatccaa ttcatcttca aagcacaact ctatttcatg ctttctgtta ttatctttct 1740
tgatactttc caaattctct gattctagaa aaaggaatca ttctcccctc cctcccacca 1800
catagaatca acatatggta gggattacag tgggggcatt tctttatatc acctcttaaa 1860
<210> 166
<211> 518
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1877885
<400> 166
ttgacaccag cagggtgaca tecgetattg etacttetet getececcae agtteetetg 60
gacttetetg gaccacagte etetgecaga eccetgecag acceeagtee accatgatee 120
atotgggtca catcototto otgottttgo toccagtggo tgcagctcag acgactccag 180
gagagagane, atcactcoct goottittace, coggeactte laggetetigt. Leeggatgig 249.
ggireetete tetgeegete etggeaggee tegtggetge tgatgeggtg geategetge 300
teategtggg ggeggtgtte etgtgegeae geecaegeeg cageceegee caagaagatg 360
gcaaagtcta catcaacatg ccaggcaggg gctgaccctc ctgcagcttg gacctttgac 420
ttctgaccct ctcatcctgg atggtgtgtg gtggcacagg aacccccgcc ccaacttttg 480
gattgtaata aaacaattga aacaccaaaa aaaaaaaa
<210> 167
<211> 1631
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1889269
<400> 167
gegagetete agegggagee gagaeggtge agggeeggag aageacette acteecagee 60
tgegeccega tgetgegegt tetgtgeete etgegeeeet ggaggeeeet tegggeeege 120
ggctgcgctt ccgacggggc ggccgggggc tcagagatcc aagtgcgcgc cctggcgggt 180
ceggaccaag getgtaggtt ceatgaggae aggeettgag tetgteetgg tetetggaat 240
cacggtgtct agtagaggcc agcacacagc aaatatataa atgtacaaat gagtgaatga 300
agagaatetg attggeetta aggaaettae geaettaaaa taattgggea gaagagaage 360
```

```
agtgaaggag tgcagaggca teacetgaaa gtttacaagt cettecaett tetetetgag 420
gcagaaagag caagggtttt tctctccatt ttatggttgg gaaaattgag gcctgcctga 480
gtgtgtgact tgtggcaagt cactctggtc atctagggca gaggctcccc agatcccagg 540
cetectgeet ecagteceea geeegeagee caggattagg cagagecage tgettteeeg 600
tggctgccct gactccttac agggatcact gagattctga tgaacagacc ttctgcccgc 660
aatgccttgg ggaatgtctt cgtcagtgag ctgctggaaa ctctggccca gctgcgggag 720
gaccggcaag tgcgtgtcct gctcttcaga agtggagtga agggcgtgtt ctgtgcaggt 780
gcagacctga aggagcggga acagatgagt gaagcagagg tgggggtgtt tgtccagcga 840
ctccggggcc tgatgaatga catcggtgag gatctgggtg tagggtggag gaggggttt 900
gggggtccct gccgatgaca gtcccgctac ccccaccagc atctaaggag agtcttcttt 960
ctgtttggag ttctgtgata agacagatga ctcacccagg gggatggagg aggatgaccg 1020
agggcagtte teteagagag ggagttetgg etetteaget tittgtgteee geeceaecet 1080
cagggttcaa gcctggccat tccaaagcag ttaagtttcc ccaagcatgc tttcaagttt 1140
tgacaattgc tgttaccttt gcctgagata ccccttcttg gttacttgaa cttttacttg 1200
teetteaage ectecagtae eteeteetee aggaageett eecaaceeae eetetgaget 1260
ttttattgga gcactgatga tcctgggtca ataatgcctg atacacattt gtcttcccca 1320
tgagactgag ccccatggga acaaaggcta tgtctgattc attctgtgtt cccagttccc 1380
agcacccage acagggettg gcacaaagaa agggaggeee cagggaggee ageggattag 1440
geetgaacag ggateateea geeeateete eeatteetet teeetggetg attetgtaac 1500 -
tttccctaaa gggaaaattg gcttctgaga taacctggct gcgggaagca gaggttgtcg 1560
tgagcagaga ttgtgccatt gcactccagc ctgggcaaca acagcgagac tccatctcaa 1620
aaaaaaaaa a
                                                                  1631
<210> 168
<211> 1548
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1890243
<400% 2.68
atgegeteca geagecugtt tgggaageag eagtetetee tteagatact gtgggaetea 60
tgctggagag gagccgcca cttccaggac ctgtgaataa gggctaatga tgagggttgg 120
tggggctctc tgtggggcaa aaaggtggta tgggggttag cactggctct cgttctcacc 180
ggagaaggaa gtgttctagt gtggtttagg aaacatgtgg ataaagggaa ccatgaaaat 240
gagaggagga aagacatcca gatcagctgt tttgcctgtt gctcagttga ctctgattgc 300
atcctgtttt cctaattccc agactgttct gggcacggaa gggaccctgg atgtggagtc 360
ttcccctttg gccctcctca ctggcctctg ggctagccca gagtccctta gcttgtacct 420
cgtaacactc ctgtgtgtct gtccagcctt gcagtcatgt caaggccagc aagctgatgt 480
gactettgcc ccatgcgaga tatttatacc tcaaacactg gcctgtgagc cctttccaag 540
teagtggaga geeetgaaag gageeteaet tgaateeage teagtgetet gggtggeeee 600
etgeaggtgg eccetgacce tgegttgeag eagggteeac etgtgageag geeegeeetg 660
gggcetette etggatgtge cetetetgag ttetgtgetg tetettggag geagggeeca 720
ggagaacaaa gtgtggaggc ctcggggagt ggcttttcca gctctcatgc cccgcagtgt 780
ggaacaaggc agaaaaggat cctaggaaat aagtctcttg gcggtccctg agagtcctgc 840
tgaaatccag ccagtgtttt ttgtggtatg agaacaggca aaaagagatg ccccgagata 900
gaaggggage cttgtgtttc tttcctgcag acgtgagatg aacactggag tgggcagagg 960
tggcccagga ccatggcacc cttagagtgc agaagctggg gggagaggct gcttcgaagg 1020
gcaggactgg ggataatcag aacctgcctg tcacctcagg gcatcactga acaaacattt 1080
cctgatggga actcctgcgg cagagcccag gctggggaag tgaactaccc agggcagccc 1140
ctttgtggcc caggataatc aacactgttc tctctgtacc atgagctcct ccaggagatt 1200
atttaagtgt attgtatcat tggttttctg tgattgtcat aacattgttt ttgttattgt 1260
```

tggtgctgtt gttatttatt attgtaattt cagtttgcct ctactggaga atctcagcag 1320 gggtttcage ctgactgtct ccctttctct accagactct acctctgaat gtgctgggaa 1380

```
cctcttggag cctgtcagga actcctcact gtttaaatat ttatttattg tgacaaatqg 1440
agotggttte ctagatatga atgatgtttg caatececat ttteetgttt cageatgtta 1500.
tattettata aaataaaage aaaagteaaa tatgaaaaaa aaaaaaaa
                                                                  1548
<210> 169
<211> 616
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1900433
<400> 169
gecageteag gtgageeete gecaaggtga eetegeagga caetggtgaa ggageagtga 60
ggaacetgca gagtcacaca gttgctgace aattgagetg tgagcctgga gcagatecgt 120
gggctgcaga cccccgcccc agtgcctctc cccctgcagc cctgcccctc gaactgtgac 180
atggagagag tgaccctggc cettetecta etggeaggec tgactgeett ggaagecaat 240
gacccatttg ccaataaaga cgatcccttc tactatgact ggaaaaacct gcagctgagc 300
ggactgatet geggaggget eetggeeatt getgggateg eggeagttet gagtggeaaa 360
tgcaaataca agagcagcca gaagcagcac agtcctgtac ctgagaaggc catcccactc 420
atcactccag getetgecac tacttgetga geacaggaet ggeetecagg gatggeetga 480
agectaacac tggcccccag cacctcctcc cetgggagge cttatcctca aggaaggact 540
tetetecaag ggcaggetgt taggeeeett tetgateagg aggettettt atgaattaaa 600
ctegececae cacece
<210> 170
<211> 1981
<212> DNA
<213> Homo sapiens
<270%
<221> misc_feature
<223> Incyte Clone No: 1909441
<400> 170
cagaacttct ttttgacacc atagattctt ctgaggtcaa cgttgcaaaa agcatagcaa 60
agtttcttcg aaatgttaga tatcgttatc aaccactatt agaaagatgt aataacgtat 120
ttttaagtaa tgtggaccac cttgatttgg attccatcag taaaatactt agtgtataca 180
aatttetaca atttaatagt tttgaattta ttataatgge taaaaagaag etaaetgaaa 240
tgattcctct gigtaatcat cctgctagct tigtaaaatt gittgtagca tigggaccca 300
ttgcaggacc tgaagaaaag aaacaactta aatcaactat gttattgatg tcagaggacc 360
taactggcga gcaagccctg gcagtgttgg gagcaatggg agatatggaa agcagaaact 420
catgtctgat taaaagagtt acttcagttc tgcataaaca tttggatggc tataaaccat 480
tagagttgtt gaagataact caagaattga cttttctgca tttccaaagg aaggagtttt 540
ttgcgaaact tagagaatta ctgcttagtt atttgaaaaa tagtttcata ccaactgagg 600
tgtctgttct ggtccgtgct atttccctgc tcccttctcc tcacttggac gaagtgggga 660
tatcccgaat tgaagccgtt ttaccacagt gtgacctaaa taacctgagt agttttgcca 720
catctgtttt aagatggatt cagcatgatc acatgtattt ggataatatg actgcgaaac 780
aactgaaact acttcaaaaa ttagatcact atggtcgtca gagactacaa cacagcaaca 840
gtttggatet gttacggaag gaacttaaat eteteaaagg aaacacgttt cetgagteac 900
ttcttgaaga aatgattgct actttacagc atttcatgga tgatattaat tacataaatg 960
ttggggagat tgcatctttt atttctagta ctgattacct cagtactttg ctactagata 1020
ggatagecte agtggetgtt cagcagattg aaaagateca teettttaca ateeetgeta 1080
ttattegtee atteagegta ttgaactatg atecacetea aagggatgaa tttttgggaa 1140
```

```
cttgcgtgca acatcttaat tcttacttag gtatattgga tccttttata ttagtgtttc 1200
ttggtttctc tttggccaca cttgaatatt ttccagaaga tctgctaaag gcaattttta 1260
acatcaaatt cttagctaga ttggattctc aacttgaaat tttatctcca tctcgaagtg 1320
caagagtcca gtttcatctt atggagttaa atagatcagt ctgcttggaa tgccctgagt 1380
ttcagattcc atggtttcat gaccgcttct gtcaacaata taataaaggt attggtggca 1440
tggatggaac acaacagcag atttttaaaa tgttagcaga ggtactagga ggaatcaatt 1500
gtgtaaaagc ctcggttctt acgecttatt accacaaagt agattttgag tgtatcttgg 1560
ataaaagaaa aaaacctctt ccgtatggaa gccataatat agcattggga caactaccag 1620
aaatgeeetg ggaateaaat ategaaatag ttggateaag getgeeacca ggggetgaaa 1680
ggattgettt ggaatttttg gattcaaaag cactttgtag aaatateeet cacatgaaag 1740
gaaaatctgc tatgaaaaaa cgacatttgg aaattctggg gtatcgtgta attcagattt 1800
cccagtttga atggaactct atggcactgt caacaaagga tgctcggatg gactacctga 1860
gagaatgtat atttggagaa gtcaagtcat gtttgtagtt tttatttaaa atgaatgtta 1920
<210> 171
<211> 1492
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1932226
<400> 171
cttetgggtg aggagtttga gettggetgg gtecagggee cageactgae tecegteeet 60
gaggaggagg aagaagagga agagggggct ccgattggga cccctaggga tcctggagat 120
gecagecage tecetggact cetgteecat ggeeteetgg eeggeetete etttgeagtg 240
gggtcctcct ctggcctcct gcccctcctg ctgctgctgc tgcttccatt gctggcagcc 300
cagggtgggg gtggcctgca ggcagcgctg ctggcccttg aggtggggct ggtgggtctg 360
ggggceteet acetgeteet thythaeagee engeacenge, detecagtet thisectache, 420
ggtgttcccc tgggccttgg agctgcctgg ctcttagctt ggccaggcct agctctacct 540
etggtggcta tggcagcggg gggcagatgg gtgcggcagc agggcccccg ggtgcgccgg 600
ggcatatete gaetetggtt gegggttetg etgegeetgt eacecatgge etteegggee 660
etgeaggget gtggggetgt gggggaeegg ggtetgtttg caetgtaeee caaaaccaae 720
aaggatgget teegeageeg eetgeeegte eetgggeece ggeggegtaa teecegeace 780
acceaacace cattagetet gttggcaagg gtctgggtcc tgtgcaaggg ctggaactgg 840
egtetggeac gggccagcca gggtttagca teccaettge eccegtggge catecacaca 900
etggceaget ggggcetget teggggtgaa eggeeeacee gaateeeeeg getactaeea 960
cgcagccagc gccagctagg gccccctgcc tcccgccage cactgccagg gactctagcc 1020
gggcggaggt cacgcacccg ccagtcccgg gccctgcccc cctggaggta gctgactcca 1080
gcccttccag cccaaatcta gagcattgag cactttatct cccacgactc agtgaagttt 1140
etecagtece tagteetete titteaceca cetteeteag tittgeteact taccecagge 1200
ccagcccttc ggacctctag acaggcagcc tcctcagctg tggagtccag cagtcactct 1260
gtgttctcct ggcgctcctc ccctaagtta ttgctgttcg cccgctgtgt gtgctcatcc 1320
tcaccctcat tgactcaggc ctggggccag gggtggtgga gggtggggaag agtcatgttt 1380
tttttctcct ctttgatttt gtttttctgt ctcccttcca acctgtcccc ttccccccac 1440
caaaaaaaga aaaagacaaa cacaaataaa atatctgagc ggaaaaaaaa aa
```

<210> 172 <211> 1613

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1932647
<400> 172
ctcggaattc ggctcgagac gggtcatgag cgcggtatta ctgctggccc tcctggggtt 60
catectecca etgecaggag tgeaggeget getetgecag tttgggacag ttcagcatgt 120
gtggaaggtg teegaeetae eeeggeaatg gaeeeetaag aacaceaget gegaeagegg 180
cttggggtgc caggacacgt tgatgctcat tgagagcgga ccccaagtga gcctggtgct 240
ctccaagggc tgcacggagg ccaaggacca ggagccccgc gtcactgagc accggatggg 300
coceggeete tecctgatet cetacacett egtgtgeege caggaggact tetgcaacaa 360
cetegttaac teecteeege tttgggeeec acageeecca geagaeecag gateettgag 420
gtgcccagtc tgcttgtcta tggaaggctg tctggagggg acaacagaag agatctgccc 480
caaggggacc acacactgtt atgatggcct cctcaggetc aggggaggag gcatcttctc 540
caatctgaga gtccagggat gcatgcccca gccaggttgc aacctgctca atgggacaca 600
ggaaattggg cccgtgggta tgactgagaa ctgcaatagg aaagattttc tgacctgtca 660
tegggggaee accattatga cacaeggaaa ettggeteaa gaaceeactg attggaeeac 720
ategaatace gagatgtgeg aggtggggea ggtgtgteag gagacgetge tgeteataga 780
tgtaggactc acatcaaccc tggtggggac aaaaggctgc agcactgttg gggctcaaaa 840
ttcccagaag accaccatcc actcagcccc tcctggggtg cttgtggcct cctataccca 900
cttetgetee teggaeetgt geaatagtge eageageage agegttetge tgaaeteeet 960
coctoctcaa gotgoccotg toccaggaga coggoagtgt cotacotgtg tgcagcocot 1020
tggaacctgt tcaagtggct ccccccgaat gacctgcccc aggggcgcca ctcattgtta 1080
tgatgggtac atteatetet caggaggtgg getgtecace aaaatgagea tteagggetg 1140
cgtggcccaa ccttccagct tettgttgaa ccacaccaga caaateggga tettetetgc 1200
gcgtgagaag cgtgatgtgc agcctcctgc ctctcagcat gagggaggtg gggctgaggg 1260
cctggagtct ctcacttggg gggtggggct ggcactggcc ccagcgctgt ggtggggagt 1320
ggtttgccct tcctgctaac tctattaccc ccacgattct tcaccgctgc tgaccaccca 1380
cactcaacct ccctctgacc tcataaccta atggccttgg acaccagatt ctttcccatt 1440
etgtecatga atcatettee ceacacacaa teatteatat etatteaeet aacageaaca 1509
ctggggagag octggaggat coggacttgc cctatgggag aggggacgeb-ggaggagtgg 1540%
diggergies organiatemagescotyto otttotocce aaaaaaaaaaaaa
                 radicion at uta'.
<210> 173
<211> 1622
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2124245
<400> 173
tgtegegeec getggeegge teegeeetea eeteeeggee geggetgeec tetgeeeggg 60
ttgtccaaga tggagggcgc tccaccgggg tcgctcgccc tccgqctcct qctqttcqtq 120
gegetaceeg ceteeggetg getgacgacg ggegeeeeeg ageegeegee getgteegga 180
gccccacagg acggcatcag aattaatgta actacactga aagatgatgg ggacatatct 240
aaacagcagg ttgttcttaa cataacctat gagagtggac aggtgtatgt aaatgactta 300
cctgtaaata gtggtgtaac ccgaataagc tgtcagactt tgatagtgaa gaatgaaaat 360
cttgaaaatt tggaggaaaa agaatatttt ggaattgtca gtgtaaggat tttagttcat 420
gagtggccta tgacatctgg ttccagtttg caactaattg tcattcaaga agaggtagta 480
gagattgatg gaaaacaagt tcagcaaaag gatgtcactg aaattgatat tttagttaag 540
aaccggggag tactcagaca ttcaaactat accetecett tggaagaaag catgetetac 600
```

```
tctatttctc gagacagtga cattttattt acccttccta acctctccaa aaaagaaagt 660
gttagttcac tgcaaaccac tagccagtat cttatcagga atgtggaaac cactgtagat 720
gaagatgttt tacctggcaa gttacctgaa actcctctca gagcagagcc gccatcttca 780
tataaggtaa tgtgtcagtg gatggaaaag tttagaaaag atctgtgtag gttctggagc 840
aacgttttcc cagtattctt tcagtttttg aacatcatgg tggttggaat tacaggagca 900
getgtggtaa taaccatett aaaggtgttt tteecagttt etgaatacaa aggaattett 960
cagttggata aagtggacgt catacetgtg acagetatca aettatatee agatggteca 1020
gagaaaagag ctgaaaacct tgaagataaa acatgtattt aaaacgccat ctcatatcat 1080
ggacteegaa gtageetgtt geeteeaaat ttgeeaettg aatataattt tetttaaate 1140
gttaagaatc agtttataca ctagagaaat tgctaaactc taagactgcc tgaaaattga 1200
cctttacagt gccaagttaa agtttacctt atteteggcc gggtgcagtg gctcatgcct 1260
gtaatcccag gactttggga ggccaatgcg ggcggatcac gaggtcagat caagaccatc 1320
ctgccaacat ggtgaaaccc tgtctctact aaaaaaaata aaaaaattag ctgggtgtgg 1380
eggtgeaege etgtagteee agetaettgg gaggetgagg eaggagaatt gettgaacce 1440
gggaggcgga ggctgcagtg agccaggatc acgccactgc actccagcct gggtgacaga 1500
gcgagactct gtttcaaaaa aaaaaaagtt gaccttattc tctaaaaggg ctggctattc 1560
atatgatgaa ttgttaagga aaacttaaag tggacaagaa caggatgtga agagaggtga 1620
<210> 174
<211> 1320
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2132626
<400> 174
gegtgaccea getgeggeeg geeageeatg gagaetggag egetgeggeg eeegeaactt 60
ctcccgttgc tgctgctgct ctgcggtggg tgtcccagag caggcggctg caacgagaca 120
ggcatgttgg agaggctgee eetgtgtggg aaggettteg eagacatgat gggcaaggtg 180
gaegtetgga agtggtgeas cetgteegag tteategtgt actatgagag ttleaceaac 240
ද්ලඥයුරලෙකුකුය. දීවලියල්ලදෙකක් පලපලෙපලලුල්ල පලපෙපලලුල ලෙසෙපලලෙසා» ඉලපෙසෙපුලුල්ල් 300
ttcatcaccg gcatccacag gcagttcttc tccaactgca ccgtggacag ggtccacttg 360
gaggaccccc cagacgaggt teteateccg etgategtta taccegtegt tetgactgtc 420
gecatggetg geetggtggt gtggegeage aaaegeaeeg acaegetget gtgagggtee 480
cggtgagatg gagtgggtca cacctggcaa gctggaagaa agttccctgg ggatgggaga 540
gegggtgggt getgecaate teeagetaet gtggecaeae eeeacetggt catgggcaga 600
cccctccctt cctgggctga cctgctccct cgaggccagc ctgctccctg gctgaggctc 660
aggetateeg eccaagetet ttgeteatte tagggeeagt ggaggaaaat gtgataagge 720
cagagettgt gtgetgggea cagaaateae etgetgeate etgtgeteeg caggetggge 780
cggagcctct gcccgcaggt ttctatgctg tttcttagca cagaatccag cctagcctta 840
geogragtet aggecetget tggaetagga etecttgett gaeeceatet etggtteetg 900
ccctggctcc tgcaccagcc ccagctcctg cctacatcca ggcagaaaga taggcagggg 960
ctcttggaag acgttccgtg ctgtgacctc cgagccctcc tggtgggaag acagctggaa 1020
aggctgggag gagaagggag gggttggggg ttcccaggag ccatgcgtgg cctgcagagt 1080
ccattccatc atgatgctgt gcccgctatg ggctgtgtcc atgaccagag gctggagtgg 1140
gggtgtgtta gagecectea eegggaettg etgtgeggat ggggeetggg eeteetteet 1200
acaggggete etetgtgggt gaggggeeet etggaatgge ateceatgag ettgtggeet 1260
ctatctgcta ccatctgtgt tttatctgag taaagttacc ttacttctgg aaaaaaaaa 1320
<210> 175
```

<210> 175 <211> 778 <212> DNA

```
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2280639
<400> 175
gegetecete getggeggae ggetgggegg egggeeggge eeggggeege ttggaatgge 60
gestectecg settegeses aastgettet setggsages steggsaggs testgggtes 120
cagegaggtg atggetggac eggeggagga ggegggagee cattgteeeg agageetgtg 180
gectetgeet eegeaggtgt caccaagagt gacetacaca egagtgagee cagggcagge 240
tgaggatgte accttectet accaeccetg tgeceatece tggetgaage tecagettge 300
cetectggee tatgettgta tggetaacce tteceteace cetgaettea geeteacgea 360
ggateggece etggtgetga etgeatgggg getggegetg gagatggeet gggtagagee 420
agcetggget geecaetgge tgatgaggag geggaggagg aagcagagga agaagaagge 480
atggatetae tgtgaaagee ttteagggee tgeteeetee gageeaacte eeggtagagg 540
gaggetgtge egaagagggt gtgtgeagge eetggetetg geetttgete tgeggaetgg 600
eggeceetg geacagaggt gacateteaa gggeceagge agecetette tagtggtgee 660
aagacgcgga tgctgcgggc tgcacttggg tcccagccca ctcgctcagc cctgaggttt 720
ccctctgctt ccccagttag cttgatggcc aagcattcca tggcgggcta tcctggtt
<210> 176
<211> 1477
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2292356
<400> 176
cetggcetgg etegetgggg cetggggage tgecegtget tecageceag tetececetg 60
getgetgeeg_getgetggee.acteceacet_ce@aggeetg_ge5tgaggee_cacagetget_12%
මුද්දියයෙකෙන් අදේශුවරයෙරු ඉදලදයුවුයේ ඉදුල් ඉදුල් අදුරු අදුරු දෙදෙදුමු දෙදෙදුමු දැනි ද
cagggettea gacceetgee cageeceagt atetgaagga accaeagtgg ageeaageee 240
gegatgtgga gaactcaggc ttcaggagac cetggeeetg etectggegg etecgggtgg 300
ctttcagetc tctctgcaac ctgagctggg ggaggagcca ggcctcatgc ccagggctgg 360
gagtggggag cctggtgtgc acgcgtgccc aggcctgcac gtggaccgac caggggaggg 420
geccagaget etggetgggt caccegeace eegeceecat etectecaga gecaceccag 480
gaaaagcceg gctggacgag gtcatggctg cegetgecet tacaagcctg tecaccagec 540
eteteettet gggggeeeca gttgeageet teageeeaga geetggeetg gageeetgga 600
aggaggccct ggtgcggccc ccaggcagct acagcagcag cagcaacagt ggagactggg 660
gatgggacct ggccagtgac cagtcctctc cgtccacccc gtcaccccca ctgccccccg 720
aggeageeca etttetgttt ggggageeca eeetgagaaa aaggaagage eeggeecagg 780
tcatgttcca gtgtctgtgg aagagctgcg ggaaggtgct gagcacggcg tcggcgatgc 840
agagacacat ccgcctggtg cacctggggt gcggcggggc ctggggtgcg gcggggcctg 900
egggttgget ggggttgtta ggeeeggeea ggeeaceeet teageteeca etggetgget 960
gtgtctcccg caggaggcag gcagagcctg agcagagtga tggtgaggag gacttctact 1020
acacagaget ggatgttggt gtggacacge tgaccgacgg getgtecage etgactecag 1080
ttttccccga gggcttccat gccagcttgc cttcccccgc cctgaagctc cgcagacttg 1140
gtgggacccg ccaaccccgc cagtacccct gaggagcgcc gggatttagt cgaggtcctt 1200
tgtcggcgcc cacggggaat attaatagct cccggggggg gggaatactt ttgaaggcag 1260
ttgataaaaa attttccccc ccaaacagag ggaggcccga gaataaagaa cccctccggg 1320
aaaaaacaca gtgggagaca tagagttgat tctccctggg tgagaaaaat ttgggtaaag 1380
eggetteaag caatttegea gageaagatt tgegggegee ggaaceeata aaggtggtaa 1440
```

1477

aaccctgggg ggtccccaag agggggaagc tcaaccc

```
<210> 177
<211> 682
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2349310
<400> 177
tetgaatgtt ttggtgaata aatetgttet teageaacee taeetgette teeaaaetge 60
ctaaagagat ccagtactga tgacgctgtt cttccatctt tactccctgg aaactaacca 120
cqttqtcttc tttccttcac caccaccag gagctcagag atctaagctg ctttccatct 180
ttteteecag eeccaggaca etgaetetgt acaggatggg geegteetet tgeeteette 240
teatectaat eccepticte cagetgatea acctggggag tactcagtgt teettagact 300
ccgttatgga taagaagatc aaggatgttc tcaacagtct agagtacagt ccctctccta 360
taagcaagaa getetegtgt getagtgtea aaagccaagg cagaccgtee teetgeeetg 420
ctgggatggc tgtcactggc tgtgcttgtg gctatggctg tggttcgtgg gatgttcagc 480
tggaaaccac etgccactge cagtgeagtg tggtggactg gaccactgee egetgetgee 540
acctgacctg acagggagga ggctgagaac tcagttttgt gaccatgaca gtaatgaaac 600
cagggtccca accaagaaat ctaactcaaa cgtcccactt catttgttcc attcctgatt 660
cttgggtaat aaagacaaac tt
<210> 178
<211> 1508
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 11, 139
<223> a or g or c or t, waknowe, or other
<220>
<221> misc feature
<223> Incyte Clone No: 2373227
<400> 178
qegtaacece ntgatetggt gataaacgta ttaceegett ttgagtgage tgataceget 60
cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg agaaagcgga agagcgccca 120
atacgcaaac cgcttctcnc cgcgcgttgg ccgattcatt aatcagcttg cacgacaggt 180
ttecegactg gaaageggge agtgagegea aegeaattaa tgtgagttag ctcacteccc 240
accecettee eegegggeet eggtteaaac gaceeggtgg gtetacageg gaagggaggg 300
agegaaggta ggaggeaggg cttgcctcae tggccaccct cccaacccca agagcccagc 360
eccatggtcc ccgccgccgg cgcgctgctg tgggtcctgc tgctgaatct gggtccccgg 420
geggegggg cecaaggeet gacceagaet eegaeegaaa tgeagegggt eagtttaege 480
tttgggggcc ccatgacccg cagctaccgg agcaccgccc ggactggtct tccccggaag 540
acaaggataa teetagagga egagaatgat geeatggeeg aegeegaeeg eetggetgga 600
ccageggetg cegagetett ggeegeeaeg gtgteeaeeg getttageeg gtegteegee 660
attaacgagg aggatgggtc ttcagaagag ggggttgtga ttaatgccgg aaaggatagc 720
accagcagag agetteecag tgegacteec aatacagegg ggagtteeag caegaggttt 780
atagccaata gtcaggagcc tgaaatcagg ctgacttcaa gcctgccgcg ctcccccggg 840
aggtetactg aggacetgee aggetegeag gecaecetga gecagtggte cacacetggg 900
totaccocga geoggtgged gtcaccotca eccacageda tgccatoted tgaggatotg 960
eggetggtge tgatgeeetg gggeeegtgg caetgeeact geaagteggg caecatgage 1020
```

```
cggagccggt ctgggaaget gcacggcctt tccgggcgcc ttcgagttgg ggcgctgagc 1080
cageteegca eggageacaa geettgeace tateaacaat gteeetgeaa eegaettegg 1140
gaagagtgcc ccctggacac aagtetetgt actgacacca actgtgcctc tcagagcacc 1200
accagtacca ggaccaccac taccccettc cccaccatcc acctcagaag cagtcccage 1260
etgecacccg ccagccctg cccagccctg getttttgga aacgggtcag gattggcctg 1320
gaggatattt ggaatageet etetteagtg tteacagaga tgeaaccaat agacagaaac 1380
cagaggtaat ggccacttca tccacatgag gagatgtcag tatctcaacc tctcttgccc 1440
tttcaatcct agcacccact agatattttt agtacagaaa aacaaaactg gaaaacaaaa 1500
aaaaaaaa
<210> 179
<211> 558
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2457682
<400> 179
ggagaaagga tggccggcct ggcggcgcgg ttggtcctgc tagctggggc agcggcgctg 60
gegagegget eccagggega eegtgageeg gtgtaeegeg aetgegtaet geagtgegaa 120
gagcagaact gctctggggg cgctctgaat cacttccgct cccgccagcc aatctacatg 180
agtctagcag gctggacctg tcgggacgac tgtaagtatg agtgtatgtg ggtcaccgtt 240
gggetetace tecaggaagg teacaaagtg ceteagttee atggeaagtg gecettetee 300
agectggtga tgetetgeeg etacegeace ttegtgeeag ceteeteece eatgtaceae 420
acctgtgtgg ccttcgcctg gctttctgga agatgacagc ctgtagctgc tgaaggaatc 480
agaggacaag ttcaggctgg actgaagacc cttggagcga gtcttcccca gttggggata 540
ctgccccgc cctgctgg
<210: 180°
<211> 00264
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2480426
<400> 180
cttggagtet gggaggagga aageggagee ggeagggage gaaceaggae tggggtgaeg
geagggeagg gggegeetgg eeggggagaa gegeggggge tggageaeca eeaactggag 120
ggtccggagt agcgagcgcc ccgaaggagg ccatcgggga gccgggaggg gggactgcga 180
gaggaccccg gcgtccgggc tcccggtgcc agcgctatga ggccactcct cgtcctgctg 240
ctcctgggcc tggcggccgg ctcgcccca ctggacgaca acaagatecc cagcetctgc 300
eegggaetge egggaeeteg aggggaeeee gggeegegag gagaggeggg accegegggg 360
eccaceggge tageegggga gtgeteggtg ceteegegat eegeetteag egeeaagege 420
teegagatee gggtgeetee getgtetgae geaceettge ettegaeege gtgetggtga 480
                                                                502
acgagcaagg acattacgac gc
<210> 181
<211> 1659
<212> DNA
```

```
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2503743
<400> 181
getgtgegge ggggeaggea tgggageege gegetetete eeggegeeea eacetgtetg 60
ageggegeae gageegegge eegggeggge tgeteggege ggaacagtge teggeatgge 120
agggatteca gggeteetet teettetett etttetgete tgtgetgttg ggcaagtgag 180
cccttacagt gccccctgga aacccacttg gcctgcatac cgcctccctg tcgtcttgcc 240
ccagtctacc ctcaatttag ccaagccaga ctttggagcc gaagccaaat tagaagtatc 300
ttetteatgt ggaecceagt gteataaggg aacteeactg eccaettaeg aagaggecaa 360
gcaatatetg tettatgaaa egetetatge caatggeage egeacagaga egeaggtggg 420
catctacatc ctcagcagta gtggagatgg ggcccaacac cgagactcag ggtcttcagg 480
aaagtotoga aggaagoggo agatttatgg otatgacago aggttcagoa tttttgggaa 540
ggaetteetg eteaactace ettteteaac ateagtgaag ttatecaegg getgeaeegg 600
caccetggtg geagagaage atgteeteae agetgeeeae tgeataeaeg atggaaaaae 660
ctatgtgaaa ggaacccaga agettegagt gggetteeta aageecaagt ttaaagatgg 720
tggtcgaggg gccaacgact ccacttcagc catgcccgag cagatgaaat ttcagtggat 780
ccgggtgaaa cgcacccatg tgcccaaggg ttggatcaag ggcaatgcca atgacatcgg 840
catggattat gattatgccc tcctggaact caaaaagccc cacaagagaa aatttatgaa 900
gattggggtg agccctcctg ctaagcagct gccagggggc agaattcact tctctggtta 960
tgacaatgac cgaccaggca atttggtgta tegettetgt gacgtcaaag acgagaceta 1020
tgacttgctc taccagcaat gcgatgccca gccaggggcc agcgggtctg gggtctatgt 1080
gaggatgtgg aagagacagc agcagaagtg ggagcgaaaa attattggca ttttttcagg 1140
gcaccagtgg gtggacatga atggttcccc acaggatttc aacgtggctg tcagaatcac 1200
tecteteaaa tatgeeeaga tttgetattg gattaaagga aactacetgg attgtaggga 1260
ggggtgacac agtgttccct cctggcagca attaagggtc ttcatgttct tattttagga 1320
gaggccaaat tgttttttgt cattggcgtg cacacgtgtg tgtgtgtgtg tgtgtgtgtg 1380
taaggtgtct tataatcttt tacctatttc ttacaattgc aagatgactg gctttactat 1440
ttgaaaactg gtttgtgtat catatcatat atcatttaag cagtttgaag gcatactttt 1500
gcatagaaat aaaaaaaata ctgatttggg gcaatgagga atatttgaca attaagttaa 1560
tottcacgtt tittgcaaact tigattitta titcatcign agtigitica aagaittata 1620
ttaastattt ggcatacong sgatatgaaa aaaaaaaaa
                                                                1659
<210> 182
<211> 2015
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2537684
<400> 182
aaaaacaaag gcaatgcatt ggcaagcctc acagcacaga gtgaccgctg cctggcgttc 60
cccagcactc ggtgtggaaa ggcccctacc tgctgtaaga ttatgggtcc atgaaagcag 120
taagetggae acagaggtgt agtgtgeggg acagagggee ttgeagatge etttetgttg 180
gtgttttagt gttaaaatac ggagagtatg gaactettca cetecatttt etcagegget 240
gtgaagcagc etectagett eggaagtaeg gacactaegt egegttttea agegtgtetg 300
ttctgcaggt aacagcatca agctgcacgt ggaagcatct cgcggttttc tagaaacagg 360
cattttetta teceteteee geteettttt eeacaaaggt gaattteata aatgtaatae 420
tagtaaagtg aatgaattac tgagtttata cagaaattta ggtaacttct cctttagtct 480
caagagcgag tottgetttt taatgggtge cgtttatgtt getgeeegee etgtgtgeet 540
```

```
tgtgctgcag ctcatacggt gtgtctgtca tctcagtctg gagtaaatgc agtgtctgcc 660
ggtgtctgat gggttctgtc cctcgtattt tctttgcctt ctatcccatt gcctggctac 720
cgctgcctgg cagccaaggg tgttggtcgc gaagctggga gtggcctctg gtggagcctg 780
catchtgtct cgtctgcctc tgctttacat ttggtgtact ttcgggcgtg gtggcagtaa 840
aatgacaccg tgattgagct tgtcagcaga gctgaaagag aaagtagaag gatgtqcatt 900
gtttcttgta agatatcttg catgtatctg tgtattcaaa ttcaaacaga gatgqtttqt 960
ccatttgtcc actgagaaat tataaactag ggacaagggg gaggaaaagt actgaaatac 1020
agtttatgaa gcaagtgtgt ctegggctgt gcttgtccca ggagccccag cagcatctga 1080
actgaggett etteagteet geaggaacag gateatetgt etcageggtg ggeagatgtt 1140
ttcatagaca gccagggagt aaacactgtt ggctctgtgg gctgtatggt ctctgccata 1200
aatagtacag agatgtggct gtgtctagta caacttttag acacagaaat ctgaatgaca 1260
tatattgttc tgtgtcaaga aacttagatt ttttttttaa ctatttaaaa acgtgaaacc 1320
tattettage teacaggeea tggagaaget ggtggggaee agacecaget cettagetgg 1380
ctgggctggg gagggggcag tgacagtggc agctgctact cactgctcag tgtggaaaac 1440
acaggacttg gcaatcacag cccgcagaac catcatgtgt ggcagaagcc tgagggatgc 1500
ggtttcttgc ccacgtgctc tgttcatttt ctgttgtttt tctgcactta aagaattcac 1560
atggaagcat gttttataaa atgaattacc agagaaacag agatgggeeg agattctcag 1620
aaatggtccc atgtgaccaa gttctgctgt ttgggtgaca gtgctttgaa gatctccttt 1680
gaggatgtgc agtcttttt ttttttttt tttgagatgg agtttgttgc ccaggctgga 1740
gtgagtggca cagtetegge teactgcaac etccacetee tgggttcaag cagttetegt 1800
geogeageet eccaagtage tgggactaca ggcatgegee accaegeeag getaattttt 1860
gtatttttag tagagatggg gtttcaccat gtctcaaact cctgacctca ggcgatccac 1920
ccacctcagc gtcccaaagt gctggggata taggggtgac cacccgcacc tgcgccaaga 1980
gtgggctttt aattagggac aaatccaatg gaagg
<210> 183
<211> 740
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2593853
<400> 183
ctgctttcgt gaagacaaga tgaagttcac aattgtcttt gctggacttc ttggagtctt 60
totageteet geeetageta aetataatat caaegteaat gatgacaaca acaatgetgg 120
aagtgggcag cagtcagtga gtgtcaacaa tgaacacaat gtggccaatg ttgacaataa 180
caacggatgg gactcctgga attccatctg ggattatgga aatggctttg ctgcaaccag 240
actettteaa aagaagacat geattgtgca caaaatgaac aaggaagtea tgeeeteeat 300
teaateeett gatgeactgg teaaggaaaa gaagetteag ggtaagggac caggaggace 360
acctcccaag ggcctgatgt actcagtcaa cccaaacaaa gtcgatgacc tgagcaagtt 420
cggaaaaaac attgcaaaca tgtgtcgtgg gattccaaca tacatggctg aggagatgca 480
agaggcaagc ctgtttttt actcaggaac gtgctacacg accagtgtac tatggattgt 540
ggacatttcc ttctgtggag acacggtgga gaactaaaca attttttaaa gccactatgg 600
atttagtcat ctgaatatgc tgtgcagaaa aaatatgggc tccagtggtt tttaccatgt 660
cattetgaaa ttttteteta etagttatgt ttgatttett taagttteaa taaaateatt 720
tagcattgaa aaaaaaaaa
                                                                  740
<210> 184
<211> 748
<212> DNA
<213> Homo sapiens
```

<220>

```
<221> misc feature
<223> Incyte Clone No: 2622354
<400> 184
ctgcaaccac ccagagccat ggctccccga ggctgcatcg tagctgtctt tgccattttc 60
tgcatctcca ggctcctctg ctcacacgga gccccagtgg cccccatgac tccttacctg 120.
atgetgtgcc agccacacaa gagatgtggg gacaagttct acgaccccct gcagcactgt 180
tgctatgatg atgccgtcgt gcccttggcc aggacccaga cgtgtggaaa ctgcaccttc 240
agagtetget ttgageagtg etgeeeetgg acetteatgg tgaagetgat aaaceagaac 300
tgcgactcag cccggacctc ggatgacagg ctttgtcgca gtgtcagcta atggaacatc 360
aggggaacga tgactcctgg attetectte ctgggtgggc ctggagaaag aggetggtgt 420
tacctgagat ctgggatgct gagtggctgt ttgggggcca gagaaacaca cactcaactg 480
eccaetteat tetgtgaeet gtetgaggee caecetgeag etgeeetgag gaggeecaca 540
ggtccccttc tagaattctg gacagcatga gatgcgtgtg ctgatggggg cccagggact 600
ctgaaccete ctgatgacce ctatggccaa catcaacceg gcaccaccec aaggetgget 660
gggaaccett caccettetg tgagatttte catcatetea agttetette tatecaggag 720
caaagcacag gatcataata aatttatg
<210> 185
<211> 648
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2641377
<400> 185
eggetegagg atccccaagt etetgaceca cetteetgee tgeteetete eteccacatt 60
ggctcagatt ctttccccgc tgtctgtggg tccacactcc cagtggcacc tccaggagag 120
aatctgattg gctcagttcg ccagataact caactttccc attggctacc tttgggtcag 180
gtgatctcca ctagacctat cgcctatgcc tgatggtggg tcacatggtg caaatgttgc 240
.ccgagagott ağtiğiyattag ggatgtegeci gegeteatgg tigacyteke tyctgetyag 300
reattadygy beaggetygg agaaggtace atgutgtgug actgyteatt tgaggtetty 360
cagetgttge ttgetggget tggeaggtgt teaaagtgae eatttttetg aagggttttt 420
ttetgagtat teeteagatg taeteeeetg gggeegaegg tettteette cacagggega 480
tgcttcccta cttgcttgtg aatgtttcct tcatctccag gttgtctggg gacaattctg 540
tettttggag geetgggeag gatttacaga gggeteeatg ceageteett cetgeegggt 600
ccacttctgg tgtagggtaa acacctgcgc attcatgtcc tagtgttg
<210> 186
<211> 2110
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 1932
<223> a or g or c or t, unknown, or other
<220>
<221> misc_feature
<223> Incyte Clone No: 2674857
<400> 186
```

```
cggcggccat ctttactcag ggcacagagg gtctctgcgg ccgtagcggc cggggctgcg 60
ctgcttcctg ccgaggctgg cccaggcagc cgcgcttcga aggacgccgc cgggagctgc 180
ggacatgcgt ggagtggcag tgctaacggc tggtgtctcg cactgttggc ctgtgaaggt 240
acgtgaaget gaaageetgg aatggetgga aaggggteat caggeaggeg geeeetgetg 300
etggggetge tggtggeegt agecaetgte caectggtea tetgteeeta caecaaagtg 360
gaggagaget teaacetgea ggecacacat gacetgetet accaetggea agacetggag 420
cagtacgacc atcttgagtt ccccggagtc gtccccagga cgttcctcgg gccagtggtg 480
ategeagtgt tetecageee egeggtttae gtgetttege tgttagaaat gtecaagttt 540
tactctcagc taatagttag aggagtgctt ggactcggcg tgatttttgg actctggacg 600
ttacaaaagg aagtgagacg gcactteggg gccatggtgg ccaccatgtt ctgctgggtg 660
acggccatgc agttccacct gatgttctac tgcacgcgga cactgcccaa tgtgctggcc 720
etgeetgtag teetgetgge eetegeggee tggetgegge acgagtggge eegetteate 780
tggctgtcag cettegecat categtgttc agggtggage tgtgcetgtt cetgggeete 840
etgetgetge tggeettggg caaccgaaag gtttetgtag teagageeet tegecaegee 900
gtcccggcag ggatcctctg tttaggactg acggttgctg tggactctta tttttggcgg 960
cageteactt ggeeggaagg aaaggtgett tggtacaaca etgteetgaa caaaagetee 1020
aactggggga cctccccgct gctgtggtac ttctactcag ccctgccccg cggcctgggc 1080
tgcagcetge tettcatece cetgggettg gtagacagaa ggacgcacge geegacggtg 1140
etggcactgg getteatgge actetactee etcetgceae acaaggaget acgetteate 1200
atctatgcct tecceatget caacateaeg getgeeagag getgeteeta eetgetgaat 1260
aactataaaa agtcttgget gtacaaageg gggtetetge ttgtgategg acacetegtg 1320
gtgaatgccg cctactcagc cacggccctg tatgtgtccc atttcaacta cccaggtggc 1380
gtegeaatge agaggetgea ceagetggtg eeeeceeaga eagaegteet tetgeacatt 1440
gacgtggcag ccgcccagac aggtgtgtct cggtttctcc aagtcaacag cgcctggagg 1500
tacgacaaga gggaggatgt gcagccgggg acaggcatgc tggcatacac acacatcctc 1560
atggaggcgg cccctgggct cctggccctc tacagggaca cacaccgggt cctggccagc 1620
gtcgtgggga ccacaggtgt gagtctgaac ctgacccaac tgcccccctt caacgtccac 1680
etgeagacaa agetggtget tetggagagg etecceegge egteetgagg gggaceagge 1740
agcecteage agecaeagge ettecaggag etgttateae taceagttte tggcaeaatt 1800
ccagcacaat tatgacaatt cagagaagca agtcaaagga ctggggcacc tgcctctgac 1860
agacaccaga ccaggtccag ggcctcctcc cacagcctca gctgggggct cttcagcaac 1920
caaagaacga anggggcccc aagttetttg tttgggcacc ccccggggta agcccacttg 1980
onsectanggg tittgatgggg, titgggsconng, stilletaggggg, elitteceting geogggtitt 2040
gaettyttee gyceecagga tteaagggtt ggeecaattt cecattyaac ttaaatttee 2100
agggaaaggc
<210> 187
<211> 773
<212> DNA .
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2758485
<400> 187
cccggagccg gggagggagg gagcgaggtt cggacaccgg cggcggctgc ctggcctttc 60
catgageccg cggcggaccc teccgcgccc cetetegete tgcctetece tetgcctetg 120
cetetgeetg geegegete tgggaagtge geagteeggg tegtgtaggg ataaaaagaa 180
ctgtaaggtg gtcttttccc agcaggaact gaggaagcgg ctaacacccc tgcagtacca 240
tgtcactcag gagaaaggga ccgaaagtgc ctttgaagga gaatacacac atcacaaaga 300
tectggaata tataaatgtg ttgtttgtgg aactccattg tttaagtcag aaaccaaatt 360
tgactccggt tcaggttggc cttcattcca cgatgtgatc aattctgagg caatcacatt 420
cacagatgac ttttcctatg ggatgcacag ggtggaaaca agctgctctc agtgtggtgc 480
teacettggg cacatttttg atgatgggee tegteeaact gggaaaagat actgeataaa 540
```

```
ttcggctgcc ttgtctttta cacctgcgga tagcagtggc accgccgagg gaggcagtgg 600
ggtcgccagc ccggcccagg cagacaaagc ggactctgag agtaatggag agtgatggaa 660
acaaagtgta cttaatgcac agcttattaa aaagatcaaa attgttatcc taatagatat 720
atttttcaa aaactataag ggcagttttg tgctattgta atttttcctc ctt
<210> 188
<211> 714
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2763296
<400> 188
gggageetee eacgetetee ageteacteg geaggeageg gggaceaggg etggeaggtt 60
aagcetetgg gggtggatee tgaaaggtgg teeageegee tggeeetgeg tgggaeeete 120
cacctggcag caggtggtga cttccaagag tgactccgtc ggaggaaaat gactccccag 180
tegetgetge agaegaeact gtteetgetg agtetgetet teetggteea aggtgeeeae 240
ggcaggggcc acagggaaga ctttcgcttc tgcagccagc ggaaccagac acacaggagc 300
agectecact actactggte catgeggetg caggeceggg gtggeceete ecetetgaag 360
ageaacteag acagegeeag geteceeate agetegggea geaectegte cageegeate 420
taggceteca geccaectge ceatgtaatg aageagagat geggeetegt egeacaetge 480
etgtagecce egaaccegge eeagceeeag gecagtaage egeagaettt agaaageeea 540
acgaccatgg agagatgggc cgttgccatg gtggacggac tcccgggctg ggcttttgag 600
attggcttag gggctactcg gctctcactc agctcccacg ggactcaaga atgcggcgcc 660
atgctgcctt aggtactgtc cccacatctg tcccaaccca gctggaggcc tggt
<210> 189
<211> 609
<212> DNA
<213> HOMO: Sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2779436
<400> 189
eggecaggge geegacagee egaceteace aggagaacat geagetegge actgggetee 60
tgctggccgc cgtcctgagc ctgcagctgg ctgcagccga agccatatgg tgtcaccagt 120
geacgggett eggagggtge teccatggat ecagatgeet gagggactee acceaetgtg 180
teaceaetge caceegggte etcageaaca eegaggattt geetetggte aceaagatgt 240
gccacatagg ctgccccgat atccccagec tgggcctggg cccctacgta tccatcgctt 300
getgecagae cageetetge aaceatgaet gaeggetgee etectecagg eeceeggaeg 360
ctcagccccc acagccccca cagcctggcg ccagggctca cggccgcccc tccctcgaga 420
etggecagee cacetetece ggeetetgea gecacegtee ageacegett gteetaggga 480
agtectgegt ggagtettge eteaatetge tgeegteeaa geetggggee categtgeet 540
geogeceett caggteeega eeteeeeaca ataaaatgtg attggategt gtggtacaaa 600
aaaaaaac
                                                                  609
<210> 190
<211> 1088
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<223> Incyte Clone No: 2808528
<400> 190
tgtagaagac agcggcgttg ccatggcggc gtctctgggg caggtgttgg ctctggtgct 60
ggtggccgct ctgtggggtg gcacgcagcc gctgctgaag cgggcctccg ccggcctgca 120
gegggtteat gageegaeet gggeeeagea gttgetaeag gagatgaaga eeetettett 180
gaatactgag tacctgatge cettteteet caaccagtgt ggatecette tetattacet 240
cacettggca tegacagate tgaceetgge tgtgeceate tgtaactete tggetateat 300
cttcacactg attgttggga aggcccttgg agaagatatt ggtggaaaac gagcagttgc 360
tggcatggtg ctcaccgtga taggaatttc actctgcatc acaagctcag tgagtaagac 420
ccaggggcaa cagtctaccc tttgagtggg ccgaacccac ttccagctct gctgcctcca 480
ggaageeest gggeeatgaa gtgetggeag tgageggatg gaeetageae tteeeetete 540
tggccttagc ttcctcctct cttatgggga taacagctac ctcatggatc acaataagag 600
aacaagagtg aaagagtttt gtaaccttca agtgctgttc agctgcgggg atttagcaca 660
ggagacteta egeteaceet eageaacett tetgeeceag eagetetett eetgetaaca 720
teteaggete ecageceage caccattact gtggeetgat etggaetate atggtggeag 780
gttccatgga ctgcagaact ccagctgcat ggaaagggcc agctgcagac tttgagccag 840
aaatgcaaac gggaggcctc tgggactcag tcagagcgct ttggctgaat gaggggtgga 900
accgagggaa gaaggtgcgt cggagtggca gatgcaggaa atgagctgtc tattagcctt 960
geetgeecca cecatgaggt aggeagaaat ceteactgee ageecetett aaacaggtag 1020
agagetgtga gecceageee caeetgaete cageacaeet ggegagtagt agetgtcaat 1080
aaagctat
<210> 191
<211> 1377
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2809230
<400> 191
gegggaette etgtgtegta tttecaagga etecaaageg aggeegggga etgaaggtgt 60
gggtgtcgag ccctctggca gagggttaac ctgggtcaaa tgcacggatt ctcacctcgt 120
acagttacge tetecegegg cacgteegeg aggaettgaa gteetgageg eteaagtttg 180
teegtaggte gagagaagge catggaggtg cegecacegg cacegeggag ctttetetgt 240
agageattgt geetatttee eegagtettt getgeegaag etgtgaetge egatteggaa 300
gteettgagg agegteagaa geggetteee taegteeeag ageeetatta ceeggaatet 360
ggatgggacc gcctccggga gctgtttggc aaagatgaac agcagagaat ttcaaaggac 420
ettgetaata tetgtaagae ggeagetaea geaggeatea ttggetgggt gtatggggga 480
ataccagett ttatteatge taaacaacaa tacattgage agagecagge agaaatttat 540
cataaceggt ttgatgctgt gcaatctgca categtgetg ccacaegagg cttcattegt 600
tatggctggc gctggggttg gagaactgca gtgtttgtca ctatattcaa cacagtgaac 660
actagtetga atgtataceg aaataaagat geettaagee attttgtaat tgeaggaget 720
gtcacgggaa gtctttttag gataaacgta ggcctgcgtg gcctggtggc tggtggcata 780
attggagcet tgetgggeae teetgtagga ggeetgetga tggeatttea gaagtaetet 840
ggtgagactg ttcaggaaag aaaacagaag gatcgaaagg cactccatga gctaaaactg 900
gaagagtgga aaggcagact acaagttact gagcacetee etgagaaaat tgaaagtagt 960
ttacaggaag atgaacctga gaatgatgct aagaaaattg aagcactgct aaaccttcct 1020
agaaaccctt cagtaataga taaacaagac aaggactgaa agtgctctga acttgaaact 1080
cactggagag ctgaagggag ctgccatgtc cgatgaatgc caacagacag gccactcttt 1140
ggtcagcctg ctgacaaatt taagtgctgg tacctgtggt ggcagtggct tgctcttgtc 1200
tttttctttt ctttttaact aagaatgggg ctgttgtact ctcactttac ttatccttaa 1260
```

```
atttaaatac atacttatgt ttgtattaat ctatcaatat atgcatacat gaatatatcc 1320
acccacctag attttaagca gtaaataaaa catttcgcaa aagattaaaa aaaaaaa
<210> 192
<211> 985
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2816821
<400> 192
gegggeeege gagteegaga eetgteeeag gageteeage teaegtgaee tgteaetgee 60
tecegeegee tectgeeege gecatgaeee ageeggtgee eeggetetee gtgeeegeeg 120
egetggeeet gggeteagee geaetgggeg eegeettege caetggeete tteetgggga 180
ggeggtgeec eccatggega ggeeggegag ageagtgeet getteecece gaggaeagee 240
geetgtggca gtatettetg ageegeteea tgegggagca eeeggegetg egaageetga 300
qqctqctqac cctggagcag ccgcaggggg attctatgat gacctgcgag caggcccagc 360
tettggecaa cetggegegg etcateeagg ceaagaagge getggaeetg ggeaeettea 420
egggetacte egecetggee etggeeetgg egetgeeege ggaegggege gtggtgaeet 480
gegaggtgga egegeageee eeggagetgg gaeggeeeet gtggaggeag geegaggegg 540
agcacaagat cgacetecgg ctgaageeeg cettggagac cetggaegag ctgetggegg 600
egggegagge eggeacette gaegtggeeg tggtggatge ggaeaaggag aactgeteeg 660
cetactacga gegetgeetg cagetgetge gaceeggagg cateetegee gteetcagag 720
tectgtggeg egggaaggtg etgeaacete egaaagggga egtggeggee gagtgtgtge 780
gaaacctaaa cgaacgcatc cggcgggacg tcagggtcta catcagcctc ctgcccctgg 840
gegatggaet caccttggee tteaagatet agggetggee cetagtgagt gggetegagg 900
gagggttgcc tgggaacccc aggaattgac cctgagtttt aaattcgaaa ataaagtggg 960
gctgggacac acgaaaaaaa aaaaa
<210> 193
<211> 1310
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2817268
<400> 193
cccacgcgtc cgggttcacg taaagacagc gagatcctga gggccagccg ggaaggaggc 60
gtggatatgg agetggetge tgccaagtee ggggeeegeg eegetgeeta gegegteetg 120
gggactetgt ggggacgcgc eccgcgccgc ggctcgggga cccgtagagc ccggcgctgc 180
gegeatggcc etgetetege geecegeget caecetectg etectectca tggcegetgt 240
tgtcaggtgc caggagcagg cccagaccac cgactggaga gccaccctga agaccatccg 300
gaacggcgtt cataagatag acacgtacct gaacgccgcc ttggacctcc tgggaggcga 360
ggacggtctc tgccagtata aatgcagtga cggatctaag cctttcccac gttatggtta 420
taaaccctcc ccaccgaatg gatgtggctc tccactgttt ggtgttcatc ttaacattgg 480
tatecettee etgacaaagt gttgcaacca acacgacagg tgctatgaaa eetgtggcaa 540
aagcaagaat gactgtgatg aagaattcca gtattgcctc tccaagatct gccgagatgt 600
acagaaaaca ctaggactaa ctcagcatgt tcaggcatgt gaaacaacag tggagctctt 660
gtttgacagt gttatacatt taggttgtaa accatatctg gacagccaac gagccgcatg 720
caggtgtcat tatgaagaaa aaactgatct ttaaaggaga tgccgacagc tagtgacaga 780
tgaagatgga agaacataac ctttgacaaa taactaatgt ttttacaaca taaaactgtc 840
```

```
ttatttttgt gaaaggatta ttttgagacc ttaaaataat ttatatcttq atqttaaaac 900
ctcaaagcaa aaaaagtgag ggagatagtg aggggagggc acgcttgtct tctcaggtat 960
cttccccagc attgctccct tacttagtat gccaaatgtc ttgaccaata tcaaaaacaa 1020
gtgcttgttt agcggagaat tttgaaaaga ggaatatata actcaatttt cacaaccaca 1080
tttaccaaaa aaagagatca aatataaaat tcatcataat gtctgttcaa cattatctta 1140
tttggaaaat ggggaaatta tcacttacaa gtatttgttt actatgaaat tttaaataca 1200
catttatgcc tagaaggaac ggactttttt tttctatttt aattacacat aatatgtaat 1260
taaagtacaa cataatatgt tgtttctctg tagcccgttg agcatatgag
<210> 194
<211> 914
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2923165
<400> 194
eggtggecat gactgeggee gtgttetteg getgegeett cattgeette gggeetgege 60
tegecettta tgtetteace ategecaceg ageegttgeg tateatette eteategeeg 120
gagetttett etggttggtg tetetaetga tttegteeet tgtttggtte atggeaagag 180
tcattattga caacaaagat ggaccaacac agaaatatct gctgatcttt ggagcgtttg 240
tetetgteta tatecaagaa atgtteegat ttgeatatta taaaetetta aaaaaageea 300
gtgaaggttt gaagagtata aacccaggtg agacagcacc ctctatgcga ctgctqgcct 360
atgtttctgg cttgggcttt ggaatcatga gtggagtatt ttcctttgtg aataccctat 420
etgaeteett ggggeeagge acagtgggea tteatggaga tteteeteaa ttetteettt 480
atteagettt catgaegetg gteattatet tgetgeatgt attetgggge attgtatttt 540
ttgatggctg tgagaagaaa aagtggggca teeteettat egtteteetg aeceaeetge 600
tggtgtcagc ccagaccttc ataagttctt attatggaat aaacctggcg tcagcattta 660
taateetggt geteatggge acetgggeat tettagetge gggaggeage tgeegaagee 720
tgaaactetg cetgetetge caagacaaga actttettet ttacaaccag égetecagat 780
aanotoaggg aaccagcact toocaaanog cagactabat otttagagga agcacaabbg 048
kgootkutto kgaaatcoccttlttetggc ggaatrgaga aagaaalaaa actatgcaga 900
tatgaaaaaa aaaa "
<210> 195
<211> 606
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2949822
<400> 195
ttttttaata atgcctttta gttggatggt aattatcctg ggttttctat gtggattatc 60
aggtcagctt caaataatga acaccctctc ttctcttcca attgttttac ttgtttcttc 120
ttcttgtctt atattagcca gaatgtcata tagtatattg accagtagct atggtggtgg 180
cgtttttatc ttattggact taaaaagaaa tacatcaaaa gtttctccat taatgatgat 240
gtttgctata gggcattgat agatagcctt caaaaagtta agaaagttct tttctttcta 300
gtcttcaagg ttaaaaagtt tttaaagatc ttaattgaat gtgaacttta tcaaatgcct 360
ttgtgatgtc tatggagata atcatgtatt tgcttcttta atacattcct gtggtgaaat 420
atgtgaataa gtgttctgat attgaattat ctttgcattt ctagaataag ccctaataag 480
tactattcaa ggtatttttc tcaaacacct gattggactc tgtaagctca tatttcattg 540
```

```
agtggattte ettetatgtt tgteagtgea attgegetat aattegegtt getgteetea 600
tctgaa
<210> 196
<211> 893
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2992192
<400> 196
ccacccgga agtcggctgg ccatggcggc gccttggagg cgatggccca cggggctgct 60
ageegtgetg eggeeeetge teaeetgeeg geeeetgeaa ggeaegaege tgeaaeggga 120
tgtgetgete tttgageatg ateggggeeg ettetteace atecteggge tgttetgege 180
gggccagggc gtcttctggg cttccatggc tgtggcagcc gtgtcccggc ccccggttcc 240
ggtgcagect ctggatgcgg aggtcccaaa tcgtggcccc ttcgacctgc gctccgcgct 300
ctggegetae ggtetggeeg teggetgegg egecategga gecetegtae teggtgetgg 360
tettetette teteteeggt etgtgegete agtggtgett egagetggag ggeageaggt 420
gaccetcace acteatgeec cetttggett gggggeccat tteacagtte etttgaagea 480
ggtatettgc atggcccacc ggggtgaagt ceetgecatg etacetetga aagteaaagg 540
ccgacgette tattteetet tggacaaaac tggacaette cetaacacaa aactetttga 600
caatactgtg ggtgcctacc ggagcttgtg aagaaatgac ctcaagtcac tcacctctcc 660
aagaggagga taaaaactga accttgggga gccaggtgtg ttggttcaca cctgttgtaa 720
teccageaet ttgggagggt gaggeaggag eactgetega geccaggetg ggeaacatag 780
cgagaccttg tctctattta caaaaaaaaa aacaaaaaaa aacgccaatc ttagaatgga 840
gtaacaacca gggtcacaca aggaggtcaa gattcattaa caacaaataa agg
<210> 197
<211> 1730
<212> DNA
《213》 KMN tapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2992458
ggccagaggc tgcccggctc ccggaagcag gctgtgaggg gcgggagcgc tgctggaacc 60
egageeggag eeggageeae ageggggagg gtggeetgge ggeetggage eggaegtgte 120
eggggegtee eegeagaeeg gggeageagg tegteegggg geeeaeeatg etggtgaetg 180
cctaccttgc ttttgtaggc ctcctggcct cctgcctggg gctggaactg tcaagatgcc 240
gggctaaacc ccctggaagg gcctgcagca atccctcctt ccttcggttt caactggact 300
tetateaggt etaetteetg geeetggeag etgattgget teaggeeece taeetetata 360
aactetacca geattactac tteetggaag gteaaattge cateetetat gtetgtggee 420
ttgcctctac agtcctcttt ggcctagtgg cctcctccct tgtggattgg ctgggtcgca 480
agaattettg tgteetette teeetgaett acteactatg etgettaace aaactetete 540
aagactactt tgtgctgcta gtggggcgag cacttggtgg gctgtccaca gccctgctct 600
totcageett egaggeetgg tatatecatg ageaegtgga aeggeatgae ttecetgetg 660
agtggateec agetacettt getegagetg cettetggaa ecatgtgetg getgtagtgg 720
caggtgtggc agctgaggct gtagccagct ggatagggct ggggcctgta gcgccctttg 780
tggctgccat ccctctcctg gctctggcag gggccttggc ccttcgaaac tggggggaga 840
actatgaccg geagegtgee tteteaagga cetgtgetgg aggeetgege tgeeteetgt 900
eggacegeeg egtgetgetg ttgggcacea tacaagetet atttgagagt gteatettea 960
```

```
tetttgtett cetetggaca cetgtgetgg acceacaegg ggcceetetg ggcattatet 1020
tetecagett catggcagee ageetgettg getetteeet gtacegtate gecaceteca 1080
agaggtacca cetteageee atgeacetge tgtecettge tgtgeteate gtegtettet 1140
ctetetteat gttgacttte tetaccagee caggecagga gagteeggtg gagteettea 1200
tageetttet aettattgag ttggettgtg gattataett teecageatg agetteetae 1260
ggagaaaggt gatccctgag acagagcagg ctggtgtact caactggttc cgggtacctc 1320
tgcactcact ggcttgccta gggctccttg tcctccatga cagtgatcga aaaacaggca 1380
eteggaatat gtteageatt tgetetgetg teatggtgat ggetetgetg geagtggtgg 1440
gactetteac egtggtaagg catgatgetg agetgegggt acetteacet actgaggage 1500
cctatgcccc tgagctgtaa ccccactcca ggacaagata gctgggacag actcttgaat 1560
tecagetate egggattgta eagatetete tgtgaetgae tttgtgaetg teetgtggtt 1620
teteetgeca ttgetttgtg tttgggagga catgatgggg gtgatggact ggaaagaagg 1680
tgccaaaagt tccctctgtg ttactcccat ttagaaaata aacactttta
<210> 198
<211> 2029
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 3044710
<400> 198
cettgacaag teagaagett gaaageaggg aaateeggat gteteggtta tgaagtggag 60
cagtgagtgt gagcctcaac atagttccag aactctccat ccggactagt tattgagcat 120
ctgcctctca tatcaccagt ggccatctga ggtgtttccc tggctctgaa ggggtaggca 180
cgatggeeag gtgcttcagc ctggtgttgc ttctcacttc catctggacc acgaggetcc 240
tggtccaagg ctctttgcgt gcagaagagc tttccatcca ggtgtcatgc agaattatgg 300
ggatcaccct tgtgagcaaa aaggcgaacc agcagctgaa tttcacagaa gctaaggagg 360
cctgtaggct gctgggacta agtttggccg gcaaggacca agttgaaaca gccttgaaag 420
ctagetttga aacttgeage tatggetggg ttggagatgg attegtggte atetetagga 480
ttagucckaa coccaagtgt gggaaasatg gggtgggtest cotgattigg amggttecag 540 (
tgagedgada gettegeaged tattgttada actuatetga tacttggadt aactegtgda 600
ttccagaaat tatcaccacc aaagatccca tattcaacac tcaaactgca acacaaacaa 660
cagaatttat tgtcagtgac agtacctact cggtggcatc cccttactct acaatacctg 720
cecetactac tactectect getecagett ceaettetat tecaeggaga aaaaaattga 780
tttgtgtcac agaagttttt atggaaacta gcaccatgtc tacagaaact gaaccatttg 840
ttgaaaataa agcagcattc aagaatgaag ctgctgggtt tggaggtgtc cccacggctc 900
tgctagtgct tgctctcctc ttctttggtg ctgcagctgg tcttggattt tgctatgtca 960
aaaggtatgt gaaggcette cettttacaa acaagaatca gcagaaggaa atgategaaa 1020
ccaaagtagt aaaggaggag aaggccaatg atagcaaccc taatgaggaa tcaaagaaaa 1080
ctgataaaaa cccagaagag tccaagagtc caagcaaaac taccgtgcga tgcctggaag 1140
ctgaagttta gatgagacag aaatgaggag acacacctga ggctggtttc tttcatgctc 1200
cttaccctgc cccagctggg gaaatcaaaa gggccaaaga accaaagaag aaagtccacc 1260
cttggttcct aactggaatc agctcaggac tgccattgga ctatggagtg caccaaaqag 1320
aatgeeette teettattgt aaccetgtet ggateetate eteetacete caaagettee 1380
cacggccttt ctagcctggc tatgtcctaa taatatccca ctgggagaaa ggagttttgc 1440
aaagtgcaag gacctaaaac atctcatcag tatccagtgg taaaaaggcc tcctggctgt 1500
ctgaggctag gtgggttgaa agccaaggag tcactgagac caaggctttc tctactgatt 1560
cegcagetea gaecetttet teagetetga aagagaaaca egtateecae etqacatgte 1620
cttctgagcc cggtaagagc aaaagaatgg cagaaaagtt tagcccctga aagccatgga 1680
gatteteata aettgagace taatetetgt aaagetaaaa taaagaaata gaacaagget 1740
gaggatacga cagtacactg tcagcaggga ctgtaaacac agacagggtc aaagtqtttt 1800
ctctgaacac attgagttgg aatcactgtt tagaacacac acacttactt tttctqqtct 1860
```

ctaccactgc tgatattttc tctaggaaat atacttttac aagtaacaaa aataaaaact 1920

```
cttataaatt totattttta totgagttac agaaatgatt actaaggaag attactcagt 1980
aatttgttta aaaagtaata aaattcaaca aacatttaaa aaaaaaaaa
<210> 199
<211> 543
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 3120415
<400> 199
ccggcgctgg agggcgagg accgggtata agaagcctcg tggccttgcc cgggcagccg 60
caggtteece gegegeeeeg ageeceegeg ceatgaaget egeegeeete etggggetet 120
gegtggeeet gteetgeage teegetgetg etttettagt gggeteggee aageetgtgg 180
cccagcctgt cgctgcgctg gagtcggcgg cggaggccgg ggccgggacc ctggccaacc 240
ccctcggcac cctcaacccg ctgaagctcc tgctgagcag cctgggcatc cccgtgaacc 300
acctcataga gggctcccag aagtqtqtgg ctgaqctqqq tccccaggcc gtqqqqqccg 360
tgaaggeeet gaaggeeetg etgggggeee tgaeagtgtt tggetgagee gagaetggag 420
catctacacc tgaggacaag acgctgccca cccgcgaggg ctgaaaaccc cgccgcgggg 480
aggaccgtcc atccccttcc cccggcccct ctcaataaac gtggttaaga gcaaaaaaaa 540
<210> 200
<211> 531
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Encyte Clone No: 126788
<400> 200
gcaagtggaa ccactggctt ggtggatttt gctagatttt tctgattttt aaactcctga 60
aaaatateee agataactgt catgaagetg gtaactatet teetgetggt gaeeateage 120
etttgtagtt actetgetae tgeetteete ateaacaaag tgeecettee tgttgacaag 180
ttggcacctt tacctctgga caacattctt ccctttatgg atccattaaa gcttcttctg 240
aaaactctgg gcatttctgt tgagcacctt gtggaggggc taaggaagtg tgtaaatgag 300
ctgggaccag aggettetga agetgtgaag aaactgetgg aggegetate acaettggtg 360
tgacatcaag ataaagagcg gaggtggatg gggatggaag atgatgctcc tatcctccct 420
gcctgaaacc tgttctacca attatagatc aaatgcccta aaatgtagtg acccgtgaaa 480
aggacaaata aagcaatgaa tacatttaaa ctcagaccat cgaatggaaa a
<210> 201
<211> 491
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 674760
<400> 201
```

```
etteteecat gaetgeegge eagttteetg eacttgttte tetegettta ttgetggaeg 60
gtgggagaag ggcaagtgca agacggaatc gagggcacct ctgggtgttc tgtacctctt 120
ttettettge accttgggaa gtggaggacg tgggatggaa gaagggeetg gaeeteeete 180
ettectecte eccacettet cetaaggage ttgeeetgea gtaageeeca acttteeett 240
cetettttee etetateaga gregregeee acceecettt eccaeegete ecctaeeeee 300
gcettectge caageegagg gegaeggtga tececagett agtaagaaaa gtaaatagge 360
cgggcgcggt agctcacgcc tggaatccca gcactgtggg aggccgaggc gggcggatcg 420
cttgagccca ggagatcagg ttggagacag cctaggcaac atggcgaaac cctgtctcta 480
caaaaaaaaa a
                                                                                                               491
<210> 202
<211> 1551
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1229438
<400> 202
ccggggggcc ggcggcgcc cgggcgggac gatgaagcgg cagaacgtgc gcacgctggc 60
getcatcgtg tgcaccttca cetacctgct ggtgggegee geggtcttcg aegegetgga 120
gteggageec gagetgateg ageggeageg getggagetg eggeageagg agetgeggge 180
gegetacaac etcagecagg geggetacga ggagetggag egegtegtge tgegeetcaa 240
geogeacaag geoggogtge agtggogett egeoggetee ttetactteg coateaccgt 300
cateaceace ateggetacg ggcaegegge acceageacg gatggeggea aggtgttetg 360
catgitetac gegetgetgg geateceget caegetegte atgitecaga geetgggega 420
gcgcatcaac accttggtga ggtacctgct gcaccgcgcc aagaaggggc tgggcatgcg 480
gegegeegac gtgtccatgg ccaacatggt getcategge ttettetegt gcatcageac 540
getgtgcate ggegeegeeg cetteteeca etaegageae tggaeettet teeaggeeta 600
ctactactgc ttcatcaccc tcaccaccat cggcttcggc gactacgtgg cgctgcagaa 660
ggaccaggec etgeacaege ageegeagta egtggeefte agettegtet acateettae 720
gggcotcacy greateggeg cottoctesa coucytogto otgegottas tyácsatgas 780.
ප්රථප්‍රදේශ්රීමය අත්ත්යන්වෙන් සහ අත්ත්රයන් සහ අත්ත්රයන් අත්ත්රයන් අත්ත්රයන් සහ අත්
gggeggegge ggaggggtg geagegegea cactaeggae acegeeteat ceaeggegge 900
agegggegge ggeggettee geaacgteta egeggaggtg etgeaettee agtecatgtg 960
ctcgtgcctg tggtacaaga gccgcgagaa gctgcagtac tccatcccca tgatcatccc 1020
gegggaeete teeaegteeg acaegtgegt ggagcagage caetegtege egggaggggg 1080
eggeegetae agegaeaege eetegegaeg etgeetgtge ageggggege caegeteege 1140
catcageteg gtgtecaegg gtetgeaeag cetgtecaee tteegeggee teatgaageg 1200
caggagetee gtgtgaetge eeegagggae etggageace tggggggegeg ggegggggae 1260
ccctgctggg aggccaggag actgcccctg ctgccttctg cccagtggga ccccgcacaa 1320
cateceteae caeteteece cageaeceec ateteegaet gtgeetgett geaccageeg 1380
gcaggaggcc gggctctgag gacccctggg gcccccatcg gagccctgca aattccgaga 1440
aatgtgaaac ttggtggggt cagggaggaa aggcagaagc tgggagcctc ccttcccttt 1500
gaaaatctaa gaagctccca gtcctcagag accctgctgg tacccagact a
                                                                                                              1551
<210> 203
<211> 936
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1236935
```

```
<400> 203
gtcagtttag tgtttgtggc attcccgctg cttttatggc acttcagtca ttttttagca 60
cacttecate catactacat gtgtcctttt ttccccttaa cttctctaat tgtgtttctt 120
atcettttet ttaaaaccat tgetteatet gggagtggtg gtteatgeet tggeeteeca 180
aagtgctggg attacaggcg tgagcaccgc gcccggccaa ctatagtgtt ttcaaaacat 240
gtgtacacat actctatgag gatgcaaatt gagatttcaa caaatatttc tcagtgactt 300
acataaagec gtgetttate ttggegetta gatgaatttt gtttggttgg ttttggtttt 360
gqttttacat atatcctagg aacatagcag gtgatataga gtggtaaaga gcacacgtcc 420
actgttagta ggtattttta tgcacttgtt ttctcatcta taaaataagg ataaaattag 480
tgcctacctc acaggatatt agggagatgg agagaatgct cagaacacaa cagggcctag 540
cacagaggaa gcacaatgct gaggaacgag aaactgcacc tgtaaattct gcagtcactt 600
taaattataa aacgagtatt tgatgtatga tcataacttt gctaagaagc catcagttat 660
aatggatgca tgaactgtag ccatccagtg agtagtgacc aggatggagg agctttatgg 720
agggggaaga aaggaacctc aaagctttcc gattcatttt gaatcatgag atgtctacat 780
gtaaaaattc tgccttggta aactttgttt ataatgtttt agataatgca ttcacatggt 840
tttataaata tataaatata tatttgggga acatat
<210> 204
<211> 432
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1359283
<400> 204
cgctgtcctg ctaaagcaga ggatcacagc tttaataaag accctaaata tttatcttgc 60
ctgtggtcat gtatagctga acaatgcaca gcgaactcat ttagtttcca tgcgcttaac 120
tgggctaact ctgcttttga gcctaatgga aagcttgggg caggtggagg accggttctt 180
tagcactcac agacgattcc cacaccacac teccatatec ggtettetet geegagaatt 240
ctcontanto and agetticky gagtacects garacostate ctcatctcot gtatttagag 300
atutgggggtt gggaagagaa tgtaaagcaa cctaaacagt aatttaagaa tggagaaaat 360
gggactaaat tattcagaca cgtttgagtg cctactcgct agcaggcatt ttccgctgcc 420
tataattatg ag
<210> 205
<211> 971
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1450703
gggagagagg ataaatagca gcgtggcttc cctggctcct ctctgcatcc ttcccgacct 60
teccageaat atgeatettg caegtetggt eggeteetge teceteette tgetaetggg 120
ggccctgtct ggatgggegg ccagcgatga ccccattgag aaggtcattg aagggatcaa 180
ecgagggetg agcaatgcag agagagaggt gggcaaggee etggatggea teaacagtgg 240
aatcacgcat gccggaaggg aagtggagaa ggttttcaac ggacttagca acatggggag 300
ccacaccggc aaggagttgg acaaaggcgt ccaggggctc aaccacggca tggacaaggt 360
tgcccatgag atcaaccatg gtattggaca agcaggaaag gaagcagaga agcttggcca 420
tggggtcaac aacgctgctg gacaggccgg gaaggaagca gacaaagcgg tccaagggtt 480
```

```
ccacactggg gtccaccagg ctgggaagga agcagagaaa cttggccaag gggtcaacca 540
tgetgetgac caggetggaa aggaagtgga gaagettgge caaggtgeec accatgetge 600
tggccaggcc gggaaggagc tgcagaatgc tcataatggg gtcaaccaag ccagcaagga 660
ggccaaccag ctgctgaatg gcaaccatca aageggatet tecagecaté aaggagggge 720
cacaaccacg ccgttagcct ctggggcctc ggtcaacacg cctttcatca accttcccgc 780
cctgtggagg agcgtcgcca acatcatgcc ctaaactggc atccggcctt gctgggagaa 840
taatgtegee gttgtcacat cagetgacat gacetggagg ggttgggggt gggggacagg 900
tttctgaaat ccctgaaggg ggttgtactg ggatttgtga ataaacttga tacactaaaa 960
aaaaaaaaa a
<210> 206
<211> 1832
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1910668
<400> 206
tcaaggaagc tgatggggag ctgggcctta cccctgatgt aggaggggca cacagctggg 120
ggtgcagage ccacctgggt acctgacece caggggatga aaatgcaagg gtgagtetge 180
ttgggeetga gagtttgate tgeaggggea ggeteatett tteteteeee tgeettetee 240
tecttetete eccagagece etttgagece etetgeetat gtecetetge etectecea 300
tgcccccagt tgctgtggct tgattctgct accctgaccc caccatgtgc caggtggcat 360
ctgccttact gccttccctg aggagctggg acatgctggg cagttgtcag atgtaaaggc 420
acagetggag cagagggcat gtcagtaatg attggtccct ggggaaggtc tggctggctc 480
cagcacagtg aggcatttag gtatctctcg gtgaccgttg gattcctgga agcagtagct 540
gttctgtttg gatctggtag gacagggctc agagggctag gcacggaggg aaggtcagag 600
gagaaggcag gcagggccca gtgagagggg agcatgcctt ccccaccct ggcttgctct 660
tggtcacagg gcggttctgg gcacttgaac tcagggccga agcagaagca caggcccagt 720
cctgqctgca agcacaatag cctgaatggc atttbaggtt aggcagggtg ggaggggagg [780]
etetekigget teagrikkigt tripgttttee aaateaaggt aacttgebee ettetgeeta 840 .
caggeettgg tettggettg teetcaceca gteggaacte cetaceaett teaggagagt 900
ggttttagge cegtgggget gttetgttee aageagtgtg agaacatgge tggtagagge 960
tetagetgtg tgegggget gaaggggagt gggttetege ceaaagagea tetgeeeatt 1020
teccacette cettetecca ecagaagett geetgagetg tttggacaaa aatecaaace 1080
ccacttggct actetggcct ggcttcagct tggaacccaa tacctaggct tacaggccat 1140
cctgagccag gggcctctgg aaattctctt cctgatggtc ctttaggttt gggcacaaaa 1200
tataattgcc teteceetet eccattttet etettgggag caatggteac agteeetggt 1260
acctgaaaag gtacctaggt ctaggccctt cttccctttc ccttcctctc ccctacccca 1320
gaactttggc tecettteec ttetetetet ggtageteea ggaggeetgt gateeagete 1380
cotgoctago atocatgaco tgttggatgt tacotocaat cagtttoctg toctacotge 1440
ctetttgget tggacetata tggecatget etggetetae cettgggaag cetgateceg 1500
gtgtgtggcc cagcttgttc aggccctggg atgctgcatc tccaggcaac tatgcacttt 1560
cccggggaga gaaccagtat gagaagtggg ggcagggcac acattcatct ttgtaggaag 1620
gtctggcctg gggtcgggtg aaggaggcc caggtcagtt ctggggtccc agtgacctgc 1680
tttgccattc tcctggtgcc gctgctgctc cctgtttctg gagctggatg ttccccagct 1740
ggcagttgag ctgcctgagc caatgtgtct gtctttggta actgagtgaa ccataataaa 1800
ggggaacatt tggccctgtg aaaaaaaaa aa
                                                                1832
```

<210> 207

<211> 567

<212> DNA

```
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1955143
<400> 207
catagateca taaateatea tetgttgcaa aaaageacat taattgattg gttgaatggg 60
gagattgaga tatttctttt ctcttcttct gctcaggtgg gggcaacttt tgggggcaga 120
tgagttetgt tgccacaaaa gttatatage acatttggtt tgcactgaat cagegattet 180
caatcctggc catgctttag aattatacaa gaaaaatctt caagtatcaa tactcagtcc 240
ctatectact gatecaatte atetatgata aagecagage attgattttt aagttetgea 300
agtgatteta atatacagee aaggetaaga actactgata tgttecaaae actectattt 360
tggagataaa gaagttgagg ctgaggatga gaccttagca cataaagttc cataactagt 420
aacagaccga agttctgtcc ttacaaataa aaaaaaaaag gggcggccgc cgacttagtg 480
gagettegte ggeeceggga atttatttee eggaeeggta cettgeaggg ggtteeaage 540
ttttcactct atagtggagg ccgtatt
<210> 208
<211> 1303
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1961637
<400> 208
gggggacaat tccacccact cgagggctgc cccctcttcc ttagcagacg aaccagtaat 60
gggggcaagg ctggggcatc ccagcccaca caccctggat gcccagcaag gccacagaaa 120
gagectgatg tecatgatee aggtggetet gagaagettg geetggaeae etgageetge 180
ggccggtact cctgccttct ccccatctat ccccaaggcc tctgcctctc agcctcttcc 240
abggtoggtt taggetgetg agttbbetgbrgebbeecam gamecagtgg satemakser 300,
ggegggbbtef, gugatggttg:ctgantaatef.cgggatttca tgagtcagagfgcaccacccc-2501
teacceage tgeetgetge ttetgaegga tettggtget eaggetgeet ggeteteega 420
gtgaggacgc agcctccata tttggtgcac tcaggcatgg ctgggacaag ccagctgccc 480
cagggttett eccetggtga ttetegeetg ettteteate teaggggagg eagtggeace 540
tecetetece tgetgacatg aagagageta tgatatgeca etgetgecaa eteateetet 600
geocecacct egaaacccac agteeccagt ggagggecac tactcatece cattggttte 660
ccaggggagg ggtgttgtct ggaagggcag gttcagatgc agccttccag atttagaggc 720
actgggagga cagtggctga gtggaggcgc ccagacctgg gcaggcagca ggctcaggcc 780
cacacettgt gatttttgaa accaaageee agaagatgat gtttacttet eteteeetgg 840
etetgeeett ettaetgeaa accatgetgt geettaggge eetteteata getgtteete 900
atggccatga ctggaacagg gatgcaacct ctttctacac aagcacagtt agttgggtga 960
agtetttttt tttgtttgtt ttagaeggag tttcactett gttgcccagg ctggagtgaa 1020
gtggcgtgac cttggctcac tgcaacctcc aggccagcct cagcctccct agtagctggg 1080
actacaggea eccactacca egectggeta attetttgta tttttagtag agatggggtt 1140
tgaccgtgtt agccaggatg gtctcgatct cctgacctcg tgatccaccc acctcggcct 1200
cccaaagtgc tgggattata ggtgtgagcc accgcgccgg gccggttgct ggcatcttaa 1260
tgttctgtag gtggaatatt tccaataaac acaaggtcgc cac
                                                                  1303
<210> 209
<211> 1355
```

<212> DNA

```
<220>
<221> misc feature
<223> Incyte Clone No: 1990762
<400> 209
geagetettt tetggaaatt teteagggga tgtatetgaa geteeaggte tetgagatae 60
tetggaggge cegacettgt ggagatgtgg ceaaceaeat gggeetggag etgggtteaa 120
accetgactt tggcactact tattagetgt gtgacettgg gacagttaat taccactetg 180
caggtcagtt tcctcatctg tgagatggat gtaataatag ggtgtgatga gatgatccct 240
agtgagtcat tggtgttgct gtggccacca ccattgttgt tactgggaga gttttggatt 300
tggaatcccg tgagcaggat tctattctgg ctgtgccatg tgccagctgg gcagctgtag 360
gaagtcactt cctctctgag ccttcacttc ccagtctcta aactggggct cacaaatgtc 420
gcattgcagt ttgggggtgg atcttttgta agaatggaca gaaaaaagat ggtcaactgt 480
aatgtgtggt gcatcgtgag ctgtcactcc cgtgtgccct ggtctcctgc tggcctcact 540
gtggtttgac tcagacttgg actttcctgg aattctgaac tttgcctctc taagcaaagc 600
cccgccaggg ggtacactct gccttgtttt ccatggtgcc gtgtttccag ccctatccaa 660
caactggett etgategget getititeae actgetgtie etgeaagget gigtggeeee 720
atggttaagg gtgagggtte tgcaagggte agecagatge gagtteeggt eetaggteea 780
ccaettactg gtcaggtgac ctcaagtaag ttgcctaacc aaggettaac ctcttaggag 840
ctcagttttt cttcctgtaa aatggggata ataatagtac ctacctcagg ggaatagggg 900
atgaaaaatg gtcttatgaa atccccctgg ccctaactgg caaaagccaa ctcagttaac 960
ggggctccat tatcactgtt gggacctggg cttgtgggag ctcaggagtc ttctcagacc 1020
tecteattge tgtgeeaggt ggaggaggtg tttgtattta etgagageaa ttgggeeaat 1080
ggcccatagt ccttgagcac ccagctgacc caggccacag aggctgctca tcttggtctg 1140
gtgaccacag gaggctgtgg ctgttgggat gacceteece agtgttgtta acaacagtec 1200
caggecatgt cctgctggcc ttgagttccc ctgtcctctt gtgaatgtcc ctagagccat 1260
ggcctcaagg ttcctgaagt tcccaataat gtgacatgct gcccagacct cactacactc 1320
cttttttatt ttgagcctgg gtgacagagc aagac
                                                                  1355
<210> 210
<211> 776
<212> DNA
<2335 Hómo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1994131
<400> 210
gttcactgcc atattcctag ggacaagtaa agttccctgt atattgtagg agctaagtgt / 60
tgaatgaatg aatggtggct gctattattg ettcacettc accetccaag agtaatctcc 120
ccattctggt ttatagtttc tgtgctcact gcttgtgata atcgtaagta tatattgttg 180
agaacagtgc ctgttttctc tttccctgaa aacacatact ttgacgttgg ctgacatagt 240
tcactcaget gttectaace actgatecet etgtateaca ggtatetegg. gggagetttg 300
tgccttgatg gatcaagttc atcatatgca gcactcaaaa tggcagcatc cttcggacct 360
caccacgcga aactacgccc gccgacagaa acatctgcaa agatacagtc tgactcagtg 420
ggttgacagg aacatgcgaa gccaccatcg gttccagcgt ctcccagact tctcgtacag 480
ttaatttgtg tcatcccatc agcaatgaag gtccctatcc agggtcctgc ttggagcagc 540
atttcatgtt cttttgctgt tttgtgcttt gccgattttg gattttattt ttcacaaaat 600
ttttatttaa aaaactcgtc accttttgga aatgcccatt gccgacttga atttttttgt 660
atggagtece cetgattttg tgtgtgtgt tetgtgttta ageaegegtt eggttggtat 720
agttttttat atgtattttt acattaaatt gaaggtaget geeteetgga aageag
<210> 211
```

<211> 817

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1997745
<400> 211
ggaggegtta gaggagetge etteggagge teagggagte cetttggage tggttgttte 60
cttggccctg cagcgcactg ctcggggctc ccaaggaggt tgtgtgtatg gttcttaatt 120
catcaggaca aagaccccca gcatgtgtgt accctgggac ccgatttctc tgggcccaca 180
totatotoca atacotoago otoagatoag accotttott ttttgtottt ottotottaa 240
tttttaaatg cetetttet tgageattee atetetett ttgaceetet eaggactggg 300
cttagctgtc cagagcctg ccggagggtg ctgggggctg tccctctgca ggcactgtgt 360
tttcctcagg ggctgtcctc agaacacccc tcctgctccc tggggctcct cagggagcca 420
tttcagetgg agtctcaggt ctcaaaaaca acttctccag gaggccaaaa aaagactggg 480
ttggcttctg gtcctcatga tggcttttat cctcctggga cactttgggt atattcatgg 540
geattgttte catetgtett ttetacetgt gecacecetg ceetgattee aeggetgeet 600
caggeaggea ggeaaggage taggeeggtg ceeggeeetg geageaaggg gtetttgtge 660
agttggagat getgeegttg tggcagageg teetgeagee eegetteeat cageaggete 720
tggggtgggg gctttgcagg ggatgctctc tgatgtttgt tccgttgttt aaataaaatg 780
cacttatttt tgtttttttt tttgcaaaaa aaaaaaa
<210> 212
<211> 484
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2009035
<400> 212
Ebitoritta Catgiattat taaatgactg tractoraca aacatatggt tgtrattitt 60
actttttgga taccattata gtgtaggcat ttcccaggtt tttttggtaa caccattttc 120
ttaatgatat gatgttgcag ccagtggatt tattacagtc ttacttatta ttgctctact 180
gttggtcctt tagtttgctt ttcactcttc tatgtaatgc tgtaagaaat gactttttcc 240
ataaactatt ttccatatat tggatgtata atttaacaca ttctaaacat taatgttaaa 300
acagacataa agcataaaaa ccgagatata tatttgatca tataaaaaatt taagctgggc 360
acagtggctc ataccctgta tcccagcact ttgggaggcc aaggtggggg tagactggtt 420
gageteaggg gtteaagace ageetgggaa catggtgaaa eecaacteta eeaaaaaaaa 480
aaaa
<210> 213
<211> 509
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2009152
<400> 213
cccagtttat taccattaga ccatacettt ttgtccaatc atttaaaaca aatttttata 60
```

```
tatataaaaa gttttaataa atacctaata tattatttaa tatgataaaa cttatattaa 180
atgaaatttt atgctgttct cttgtcaatc tgtcttttgt tatcttgctg gtgtgcctgt 240
catgtgaggg actgcaatct gatatgccta ttttccacag tcaaagcaat tacaagagaa 300
ttgttacaat tacccagtta tgtcaagaga ttttttttta attcactaag gtagagataa 360
ggagaatgta ttaaaatagg atattttaat tataaatgca tgactgggga gggggtattg 420
tttttgaata aaatatgagg ttatttgcca tgacaaaaaa aaaaagaagt aggaaaatcc 480
catggaaatt tatgttcctt ctaactttt
<210> 214
<211> 1130
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2061752
<400> 214
ggatttatca cattctgcct tgaatcatag ggaacagcat gtgtagtgga atgaacacag 60
geetetgaat eeaagatatg agtttaaate eeagetttgg aggtggttae ttaaagtete 120
agtgccttca ttcttcttcc tatataaagt agatattaca atatctaact tacagagtca 180
ttgggagcta tacatgcagc gattgggtaa agcacctggc acatggcaag cgattagcaa 240
atgetggtta ettetaette tttetettee etttteecag tetateataa ttteettgag 300
ageaggeace atgtettatt taccettgta ttteceacag tactteecat agtgagttac 360
cettagtaaa taeteagtaa gttgaattga atttaaatta eetgtaagte ttaaaatgtg 420
ggattaaatt aagaatatat tgteetggaa ataeecaaat gtetattgat ggatgaatgg 480
ataaacaaaa tgtggtatac acataatgga atattattca gccttaaaaa ggaatgaaat 540
tetgacatgt getacaatat gatgaacetg gaagacatta tatgtgaaat aageeagaca 600
gaaaaggaca aatactatat gattccactt atatgaagta cctagagtag tgtaattcat 660
agaaacagaa agtacaggtt gacatccaaa atctgaaatg agaaatgctc caaaaactga 720
aactttttca atgccgacac gatgctcaaa gaaaatgcta attggagcat ttcagatttt 780
ggatttttgg atttgggatg ctcaactggc ataatgtgaa tattccaaac tctgaaaaaa 840
tetgaagyst, aaaacaette tggteteaag gattetggat anaggatket caatgtgead $00.
catgtagaal ygrggttgca aggtgggagg agagaatgga gagttactgt ttaatgatac 960°
aatgtttccg tttgggaaga tggaaagttt tggagatgtg tgatggttat ggttgcgcaa 1020
caatgggaag gtacttagta ctgcttaact gtgcacactt aaaaatggta aaaatgataa 1080
<210> 215
<211> 1273
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2061933
<400> 215
attttctccc ttcagcaagc actcattaag gagtgaggct gagtatttta agatagagtg 60
agatctgtga gtgattgaaa ggtgatattt aaaaacttgg atttcattcc agtgtcaggt 120
ttgggtttta agttcctttg gtccagggaa gggtccaagc agccacagtt gccctaaatc 180
tccatcatta agtcttccag caaggttaag tgcagtatgg aaggagaagg gggaagagga 240
cggtaacggc cccacactcc aggctgagaa agagtaatta ggaggcctga ggagggccg 300
aggaaagget gttggggtgt getggggttg gtaccegage geetteeeet caceteaace 360
```

agagaagagc atccggttgc tttttaaagc ttttagcctg ccctagcaag gacaaagcat 420

```
gttagattag agatgettet getgategea ggggttetta tttgaaaaca tetatgatgg 480
gggtggggtg ggaggagaca ggttgtggtt atgcaggaaa atcttgtcct aaaaatatat 540
gagtttgggg gtaaggggtg ggatagccaa gcaaaatcag taattatttt aaaatgaaca 600
tatgtatttt tattaacttt tagttaaata cagattttac aacgaggtca gcataagcct 660
aaatctatat agagggctaa ctcaggcatt gtcttgttta tttgtagact ggattaaaaa 720
caacctgtcc tgttttgtca gttcccagct tcttcgttta gaataaatta gaccaaaaga 780
agaaacgtgc ttgtctctgt atacccgcag aatgaagtta ctgttgttaa aactggattt 840
tttcatttta ctaggttccg aagagtccag atgcttggta gatgttcaat acgtgatttt 900
ttttttaatt gaatgtgttc atttaaaatc ctccttaaca tttctagaaa gacttctttc 960
aataaataat ggaatettag aggaaaagtg gttttttaaa agetagggaa eteeteeact 1020
aaaagtaacc attggaaacc tcgaatgagg gctaaagttt taatcataag agaaaaggca 1080
gcataatgaa atgtgtacac atacatagtc agtggtccat tttaggaagc cagtggcgtc 1140
tetetttatg ttgtttetet tetgagteat ggtaaaacaa taaattatea tetetaggtg 1260
gaaaaaaaa aaa
<210> 216
<211> 1279
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2081422
<400> 216
ctttaacaga aggatggggg atagtcagat agtcggagga agtgggtgat ttgaacaagt 60
tcagagcagg gaggaaggct gtgttgggga cttccagctt gctctcctca tgcatgaagc 120
cactcattce etttetetet eccecacce ttetteccet caetttette etttectcae 180
ttctcctttc ccctctgtgc agagctcttg gcaccagtca agctgtccca cccctcaggg 240
cecteteagt gaetgatgee catggeteee tectectaca eccaaagace etggettgee 300
catgtctctg atgagaattc aaagggagct gtgtttatat aacgtagagg gatttacctg 360
@ggdthttbcc_thtactcast: bcctcssaac_tgtacattta_tggdstaggs=tgtcagtsct@420_
hazagittike thatomasad aglaggtggc aagtaattat tatoataaat coagoagytt 480
ctagagaagc caagttggag gagaaagcag gatagagtcc accatgacca ttgattgttg 540
ggcacattet ttetaagaaa cagattaatt ceattgtate tgttetetgt tateccatae 600
cagettatga ttagagtett gageteacaa ettggteete taagaggtag teagtggtea 660
gegetteage ttgaccacag egtttggtte tttetttaag tgttgtgttg taatgettgg 720
attataaaag cettaacaeg geeccatttg atcagtteee tgeeaactet tgtateetea 780
tttcactaag ctttgttaca ctcactagac tgttaacaac ggagaaaaac ctgtgggtac 840
tgaatatqcc atatacaact tgctatttat tctqttccct qtttaqaaqq ccatqqctac 900
ecttaactat etgaactett eetgteetgt aagaetgage teaetggeaa tateetatag 960
getgetttee ctaageetee ceatetttet teeteectee ttetaettet eteetaeete 1020
ettttccctc tctcccctac tcacctgctt tccttttgcc cctcccacat cctcttcccc 1080
cttcttgtca tttttccatg tcaagaaatt tccagatata taggaatatg atggagaatg 1140
ctgacaggca gttctttgag tagtcaaatt aagatgtaat ggttgaattg tataatggca 1200-
atcacataaa ctacatatat aaagcttcta gcttagtaaa ctctaaatgt gtttttttaa 1260
actaaagaat gagggggg
                                                                 1279
<210> 217
<211> 899
<212> DNA
<213> Homo sapiens
<220>
```

```
<221> misc feature
<223> Incyte Clone No: 2101278
<400> 217
tggtttggga atgettegaa ttttattttt tetaetecea attaateagg agttgatgat 60
cccatgagca ggaccgcctc catgattggg gagcatgcac ttgtgactgc agggtaagag 120
tqqqaaqata ggtttgtgga gtggcaccga caggactgtg attgtgtgtg ggcctgcccc 180
acatttetet gggggatget tatgtgagag tgggeecagt gaaagagtta ecaageeace 240
cacaccecta acactgttet ggatgagaga tgagagcaga ccggcttcte cccatcagtg 300
cattgtgcct gttgtacacc cctggaggag ccctggagcc agcccaggtg gggtacacaa 360
tetttttaaa tteeatatgg ttgeeagett atttetttea ettgtttaet gtaatatetg 420
gcgtgttttt atttatctaa ttttgtattc agttataacc atggtagggg tagtgaatat 480
atgacaggtg taatccctgg tgctgcagtg gaccttcttt tcttttggac aagataatac 540
tgtgagtttc ceteetteet teeetetaat ttgtttteet ttttteecea geetettgea 600
tececttett ttetaceetg teetacaact ateatatgea cagtettete tetttgtgtg 660
tgactgttac aaaatttcac ttttcaaaat cgaaatcagg tgtttgctca aatgagggga 720
gatttttttt tttttttt ttttaaatge tgagaettea geagagtaet tteettttgg 780
tggttteecc caaaaaccca tcagtetggg agagcattgg gagtggaaat catgttgcct 840
gggatgctgg tttctttgaa aattatataa aacgtatgta aaaggtcccc ccatttggg 899
<210> 218
<211> 645
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2121353
<400> 218
caaagtgctg ggattacagg tatgagccac cgcaccgggc ctgttctatt tttctagtta 60
agggaactga agetcagaga ggtgtcacca gcaggtgttc attcccatgc cagccttgcc 120
cebragatita tuccunggalag generigaga geceletigge tecageorgg tectologies, $80,
ಆಳಿಸಿದ್ದಳಿಕೆಲ್ತಣಿಗಳಿಸಲಾಗಿಕೆ tetttgteec gaetetggee etgettacag gggecactae 240
"etgetggtge etceataaca agegtetgge gttgagacee etggeatgge aggggetttg 300
gggtetggtt tecacaagge ttagecatgg cagaaceteg ttttatttta actetttgec 360
cctacaaaca aacagcagta cttgccagaa ccattcttgg gattcaggag ctcgggcgac 420
tgccttggcc tctggccgca cccaggaggg tggggttgga tctgtgtagt tgccaggccc 480
acacctgcca gcagggggct gactggatcc atgctttact gtgtttaatg ggggtaacag 540
gggtccctac agccctccca gctaaacatt tggaacaaaa caccagccct tttgtagtgg 600
atgcagaata aaattgttaa tccaatcacc tccaaaaaaa aaaaa
<210> 219
<211> 703
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2241736
<400> 219
ccacgegtec getgtaaacc agaaaaatgt tggttateta gaaaacttga gagagcatgt 60
agattaactt ttetetttgg agttetaaaa cattaactgg aaagattaga taatatacta 120
aatgtataca gaagtataca gactatacaa agactgaaac aagtcccttt tgcactacaa 180
```

PCT/US99/14484 WO 00/00610

```
ctctataaca ttaccgcaga aattttggtt ctatgtagca tggacctcct aaggaattct 240
gtttctttta gcattgagat ccctggtgct ctttttttac ctcagaattg gtacaatcat 300
tattaaacgt taatttattt caaacttttt aattgaaaaa aggaaaggga aacttaattg 360
gggataaatt caggcatcat attattatga tagagtetee tgagtggtte gtetataggt 420
aatgaactca ttggtgttat ttettggaca tettggeett ttaatcaaag aetgtgtget 480
gctatttgct atgagcaagg tttctcaaaa gcaaaaggtg cttggaccat ttggatcacc 540
tgagttagaa tetetaggta tagggeecag gtatetgeat ttteacaggt ttettgtagg 600
tgactttctg caagctaaag tatgagaacc attggcttgg atgtagttct aaacttttag 660
gtctgtaaat cttgaaatct tgaactgaag gtcaactatt ggc
                                                                703
<210> 220
<211> 536
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2271935
<400> 220
ctttcatcat aattaaagtg ctgtcaggga aaatggcatg gctgagtttt gctgctgttg 60
aaatgaccct ceteetecae teetettege tteteteatt tgetaaagtg gteetttete 120
tgcctgaaat caggcccttt ggtgatggaa attttagctt aaagcagagt tctaagcaga 180
atcctaaccc tgcgagggtg gggagaaaat caatgttttg agctggtgtc tgtttgcagc 240
gaggtgctgg tgaggccatt ttcatcagga ggaacggtgg tggtggctac ttctgggctt 300
tagatecaeg caaggtetee taaatacaag teaetgteat ggtacacaat ttagcaaaac 360
ttggaggetg attttecceg ttgacttage tagggteagg aggaagetgt ttagaagtac 420
aqaqqttctg catctgggag ggtaaaatcc aaacgcctct catgctcaga gggaaagcat 480
gcctgcatgt ttactatcac tgctggccta cgtgcttgtg tgctgaattt agatgg
<210> 221
<211> 790
<2125 以以A
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2295344
<400> 221
ttqacqtttt cttataatga qtttttcttt ataattttta atttatqctg taatgtttct 120
tatttacaat qttatctctt aaatctttqa qtacattaca ttttctcccc tgataatctc 180
ttetaaatta eettetetag ttggttttet teeetteett aatgttagee attetteagg 240
tgaaggttaa\testeaatgt actetteatg tttaagggga gggtetaaaa cettgtgggt 300
aggacttacc aacggagttt cattgcatga tgatcttatt gagcttattg gtagccctta 360
teteagtate tttagttttt ettgggetgg teagatttte aagagaagae tttteattte 420
ctttgtggag ggaaaaggcc ttttaccagc actcttcaag ctcagtaggg gaaagacttc 480
aagcactcag gaagcatgca ttcactttat ttggaacaat accettactt gtaactgtgc 540
ctcaggtgcc atagtccaca gagacttctt ttacctgtcc agagaataaa attagttgtc 600
tgttggggta acaaaaagtg tggagctgaa gagggtacct ataaatgaag ttgttttctg 660
geegggegea gtggeteaeg cetgtaatee eageaetteg ggaggeeaag gtggagggat 720
cacttgagtc caggagtttg agaccagcct gggcaacata ctgagactcc gtctctccaa 780
                                                                790
```

aaaaaaaaa

```
<210> 222
<211> 1045
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2303994
<400> 222
gggaagttga ggctgcagtg aactatgatt ttaccactgc actccagctt gggcaacaag 60
atgagaccet gtetcaaaaa aaaaaaaaag ttttetagaa taagcaggat gattgtttaa 120
tttgaagatg gaacaggaaa ctagagtgca tttaaaaatac tctgtcttca ttttaacatg 180
ttgaatggaa taactgcata tcaccatgag tttgttttgc ttttcataca gacttgtatg 240
tgtcatttga gtggtttcca gattggagcg aggttattct gatctaaatg aacagcattt 300
ttttccttag cctctgtttg ccactctggg tatctctcct atgggcaaag ccattagaaa 360
tgcataaaac ctcgagacat ggtttttggc aaaaactcca tgactttaaa ctagctcttt 420
tactactgac ctttcacaga gaaaaaatat ttcccttgaa aaaaactggg cttgtcattt 480
tttcccttgt agctttaagc agagacataa gtgccttgca ttacacatag taaactttct 540
ttaaaaaaaa aaaaaaagat tttggaqact accagggtaa gattccaact tgtccaaaag 600
etttetggee ttacatattt tattataaaa atteteaagt etggtaatet tetatgteag 660
agctagtgat ttcaaaaggt ttcacaattc cccaagacaa aagtgatttt cgttcattat 720
aataaggtta agtgatatgt gattcataac aattttgatg tgaagaaggg aaggacatca 780
ttgacttaat aatagtatca gtcggtgcaa cagttggcaa catgtgcctt cacactttac 840
cataaagaga cgggtttgag ggtttgcctt ctaaagtctg caacttcaag aaaaaaaatc 900
gacaccgtgg attgaccttc ccgggtccac taatataaag ccaataaagc ttaaaaacac 960
ctttggtaac ccatgtaatt taactccggt ccagtggccc tataattcca attaaaaatg 1020
qttcaatctc ttggaaaaaa aaaaa
<210> 223
<211> 553
<212> DNA
<213> Homo sapiers
<220>
<221> misc feature
<223> Incyte Clone No: 2497805
<400> 223
ctggcagate eggacgggca ggactgggtg tgteccatga gagcacetee tteetggeet 60
ttcctgtgga ctttgtccca caccacctgc ctgggttcct tcctttagtc acttccagct 120
ceaggeacag cagttggtga ctccttggtg ggagccgtgt cccacccggt cctgatactg 180
cogtettete tttcacagte etecaggett gggccageet tgggggcage agagettetg 240
gggtgagtgt cgagatectg tgtectgaga geggtagtea gggagaggge tggtegggge 300
agggctgccc gggcaggaca caggatgcgg ccggccaggc tggggccaag gtgttcagac 360
etggaetttg ggetegtget ttetteatgg ttgegeettg etegetqtee ettggaqtet 420
tcatttggtt ttgctttttt tgtttgtttg ttttcaccta atttttgcca gacttaagct 480
agttttgctg ccttttgaaa ctagtggaag aatcatttta ttcctgggga taatttgggg 540
gcttttgaat cca
<210> 224
<211> 706
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc_feature
<223> Incyte Clone No: 2646362
<400> 224
ccgaccccca acctcaagtt gccgccggaa gagcggctca tctgaacgct ggggcctgct 60
gcagecacca acactgccca ggactgcggg ttgctggett gtacaccgca gctgccaccg 120
agacaccago etetgatgge teaggaggao ttgtggggag aggetggggg cacccatgtg 180
gtgggctctg tgcagcatgt tgcctctgct tggctgtgcc tgcagctcag ggtgctgggg 240
etegggaece accecetge ttgeggaace aacttttete tgtgtgteea geaggeecea 300
caacccctc teetttettt cagttetece atgeageega ggeeegggee ceteaggaet 360
ccaaggagac ggtgcagggc tgcctgccca tctaggtccc ctctcctgca tctgtctccc 420
ttcattgctg tgtgaccttg gggaaaggca gtgccctctc tgggcagtca gatccaccca 480
gtgcttaata gcagggaaga aggtacttca aagactctgc ccctgaggtc aagagaggat 540
ggggctattc acttttatat atttatataa aattagtagt gagatgtaac aaaagcttta 600
ttggtgtgtt tgagctggtg ggtgccacat atttggggat ttgaagaagg aggtgagatg 660
tctggatggg gactgggatg ggtagaggat tcagtgatac tccgag
<210> 225
<211> 509
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 492
<223> a or g or c or t, unknown, or other
<220>
<221> misc feature
<223> Incyte Clone No: 2657146
<400> 225
paaatt\times මුවකර්ද්යයන්ද )tgeetttයල්ව gtréatgige ageataaagt tgeitttigtව ිරී
acaattcatg tigttitgta atggttgatc aaagcaaaga aagacatgtg ttactacgca 120
tgatctgtca atgtttaagg etgttgttgg ttettgtgae tttgetaata tgtttttete 180
ctgacaggtt aacctgccct cttaactcag cagtggttct agcgtcctat gccgtacaat 240
gtaagtcaca aagggagcat ttcacggatg gacaggttgt tctgatcagt gtgtggagaa 300
agteactggt teetectget tgaccaagte eetetteece aggaateetg etgggeagea 360
tatctctggc tgtccagata tgtgtttcta ctcagactgg cactctcctg tagcatgggg 420
atgttagatt aaggaaggtg gttaaagggg aaagaatgaa tgaactgtgg tgtgaaattt 480
cttccaagga gnccatccga cagcagaca
                                                                   509
<210> 226
<211> 2153
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2755786
<400> 226
gaaggeggtg getgaggegg tteeggaggt tetagtgteg gagttgggtg eaggeaggtg 60
ccatgggccc gcttgaggca cactgagggg acgcggggct gggccatggc cggcgctcgg 120
```

```
quequegeeg degetgeete ggeggggtee teggeetett caggeaacea geegeeteag 180
gagetgggge ttggggaget getggaggag ttetecegga eteagtaceg ggeeaaggat 240
ggcageggga ceggeggete taaggttgag egeattgaga agagatgtet ggagetgttt 300
ggccgagact actgtttcag cgtgattcca aacacgaatg gggatatctg tggccactat 360
ccccggcaca tcgtgttcct ggagtatgag agttctgaga aggagaaaga cacgtttgag 420
agtaccgtac aggtgagcaa gttgcaagac ctcatccacc gcagcaagat ggcccggtgc 480
agaggacggt ttgtctgccc agtaatcctg ttcaagggca agcacatttg caggtcggcc 540
acactggctg gatggggaga gctgtatgga cgctcaggct acaactattt tttctcaggg 600
ggtgcagatg atgcctgggc agatgtggag gacgtcacgg aggaggactg tgctcttcga 660
agtggtgaca cgcatctttt tgataaggtc agaggctatg acatcaagct gcttcgatac 720
ctgtcagtca aatacatctg tgacctgatg gtggagaaca agaaggtgaa gtttggcatg 780
aatgtaacct cetetgagaa ggtggacaaa geecageget atgeegaett eacteteete 840
tccatcccgt atccaggctg tgaatttttc aaggaatata aagatcggga ttacatggca 900
gaagggetea tatttaactg gaageaggae tacgttgatg eeccattgag cateeeegae 960
tteetgacte aetetetgaa eattgactgg agecagtate agtgttggga tetggtgeaa 1020
caaacacaaa actacctgaa gctgctgctt tccttagtta acagtgatga tgacagcggg 1080
etgetggtae actgtatete aggetgggat eggacecece tetteatete ecteetgege 1140
ettteettqt gggetgatgg getcateeae aegteeetga ageeeaetga gateetetae 1200
ctcactgtgg cctatgactg gttcctcttc gggcacatgt tggtagatcg gctcagcaaa 1260
ggggaggaga ttttcttctt ctgcttcaat tttttgaagc atattacctc cgaggagttc 1320
tetgetetga agaeccagag gaggaagagt ttgecagece gggatggagg etteaceetg 1380
gaagacatet geatgetgag acgaaaggae egtggeagea ceaceageet tggcagegae 1440
ttctccctgg tcatggagag ttccccagga gccactggga gcttcaccta tgaggccgtg 1500
gagetggtee cageaggage gecaacteag geagettgge ttgeageeet gagtgatega 1560
gagactegge tgeaggaggt gegeteagee ttettggetg egtaeageag eacagtgggg 1620
ettegggcag tagececcag teetteeggt gecategggg geetgetgga geaatttgee 1680
cgtggtgttg gactccggag catcagcagc aatgccttgt gaagaagcca gcccatgaca 1740
ttttcctgct cctctctcag ctgagccctt agcagagaat caaagccatg cctggccgaa 1800
ggggtacttc caggtcaggg gaaatttcag tcccccatct ccatcatgaa catggcagcc 1860
ccaaagctga gcaaggccaa agacagggtt ttccaacccc cagcctcttg actggtgacc 1920
accaccectt ettgtcactg teteccacce accecatett tgetgggatt cecateaact 1980
ctcagaactg tgtggggttt ccctggggcc ttgtggaagc catgacttca caaagaccct 2040
acctgteagt tettgtttet ggggaggagg gateacetge actgagaatg aggeagtttg 2100
acadagatea casaatsana teaaagtett titgastage esassadsaa daa 🗀 🦙 2188
<210> 227
<211> 791
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2831245
<400> 227
ttaactgagg actaagttga tctatgcagg gtctgagtcc aaaccctggt gtcaaggtgt 60
taagtgcaaa ttattattat tattttttaa agaaaacact cttgttacaa tttggacaga 120
gagaatggta tggagatgaa aggttetegt gtatggettt tgeteetatt tatgtggaaa 180
gcacgcccta cattetttca aagetgtgtt gttcccttta ttctcagtcc ccagaattgt 240
gtgcaaacac actetettgg eccaggggtt tggctgggtg tgttteette tggaagtett 300
cactageact cttgagttag ctggcaggag atcccttaaa accatttcca agcagttttt 360
ctcacttccc tataggggct aatcctgtac tttccacttc agttccagct getgttgctt 420
gggaagaaac aaatttctgc tgtgttctca atctccagac ggtccatgaa aatttaatgt 480
ataagaacaa agaggetggg cgcagtggct aacgcetgta atacetgcae tttgggagge 540
tgaggtgggt ggatcacctg aggtcagaag ttcgagaaca gcctagccaa catggcgaaa 600
ccctgtctct actaaaaata ccaaatttgc tgaacgtgat ggtgggggct gttaacccca 660
```

```
qtacttqqqa ggctqaggca qqaaatcqct gaactcggga agcaaaqgtt gcattaaggq 720
tacgageteg aatteggtat catgttaaaa eegttteegg gttaaattgg tateegeeca 780
caattcccac a
<210> 228
<211> 870
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 3116250
<400> 228
cctgttctcg ccctcaaatg ggaacgctgg cctgggacta aagcatagac caccaggctg 60
agtatectga cetgagteat ceccagggat caggageete cagcagggaa cettecatta 120
tattetteaa geaacttaca getgeacega cagttgegat gaaagtteta atetetteee 180
tecteetgtt getgecacta atgetgatgt ceatggtete tageageetg aateeagggg 240
tegecaqaqq ccacagggac egagqecagg ettetaqgag atggetecag gaaggeggec 300
aagaatgtga gtgcaaagat tggttcctga gagccccgag aagaaaattc atgacagtgt 360
ctgggctgcc aaagaagcag tgcccctgtg atcatttcaa gggcaatgtg aagaaaacaa 420
gacaccaaaag gcaccacaga aagccaaaca agcattccag agcctgccag caatttctca 480
aacaatgtca gctaagaage tttgctctgc ctttgtagga gctctgagcg cccactcttc 540
caattaaaca ttctcagcca agaagacagt gagcacacct accagacact cttcttctcc 600
cacctcactc teccactgta eccaceceta aateatteca gtgeteteaa aaageatgtt 660
tttcaagate attttgtttg ttgctetete tagtgtette ttetetegte agtettagee 720
tgtgccctcc ccttacccag gcttaggctt aattacctga aagattccag gaaactgtag 780
cttcctagct agtgtcattt aaccttaaat gcaatcagga aagtagcaaa cagaagtcaa 840
taaatatttt taaatgtcac aaaaaaaaaa
<210> 229
<211> 764
1212 1014 V
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 3129630
<400> 229
gcacctgcga ccaccgtgag cagtcatggc gtactccaca gtgcagagag tcgctctggc 60
ttctgggett gteetggete tgtegetget getgeeeaag geetteetgt eeegegggaa 120
geggeaggag eegeegga cacetgaagg aaaattggge egattteeac etatgatgea 180
teateaecag geaeceteag atggeeagae teetgggget egttteeaga ggteteaeet 240
tgeegaggea tttgeaaagg eeaaaggate aggtggaggt getggaggag gaggtagtgg 300
aagaggtetg atggggeaga ttatteeaat etáeggtttt gggatttttt tatatataet 360
gtacattcta tttaaggtaa gtagaatcat cctaatcata ttacatcaat gaaaatctaa 420
tatggcgata aaaatcattg tctacattaa aacttcttat agttcataaa attatttcaa 480
atecateate tetttaaate etgeeteete tteatgaggt aettaggata geeatgattt 540
cagtttcaca taagaatgtt tactcaatgt ttaagtgtgt tgccccaaaa ttccccaacta 600
acaaggcaga actaggggac ttgacettgg gacetttttg ggteetaaac tecaggtaag 660
tataaacaat ttcaattggc ctttcccctt gccaagaaaa aaaaaaataa aggggcgggg 720
                                                                  764
gggttccccg acccccggaa tttccggaaa cccttggtaa aacc
```

```
<210> 230
<211> 540
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 007632
<400> 230
atettgtgge gateatgtat aagetggeet eetgetgttt getttteata qgattettaa 60
atcetetett atceteteet eteettgaet eeagggaaat atcettteaa eteteaqeae 120
ctcatgaaga cgcgcgctta actccggagg agctagaaag agcttccctt ctacaqatac 180
tgccagagat gctgggtgca gaaagagggg atattctcag gaaagcagac tcaagtacca 240
acatttttaa cccaagagga aatttgagaa agtttcagga tttctctgga caagatccta 300
acattttact gagtcatctt ttggccagaa tctggaaacc atacaagaaa cgtgagactc 360
ctgattgctt ctggaaatac tgtgtctgaa gtgaaataag catctgttag tcagctcaga 420
aacacccatc ttagaatatg aaaaataaca caatgcttga tttgaaaaca gtgtggagaa 480
aaactaggca aactacaccc tgttcattgt tacctggaaa ataaatcctc tatgttttgc 540
<210> .231
<211> 857
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1236968
<400> 231
cacatttgaa cgcgcatgga cttccttcta cctaaacttt cgaacttttt ttagacacag 60
gaagtagcaa gaagggagat gccaagtgac aatcaccagg aagatgcctc tctctagtga 120
ငင်းမှုတ္တန်းခံရရှိ င်းရှိခေတ္တေစည်း teger geaaa ecacagidede cocatedoty coagaandee 200
ccabgigge actgioctea gacagotect ggagotigtg gataagcact ggaatggote 240
eggeteeete eteeteaaca agaagtttet eggaaagttt gaagcaaaaa etggteagag 300
tgctggagga aaacctcatt ttgtcagaaa aaattcaaca gttggaggaa ggtgctgcca 360
teteaattgt gagtgggeaa cagteacata ettatgatga tettetgeac aaaaaccaac 420
agetgaecat geaggtgget tgeetgaace aggagettge eeagetgaaa aagetggaga 480
agacagttgc cattetecat gaaagteaga gateeetggt ggtaactaat gagtatetgc 540
tgcagcagct gaataaggag ccaaaaggtt attccgggaa agcgctcctg cctcctgaga 600
agggtcatca tctggggaga tcatcgccct ttgggaaaag cacgttgtct tcctcctcac 660
cagtggcaca tgagactggt cagtatctaa tacagagcgt cttggatgct gccccagagc 720
etggettata gagetageat ggaacteaca ceacagette cetggtecac agaggetete 780
accepteatty ccaccagtat ggtggtatgt actcacaaag attaagaaag aaatgtattc 840
tgattaaaaa aaaaaaa
<210> 232
<211> 1010
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1334153
```

```
<400> 232
gggaaccacc ttctgtagga cagtcaccag gccagatcca gaaggcttga ggccctgtgg 60
tececatect tgggagaagt eageteeage accatgaagg geatectegt tgetggtate 120
actgcagtgc ttgttgcagc tgtagaatct ctgagctgcg tgccgtgtaa ttcatgggaa 180
aaateetgtg teaacagcat tgeetetgaa tgteeeteac atgeeaacac cagetgtate 240
agetecteag ceagetecte tetagagaea eeagteagat tataceagaa tatgttetge 300
tcagcggaga actgcagtga ggagacacac attacagcct tcactgtcca cgtgtctgct 360
gaagaacact ttcattttgt aagccagtge tgccaaggaa aggaatgcag caacaccage 420
gatgccctgg accetecect gaagaacgtg tecageaacg cagagtgccc tgcttgttat 480
gaatctaatg gaactteetg tegtgggaag eeetggaaat getatgaaga agaacagtgt 540
gtctttctag ttgcagaact taagaatgac attgagtcta agagtctcgt gctgaaaggc 600
tgttccaacg tcagtaacgc cacctgtcag ttcctgtctg gtgaaaacaa gactcttgga 660
qqaqtcatct ttcgaaagtt tqaqtqtgca aatqtaaaca gcttaacccc cacqtctgca 720
ccaaccactt cccacaacgt gggctccaaa gcttccctct acctcttggc ccttgccagc 780
ctccttcttc ggggactgct gccctgaggt cctggggctg cactttgccc agcaccccat 840
ttetgettet etgaggteea gageacecee tgeggtgetg acaecetett teeetgetet 900
geceegttta aetgeecagt aagtgggagt caeaggtete eaggeaatge egaeagetge 960
<210> 233
<211> 1981
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1396975
<400> 233
cagcactttg ggaggetggt ctcgaactcc tgatctcagg tgattcaccc gcctcagcct 60
tecaaagtge tgggattata ggtgtgagee accgegeeeg geetggatet gttttettag 120
cacgcagtga ggaatctttg tacttaaggc cagggcaaca aagtcaagag gtcaaggtgt 180
aggyccatya gyconggane habychycay golagyytti odateocego tycuctagyc 240.
actomoution cargoscage traggeacet gaggaagtea gricagaaat alctageaga 300
qacetettaa acceccatee cageaceeca teetgttgtt eecagagetg gteteccatg 360
agtgtgctag agccagatag ccgtggcccc ccacccatct cactcacaca cacaggcatc 420
catacacccc agaagacttc ccaaatgagg ccagactcag ggtcacgggg aatgtgcttc 480
tgcccctgta agggctttgg ggaaggggc aacatagtag aggctggaaa gagcccccaa 540
acctgtgccc atgcccctcc agccctgcgt ttccattctg ccttctcaga gtgcccttgc 600
tgcacccaga ccaccggcca ggagagacct teteteccac tecageccet etcactgccc 660
ttcaactaga getttcaect ttttacattt eeettetgaa ggacacaaat etgettttet 720
gcccatacac tggcccaagg gctcacctaa cttgggaggg aaggggctgt tggtacaagg 780
atgattttct gttagactgc cattttgcac ggtctccccc ttcccatctg atgtgtcctg 840
cccctcagct ctttgcctta tctgtgtcac tgtcacttta gcaaaaatac agcggccatt 900
tgtatcagcc tctggtggtt gcttgtgagg tgggactctt gcgggaacag gtggactttg 960
ggaggagtgg gcagggaggg agtggtagtg gcagttctcg agctatctga ttaagccatt 1020
ccgttagttc agttgtgccc tggagggcag gggacagggt cagtatctct ggggctgcag 1080
geoctottgc cttggccctc ctggcatggg gtaaccacca gctcagctct cctcctccag 1140
ctttcctctc tctagcacac cccagccagg gcaaggatgc ccacgggcat agctacagca 1200
accectgegg gatttggtgt ccacacega gaggecagge cagatgggaa agggattage 1260
gcctcttccc tcacactctg ccaggctgcc gggagcttgg gccaggtcta aggtaatgag 1320
qtgctcctct tcctgctgga aaaaccggac agactcagaa ccacaaaggc aggtgctgcc 1380
ageotygege ettectetet gettaggety gytgagetty tecaggeety tyceteacec 1440
ettetetett etaggeteag tgtatgetta ateaggeatg gtgeateaga gegggaagga 1500
gccatcaaca gtgtatactt ctggagcctt ctactgataa acagaggccc cagaagacga 1560
tttgacttac ctgagetece agetgggaet taaacecagg tgtgtetgag teacaactet 1620
```

```
teggggatge egtggtgage tggggetgag etcetgtatt eecaeteeee caccecacec 1680
ecacteetge catateaggg etggtetetg tggacteage ceagggetge etcetettg 1740
tcaccccaaa gtggggcagc cagggacagc cagggtgtgt tcagaatggg ttcttcctgc 1800
agggcaggaa gggcagattg ttaaaggggc tgcggcccag accaccctgg tccctcctcc 1860
ggcagtgact cagacccaca ctgtgccgtg cagctgtgtg ccctgcacac ccgcttgacg 1920
gegeactget caettetggg gggeeettte agaggeactt ttaaageaaa taaaacattt 1980
a
                                                                   1981
<210> 234
<211> 744
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1501749
<400> 234
gegeeeggtt eteectegea geacetegaa qtgegeeet eqeectectq etegegeee 60
geogecatgg etgectecce egegeggeet getgteetgg ecetgacegg getggegetg 120
ctectgetee tgtgetgggg eccaggtgge ataagtggaa ataaactcaa getgatgett 180
caaaaacgag aagcacctgt tccaactaag actaaagtgg ccgttgatga gaataaagcc 240
aaagaattee ttggeageet gaagegeeag aageggeage tgtgggaeeg gaeteggeee 300
gaggtgcagc agtggtacca gcagtttctc tacatgggct ttgacgaagc gaaatttgaa 360
gatgacatca cctattggct taacagagat cgaaatggac atgaatacta tggcgattac 420
taccaacgtc actatgatga agactetgca attggtcccc ggagccccta cggctttagg 480
catggagcca gcgtcaacta cgatgactac taaccatgac ttgccacacg ctgtacaaga 540
agcaaatage gattetette atgtatetee taatgeetta cactaettgg tttetgattt 600
getetattte ageagatett ttetacetae tttgtgtgat caaaaaagaa gagttaaaac 660
aacacatgta aatgcctttt gatatttcat gggaatgcct ctcatttaaa aatagaaata 720
aagcattttg ttaaaaaaaa aaaa
<210× 235
<211> 979
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1575240
<400> 235
gggatgaage ceageaagtt cacagggate egggaagttg tgtggetgga aacceaggea 60
gggctgcacc acagggacca tttgctggag atgcagcact tgccacagcc accaccactg 120
acagcatgae acceacaaaa agggageete cagetgeace cetgetgetg egagtaette 180
ctcagctgtc tgccatgagc ttaaggttaa gtaccaggag ggaggatatg attgggcaaa 240
ectcaggcat gtgttcattc tgtagcttcc agaacatgcg aggagagagc atctggctcc 300
tttgtctcga ggaggagggg gcaggactct gccagaactc actcgataaa agattttccc 360
aaaaggaagg gtgttcagat gacaaaagtc cactacacca ctttccttgg ctatctgatg 420
caccccatc ttcccatgcg cgcacctcag aaatcaggct cccacctgac ataacacaac 480
catgoetcae aaaaagacag tggtttatee etteeetagg agaaaagaga ggeaatgeea 540
agetgettea teaactgtta atacttette cageceqeaa eecaqqatat etqeaqqtqt 600
ctctccctct ggtttggtca tggctctctc tgttctagaa tqtatgggtt aaaqtcggct 660
gecacaceat geceteggea gtgtggteea aggaceeetg agggteetea aggteettee 720
tttcccaacc ccacgtggtt ttcttcagtc aggataccat actgcaacag accgaaggcg 780
```

```
gaagcagcta tgaggatgca gcagccttct gttaagccag gctttaagga tctgcaaaaa 840
tgtaaaacga tgccactcct actgatgaaa tatattgttt tggaaaatat aggtttaaaa 900
atttttttaa ggtaacatgt aatggatgta tagtcttcaa atggatgaat aaatgttttt 960
cagagttaaa aaaaaaaa
<210> 236
<211> 760
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 1647884
<400> 236
cecgaetgtg cgccgcgget ggctcgggtt cecgggecga catgggcgcc gccgcgtggg 60
caeggeeget gagegtgtet tteetgetge tgettetgee geteeegggg atgeeegegg 120
geteetggga eeeggeeggt taeetgetet aetgeeeetg eatgggtaag geeteeeaag 180
ccctctgctc agatggagaa actgaggccg ggagaggaaa agccactcct cagatgcgcc 240
cagagacacc ttcacaggtc caggagagaa cctcagagcg ggacggggca tgctcttctc 300
ctetetgeet tagttgeaag ggeacagagg ggeeaacgtg tecaacttte catttgacag 360
atgagaaaac tgaggctggg agaggttacg tgacttgctt gaggtctaag ccagtccagg 420
gtecagtaaa tggagttagt ggggcaggac ttgatgtcac tgacccacgc tggctcctgg 480
tgatttttca ttgattcagc aaatatttat ggggcaccta ttctgtgccg ggccctgttc 540
tetgtactgg gaatacegca gtgaataaga taaacteegt gteettgtag ageetteatt 600
ttagttgggg aagacaaaca attgagaata agtaggccag gcgcggtggc tcacttctgt 660
aateccaeca etttgagaga eegaggeagg ateaettgaa geeaggaget egagateage 720
ctaggcaaca tagtgaaaat ccaatctcaa aaaaaaaaa
<210> 237
<211> 1.080
<212> DNA
2213> Domo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 1661144
<400> 237
tttttttgtat ttttagtaga gatgggteta accatgttge etaggetggt etegaactee 60
tgageteaag egateetett geeteaacet eecaaagtge tgggattgea getgtgagee 120
acceptacecy geographic tetaaateac agtacatety giteceagty cecaggetet 180
cagggcagag ggtccagtgt gatcactttg catggcctct ctcccctcct gagcttgtgc 240
cagggeeeca gggetgaeet ggagaaggaa aatggeagag ggtgaagatg gggtgtettgg 300
tttggggace atectggece ceettgteae tgttggcate tettetgeae agtggcattg 360
ctgggaggtg cttactgtgc ctattcaagg ggctggcagc cgcagcctca ctgcagatca 420
gggaettgge tteeeggttg accaeaggte caagaacetg eagggteeag ceteeecee 480
atccccagtc ttccccaccc tggcccggcc ctccaggtgc agaaacatgc aggcccctct 540
ccaggactgt gggaggagtg tgtccctcag actggcctgt gtcctggctc ctcttaccac 600
ctcttccaga ggttgtcacc tgcagctgcc ccaggataaa ggcaaggcca gagaggactc 660
ctgaactcct gtgtgcctgg ggtggcaggg gcaaacatag ccaactggtg gcctgagcgg 720
ggccatggtg aggacaccet tggtggcttg teccacatea agetgggagg tgacaetgag 780
gatgcattag tetgcagegt atgataaaaa eggcatttea ggecaggegt ggtggeteat 840
gcctgtcacc ccagcacctt gggaggccga ggtgggcgga tcatatgagg tcaggacttt 900
gagaccagcc tggccaacat ggtgaaaact catctgtact aaaaaaacaa aaattatgtg 960
```

```
ggttggtggt gtgcgcctgt aatcccagct acttgggagg ctgaggcagg agaatcactt 1020
gaacetggga ggeggagget acaacgagee gaaattgeae caetgeaete cagegetgat 1080
<210> 238
<211> 1129
<212> DNA
<213> Homo sapiens
<220>
<221> misc feàture
<223> Incyte Clone No: 1685409
<400> 238
caacgtcega cagaacgagg ggacgtaacg gaggcaggtt ggagcegctg cegtegecat 60
gaccegeggt aaccagegtg agetegeeeg eeagaagaat atgaaaaage agagegaete 120
ggttaaggga aagcgccgag atgacgggct ttctqctqcc qcccqcaagc agaggtagcc 180
ccagggaggg gagggaaagg gacggtggag acctgggtta qaccaagggt tataqaagga 240
aagagageta eeteaggget tgaatgtgga etagtegtga ggageagagt geattgette 300
ctctagggtt ttatttcctc cccaccctcc aaattgttag ctcacagcct tacaggaaag 360
gacgggggcg ggcgcctgcc ctcagtctga tttctgagcg tccctgggtc tgaccttaag 420
ggcaagggca gggagcttca catttcaaat acagttgtgg ttacggcagc ccagtacttt 480
tggccctcct tgctgttegg ttctcctccc ttctcccaac ctcctcactg gtgttgctgg 540
gtgtggtcct caatacagaa tagagaccct tgggcctgtg tcaccagact tctgacccct 600
tgggcaacag ccagatggag actggtcgcc ttttgagcct cagetetett cetettgttc 660
tectagggtg ggagtacage agecaaacge tgaacttagt eccatecact tecatettat 720
cetttgtgcc etteateece etgeatettg teetttttge eetetggtae eteccagtge 780
cccatcatct ctacccccag ggactcggag atcatgcagc agaaqcaqaa aaaqqcaaac 840
gagaagaagg aggaacccaa gtagctttgt ggcttcgtgt ccaaccctct tgcccttcgc 900
ctgtgtgcct ggagccagtc ccaccacgct cgcgtttcct cctgtagtgc tcacaggtcc 960
cagcaccgat ggcattccct ttgccctgag tctgcagcgg gtcccttttg tgcttccttc 1020
ccetcaggta gcctctctcc ccctgggcca ctcccggggg tgagggggtt accccttccc 1080
agtgtttttt attectgtgg ggetcaecce aaagtattaa aagtagett
<210> 239
<211> 2370
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 122, 124
<223> a or g or c or t, unknown, or other
<220>
<221> misc feature
<223> Incyte Clone No: 1731419
<400> 239
agaaacttgg cccaagtttg tgacggttct gggtatgaaa gaagtcagtg tttcccaagt 60
gcctgccatg tgcgaggctc tgtgctgggg cgggtgcatg tgtgcgttgg gggcgtggac 120
angnggggtg ggaaaggcct gtgacatttc ctctggtggt ttccacgaac ccaggcgtca 180
ecceteggtg gagataaagt ggageeacce agetecaceg tgteteagee tggggtegge 240
ctetgetget tetggaetea gtgaeeetgg getgteaggg agettetgag cettggtttt 300
cctgtcgagt aagatggagg taatcgtgtc ttatggggtt gttttgaggg ttaaatgagc 360
tggtggctgt gtgggaaaga getetgeete eegeagggag gaactgtget gttettatta 420
```

```
ttgtgaactt agtgacaagt gtggcactat tacccatttc cttgtctgcc cccaaccctg 480
gggtettggg cagagaacag gagttettge cattttetee cageteecae ettgtgetgg 540
cttgcgggtg ctgaggtcat atttgctggg tgaaagggtg caggccagat atgagccagg 600
cetggcagag agggttttgg teageagtga tacetgeagt gttetetgea gttggtttgg 660
getggeeetg eteetgagaa eteetgggtt gteeetteag geaaceaggg aaggeteett 720
ggagcagcag cateteceet taceaetege egacaeeage tteegeetga eeeagagaag 780
gagtttgggg acagccacag cacgtccagg gcttccaagg cagctggcag agccaatgag 840
gagaccccaa cacccatccg acggctgcag ctctccctga cgtgtgttac cgcagccctg 900
gteccagecg ctgtgettet cagggeetge etgeccagec egggtggata tggtgeccag 960
gegggeeeeg gggacacaat gagggeeatt etcagageea ggeagagegt gtggggeagt 1020
cctgtcagtc ctatgtgcaa cagctgggat attgtttagg gagtgctggc atcaggccgg 1080
ggeteteete etetggeeet geeetttggg atgageaage eeecaaagge etteetgggt 1140
teetetggtg caegtgeeet ggagttaeee ttetgaagga ggtagaettg teeteetgte 1200
ctgggtgcct ggggtgcagg ggtgtgaatt gggctatgtc aagatatgct gggcagtact 1260
gtgaggtggg ggcagagggg agaaggtgtc ccaggaggag ccttcctgga ggggatgata 1320
gtccagcatg ttctgaagtg ggagtagggt gcggcaggag tagggtacca gagaatgagt 1380
gagtcaggca geagecteca etgegeettg gacacaggtg geegacagtg tecacetgga 1440
etggetttge acceettetg aggteacagt tgtgteeett gaaaacttgg geaggageae 1500
ctgactggcc cagcttgggt catgccctag gcccagcagt gcgggaggcc aggaaagtag 1560
gettggggag getggeetet cetecagttt gaageatgge aggggtteeg ggggaggetg 1620
etggggggcc tgcgagcatg tccagagcag gaatgettgg ggtggtgtgt getttgetcg 1680
tetgggetta tetggeegtg gggaagetgg ttgtgeggat gaegtteaet gagetgtgea 1740
egeateatee atggagtetg eggtgtgagt cettttgeeg etecagggte acageetgee 1800
tecetgetee agecceetgg etgaggeeet teetetgeee eatgetette teagacagga 1860
atcctgtgga atgtcatctc tttggggagg ccgtctctga ccctgtatgc aaaggccttc 1920
tcccacatta tttttggcac cccactttct tccccgtgaa agcaaattgt ttggtgtctt 1980
tetgteceae tacagtatag geeeggttea gacagaggee ttgtecaeta ggeetgeget 2040
atctctgcgg agcccagcca aagcaggggc caggcgaatc ttttgttaaa agaacaatgc 2100
gegetgggea eagtgeteae geetgtaate eeageaettt gggagteega agetggagga 2160
tcacttgaac ccaagagttt gagaccaccc tgggcaacat aaggagaacc catctctaca 2220
caaaattagc tgggcgtggt ggtgtatgcc tgtagtccta gctacttggg aggctaaggt 2280
gggaggtgge tgaggtggga ggateaettg ageetgggag gttgttgeag tgagageeat 2340
gategegeta etgggeaata gageagaace
                                                                  2370
<210> 240
<211> 981
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2650265
<400> 240 ·
cggactgccc tgagggcggg aaagggtggt cactgggtca gcccgaagca cctgacatga 60
gggcggggac cccgaaatgc acacgaagtc cggaactggt cttctgtgat tttcattcgc 120
cctggtctct gttccctttc gtactcaaag ctcgtgcatc cagggagggg aaaccggaga 180
tagggtette gggeeeeggg eagaeeetet gtgeegetge aaaeegttge ageetgagge 240
tgtcaggtcc tcccccagac acctgcggac cctccctctc ctggcttccc gtctggtcat 300
ggogagattc tgggtotgog tagooggtgo tggottottt ottgcatttt tggttttgca 360
ttcgcgtttt tgtggctctc cagttttgag gaactttact tttgcagttt cctggagaac 420
tgagaaaatt ctttaccggc tggatgtggg ttggcctaag cacccagaat attttaccgg 480
aacaacattt tgtgttgcag ttgactccct caatggattg gtttacatag gtcaaagagg 540
ggataacatc ccaaagatat tagtgttcac agaggatgga tatttcctac gagcctggaa 600
ttatacagtt gacacacctc atggtatatt tgcagccagt actctatatg aacaatccgt 660
ctggatcacg gatgtaggaa gtggtatgta tagtaatatc tattaaatta tcttactgga 720
```

```
aatcacatct ttgcacatgt cettgtttgt attgtttaaa atcagagttg ctgaatctaa 780
ttgtaatttc tttaacgatt catgaaatca catgttttta acaaacttta ttttgtactt 840
ctgtggaatt aagaaattta acaagggetg gacgccgtgc tcacgcctgt aatcccagca 900
ctttgggagg ccgaggcggg cggatcacga ggtcaggaga tcgagacgat cctggccaac 960
acggtgaaac ccccgtctcc a
<210> 241
<211> 1204
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2677129
<400> 241
aqqaqaqqaa ggtaattaca ttaagcatta taatataqtg tqttaaatgc taatgatcat 60
aatcattgaa cccttctcag tcctcatctt atttaaatct qqtattttag cagacttttt 120
tgccttactg ctattaatta atttttttt ggtctctttc ttccttgctt accctttgtt 180
taacaaccaa atcaactcta gatcaatgaa tgaaataaaa aatctccagt acctacctcg 240
gaccagtgaa ccccgcgaag ttctctttga agataggact agagctcatg ctgatcatgt 300
eggteagggg tttgaetgge agagtaegge tgetgttgga gttttgaaag etgtaeaatt 360
tggtgaatgg agtgaccaac ctcgcataac caaagatgtg atttgttttc atgctgagga 420
ttttactgat gttgtacaaa gacttcagtt agatcttcat gaacctccag tttcccagtg 480
cgtacagtgg gtagatgaag ctaaactaaa ccaaatgagg cgggaaggca ttcgttatgc 540
tagaattcag ctttgcgaca atgatatcta cttcatccct agaaatgtca ttcatcagtt 600
caaaacagtt tcggcggtgt gcagcttagc ctggcatata aggcttaaac agtaccaccc 660
tgttgtggaa gccactcaaa acacagaaag caattctaac atggactgtg gtttaactgg 720
aaagcgagaa ttagaagttg actcccaatg tgtgaggata aaaactgaat ctgaagaagc 780
atgcacagag attcagctgt taacaactgc ttcatcatct ttcccacctg catcagaact 840
taatctacag caagatcaga agactcagec tattccagtt ttaaaaagtgg aaagtagact 900
ggactetgae cagcaacaca atetgeaaga acatteaace aettetgtgt gatatgtaca 960
tattcaaaca gatttttthaa obsttttaaa ttstgatgtg aagttatagt tttataactg 1020
guttäegtta-agtttttattg gagaaatett geetataatt etataaagag aaatgacatt 1080
cacaaatgte agcatatett tttacacaga tatgeaagtt agagtgtate tateeggtag 1140
tacgtatgta taagtggtct gegeacttet gttttaaggg tgaggtacat ceatetetet 1200
cgag
                                                                  1204
<210> 242
<211> 784
<212> DNA .
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 3151073
<400> 242
cacagacaaa cegtcaacag etggtetege atgteetttg tteeeggtet getettgtgt 60
ttegttetee teetgtgtgt tagecetgtg tacetteeet etegtteace etecacattt 120
cccatctctg agcccctcag ctttataggg atgtcagctt ggccccaatg tagtcccatt 180
tacagecaga etcetggaet tgeetatgag ecatetteat ttecaaaaag gegatattgg 240
gtatgtacat tgcatgaaat aaagtgggaa tgtcccagaa gcagaaggac atctgatgca 300
gtccacgcca ataaattggg cttaccttta aaaatcatct gaatatgcag gtcttagggc 360
agagaatata gacagcttaa gattttctaa actacaagtc ccacccaaaa tacggtattt 420
```

```
teatgattte ceaaaggttg accateagea agactggata ttttteagae ttaagatgae 480
tgttcagtag ctgatgttct ggaaaagatc tgggccttca ccatgaaatc ttaaatgtga 540
gcagttactg gatgttgaat ttgaaaccta ttcatttctt tttttaaaac aagcttggtc 600
atttctgtgc aatgctataa ttcggaacga aacaaagcac aatgttaata aggtagacac 660
taattcattc ctctgaagag agatctcttc cagacatttt aagccagggc aagaaatgtt 720
taaagatgtt ttctgcagtt gccgtagaaa cactccttag cagtcatctt ggctgttggt 780
aaaa
                                                                  784
<210> 243
<211> 426
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 3170095
<400> 243
ctccattaaa ccaccaccag ctccccaagc cacccttca gccatgaagt tcctqctcct 60
ggtcttggca gccctcggat tcctgaccca ggtgatccca gccagtgcag gtgggtcaaa 120
atgtgtgagt aacaccccag gatactgcag gacatgttgc cactgggggg agacagcatt 180
gttcatgtgc aacgcttcca gaaaatgctg catcagctac tccttcctgc cgaagcctga 240
cctaccacag ctcatcggta accactggca atcaaggaga agaaacacac aaaggaaaga 300
caagaagcaa caaacgaccg taacatcata ataaccactg ctatcgcctc caccaactca 360
gagaaatate atttecacag ttecaattee tectacattg etgagtacta gecaaggete 420
ctcttt
<210> 244
<211> 1732
<212> DNA
<213> Homo sapiens
<220>
<221>
<222> 1651, 1655
<223> a or g or c or t, unknown, or other
<220>
<221> misc feature
<223> Incyte Clone No: 3475168
<400> 244
egggaceaga geaegtteet ggetgeagag geeaeaagte aegetgtete tgagagtgga 60
atgtcaccat cgcccaggtg gggatttttg tgtgttttgt tcactgctgt acacccagcc 120
cccagcacag cgcctgtcca ggacaagtgc ccagtaaaca cttgggaagc aatgcaagcg 180
tecteccage agetectgea aacagaceee egacecaage ettteettet geetecactg 240
ccaccactgc tgctcatctc tgctggcaca gaagtetett ccctggtett ccagaaatcc 300
cetetecaca etcagecaga gggagetatt aaaactgegg gecageceae atcagtecae 360
agcaaagtee tetetaaggg atetetgttg ettggagaat aaaccetegg atteetteet 420
tggetetegg ggeeteetet etgaeeteee tetgteteet etceeageet teeteeteae 480
teacceteca gecatgetgg etteeteett geteetgaaa eageetgaga gecacaetge 540
ecegggeect tigeactgge tgttteetet geetggagea etteteetag geatecaeag 600
ggetecetec cacaacteet tegggtgeec acatgggaag ceatecetga ecaececece 660
gactteette tgageaaggt agggtettte tacctagtea tgagggeagg gatttttgte 720
tgttgtgtte tetgtgtgee cecagtgeea 'teccagtgee tggeagatgg taagtgeteg 780
```

acacacattg gctgactgcc tgaatgaaca actctatgag ccgatggcag ataaggacac 840

```
tgaggteete tggggtaggt gaccageeca aggecacaca getggtetga gattaggeca 900
ggagaggage cegggttggt caeateetgg agttggegte ttggaaaetg cateaggaga 960
ataacaaaga tgagacgcag gctctaacaa gtggatacca gtgactctcg ccccgccagc 1020
cecagecetg cageettggg ceettecagg agteatggte tgeetgeetg gggeafteca 1080
ggettegace caggteetge actttetatt ttgageetet tagteetgag gaetgtgtgt 1140
teccageagg eggegegge eagaggetga geetgggtgt ggetgteace etatetgggg 1200
ccagagaccc agattcccgg gcccttaacc tgttggctgc tgagggctct ggcataagcc 1260
etgtteeetg ettgattgte teeeetteaa geeeetgeee tggtategta teggeecate 1320
teacettgga ttatateeet gtttggeeee atttgaatee tggetetgee eettteeage 1380
aatgtgacct tgggcaagtc acttcatctc tctggtctca gttcttcatc tggaaatggg 1440
acaataagag tacctgtctc tggccatgtg tggtgactca tgcctgtaac cccagcgctt 1500
tgggaagccg agccgagaga attgcttgag accaggagtt tgagatcagc cctgggcaac 1560
atagtgagac ccctgtctct acaaaattct aaaaaaatta qccqgttqtq qtqqtqtq 1620
cetgtagtee cagetattet agaggetgag neggnaggat tgettgagee cageagtttg 1680
aggetgeagt gagetatgat tatgecegtg aaggeeeec aaaaaaaaaa aa
<210> 245
<211> 918
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 3836893
<400> 245
agectetagg teattgtggt geettgtage tgteeeggga geeetcagea geagttggag 60
ctggtgcaca ggaaggatga ggaagaccag gctctggggg ctgctgtgga tgctctttgt 120
ctcagaactc cgagctgcaa ctaaattaac tgaggaaaag tatgaactga aagaggggca 180
gaccetggat gtgaaatgtg actacacget agagaagttt gecageagee agaaagettg 240
gcagataata agggacggag agatgcccaa gaccctggca tgcacagaga ggccttcaaa 300
gaatteecat ceagteeaag tggggaggat catactagaa gactactatg atcatggttf 360
actigogogto ogsåtögster adottomagt ggmagmattet ggmatgtate meteretat 420 -
ctaccagect eccaaggage etcacatget gttegatege ateegettgg tggtgaccaa 480
gggtttttca gggacccctg gctccaatga gaattctacc cagaatgtgt ataagattcc 540
tectaceace actaaggeet tgtgcccact etataceage eccagaactg tgacecaage 600
tecacecaag teaactgeeg atgteteeae teetgactet gaaateaace ttacaaatgt 660
gacagatate atcagggtte eggtgtteaa cattgteatt eteetggetg gtggatteet 720
gagtaagage etggtettet etgteetgtt tgetgteaeg etgaggteat ttgtaeceta 780
ggcccacgaa cccacgagaa tgtcctctga cttccagcca catccatctg gcagttgtgc 840
caagggagga gggaggaggt aaaaggcagg gagttaataa catgaattaa atctgtaatc 900
accagctaaa aaaaaaaa
<210> 246
<211> 676
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 4072159
<400> 246
getcacacag ctcccggcca ggtcacccgc catggtcctc cctctgccct ggctctctcg 60
```

```
gtaccatttc cttcgcctcc ttctgccctc ctggtccttg gcaccccagg gctcccatgg 120
 gtgctgctcc caaaacccca aagcaagcat ggaagagcag accaactcca gaggaaatgg 180
 gaagatgaeg teeceteeca ggggeeetgg gacccacege acagetgage tggeeegage 240
 tgaagagttg ttggagcagc agetggaget gtaceaggec etecttgaag ggeaggaggg 300
 agcctgggag gcccaagccc tggtgctcaa gatccagaag ctgaaggaac agatqaggag 360
 gcaccaagag agcettggag gaggegeeta agttteeece agtgeecaca geacceteeg 420
 gcactgaaaa tacacgcacc acccaccagg agccttggga tcataaacac cccagcgtct 480
 teccaggeca gagaaagtgg aagagaccac aaacegcagg caattggcag gcagtggggg 540
 agccaggget etgcagtett agtcccattc ccetttgatc tcacagcagg cagggcacca 600
 caggeettae taggaattea eeetggaeea tgeeetaaaa taaceteaee eeaaatacaa 660
 taaagggacg aggcaa
 <210> 247
 <211> 2255
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte Clone No: 1003916
 ceggtgegte etgggtetgt etgegeggag tteeeegggg egegaggaga ggggaetgga 60
 gaaagaggag ggccgggcag cggaggggag gaggcggtgc gtgcctcgcc tgccaaaggg 120
 agateegete etetgegtge gateeeegge geeegeege geeeaeageg eteegeeaga 180
 getgeegeeg eggaetegee gggagtgggg gteteegetg gtgeeageee gettetggag 240
 acceteegee teetgeeaac ceetgetett eeaggteggg ceeeggggtt etgeggetgt 300
 tagggacaga ggcaaagaag ggcaggacgg tccggtttcc cgtggatgtt cccgcccgag 360
 aaagacagca agttgtgtgt gcgcccggga cgcgggaggg aaggtagccg ccgcccgcca 420
 gecatggace atcatettta gtgeagagga tggaaagttg atgeecagta agaetgaaga 480
 tccattctgc attacggaac tgtggattat ctgtgggtcc ctggtgattt cacaccttca 540
 ttcactcctg cagtccctga acacttactt ggggtcctca ttgccctatc tggtgaaaga 600
 tgggatgdag cetggettyt actggagtaa totgggettt getgletttt entttgtgetg 660.
_{
m s}phhich subsets agragative tithat georgia actigaeteta {
m gagarrian} ac{
m gagarrian} {
m gagarrian} {
m gagarrian}
 etgtgteett eggtacette eggaggtget eatateetgt geatgatgag agteggeaga 780
 tgatggtgat ggtggaggaa tgtgggeget atgeeteett eeagggeate eecagegeag 840
 aatggaggat ctgcaccata gtgaccggcc tgggttgtgg cctcctcctc ctggtggcgc 900
 teactgeeet catgggttge tgtgttteeg aceteatete caggacagtg ggaagagtgg 960
 etggaggaat teagtttett gggggettgt tgattggtge tggetgtgee etetacecet 1020
 tgggctggga cagtgaggaa gtccggcaga cttgtggcta cacttctggc cagtttgacc 1080
 tggggaagtg tgaaatcggc tgggcctact actgcacggg agcaggtgcc actgccgcca 1140
 tgctgctgtg cacgtggctg gcttgctttt cgggcaagaa acagaagcac tacccatact 1200
 gagatggage taccaagage agacagagga gaagatggge caaagggget tggagaggte 1260
 aaaacatcca cctaccttca aaaggtggga tagtagttct aatccaatac aatgctaata 1320
 aaatgaaacc cgataaaatc aggaacatga tataggaagg aaggattgta ggagatttgt 1380
 gggggaaaaa aaaggagagt atagaatgat ggagaaaaat ggaccaaagg ctaaaaatat 1440
 tgcagggcat cgggtgtttc tattccacag agtattgtta atgtacaaca cacacacac 1500
 cacacacaca cacacacaca cacacacaca acaaatctac atatacaaac aagggtttgg 1560
 gttttagttt tttttttta aggtgaggac tcagaaaatc aaagggctag tagaaacagt 1620
 gttatgttgg gaagcagggt acccccaaag atgttccctg taggtcacgg cactcccaaa 1680
 agcacacaag cacatacaga catatgcatc cccacacacg cctatgcaca aacgtggatt 1740
 atcgcacaga ctgggaggtt tagtggtgca tttctcctct gttttctttt taatatacat 1800
 ttaaaaataca gtattatcac tttataaaac atacattaag cctaataaat ggaccaataa 1860
 gecaaactat cagtattttg tatateetge ataaacteta atttagttee teaacatatt 1920
 ttcagtgttt atgcagacct ttagagttaa gcctttgtat ttccatgtta ttccacaata 1980
 tgcaatattt ctctgagtag cttctgctat gatattctta tgaagaaaag gggcaacttt 2040
```

```
ctgtccacta taggagagaa ttcagccgaa gatatgagag taatgagaga cattttccag 2100
teattggate gtgttttett ttgteeatta ttgtaetgtg etgtaecaea tttatteta 2160
tattcatttt gtaaaaaatt taaaagtgct attttgtttg tatttgaaaa tctctqtqaa 2220
taaattctct ctttgatcaa tagcaaaaaa aaaaa
<210> 248
<211> 1223
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2093492
<400> 248
gaegetteac cagegteetg gtggtgteea gteteteace cetgtgegtg etgetetgga 60
gggaactcac aggcatccag ccaggcacat ccctgctcac cctgatgggc ttcaggctgg 120
agggcatttt cccagcggcg ctgctgcccc tgttgctgac catgattctt ttcctgggcc 180
cactgatgca getetetatg gattgccett gtgacetgge agatgggetg aaggttgtee 240
tggcccccg ctcctgggcc cgctgcctca cagacatgcg ttggctgcgg aaccaagtga 300
tegeceeget gacagaggag etggtgttee gggeetgtat getgeeeatg ttageaeegt 360
geatgggeet gggeeetget gtgtteaeet geeegetett ttttggagtt geeeatttte 420
accatattat tgagcagctg cgtttccgcc agagcagcgt ggggaacatc ttcttgtctg 480
etgegtteea gtteteetae acagetgtet teggtgeeta caetgettte etetteatee 540
geacaggaca cetgattggg ceggttetet gecatteett etgeaattae atgggtttee 600
cagetgtttg egeggeettg gageacecae agaggeggee eetgetggea ggetatgeee 660
tgggtgtggg actetteetg ettetgetee ageeesteac ggaeeseaag etetaeggea 720
geetteeeet tigigigett tiggageggg caggggaete agaggeteee eigigeteet 780
gacctatget cetggatacg ctatgaacte teaceggete cecagecete eccaceaagg 840
ggtactgcag gggaagggct ggctggggtc cccgagatct caggaatttt tgtaggggat 900
tgaagccaga gctagttgcg tcccagggac caagagaaag aagcagatat ccaaagggtg 960
cagccccttt tgaaaggggt gtttacgagc agctgtgagt gaggggacaa ggggcaggtc 1020
chaggangona nacactocct. Enchoacttt gganlogstgo thutchtago tuckbtocht 1050 1750
ក៏ដើម្បីដឹងថ្ងៃក៏ ឬកែកឡើមួញដែរ tittaittat aaacoicte eccacecee accecesae T140 🗀 🕒
ttcctgggtt ttctcattgt ctttttgcat cagtactttg tattgggata ttaaagagat 1200
ttaacttggg taaaaaaaaa aaa
<210> 249
<211> 1188
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2108789
<400> 249
gcccctccca gcctgccaag aaaacggtag gggagcatga tggggccttt gaggcagggt 60
cgcagggaca agctcagctt taggcaccat ctgttcccat cgcgcctgct gctgtgaccc 120
gttttggaaa actggtgtgt accgaggcgc tgactgcacg gctgaccgcc tgctcgtgcc 180
tteattetge ageggeatgg teceteceat tetggeteea eetgeageet eeetgggtgg 240
cctaggetee eecgaceaag agaceteeet eteatgatea etggtacetg ggggeetgaa 300
ttctggcccc cggctcccca cacagctggg actggcctgg atggctgtcc tggtagcccc 360
tgcccaccct gacagaggga gctgggcctc ccctcatcct ctgtaactcc cgccttcacc 420
agaetegagg acaecetgge cetgetgagg catacagage tteageceag cacagaagea 480
```

```
agacaaaatc agtggctctt agagtttaga aaacaagaca gactctcaga tgaaagatct 540
gacaagcace gtggccagtc acagggagag acttgatgtc tggcctttta attcctcctc 600
tgccagggtg ggtcctggga cctctaatgt gggcatgtcg tccaccccag gacgagccat 660
cagggacaga coccccacco ccaaggctgc agccacacca tgtttcaggc ttggggctgg 720
ggcaggettg ggetcaatce tgggcaceca ggggcagece accectaace tggctectac 780
ccaccttgcc cttgaaggat gggcctgctg cacgtctccc tcctccaccc cataccacac 840
tggggggtet gagecaecce ceteagecee gtteggetea gaeegaeece caetecatee 900
ccagacetge agcacaagtg cgcgggcctg tecteccagg ggcctgggcg actecatatg 960
caatcagtag cgagcagccg ggccccacag accetcatge actetettac gtgccattet 1020
ccccagactt tttttgtact taatgtatga aagatccaaa ctaatattgc tgtaaaaagg 1080
agagacaaat taatataget tattetataa atatatetgt atataaaggt ttetgtatat 1140
tgtatagagc tgtgtataaa ctggatgtag aagcacaaaa aaaaaaaa
<210> 250
<211> 1792
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2171401
<400> 250
cgccgctggg gccggcccgc acggcttcat ctgagggcgc acggcccgcg accgagcgtg 60
cggactggcc tcccaagcgt ggggcgacaa gctgccggag ctgcaatggg ccgcggctgg 120
ggattettgt ttggceteet gggegeegtg tggetgetea getegggeea eggagaggag 180
cageccegg agacagegge acagaggtge ttetgecagg ttagtggtta ettggatgat 240
tgtacctgtg atgttgaaac cattgataga tttaataact acaggetttt cccaagacta 300
caaaaacttc ttgaaagtga ctactttagg tattacaagg taaacctgaa gaggccgtgt 360
cctttctgga atgacatcag ccagtgtgga agaagggact gtgctgtcaa accatgtcaa 420
tetgatgaag tteetgatgg aattaaatet gegagetaca agtattetga agaagecaat 480
aatctcattg aagaatgtga acaagctgaa cgacttggag cagtggatga atctctgagt 540
gaggaaacad agaaggotgt tottcagtgg @nccagcatg atga@bottc agataacttc 600 /
ම්පූදියක්ලදේපු සුදුම්ක්රීන්දයක් අද්දේශයේ ලදේශක්වන් tagatifieget tertaatect 660
gagcgctaca ctggttacaa gggaccagat gcttggaaaa tatggaatgt catctacgaa 720
gaaaactgtt ttaagccaca gacaattaaa agacctttaa atcctttggc ttctggtcaa 780
gggacaagtg aagagaacac tttttacagt tggctagaag gtctctgtgt agaaaaaaga 840
gcattctaca gacttatatc tggcctacat gcaagcatta atgtgcattt gagtgcaaga 900
tatcttttac aagagacctg gttagaaaag aaatggggac acaacattac aqaatttcaa 960
cagcgatttg atggaatttt gactgaagga gaaggtccaa gaaggcttaa gaacttqtat 1020
tttctctact taatagaact aagggcttta tccaaagtgt taccattctt cgagcgccca 1080
gattttcaac tetttactgg aaataaaatt caggatgagg aaaacaaaat gttacttetg 1140
gaaatacttc atgaaatcaa gtcatttcct ttgcattttg atgagaattc attttttgct 1200
ggggataaaa aagaagcaca caaactaaag gaggactttc gactgcattt tagaaatatt 1260
tcaagaatta tggattgtgt tggttgtttt aaatgtcgtc tgtggggaaa gcttcagact 1320
cagggtttgg gcactgctct gaagatctta ttttctgaga aattgatagc aaatatgcca 1380
gaaagtggac ctagttatga attccatcta accagacaag aaatagtatc attattcaac 1440
gcatttggaa gaatttctac aagtgtgaaa gaattagaaa acttcaggaa cttgttacag 1500
aatattcatt aaagaaaaca agctgatatg tgcctgtttc tggacaatgg aggcgaaaga 1560
gtggaatttc attcaaaggc ataatagcaa tgacagtctt aagccaaaca ttttatataa 1620
agttgctttt gtaaaggaga attatattgt tttaagtaaa cacattttta aaaattgtgt 1680
taagtotatg tataatacta etgtgagtaa aagtaatact ttaataatgt ggtacaaatt 1740
```

<210> 251

```
<211> 2005
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2212530
<400> 251
gegaggeggg aggaggtgag geteeggege acaeccaaac egegetgege eegeteette 60
cgggccccgg agatggcgcc tccaccggga tgagctagcc agcctgggca ataccagagg 120
eggecetegg egegegeagg ggacegaget ggtegeecca acegggtttg atttetgatg 180
actctggcct gagttccagg atggtttttt cttgggacca gacatgaaca aaagttgacc 240
teatgageae tteaacetet eeagetgeea tgeteeteeg gaggetgegg egacteteet 300
ggggcagcac tgctgtccag ctcttcatcc taacagtggt gacgtttggc ctgctggccc 360
ccctggcctg tcaccgactt ctacactctt acttctatct gcgccattgg catctgaacc 420
aaatqaqcca agagttcctg cagcaaagct tqaaaqaggg tqaqqctqcc ctccactatt 480
ttgaggaget teeetetgee aatggeteag tgeeeattgt etggeaggee acceeegge 540
cctggctggt gatcaccatc atcactgtgg acaggcagcc tggcttccac tacqtcctqc 600
aggttgtgtc ccagttccac cggcttcttc agcaatgtgg cccccagtgc gaggggcacc 660
aactetteet gtgcaacgtg gagegtagtg tgagecattt tgatgccaag ttgeteteca 720
agtatgtccc tgtggccaat cgctatgagg gcactgagga tgattatggt gatgaccctt 780
cgaccaactc gtttgagaaa gagaagcagg actatgtcta ttgcctggag tcatccctgc 840
agacctacaa cccagactac gtcctgatgg tagaagacga tgctgtacca gaagagcaga 900
tetteceagt ettggageae ettetgeggg etegettete tgageeacat eteagagatg 960
ccctttatct caagctgtat caccccgaga ggctccagca ctacatcaat ccagagccca 1020
tgcggatcct ggaatgggtt ggtgtaggca tgttgctggg gcccttacta acctggatat 1080
acatgaggtt tgccagccgc ccagggttta gctggcctgt aatgctcttc ttctccctgt 1140
atagcatggg tetggtggag etggtgggte ggeactattt eetggaactg eggeggetga 1200
gtccttccct gtacagtgtg gttcctgcct ctcagtgttg caccccagcc atgctcttcc 1260
eggeacetge ggeeegeegg acceteacet acetgteeca agtgtactge cacaaggget 1320
ttggcaagga catggcactg tactcgctgt tgagggccaa gggagagagg gcctatgtag 1380
tggagcegaa cetegtgaaa cacateggge tettetecag teteeggtae aaettteate 1440
committeet gragginges assagation Ottoggmagt toggmastic tigaciatio 1500
deatathman crotttatht agasatggtr gootgoaggt atticactgt ttactgttgt 1560
tagagatata ggcactgggg cagctgagga acctcaatat gttaagagcc ttggctttgg 1620
tagecteetg geaggageag cagtttgeea eaggteegga eeteteeete eacacageea 1680
cactgoctca tgcagtctga cccacccagt gagggtgcat ttgaacactg attatattct 1740
ccatttgttt ttaagctctg ctttgtgtta gagcttgtga ctgccaaaaa ttttgtgcac 1800
agtgatatga ctgttttagg atcttaaggg tagaattttg tgaaaggtga gatcctttgg 1860
aattgagttc tttctcattg ggtatgaaaa tggatgtatg tttagaatat atgcccaacg 1920
aggeaggace atgtggatag attecatttg tttccttgac ctgatgtaat aaaaactgat 1980
aaaagccgtg cagtgcccgg catct
                                                                  2005
<210> 252
<211> 471
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2253036
<400> 252
tgggtatgtc tcatggagag gtgctttcac tgcttccctg ttcacctagt cttcaatctg 60
gtccagagtt tcagccccat ctctggagtt gagtcctgcc ttctccctca atgtgacaaa 120
```

```
tgttggccaa tggtatatcg cagttgtgat gcaagcagag gcttggtaaa tgcctgcata 180
ctggggtttg teetettgga atgeteattt gtgggageee tgaacaacta tgtaagaagt 240
ctggctaccc tgctggagag aacacatggt gggaagagac taaaattatg tgaagagagt 300
caggocaged atdecagett etetgetgag decegecate agecaacetg ceagetgaat 360
gcaaccgtaa gagtgatcac cagcaagatc actagaaaaa ccacctaact gagcccaccc 420
tggattgaac aatcataaac aaataaaatg gttattgttt taaaaaaaaa a
<210> 253
<211> 3775
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2280161
<400> 253
teectgagag gtgtccactg atgtctcctc ctcatttcat ttagcagctc ttagtttgtg 60
aagaatctgt agatgctcaa agtataattg ccccagggaa tttatgctaa tcacaacctc 120
ttetteagae accaagteta cettgaatgg gtttgetgtg atatggeaet teaggtetee 180
ttttccatct gccaatatca gactgcctgt gtccccagag catgaaatca gccttacagt 240
gettggettg ettgtgagga eateeggaae tteaaatetg ggttttagag gagtetette 300
gttaatttta agcctgaaaa tgtttccttc tataccataa atttcagcca ggagaggaac 360
cttacttgct tcattgatga tttggaacct ggtgctgtct tcatctgttg tgactgaatc 420
caataatgcc cgataggtgg acttettgga aagccactgt ttetgacgcc tgtaaaatgc 480
gatettgtta cagtetetga aaatgttttt atetacaget teatetteaa caettattte 540
ctettteact getgetteea tggettetet gteacteega ecageteeca geteteagga 600
caagggccct gggcgatctt ttaaaaaaagc cgattgggtg tctttctaaa attacaacca 660
gtacttcatc gtcaagtttc tgggaaggga gtcccctcca gattctcatg gagtgacaaa 720
tettgaetet tgeteetgga attttteagg cecaaactag egtttetaea atgatttatt 780
tggcaaattt gtcttgatta tgggtggctg atgaggaacg tgcttttgtt aggaaccgaa 840
actgggcggc ggtgagggcg tgtacgcaat gagtccggaa gagggtgaaa tgctttcggt 900
aggraetage oggetgigaa gatggeggeg getgryttgge tteaggryft gwekyleart 160 jillian 🔻
ල්ද්ර්ල්ර්ල්ර්රීමේ අමුමුල්ලිස්ද්දිa_cocqueacea සඳහල්ලිස්ද්ර් toagrycogg accggcaace 1020 ං වර්ගම
gtagctgctg ccgaccggtc caaatggcac attccgatac cgtcggggaa aaattatttt 1080
agttttggaa agatcctctt cagaaatacc actatcttcc tgaagtttga tggagaacct 1140
tgtgacctgt ctttgaatat aacctggtat ctgaaaagcg ctgattgtta caatgaaatc 1200
tataacttca aggcagaaga agtagagttg tatttggaaa aacttaagga aaaaagaggc 1260
ttgtctggga aatatcaaac atcatcaaaa ttgttccaga actgcagtga actctttaaa 1320
acacagacet tttctggaga ttttatgcat cgactgcctc ttttaggaga aaaacaggag 1380
gctaaggaga atggaacaaa ccttaccttt attggagaca aaaccgcaat gcatgaacca 1440
ttgcaaactt ggcaagatgc accatacatt tttattgtac atattggcat ttcatcctca 1500
ggtccctatg aatacctcac acttgaagac tatcccttga tgattttttt catggtgatg 1620
tgtattgtat atgteetgtt tggtgttetg tggetggeat ggtetgeetg etaetggaga 1680
gateteetga gaatteagtt ttggattggt getgteatet teetgggaat gettgagaaa 1740
gctgtcttct atgcggaatt tcagaatatc cgatacaaag gagaatctgt ccagggtgct 1800
ttgatccttg cagagetget ttcagcagtg aaacgetcae tggetegaac cetggteate 1860
atagtcagtc tgggatatgg catcgtcaag ccacgccttg gagtcactct tcataaggtt 1920
gtagtagcag gagccctcta tcttttgttc tctggcatgg aaggggtcct cagagttact 1980
gggtattttt cttatccctt gactctgata gtaaacctgg ccctctcagc agttgacgcc 2040
tgtgttattt tatggatatt tattageetg acteaaacaa tgaagetatt aaaacttegg 2100
aggaacattg taaaactctc tttgtatcgg catttcacca acacgcttat tttggcagtg 2160
gcagcatcca ttgtgtttat catctggaca accatgaagt tcagaatagt gacatgtcag 2220
teggactggc gggagetgtg ggtagacgat gecatetgge gettgetgtt etecatgate 2280
ctctttgtca tcatggttct ctggcgacca tctgcaaaca accagaggtt tgccttttca 2340
```

```
ccattgtctg aggaagagga ggaggatgaa caaaaggagc ctatgctgaa agaaagcttt 2400
gaaggaatga aaatgagaag taccaaacaa gaacccaatg gaaatagtaa agttaacaaa 2460
gcacaggaag atgatttgaa gtgggtagaa gagaatgttc cttCttctgt gacagatgta 2520
gcacttccag cccttctgga ttcagatgag gaacgaatga tcacacatt tgaaaggtcc 2580
aaaatggagt aaggaatggg aagatttgca gttaaagatg gctaccatca gggaagagat 2640
cagcatetgt gtcagtette tgtacggete catgggatta aaggaagcaa tgacateetg 2700
atctgttcct tgatctttgg gcattggagt tggcgagagg tgtcagaaca aagagaacat 2760
cttactgaaa acaagttcat aagatgagaa aaatctacga gcttcttatt tacaacactg 2820
etgecccett teeteecaga etetgacatg gatgtteatg caacttaagt gtgttgttee 2880
tgaactttct gtaatgtttc attttttaaa tetgacaaac taaaaagttt aacgtcttct 2940
aaaagattgt catcaacacc ataatatgta atctccagga gcaactgcct gtaattttta 3000
tttatttagg gagttacata ggtgatgggg gaaattgtta actacctttc attttcctgg 3060
gaagtcaagg ttacatcttg cagaggttgt tttgagaaaa aagggccctt ctgagttaag 3120
gattcagatc atttaaaaaa gcaaaatcaa gtgcaatttt gtttacaaat ggtgtatatt 3240
aaagattttt ctatttcaga tgtactttaa agagaaatat tagcttaact cttttgacat 3300
etgetattgt gacacatece attgetggca atgtggtgca cacteegaaa ettttaacta 3360
ctgttttgta agcctccaag ggtggcattg cagggtcctt aggcaatgtt ttgtttgcct 3420
ttatqcaqaq aggtgctcca aqtqctqtqa ttqaqcaccq tqctaqagga actqtaatqc 3480
ttcagaagtt gtagettata caaaggaaac aggteetget ggettaattt aaacagttat 3540
tgcatgaagt agcgtggagg ccctggactg ctgctcgttc tttaggatgg actgttctgg 3600
tatctggtat tggtttagag actgttaata agggacatca caaggtgatg ggattcattt 3660
gaageactet atttetgttt taatggtttt atccaatttt geetteecaa gatttttgtt 3720
ctacataaaa agttcatgcc actttttaat ataaaaaaat ttaacaaaaa aaaaa
<210> 254
<211>.1856
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<2223> Incyte Clone No: 2237485 :-
<400> 254
eggeegeace eggeeggage ggagggeaga gegegegeee agttgeeegg geaceaaate
ggagcgeggc gtgcgggagg gcccagagca ggactggaaa tgtcctggcc gcgccgcctc 120
etgeteagat acctgtteee ggeeeteetg etteaeggge tgggagaggg ttetgeeete 180
ettcatecag acageaggte teatectagg teettagaga aaagtgeetg gagggetttt 240
aaggagteae agtgeeatea catgeteaaa cateteeaca atggtgeaag gateacagtg 300
cagatgccac ctacaatcga gggccactgg gtctccacag gctgtgaagt aaggtcaggc 360
ccagagttca tcacaaggtc ctacagattc taccacaata acaccttcaa ggcctaccaa 420
ttttattatg gcagcaaccg gtgcacaaat cccacttata ctctcatcat ccggggcaag 480
atecgeetee geeaggeete etggateate egagggggea eggaageega etaceagetg 540
cacaacgtcc aggtgatctg ccacacagag gcggtggccg agaagctggg ccagcaggtg 600
aaccgcacat gcccgggctt cctcgcagac gggggtccct gggtgcagga cgtggcctat 660
gacctetgge gagaggagaa eggetgtgag tgeaceaagg eegtgaaett tgecatgeat 720
gaactteage teateegggt ggagaageag tacetteace acaacetega ceacetggte 780
gaggagetet teettggtga catteacaet gatgecaece agaggatgtt etaceggeee 840
tecagttace agreecetet geagaatgee aagaaceaeg accatgeetg categeetgt 900
eggateatet ateggteaga egageaceae ceteceatee tgeeceeaaa ggeagacetg 960
accateggee tgcaegggga gtgggtgage eagegetgtg aggtgegeee egaagteete 1020
tteeteacce gecaetteat etteeatgae aacaacaaca eetgggaggg ceaetactae 1080
cactactcag acceggtgtg caagcacece acetteteca tetacgeeeg gggeegetac 1140
```

ageogoggeg tectotogto cagggtoatg ggaggeacog agttogtgtt caaagtgaat 1200 cacatgaagg toaccoccat ggatgoggoo acagcotoac tgotoaacgt ottoaacggg 1260

```
aatgagtgeg gggccgaggg ctectggeag gtgggcatec ageaggatgt gaeceacaec 1320
aatggetgeg tggeeetggg catcaaacta eetcacaegg agtaegagat ettcaaaatg 1380
gaacaggatg cccgggggcg ctatctgctg ttcaacggtc agaggcccag cgacgggtcc 1440
agcecagaca ggccagagaa gagagecaeg tectaceaga tgecettggt eeagtgtgee 1500
teetettege egagggeaga ggaeetegea gaagaeagtg gaageageet gtatggeegg 1560
geocetggga ggeacacetg gteeetgetg etggetgeac ttgeetgeet tgteeetetg 1620
ctgcattgga acatccgcag atagaagttt tagaaagttc tatttttcca aaccaggatt 1680
ccttactatt gacagatttt ctttaccaaa agaaaagaca tttattcttt tgatgcactt 1740
gaatgccaga gaactgtcct tetttttete etetecetee eteccagece etgagtcatg 1800
aacagcaagg agtgtttgaa gtttctgctt tgaactccgt ccagcctgat ccctgg
<210> 255
<211> 1545
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2380344
<400> 255
ggetggaetg gaacteetgg teecaagtga teeaceegee teageeteee aaggtgetgt 60
gattataggt gtaagccacc gtgtctggcc tctgaacaac tttttcagca actaaaaaag 120
ccacaggagt tgaactgcta ggattctgac tatgctgtgg tggctagtgc tcctactcct 180
acctacatta aaatetgttt tttgttetet tgtaactage etttaeette etaacacaga 240
ggatetgtea etgtggetet ggeccaaace tgacetteae tetggaacga gaacagaggt 300
ttotacceae acegteceet egaageeggg gacageetea eettgetgge etetegetgg 360
ageagtgccc tcaccaactg tctcacgtct ggaggcactg actegggcag tgcaggtagc 420
tgagcetett ggtagetgeg gettteaagg tgggeettge eetggeegta gaagggattg 480
acaageeega agattteata ggegatgget eecaetgeee aggeateage ettgetgtag 540
tcaatcactg ccctggggcc aggacgggcc gtggacacct gctcagaagc agtgggtgag 600
acateaeget geeegeeeat etaacetttt catgteetge acateaeetg atceatggge 660
taatgigaac totgtoccaa ggaacecaga gottgagtga-getgiggetc agacccigaa 720 -
ggggbetget tagaedaect ggtttatgtg acaggaettg cattefectg gaacatgagg 780
gaacgccgga ggaaagcaaa gtggccaggg aaggaacttg tgccaaatta tgggtcagaa 840
aagatggagg tgttgggtta teacaaggea tegagtetee tgeatteagt ggacatgtgg 900
gggaaggget geegatggeg catgacacac tegggactea cetetgggge cateagacag 960
cegitteege ceegateeac giaceagetg etgaagggea actgeaggee gatgetetea 1020
tcagccaggc agcagccaaa àtctgcgatc accagccagg ggcagccgtc tgggaaggag 1080
caagcaaagt gaccatttct cctcccctcc ttccctctga gaggccctcc tatgtcccta 1140
ctaaagccac cagcaagaca tagctgacag gggctaatgg ctcagtgttg gcccaggagg 1200
teageaagge etgagagetg ateagaaggg eetgetgtge gaacaeggaa atgeeteeag 1260
tetetgtgeg egatgeeetg ttgaaccaga tggteeacge ettecagcag etgeagcage 1320
atcatggegg egaggegggg getgggtgtg ttcacacaaa ggaagaagag tgacctecet 1380
ggaagaagat ggaattetge cageggecag getteaaace tgaactgeae egetggetee 1440
tecetggete tecageetge eegectacte tgeggetttt aagaetttge caateeccat 1500
agggagecag gteeteaaaa taaacetgee tetatataga cacat
<210> 256
<211> 1671
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte Clone No: 2383171

```
<400> 256
gaatteggac getetetggg ceaatatgge agegeecage aacaagacag agetggeetg 60
gagtcegegg ctggccgegt gagtaggtga ttgtctgaca agcagaggca tgagctgggt 120.
ccaggecace ctactggece gaggectetg tagggeetgg ggaggeacet geggggeege 180
cctcacagga acctccatct ctcaggtccc tcgccggctc cctcggggcc tccactgcag 240
egeagetgee catagetetg aacagteeet ggtteeeage ceaceggaac eeeggcagag 300
geceaecaag getetggtge eetttgagga eetgtttggg eaggegeetg gtggggaaeg 360
ggacaaggcg agcttectge agacggtgca gaaatttgcg gagcacagcg tgcgtaagcg 420
gggccacatt gacttcatct acctggccct gcgcaagatg cgggagtatg gtgtcgagcg 480
ggacctggct gtgtacaacc agctgctcaa catcttcccc aaggaggtct tccggcctcg 540
caacateate cagegeatet tegteeacta eeeteggeag caggagtgtg ggattgetgt 600
cctggagcag atggagaacc acggtgtgat gcccaacaag gagacggagt tcctgctgat 660
teagatettt ggaegeaaaa getaeeceat geteaagttg gtgegeetga agetgtggtt 720
coctegatte atgaacgtea accepttece agtgeecegg gacetgeece aggaecetgt 780
ggagetggee atgtttggee tgeggeacat ggageetgae ettagtgeea gggteaccat 840
ctaccaggtt cctttgccca aagactcaac aggtgcagca gatecccccc agccccacat 900
egtaggaatc cagagteecg atcageagge egecetggee egecacaatc cageeeggee 960
tgtctttgtt gagggcccct tctccctgtg gctccgcaac aagtgtgtgt attaccacat 1020
cctcagaget gacttgctgc ccccggagga gagggaagtg gaagagacgc cggaggagtg 1080
gaacetetac taccegatge agetggacet ggagtatgtg aggagtgget gggacaacta 1140
cgagtttgac atcaatgaag tggaggaagg ccctgtcttc gccatgtgca tggcgggtgc 1200,
teatgaceag gegaegatgg etaagtggat ceagggeetg eaggagacea acceaaceet 1260
ggcccagatc cccgtggtct tccgcctcgc cgggtccacc cgggagctcc agacatcctc 1320
tgcagggctg gaggagccgc ccctgcccga ggaccaccag gaagaagacg acaacctgca 1380
gegacageag cagggecaga getagtetga geeggegega gggeaeggge tgtggeeega 1440
ggaggcggtg gactgaaggc atgagatgcc ctttgagtgt acagcaaatc aatgttttcc 1500
tgcttggggc tctcttccct catctctagc agtatggcat cccctcccca ggatctcggg 1560
etgecagega tgggcaggeg agacecetec agaatetgea ggegeetetg gtteteegaa 1620
```

```
<210> 257

×211> 7994

<212> DNA

<213> Homo sapiens
```

<220>

<221> misc feature

<223> Incyte Clone No: 2396046

<400> 257

```
aattttaggg agaatgtggg ggggtggggt gttactttee attttacaca tatttgtatt 60 ttcagatttt caacaataac agtattcaat acataatcag aaaaaagaga tgtggaggag 120 gaggagagaa acttcccaag gageteeett gggtgetget ggeteetaat tagtgtaace 180 tgttaatcac atgttgeteg gtgttagage ggteeetetg tgetetgeet ggcagggege 240 tgttggeetg gteteeeteg etatttetat ttgeaageat gggetttett eccageagaa 300 tetggtteet gggaagagta atgttecaaa ggeetetgat atgeetegat geeeteetgt 360 ettecagage eccaacetea etecetttee ecaceataca aaacacacet eccaggggte 420 acatttgggg gteeegeee etgeteeaat geeatggtg ecceaageac agggettteg 480 eetgagttgt eagteetegg atgeatttga ggggeageta gggtggget ggggggtee 540 ageagetggg gageegagae teagaateat teacacactt etatttggag ettttgtgga 600 agttteeaga atteeataat atteacetee tgaatggtg etgeeeetta teageeaggg 660 etggggttte eagtgeeete ggagagettg etttagagte ttggagagae ggeeatggte 720 tgegtttgta tgeetgtea atetacea eateacaat tgaatataca acattaceta 780 attgtgtgat ea
```

```
<210> 258
<211> 3045
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2456587
<400> 258
gtgagagggg ctgatggaag ctgataggca ggactggagt gttagcacca gtactggatg 60
tgacagcagg cagaggagca cttagcagct tattcagtgt ccgattctga ttccggcaag 120
gatecaagea tggaatgetg cegtegggea acteetggea caetgeteet etttetgget 180
tteetgetee tgagtteeag gacegeaege teegaggagg acegggaegg cetatgggat 240
qcctggggcc catggagtga atgctcacgc acctgcgggg gaggggcctc ctactctctg 300
aggegetgee tgageageaa gagetgtgaa ggaagaaata teegatacag aacatgeagt 360
aatgtggact gcccaccaga agcaggtgat ttccgagctc agcaatgctc agctcataat 420
gatgtcaagc accatggcca gttttatgaa tggcttcctg tgtctaatga ccctgacaac 480
ccatgttcac tcaagtgcca agccaaagga acaaccctgg ttgttgaact agcacctaag 540
gtettagatg gtaegegttg etatacagaa tetttggata tgtgcateag tggtttatge 600
caaattgttg gctgcgatca ccagctggga agcaccgtca aggaagataa ctgtggggtc 660
tgcaacggag atgggtccac ctgccggctg gtccgagggc agtataaatc ccagctctcc 720
gcaaccaaat cggatgatac tgtggttgca attccctatg gaagtagaca tattcgcctt 780
gtettaaaag gteetgatea ettatatetg gaaaccaaaa eeeteeaggg gaetaaaggt 840
gaaaacagtc tcagctccac aggaactttc cttgtggaca attctagtgt ggacttccag 900
aaattteeag acaaagagat actgagaatg getggaceae teacageaga ttteattgte 960
aagattegta actegggete egetgacagt acagtecagt teatetteta teaacecate 1020
atecacegat ggagggagae ggatttettt eettgeteag eaacetgtgg aggaggttat 1080
cagetgaeat eggetgagtg etaegatetg aggageaace gtgtggttge tgaecaatae 1140
tgtcactatt acccagagaa catcaaaccc aaacccaagc ttcaggagtg caacttggat 1200
cettgtecag ccagtgaegg atacaageag atcatgeett atgaceteta ccateceett 1260
cctcggtggg aggccacccc atggaccgcg tgctcctcct cgtgtggggg gggcatccag 1320
agceggycag titectgigt ggaggaggac abecaggggs atgbeacts agtggaagag [1380]
ກໍ່ຜູ້ສັດຂໍລົງສູ່ປະຕິ ຜູ້ກິດຄວາມເຕີດ ກົດສ່ຽນກຽດຂໍດ atogogouge cotycalcat tittgactge 1440
cctaaatggc tggcacagga gtggtctccg tgcacagtga cgtgtggcca gggcctcaga 1500
taccgtgtgg tectetgeat cgaccatega ggaatgeaca caggaggetg tageccaaaa 1560
acaaageece acataaaaga ggaatgeate gtaceeacte eetgetataa acecaaagag 1620
aaacttccag tcgaggccaa gttgccatgg ttcaaacaag ctcaagagct agaagaagga 1680
getgetgtgt cagaggagee etegtteate ceagaggeet ggteggeetg cacagteace 1740
tgtggtgtgg ggacccaggt gcgaatagtc aggtgccagg tgctcctgtc tttctctcag 1800
teegtggetg acctgeetat tgacgagtgt gaagggeeca agecageate ceagegtgee 1860
tgttatgcag geccatgcag eggggaaatt eetgagttea acceagaega gacagatggg 1920
ctctttggtg gcctgcagga tttcgacgag ctgtatgact gggagtatga ggggttcacc 1980
aagtgeteeg agteetgtgg aggaggtgte caggaggetg tggtgagetg ettgaacaaa 2040
cagacteggg agcettgetg aggagaacet gtgegtgace acegeeggec eccacagete 2100
ctgaagteet geaatttgga teeetgeeca geaagteetg teatetagga agaageagta 2160
tegacteage atggaaegee tgeaaegtte tttgttagge aaceaagagg eetggettet 2220
catcetgetg teaccaacta getetgtgge etagggegag gtgtetgeee tttatgttte 2280
cacatetgea aagtgaactg gttgtacetg atgatetgag ateceatgae ttgeteacat 2340
gtoccatgat tetttatttt gtaggeagaa geattaaaca getaeteetg etgetgtgtg 2400
ctaatcatte ctgtaattte tgttetgett atttgecatt atttgaaaaa catgcaaaag 2460
ggtettteta accacattee tgtgttgtaa caacacecaa atgetgagge agtgeegagg 2520
agteagtgee tgggaettge ttaaaaetge tgggaetegt ggteeetaaa ecettetttg 2580
agcaccaaaa cgaataggac atgagatgtt acttctcatt ctcaaagtac taactatgtt 2640
taagttacaa aaggttaggt tatcctgtga cocttttgtt gactcacaga caagaacagt 2700
tgttgagett aatgttgteg eatttgetee agataaaete aattetetga ttteeeaeca 2760
```

gecaactgte aagecaacag geaagacete teactgggea cagecaggag tttettgggt 2820

```
cgaccataca cattgaaaca tttgtagaag gttgctaatt gcaacaataa aggggaccaa 2880
agtataatgg cctaatctca tccaagagtc aaaacagatt ttccccctaa aaatgataat 2940
tgtatagagg tgcctttcct gtggaatatc tcactctgat gtcagagaaa aatctctcct 3000
<210> 259
<211> 2445
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2484813
<400> 259
geatettgge agggteeggg gaegtggaet atttegeaca ceacaceacg gggagggatt 60
tttttctatt ttccctacga aaaacagatc tttttaagga tggtgctgct ccactggtgc 120
etgetgtgge teetgtttee acteagetea aggaeecaga agttaeecae eegggatgag 180
gaactttttc agatgcagat ccgggacaag gcattttttc atgattcgtc agtaattcca 240
gatggagetg aaattageag ttatetettt agagataeae etaaaaggta tttetttgtg 300
gttgaagaag acaatactcc attatcagtc acagtgacgc cctgtgatgc gcctttggag 360
tggaagetga geetceagga getgeeagag gacaggageg gggaaggete aggtgatetg 420
gaacctcttg agcagcagaa gcagcagatc attaatgagg aaggcactga gttattctcc 480
tacaaaggca atgatgttga gtattttata tcgtctagtt ccccatccgg tttatatcag 540
ttggatette tttcaacaga gaaagacaca catttcaaag tatatgccac cacaactcca 600
gaatetgate agecatacce tgagttacce tatgacceaa gagtagatgt gacetcactg 660
gggcgcacca cggtcacttt ggcctggaaa ccaagcccca ctgcctcttt gctgaaacaa 720
cccattcagt actgtgtggt catcaacaaa gagcacaatt tcaaaagtct ctgtgcagtg 780
gaagcaaaac tgagtgcaga tgatgctttt atgatggcac cgaaacctgg tctggacttc 840
ageceetttg aetttgeeca etttggattt eettetgata atteaggtaa agaaegeagt 900
ttccaggcaa agcettetee aaaactgggg egteatgtet actecaggee caaggttgat 960
attragama, Lotgostago maacaagano abuti caron tetotganet garaccegao 1020.
adycagbastilaerbugacyti atttytygges aacabsaaca gcaacatyag eaccycttat 1080
gtaggtacct ttgccaggac caaggaagaa gccaaacaga agacagtcga gctaaaagat 1140
gggaagataa cagatgtatt tgttaaaagg aagggagcaa agtttctacg gtttgctcca 1200
gtotottoto accaaaaagt cacottottt attoactott gtotggatgo tgtocaaato 1260
caagtgagaa gagatgggaa acttettetg teteagaatg tggaaggeat teageagttt 1320
cagettagag gaaaacetaa agetaaatae etegttegae tgaaaggaaa caagaaagga 1380
gcatctatgt tgaaaattct agctaccaca aggcctacta agcagtcatt tccctctctt 1440
cetgaagaca caagaateaa ageetttgae aageteegta eetgtteete ggeeaeegtg 1500
gcttggctag gcactcagga aaggaacaag ttttgcatct acaaaaaaga agtggatgat 1560
aactacaatg aagaccagaa gaaaagagag caaaaccaat gtctaggacc agatataagg 1620
aagaagtcag aaaaggtcct ctgtaaatat ttccacagtc aaaacctqca qaaaqcaqtq 1680
accacagaaa caattaaagg tetteageet ggeaaatett acetgetgga tgtttatgte 1740
ataggacatg gggggcactc tgtaaagtat cagagtaagg ttgtgaaaac tagaaagttc 1800
tgttagttac cttcttatag agatatatta tgtagaactc caggagggac attaaatcac 1860
tttaagtata aactgactac tcccacagtt gagagaagtt gtgacctgta cttgtactat 1920
ggaaggaagg atatcaacgt gtgtatattg atgtttatat aagtaactct tgaaggagac 1980
ttgttctagc gtgccccatg gtacctagtg tgtgtctgat gccggttggt gtcaaagata 2040
gagggettet tgaaggaaet tgecatteet tgetttgace aetgeatgaa etgettetaa 2100
attattttat tacctaaaaa tttaaaaatat gccattcatt gcacacaccc acaaatgcaa 2160
atcattcctc tctatagatg ctaggatata tataaattat tttataaatt cttgttttaa 2220
atgtcagtgt ttctatgatt gtaaactatt aaattctttt cctattaaag tacagatcta 2280
atctaagtat tattaagttg atagccetet agtcagttat attgctattg taaattettg 2340
tttgttgagt aaaatgttta aatactatat gtatctcatg tacaaagttg acatacatta 2400
```

2445

```
<210> 260
<211> 672
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2493851
<400> 260
cccacgggcg cccagcctag gagtcgtccc ccaggcaatc cccagtactc ctgatgctgg 60
agagecagee acactgeaca gtgccccggg ggcggtttet accaccetaa ggggtattet 120
tggctccagg catcagagtc catgtggctt gtggggccct catttetttc atgcccactg 180
gggaaggttc caccagcagg gctgttactg gcggggtcct ctgggagggg ggcaagaagg 240
ccagccacac caaggcactg gagetecacg acteetggee ttegattgga ggeeeetete 300
tgccagetet geceettggg gggcaccagg caggactgce agecgetete etggcaggtg 360
acatcagect teaageteae tgtgeeetea ceattteatg etceeecaag gteetggtea 420
tqtcttctct tqqqtatctt cccaqqacaq qcactgqcac tqqaqccctq gcacttqttt 480
ctgggttcca tgcttcccag gtgtgatggt gaatgctgag tgtcagcttg actggattga 540
aggatgeaaa gtattgteac tgggtgtgte tgtgagggtg ttgecagagg agatteeeat 600
ttgagtcagt gggctgggag aggcagaccc accetcaatc caggtgggca ccacctaatc 660
                                                                  672
ggctgccagc aa
<210> 261
<211> 1183
<212> DNA
<213> Homo sapiens
<220>
<221> mis: feature
223> Incyce Clone No: 2495719
<400> 261
gagagaaatg atgtgacagg agcaagegaa ctacaacccc gccccgccgt tcctgcccca 60
ccactgcggc ggcgggcgct acgttccgga agcggaaatg gacgagaggt cagggtaggt 120
ttttgaagat ggeggeete aaggetetgg tgteeggetg tgggeggett eteegtggge 180
tactageggg eeeggeageg accagetggt eteggettee agetegeggg tteagggaag 240
tggtggagac ccaagaaggg aagacaacta taattgaagg ccgtatcaca gcgactccca 300
aggagagtee aaateeteet aaceeetetg geeagtgeee catetgeegt tggaacetga 360
agcacaagta taactatgac gatgttctgc tgcttagcca gttcatccgg cctcatggag 420
gcatgctgcc ccgaaagatc acaggcctat gccaggaaga acaccgcaag atcgaggagt 480
gtgtgaagat ggcccaccga gcaggtctat taccaaatca caggcctcgg cttcctgaag 540
gagttgttec gaagagcaaa ccccaactca accggtacet gacgcgctgg gctcctgget 600
ccgtcaagcc catctacaaa aaaggccccc gctggaacag ggtgcgcatg cccgtggggt 660
caccecttet gagggacaat gtetgetaet caagaacace ttggaagetg tateactgae 720
agagageagt gettecagag tteeteetge acetgtgetg gggagtagga ggeecaetea 780
caagecettg gecacaacta tacteetgte ceaceceace aegatggeet ggteeeteea 840
acatgcatgg acaggggaca gtgggactaa cttcagtacc cttggcctgc acagtagcaa 900
tgctgggagc tagaggcagg cagggcagtt gggtcccttg ccagctgcta tggggcttag 960
gccatgctca gtgctgggga caggagtttt gcccaacgca gtgtcataaa ctgggttcat 1020
gggcttaccc attgggtgtg cgctcactgc ttgggaagtg cagggggtcc tgggcacatt 1080
gecagetggg tgetgageat tgagteactg atetettgtg atggggeeaa tgagteaatt 1140
gaattcatgg gccaaacagg tcccatcctc ttcaaaaaaa aaa
```

```
<210> 262
<211> 1266
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2614153
<400> 262
geetgaceae geagttettg ggtetgtget getggeetgg ggttgtggtt gaggeegggt 60
ctccgctcct gtgcccggga agatggtgct aggtggttgc ccggttagtt acttacttct 120
gtgcggccag gcggctttgc tgctggggaa tttacttctg ctgcattgtg tgtctcggag 180
ccactegeaa aatgegaceg etgageetga geteacatee getggegeeg eecageegga 240
gggccccggg ggtgctgcga gctgggaata tggcgacccc cactctccgg tcatcctctq 300
ctettaceta cetgatgaat ttatagaatg tgaagaceca gtggatcatg ttqgaaatgc 360
aactgcatcc caggaacttg gttatggttg tctcaagttc ggcggtcagg cctacagcga 420
egtggaacac acttcagtcc agtgccatgc cttagatgga attgagtgtg ccagtcctag 480
gacctttcta cgagaaaata aaccttgtat aaagtatacc ggacactact tcataaccac 540
tttactctac tccttcttcc tgggatgttt tggtgtggat cgattctgtt tgggacacac 600
tggcactgca gtagggaagc tgttgacgct tggaggactt gggatttggt ggtttgttga 660
cettattttg ctaattactg gagggetgat gccaagtgat ggcagcaact ggtgcactgt 720
ttactaaaaa gagctgccat catggcccag ggaggcgggt gaaagctccg tcttctgaat 780
tcatctctac aggetcaaaa etectetttg atatcagaec tgatgttatt tteettettt 840
tggagggcat ttgtttggtt aagaaggett etttggaett tggaatttea acccagattt 900
taccttgcag acggaatgac aagcaaaaag tgttgtgggg aatcaaattt gttcctttcc 960
tcatgcacaa aacataaagg atagtggcga gtttacaagc tgtggatggg tttccatagt 1020
etteettet gtacattget atatetteag teetttggag caagtggace taacaagttg 1080
agcaaaatga atatttggat ccatgttcct cttgtgaccc tgagtcttca tgcaaggaga 1140
tetgaagetg aacaatgaaa atetteagea gaaatagaaa tggeegtgga ttgtaataca 1200
cactgaaatt ctgactttct gaatttaaat gtagaataaa ttttaccaac ttggaaaaaa 1260
aaaaaa
                                                                  1266
<210> 263
<211> 1093
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2655184
<400> 263
gatggcttgt ttttcatttt ttttgtgctt tttggtccat ctattaataa aaatgaaccc 60
cgttacagag tcaccatcat gtctcttctc accaccctct gaatctgcat tagccagtca 120
actagecett teagegteat gtgaccageg egececatte agettggetg gtgtegttte 180
acatgaccca ggctggccag tcgtcaggtt gcaccgccct ttggttcccg agcatgctgt 240
ttteteteag cettetetee aacettaace aaateggeag cagecacete gacegeecac 300
acattcctgg ccaatcagct cagctgttta tttaccaaat gtcttcacaa caactacagc 360
agcagcette ggetaacaaa aaagcaggaa aaatecacaa caccecette gccaaccaac 420
taaatccaac gcaacatctg gcaaaacctt ttcagcaaat tcttcctggc cgtcagtccg 480
gcagceteac etcaccattt etagettgtt gaaacecaaa actaatetee aagaaggaga 540
agettetete geageeggag eaggteeett tetagagata ggagaagaga gagategetg 600
tetegggaga gaaateacaa geegteeega teetteteta ggtetegtag tegatetagg 660
tcaaatgaaa ggaaatagaa gacagtttgc aagagaagtg gtgtacagga aattacttca 720
```

```
tttgacagga gtatgtacag aaaattcaag ttttgtttga gacttcataa gcttggtgca 780
tttttaagat gttttagctg ttcaaatctg tttgtctctt gaaacagtga cacaaaggtg 840
taatteteta tggtttgaaa tggateatae gaggeatgta ataccaagaa ttgttaettt 900
acaatgttcc cttaagcaaa attgaatttg.ctttgaactt ttagttatgc acagactgat 960
aataaacctc taaacctgcc cagcggaagt gtgttttttt taaatttaaa tacagaacca 1020
ctggcaaaaa ttgaactaag atttactttt ttttccatag ctgggatata ggggggatcc 1080
tctagagtcg acc
<210> 264
<211> 1056
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 2848362
<400> 264
geetgacatg cetgateete tettttetge agtteaaggg aaagaegaga tettgeacaa 60
ggcactctgc ttctgccctt ggctggggaa gggtggcatg gagcctctcc ggctgctcat 120
ettactettt gtcacagage tgtccggage ccacaacace acagtgttcc agggcgtggc 180
gggccagtcc ctgcaggtgt cttgccccta tgactccatg aagcactggg ggaggcgcaa 240
ggectggtgc cgccagctgg gagagaaggg cccatgccag cgtgtggtca gcacgcacaa 300
ettgtggetg etgteettee tgaggaggtg gaatgggage acagecatea cagaegatae 360
cetgggtggc acteteacca ttacgetgeg gaatetacaa ceccatgatg egggteteta 420
ccagtgccag agcctccatg gcagtgaggc tgacaccctc aggaaggtcc tggtggaggt 480
gctggcagac cccctggatc accgggatgc tggagatctc tggttccccg gggagtctga 540
gagettegag gatgeecatg tggageacag catetecagg ageetettgg aaggagaaat 600
ccccttccca cccacttcca tccttctcct cctggcctgc atctttctca tcaagattct 660
agcagccage gecetetggg etgeageetg geatggaeag aagceaggga cacatecace 720
cagtgaactg gactgtggcc atgacccagg gtatcagctc caaactctgc cagggctgag 780
agacacgtga aggaagatga tgggaggaaa agcccaggag aagtcccacc agggaccagc 840
ccagnetyca gacttecoac tiggecache ggacteutty tietgethic geaagagaet see
acholigesty-Lakksbyott etootggaet etggaageag gyachggirg:agggagtggg**** 🖑 🗀
gaggtggtaa gaacacctga caacttetga atattggaca ttttaaacac ttacaaataa 1020
atccaagact gtcatattta gctggaaaaa aaaaaa
<210> 265
<211> 1183
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte Clone No: 2849906
<400> 265
ggageteage egagggetge acaaagaeet teetggeetg eeceagaeag agetgaggae 60
ccctggccgt gggcttgggc ctcggcttca caggatgggg ctgccagtgt cctgggcccc 120
tectgeecte tgggttetag ggtgetgege cetgeteete tegetgtggg egetgtgeae 180
agcetgeege aggeeegagg acgetgtage eeceaggaag aggegegga ggeagegge 240
gaggetgeag ggeagtgega eggeggegga agegteeeta etgaggegga eccaeetetg 300
eteceteage aagteggaca ecagaetgca egagetgcae eggggeeege geageageag 360
ggccctgcgg cctgccagca tggatctcct gcgcccacac tggctggagg tgtccaggga 420
catcaccgga ccgcaggcag ccccctctgc cttcccacac caggagctgc cccgggctct. 480
```

```
gccggcagct gcagccaccg cagggtgcgc tggcctcgag gccacctatt ccaacqtqqq 540
 getggeggee etteeegggg teageetgge ggceageeet gtggtggeeg agtatqeeeg 600
 cgtccagaag cgcaaaggga cccatcgcag tccccaagag ccacagcagg ggaagactga 660
ggtgaccccg gccgctcagg tggacgtcct gtactccagg gtctgcaagc ctaaaaggaq 720
ggacccagga cccaccacag acccgctgga ccccaagggc cagggagcga ttctggccct 780
ggcgggtgac ctggcctacc agaccctccc gctcagggcc ctggatgtgg acagcggccc 840
cctggaaaac gtgtatgaga gcatccggga gctgggggac cctgctggca ggagcagcac 900
gtgcggggct gggacgcccc ctgcttccag ctgccccagc ctagggaggg gctggagacc 960
cetecetgee teectgeest gaacacteaa ggacetgtge teetteetee agagtgagge 1020
cogtococog cocogococg cottoacagot gacagogoca gtoccaggto cocogococo 1080
cagecegtga ggteegtgag gteetggeeg etetgacage egeggeetee eeqqqeatee 1140
 tagagaagge cegegtetaa ataaagegee aegeagagtg ate
 <210> 266
 <211> 840
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <223> Incyte Clone No: 2899137
<400> 266
geatgteatg geegeeteea tggeeegggg aggegtgagt geeagggtte tactgeagge 60
tgccaggggc acctggtgga acagacctgg gggcacttcc gggtcggggg agggggtggc 120
getggggaca accagaaagt tteaagegae aggetegege eeggetggag aggaggaege 180
gggcggcccg gagcggcccg gggacgtggt gaacgtggtg ttcgtagacc gctcaggcca 240
gcggatccca gtgagtggca gagtcgggga caatgttett cacctggccc agcgccacgg 300
ggtggacctg gaaggggcct gtgaagcctc cctggcctgc tccacctgcc atgtgtatgt 360
gagtgaagac cacctggatc teetgeetee teecgaggag agggaagacg acatgetaga 420
catggccccc ctcctccagg agaactcgcg getgggctgc cagattgtgc tgacaccgga 480
cotggaagga goggaattoa cootgoocaa gatoaccagg aacttotacg tggatggoca 540
tytococaag occoractyac atgaacacct ggaccattee acategocat ggeoccaggg 600
cocagartiga 353322agcc aggtgccagc cotgoccaga gtgcggacag gcccgggaga 660
gacgtggaag cccctgtgaa ggacaacacc cctgcttggg agagagtccc atgtccaggc 720
totggtgggg acagggcccc tagtggggtg gccttcccca ggcccctqaq aatcagggtt 780
<210> 267
<211> 606
<212> DNA
<213> Homo sapiens
<220>
. <221> misc feature
<223> Incyte Clone No: 2986229
<400> 267
aataatgttt gagacagaag agaccattgg ctagtattta gcaattatca tagttatttg 60
atttatatta aaaagcattt gtctttccac taaaacataa agggaataag ggcctagagt 120
tatatgagtt aatagtaatt atagtcaagc tggggttaaa aatttgttgt agatgatgca 180
tacttgggga taattaagag taccatctaa ttttctgtca ctttagaaag gaacaagtgg 240
caactitigtt gactatgtgg agaaagccag atgttcttta ctcagtaata cctgttactt 300
etetttttt cettttagca etgaacetae cagatgtatt tgggttggte gteeteccat 360
tggaactgaa actacggate ttccgactte tggatgtteg ttccgtettg tetttgtetg 420
```

```
cggtttgtcg tgacctcttt actgcttcaa atgacccact cctgtggagg tttttatatc 480
tgcgtgattt tcgaggtgat ttccgtaatg acatattcac aagaaagggc tcttattgtc 540
ttgattactc agctcaccaa aagtttttag ttgtaggatt tttctgttgc aaatgattac 600
aataaa
<210> 268
<211> 1025
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte Clone No: 3222081
<400> 268
gtccttcgag ctactccgtc tggccccgcc ttttctctgc tctcctgaac ctttaggctt 60
gtctcggccc atttgaagac caggaagttg atcaatcccg aggctgctga gagacggtgg 120
cgcgattggg acagtcgcca gggatggctg agcgtgaaga tgcagcgggt gtccgggctg 180
ctctcctgga cgctgagcag agtcctgtgg ctctccggcc tctctgagcc gggagctgcc 240
cggcagcccc ggatcatgga agagaaagcg ctagaggttt atgatttgat tagaactatc 300
cgggacccag aaaagcccaa tactttagaa gaactggaag tggtctcgga aagttgtgtg 360
gaagttcagg agataaatga agaagaatat ctggttatta tcaggttcac gccaacagta 420
cctcattgct ctttggcgac tcttattggg ctgtgcttaa gagtaaaact tcagcgatgt 480
ttaccattta aacataagtt ggaaatctac atttctgaag gaacccactc aacagaagaa 540
gacatcaata agcagataaa tgacaaagag cgagtggcag ctgcaatgga aaaccccaac 600
ttacgggaaa ttgtggaaca gtgtgtcctt gaacctgact gatagctgtt ttaagagcca 660
ctggcctgta attgtttgat atatttgttt aaactctttg tataatgtca gagactcatg 720
tttaatacat aggtgatttg tacctcagag cattttttaa aggattcttt ccaagcgaga 780
tttaattata aggtagtacc taatttgttc aatgtataac attctcagga tttgtaacac 840
ttaaatgatc agacagaata atattttcta gttattatgt gtaagatgag ttgctatttt 900
totgatgoto attotgatac aactattttt ogtgtoaaat atotactgtg occaaatgta 960
ctcaatttaa atcattactc tgtaaaataa ataagcagat gattettata atgaaaaaaa 1020
                                                                  1,025
```